

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/37809</b> <b>(43) International Publication Date:</b> 29 July 1999 (29.07.99)
<b>(21) International Application Number:</b> PCT/US98/01260 <b>(22) International Filing Date:</b> 21 January 1998 (21.01.98) <b>(71) Applicant (for all designated States except US):</b> AXYS PHARMACEUTICALS, INC. [US/US]; 11099 North Torrey Pines Road, La Jolla, CA 92037 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BROOKS-WILSON, Angela, R. [CA/US]; 12685 Camino Mira Del Mar #145, San Diego, CA 92130 (US). BUCKLER, Alan [US/US]; 2315 Lagoon View Drive, Cardiff, CA 92007 (US). CARDON, Lon [US/US]; 12240 Katydid Circle, San Diego, CA 92129 (US). CAREY, Alisoun, H. [GB/US]; 3145 Galloway Drive, San Diego, CA 92122 (US). GALVIN, Margaret [US/US]; 7768 Corte Promenade, Carlsbad, CA 92009 (US). MILLER, Andrew [US/US]; 3717 Nobel Drive #1239, San Diego, CA 92122 (US). NORTH, Michael [GB/US]; 11099 North Torrey Pines Road, La Jolla, CA 92037 (US). <b>(74) Agent:</b> SHERWOOD, Pamela, J.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ASTHMA RELATED GENES  <b>(57) Abstract</b>  A genetic locus associated with asthma is identified. The genes within the locus, <i>ASTH1I</i> and <i>ASTH1J</i> , and the regulatory sequences of the locus are characterized. The genes are used to produce the encoded proteins; in screening for compositions that modulate the expression or function of ASTH1 proteins; and in studying associated physiological pathways. The DNA is further used as a diagnostic for genetic predisposition to asthma.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ASTHMA RELATED GENES

## INTRODUCTION

Asthma is a disease of reversible bronchial obstruction, characterized by  
5 airway inflammation, epithelial damage, airway smooth muscle hypertrophy and  
bronchial hyperreactivity. Many asthma symptoms can be controlled by medical  
intervention, but incidence of asthma-related death and severe illness continue to  
rise in the United States. The approximately 4,800 deaths in 1989 marked a 46  
percent increase since 1980. As many as 12 million people in the United States  
10 have asthma, up 66 percent since 1980, and annually, the disease's medical and  
indirect costs are estimated at over \$6 billion.

Two common subdivisions of asthma are atopic (allergic, or extrinsic) asthma  
and non-atopic (intrinsic) asthma. Atopy is characterized by a predisposition to  
raise an IgE antibody response to common environmental antigens. In atopic  
15 asthma, asthma symptoms and evidence of allergy, such as a positive skin test to  
common allergens, are both present. Non-atopic asthma may be defined as  
reversible airflow limitation in the absence of allergies.

The smooth muscle surrounding the bronchi are able to rapidly alter airway  
diameter in response to stimuli. When the response is excessive, it is termed  
20 bronchial hyperreactivity, a characteristic of asthma thought to have a heritable  
component. Studies have demonstrated a genetic predisposition to asthma by  
showing, for example, a greater concordance for this trait among monozygotic twins  
than among dizygotic twins. The genetics of asthma is complex, however, and  
shows no simple pattern of inheritance. Environment also plays a role in asthma  
25 development, for example, children of smokers are more likely to develop asthma  
than are children of non-smokers.

In recent years thousands of human genes have been cloned. In many  
cases, gene discovery has been based on prior knowledge about the corresponding  
protein, such as amino acid sequence, immunological reactivity, etc. This approach  
30 has been very successful, but is limited in some important ways. One limitation is  
that genes in these cases are identified based on knowledge of molecular level  
protein properties. For a large number of important human genes, however, there

is little or no biochemical data concerning the encoded product. For example, genes that predispose to human diseases, such as cystic fibrosis, Huntington's disease, *etc.* are of interest because of their phenotypic effect. Biochemical characterization of such genes may be secondary to genetic characterization.

5           A solution to this impasse has been found in combining classical genetic mapping with the ability to identify genes and, if necessary, to sequence large regions of chromosomes. Population and family studies enable genes associated with a trait of interest to be localized to a relatively small region of a chromosome. At this point, physical mapping can be used to identify candidate genes, and  
10       various molecular biology techniques used to pick out mutated genes in affected individuals. This "top-down" approach to gene discovery has been termed positional cloning, because genes are identified based on position in the genome.

          Positional cloning is now being applied to complex genetic diseases, which affect a greater fraction of humanity than do the more simple and usually rarer  
15       single gene disorders. Such studies must take into account the contribution of both environmental and genetic factors to the development of disease, and must allow for contributions to the genetic component by more than one, and potentially many, genes. The clinical importance of asthma makes it of considerable interest to characterize genes that underlie a genetic predisposition to this disease. Positional  
20       cloning provides an approach to this goal.

#### *Relevant Literature*

          The symptoms and biology of asthma are reviewed in Chanez *et al.* (1994) Odyssey 1:24-33. A review of bronchial hyperreactivity may be found in Smith and  
25       McFadden (1995) Ann. Allergy, Asthma and Immunol. 74:454. Moss (1989) Annals of Allergy 63:566 review the allergic etiology and immunology of asthma.

          The genetic dissection of complex traits is discussed in Lander and Schork (1994) Science 265:2037-2048. Genetic mapping of candidate genes for atopy and/or bronchial hyperreactivity is described in Postma *et al.* (1995) N.E.J.M.  
30       333:894; Marsh *et al.* (1994) Science 264:1152; and Meyers *et al.* (1994) Genomics 23:464.

Lawrence *et al.* (1994) Ann. Hum. Genet. **58**:359 discuss an approach to the genetic analysis of atopy and asthma. Genetic linkage between the alpha subunit of the T cell receptor and IgE reactions has been noted by Moffat *et al.* (1994) The Lancet **343**:1597. Caraballo and Hernandez (1990) Tissue Antigens **35**:182 noted  
5 an association between HLA alleles and allergic asthma. Evidence of linkage of atopy to markers on chromosome 11q has been seen in some British asthma families (Cookson *et al.* (1989) Lancet **i**:1292-1295; Young *et al.* (1991) J. Med. Genet. **29**:236, but not in other British families (Lympny *et al.* (1992) Clin. Exp. Allergy **22**:1085-1092) or in families from Minnesota or Japan (Rich *et al.* (1992)  
10 Clin. Exp. Allergy **22**:1070-1076; and Hizawa *et al.* (1992) Clin. Exp. Allergy **22**:1065).

The association of a polymorphism for the FcεRI-β gene and risk of atopy is described in Hill *et al.* (1995) B.M.J. **311**:776; Hill and Cookson (1996) Human Mol. Genet. **5**:959; and Shirakawa *et al.* (1994) Nature Genetics **7**:125; an association of  
15 FcεRI-β with bronchial hyperreactivity is described in van Herwerden (1995) The Lancet **346**:1262.

Collections of polymorphic markers from throughout the human genome have been tested for linkage to asthma, described in Meyers *et al.* (1996) Am. J. Hum. Genet. **59**:A228 and Daniels *et al.* (1996) Nature **383**:247-250. No linkage to  
20 human chromosome 11p was detected in these studies.

#### SUMMARY OF THE INVENTION

Human genes associated with a genetic predisposition to asthma are provided. The genes, herein termed *ASTH1I* and *ASTH1J*, are located close to  
25 each other on human chromosome 11p, have similar patterns of expression, and common sequence motifs. The nucleic acid compositions are used to produce the encoded proteins, which may be employed for functional studies, as a therapeutic, and in studying associated physiological pathways. The nucleic acid compositions and antibodies specific for the protein are useful as diagnostics to identify a  
30 hereditary predisposition to asthma.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Genomic organization of the *ASTH1I* and *ASTH1J* genes. The sizes of the exons are not to scale. Alternative exons are hatched. The direction of transcription is indicated below each gene.

5

## DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The provided *ASTH1* genes and fragments thereof, encoded protein, *ASTH1* genomic regulatory regions, and anti-*ASTH1* antibodies are useful in the identification of individuals predisposed to development of asthma, and for the modulation of gene activity *in vivo* for prophylactic and therapeutic purposes. The encoded *ASTH1* protein is useful as an immunogen to raise specific antibodies, in drug screening for compositions that mimic or modulate *ASTH1* activity or expression, including altered forms of *ASTH1* protein, and as a therapeutic.

Asthma, as defined herein, is reversible airflow limitation in a patient over a period of time. The disease is characterized by increased airway responsiveness to a variety of stimuli, and airway inflammation. A patient diagnosed as asthmatic will generally have multiple indications over time, including wheezing, asthmatic attacks, and a positive response to methacholine challenge, *i.e.* a PC<sub>20</sub> on methacholine challenge of less than about 4 mg/ml. Guidelines for diagnosis may be found in the National Asthma Education Program Expert Panel. Guidelines for diagnosis and management of asthma. National Institutes of Health, 1991; Pub. #91-3042. Atopy, respiratory infection and environmental predisposing factors may also be present, but are not necessary elements of an asthma diagnosis. Asthma conditions strictly related to atopy are referred to as atopic asthma.

The human *ASTH1I* and *ASTH1J* gene sequences are provided, as are the genomic sequences 5' to *ASTH1J*. The major sequences of interest provided in the sequence listing are as follows:

	<i>ASTH1J</i> 5' Genomic Region	DNA	(SEQ ID NO:1)
	<i>ASTH1J</i> alt1	cDNA	(SEQ ID NO:2)
30	<i>ASTH1J</i> alt2	cDNA	(SEQ ID NO:3)
	<i>ASTH1J</i> alt3	cDNA	(SEQ ID NO:4)

	ASTH1J protein	protein	(SEQ ID NO:5)
	<i>ASTH1I</i> alt1	cDNA	(SEQ ID NO:6)
	ASTH1I alt1 protein	protein	(SEQ ID NO:7)
	<i>ASTH1I</i> alt2	cDNA	(SEQ ID NO:8)
5	ASTH1I alt2 protein	protein	(SEQ ID NO:9)
	<i>ASTH1I</i> alt3	cDNA	(SEQ ID NO:10)
	ASTH1I alt3 protein	protein	(SEQ ID NO:11)
	CAAT box "A" form	DNA	(SEQ ID NO:12)
	CAAT box "G" form	DNA	(SEQ ID NO:13)
10	<i>ASTH1J</i> 5' promoter region	DNA	(SEQ ID NO:14)
	Mouse <i>asth1j</i>	cDNA	(SEQ ID NO:338)
	Mouse <i>asth1j</i>	protein	(SEQ ID NO:339)
	Polymorphisms	DNA	(SEQ ID NO:16-159)
	Microsatellite flanking sequences	DNA	(SEQ ID NO:160-281)
15	Microsatellite repeats	DNA	(SEQ ID NO:282-292)
	Intron-Exon boundaries	DNA	(SEQ ID NO:293-335)

The *ASTH1* locus has been mapped to human chromosome 11p. The traits for a positive response to methacholine challenge and a clinical history of asthma were shown to be genetically linked in a genome scan of the population of Tristan da Cunha, a single large extended family with a high incidence of asthma (discussed in Zamel *et al.* (1996) Am. J. Respir. Crit. Care Med. **153**:1902-1906). The linkage finding was replicated in a set of Canadian asthmatic families. The region of strongest linkage was the marker D11S907 on the short arm of chromosome 11. Additional markers were identified from the four megabase region surrounding D11S907 from public databases and by original cloning of new polymorphic microsatellite markers. Refinement of the region of interest was obtained by genotyping new markers in the studied populations, and applying the transmission disequilibrium test (TDT), which reflects the level of association between marker alleles and disease status. TDT curves were superimposed on the

physical map. Molecular genetic techniques for gene identification were applied to the region of interest. A one megabase genomic region was sequenced to high accuracy, and the resulting data used for the sequence-based prediction of genes and determination of the intron/exon structure of genes in the region.

5

#### Nucleic Acid Compositions

ASTH1I produces a 2.8 kb mRNA expressed at high levels in trachea and prostate, and at lower levels in lung and kidney and possibly other tissues. ASTH1I cDNA clones have also been identified in prostate, testis and lung libraries. Sequence polymorphisms are shown in Table 3. ASTH1I has at least three  
10 alternate forms denoted as alt1, alt2, and alt3. The alternative splicing and start codons give the three forms of ASTH1I proteins different amino termini. The ASTH1I proteins, alt1, alt2 and alt3 are 265, 255 and 164 amino acids in length, respectively.

A domain of the ASTH1I and ASTH1J proteins is similar in sequence to  
15 transcription factors of the *ets* family. The *ets* family is a group of transcription factors that activate genes involved in a variety of immunological and other processes. The family members most similar to ASTH1I and ASTH1J are: ETS1, ETS2, ESX, ELF, ELK1, TEL, NET, SAP-1, NERF and FLI. The ASTH1I and ASTH1J proteins show similarity to each other. Over the *ets* domain they are 66%  
20 similar (i.e. have amino acids with similar properties in the same positions) and 46% identical to each other. All forms of ASTH1I and ASTH1J have a helix turn helix motif, characteristic of some transcription factors, located near the carboxy terminal end of the protein.

ASTH1J produces an approximately 6 kb mRNA expressed at high levels in  
25 the trachea, prostate and pancreas and at lower levels in colon, small intestine, lung and stomach. ASTH1J has at least three forms, consisting of the alt1, alt2 and alt3 forms. The open reading frame is identical for the three forms, which differ only in the 5' UTR. The protein encoded by ASTH1J is 300 amino acids in length.

Mouse coding region sequence of *asth1j* is provided in SEQ ID NO:326, and  
30 the amino acid sequence is provided in SEQ ID NO:327. The mouse and human proteins have 88.4% identity throughout their length. The match in the *ets*



domain is 100%. The mouse cDNA was identified by hybridization of a full-length human cDNA to a mouse lung cDNA library (Stratagene).

The term "*ASTH1* genes" is herein used generically to designate *ASTH1I* and *ASTH1J* genes and their alternate forms. The two genes lie in opposite  
5 orientations on a native chromosome, with the 5' regulatory sequences between them. Part of the genomic sequence between the two coding regions is provided as SEQ ID NO:1. The term "*ASTH1* locus" is used herein to refer to the two genes in all alternate forms and the genomic sequence that lies between the two genes. Alternate forms include splicing variants, and polymorphisms in the sequence.  
10 Specific polymorphic sequences are provided in SEQ ID NOs:16-159. For some purposes the previously known EST sequences described herein may be excluded from the sequences defined as the *ASTH1* locus.

The DNA sequence encoding *ASTH1* may be cDNA or genomic DNA or a fragment thereof. The term "*ASTH1* gene" shall be intended to mean the open  
15 reading frame encoding specific *ASTH1* polypeptides, introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 1 kb beyond the coding region, but possibly further in either direction. The gene may be introduced into an appropriate vector for extrachromosomal maintenance or for integration into the host.

20 The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns removed by nuclear RNA splicing, to create a continuous open reading frame  
25 encoding the *ASTH1* protein.

The genomic *ASTH1* sequence has non-contiguous open reading frames, where introns interrupt the protein coding regions. A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally  
30 present in a native chromosome. It may further include the 3' and 5' untranslated regions found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc.,

including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence.

Genomic regions of interest include the non-transcribed sequences 5' to  
5 *ASTH1J*, as provided in SEQ ID NO:1. This region of DNA contains the native promoter elements that direct expression of the linked *ASTH1J* gene. Usually a promoter region will have at least about 140 nt of sequence located 5' to the *ASTH1* gene and further comprising a TATA box and CAAT box motif sequence (SEQ ID NO:14, nt. 597-736). The promoter region may further comprise a consensus *ets*  
10 binding motif, (C/A)GGA(A/T) (SEQ ID NO:14, nt 1-5). A region of particular interest, containing the *ets* binding motif, TATA box and CAAT box motifs 5' to the *ASTH1J* gene, is provided in SEQ ID NO:14. The position of SEQ ID NO:14 within the larger sequence is SEQ ID NO:1, nt 60359-61095. The promoter sequence may comprise polymorphisms within the CAAT box region, for example those  
15 shown in SEQ ID NO:12 and SEQ ID NO:13, which have been shown to affect the function of the promoter. The promoter region of interest may extend 5' to SEQ ID NO:14 within the larger sequence, e.g. SEQ ID NO:1, nt 59000-61095; SEQ ID NO:1, nt 5700-61095, etc.

The sequence of this 5' region, and further 5' upstream sequences and 3'  
20 downstream sequences, may be utilized for promoter elements, including enhancer binding sites, that provide for expression in tissues where *ASTH1J* is expressed. The tissue specific expression is useful for determining the pattern of expression, and for providing promoters that mimic the native pattern of expression. Naturally occurring polymorphisms in the promoter region are useful for determining natural  
25 variations in expression, particularly those that may be associated with disease. See, for example, SEQ ID NO:12 and 13. Alternatively, mutations may be introduced into the promoter region to determine the effect of altering expression in experimentally defined systems. Methods for the identification of specific DNA motifs involved in the binding of transcriptional factors are known in the art, e.g.  
30 sequence similarity to known binding motifs, gel retardation studies, etc. For examples, see Blackwell *et al.* (1995) Mol Med 1: 194-205; Mortlock *et al.* (1996)

Genome Res. 6: 327-33; and Joulin and Richard-Foy (1995) Eur J Biochem 232: 620-626.

The regulatory sequences may be used to identify *cis* acting sequences required for transcriptional or translational regulation of ASTH1 expression, especially in different tissues or stages of development, and to identify *cis* acting sequences and *trans* acting factors that regulate or mediate ASTH1 expression. Such transcription or translational control regions may be operably linked to a ASTH1 gene in order to promote expression of wild type or altered ASTH1 or other proteins of interest in cultured cells, or in embryonic, fetal or adult tissues, and for gene therapy.

The nucleic acid compositions of the subject invention may encode all or a part of the subject polypeptides. Fragments may be obtained of the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt, more usually at least about 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening, etc. Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide. For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA, and will prime towards each other.

The *ASTH1* genes are isolated and obtained in substantial purity, generally as other than an intact mammalian chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include an *ASTH1* sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more

nucleotides with which it is not normally associated on a naturally occurring chromosome.

The DNA sequences are used in a variety of ways. They may be used as probes for identifying *ASTH1* related genes. Mammalian homologs have  
5 substantial sequence similarity to the subject sequences, *i.e.* at least 75%, usually at least 90%, more usually at least 95% sequence identity with the nucleotide sequence of the subject DNA sequence. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, *etc.* A reference sequence will  
10 usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990) J Mol Biol **215**:403-10.

Nucleic acids having sequence similarity are detected by hybridization under  
15 low stringency conditions, for example, at 50°C and 10XSSC (0.9 M saline/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1XSSC. Sequence identity may be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1XSSC (9 mM saline/0.9 mM sodium citrate). By using probes, particularly labeled probes of DNA sequences, one can isolate  
20 homologous or related genes. The source of homologous genes may be any species, *e.g.* primate species, particularly human; rodents, such as rats and mice, canines, felines, bovines, ovines, equines, yeast, *Drosophila*, *Caenorhabditis*, *etc.*

The DNA may also be used to identify expression of the gene in a biological specimen. The manner in which one probes cells for the presence of particular  
25 nucleotide sequences, as genomic DNA or RNA, is well established in the literature and does not require elaboration here. mRNA is isolated from a cell sample. mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences. Alternatively, mRNA sample  
30 is separated by gel electrophoresis, transferred to a suitable support, *e.g.* nitrocellulose, nylon, *etc.*, and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ*

hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use. Detection of mRNA hybridizing to the subject sequence is indicative of *ASTH1* gene expression in the sample.

The subject nucleic acid sequences may be modified for a number of purposes, particularly where they will be used intracellularly, for example, by being joined to a nucleic acid cleaving agent, *e.g.* a chelated metal ion, such as iron or chromium for cleavage of the gene; or the like.

The sequence of the *ASTH1* locus, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength, sequence of the encoded protein, *etc.* The DNA sequence or product of such a mutation will be substantially similar to the sequences provided herein, *i.e.* will differ by at least one nucleotide or amino acid, respectively, and may differ by at least two but not more than about ten nucleotides or amino acids. The sequence changes may be substitutions, insertions or deletions. Deletions may further include larger changes, such as deletions of a domain or exon. Other modifications of interest include epitope tagging, *e.g.* with the FLAG system, HA, *etc.* For studies of subcellular localization, fusion proteins with green fluorescent proteins (GFP) may be used. Such mutated genes may be used to study structure-function relationships of *ASTH1* polypeptides, or to alter properties of the protein that affect its function or regulation. For example, constitutively active transcription factors, or a dominant negatively active protein that binds to the *ASTH1* DNA target site without activating transcription, may be created in this manner.

Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for scanning mutations may be found in Gustin *et al.*, *Biotechniques* 14:22 (1993); Barany, *Gene* 37:111-23 (1985); Colicelli *et al.*, *Mol Gen Genet* 199:537-9 (1985); and Prentki *et al.*, *Gene* 29:303-13 (1984). Methods for site specific mutagenesis can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, CSH Press 1989, pp. 15.3-15.108; Weiner *et al.*, *Gene* 126:35-41 (1993); Sayers *et al.*, *Biotechniques* 13:592-6 (1992); Jones and Winistorfer, *Biotechniques* 12:528-30 (1992); Barton *et al.*, *Nucleic Acids Res* 18:7349-55

(1990); Marotti and Tomich, *Gene Anal Tech* 6:67-70 (1989); and Zhu *Anal Biochem* 177:120-4 (1989).

### Synthesis of ASTH1 Proteins

The subject gene may be employed for synthesis of a complete ASTH1  
5 protein, or polypeptide fragments thereof, particularly fragments corresponding to functional domains; binding sites; *etc.*; and including fusions of the subject polypeptides to other proteins or parts thereof. For expression, an expression cassette may be employed, providing for a transcriptional and translational initiation  
10 region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. Various transcriptional initiation regions may be employed that are functional in the expression host.

The polypeptides may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression.  
15 For large scale production of the protein, a unicellular organism, such as *E. coli*, *B. subtilis*, *S. cerevisiae*, or cells of a higher organism such as vertebrates, particularly mammals, *e.g.* COS 7 cells, may be used as the expression host cells. In many situations, it may be desirable to express the *ASTH1* gene in mammalian cells, where the *ASTH1* gene will benefit from native folding and post-translational  
20 modifications. Small peptides can also be synthesized in the laboratory.

With the availability of the polypeptides in large amounts, by employing an expression host, the polypeptides may be isolated and purified in accordance with conventional ways. A lysate may be prepared of the expression host and the lysate purified using HPLC, exclusion chromatography, gel electrophoresis, affinity  
25 chromatography, or other purification technique. The purified polypeptide will generally be at least about 80% pure, preferably at least about 90% pure, and may be up to and including 100% pure. Pure is intended to mean free of other proteins, as well as cellular debris.

The polypeptide is used for the production of antibodies, where short  
30 fragments provide for antibodies specific for the particular polypeptide, and larger fragments or the entire protein allow for the production of antibodies over the surface of the polypeptide. Antibodies may be raised to the wild-type or variant

forms of ASTH1. Antibodies may be raised to isolated peptides corresponding to these domains, or to the native protein, e.g. by immunization with cells expressing ASTH1, immunization with liposomes having ASTH1 inserted in the membrane, *etc.*

Antibodies are prepared in accordance with conventional ways, where the  
5 expressed polypeptide or protein is used as an immunogen, by itself or conjugated to known immunogenic carriers, e.g. KLH, pre-S HBsAg, other viral or eukaryotic proteins, or the like. Various adjuvants may be employed, with a series of injections, as appropriate. For monoclonal antibodies, after one or more booster injections, the spleen is isolated, the lymphocytes immortalized by cell fusion, and  
10 then screened for high affinity antibody binding. The immortalized cells, *i.e.* hybridomas, producing the desired antibodies may then be expanded. For further description, see Monoclonal Antibodies: A Laboratory Manual, Harlow and Lane eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1988. If desired, the mRNA encoding the heavy and light chains may be isolated and  
15 mutagenized by cloning in *E. coli*, and the heavy and light chains mixed to further enhance the affinity of the antibody. Alternatives to *in vivo* immunization as a method of raising antibodies include binding to phage "display" libraries, usually in conjunction with *in vitro* affinity maturation.

#### Detection of ASTH1 Associated Asthma

20       Diagnosis of ASTH1 associated asthma is performed by protein, DNA or RNA sequence and/or hybridization analysis of any convenient sample from a patient, e.g. biopsy material, blood sample, scrapings from cheek, *etc.* A nucleic acid sample from a patient having asthma that may be associated with *ASTH1*, is analyzed for the presence of a predisposing polymorphism in *ASTH1*. A typical  
25 patient genotype will have at least one predisposing mutation on at least one chromosome. The presence of a polymorphic *ASTH1* sequence that affects the activity or expression of the gene product, and confers an increased susceptibility to asthma is considered a predisposing polymorphism. Individuals are screened by analyzing their DNA or mRNA for the presence of a predisposing polymorphism, as  
30 compared to an asthma neutral sequence. Specific sequences of interest include any polymorphism that leads to clinical bronchial hyperreactivity or is otherwise associated with asthma, including, but not limited to, insertions, substitutions and

deletions in the coding region sequence, intron sequences that affect splicing, or promoter or enhancer sequences that affect the activity and expression of the protein. Examples of specific *ASTH1* polymorphisms in asthma patients are listed in Tables 3-8.

5           The CAAT box polymorphism of SEQ ID NO:12 and 13 (which is located within SEQ ID NO:14) is of particular interest. The "G" form, SEQ ID NO:13, can be associated with a propensity to develop bronchial hyperreactivity or asthma. Other polymorphisms in the surrounding region affect this association. It has been found that substitution of "G" for "A" results in decreased binding of nuclear proteins to the  
10 DNA motif.

          The effect of an *ASTH1* predisposing polymorphism may be modulated by the patient genotype in other genes related to asthma and atopy, including, but not limited to, the Fcε receptor, Class I and Class II HLA antigens, T cell receptor and immunoglobulin genes, cytokines and cytokine receptors, and the like.

15           Screening may also be based on the functional or antigenic characteristics of the protein. Immunoassays designed to detect predisposing polymorphisms in *ASTH1* proteins may be used in screening. Where many diverse mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools.

20           Biochemical studies may be performed to determine whether a candidate sequence polymorphism in the *ASTH1* coding region or control regions is associated with disease. For example, a change in the promoter or enhancer sequence that affects expression of *ASTH1* may result in predisposition to asthma. Expression levels of a candidate variant allele are compared to expression levels of  
25 the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β-galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like. The activity of the encoded *ASTH1* protein  
30 may be determined by comparison with the wild-type protein.



A number of methods are available for analyzing nucleic acids for the presence of a specific sequence. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express

5 *ASTH1* genes, such as trachea cells, may be used as a source of mRNA, which may be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki, *et al.* (1985) Science **239**:487, and

10 a review of current techniques may be found in Sambrook, *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2–14.33. Amplification may also be used to determine whether a polymorphism is present, by using a primer that is specific for the polymorphism. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for

15 examples see Riley *et al.* (1990) N.A.R. **18**:2887-2890; and Delahunty *et al.* (1996) Am. J. Hum. Genet. **58**:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, *e.g.* fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM),

20 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, *e.g.* <sup>32</sup>P, <sup>35</sup>S, <sup>3</sup>H; *etc.* The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, *etc.* having a high affinity binding partner, *e.g.*

25 avidin, specific antibodies, *etc.*, where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.* amplified or cloned fragment, is analyzed by

30 one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or other methods, and the sequence of bases compared to a neutral *ASTH1* sequence. Hybridization with the variant sequence may also be used to

determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilised on a solid support, as described in US 5,445,934, or in WO95/35505, may also be used as a means of detecting the presence of variant sequences. Single strand

5 conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), mismatch cleavage detection, and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease

10 (restriction fragment length polymorphism, RFLP), the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

The hybridization pattern of a control and variant sequence to an array of

15 oligonucleotide probes immobilised on a solid support, as described in US 5,445,934, or in WO95/35505, may be used as a means of detecting the presence of variant sequences. In one embodiment of the invention, an array of oligonucleotides are provided, where discrete positions on the array are complementary to at least a portion of mRNA or genomic DNA of the *ASTH1* locus.

20 Such an array may comprise a series of oligonucleotides, each of which can specifically hybridize to a nucleic acid, *e.g.* mRNA, cDNA, genomic DNA, *etc.* from the *ASTH1* locus.

An array may include all or a subset of the polymorphisms listed in Table 3 (SEQ ID NOs:16-126). One or both polymorphic forms may be present in the array,

25 for example the polymorphism of SEQ ID NO:12 and 13 may be represented by either, or both, of the listed sequences. Usually such an array will include at least 2 different polymorphic sequences, *i.e.* polymorphisms located at unique positions within the locus, usually at least about 5, more usually at least about 10, and may include as many as 50 to 100 different polymorphisms. The oligonucleotide

30 sequence on the array will usually be at least about 12 nt in length, may be the length of the provided polymorphic sequences, or may extend into the flanking regions to generate fragments of 100 to 200 nt in length. For examples of arrays,

see Hacia *et al.* (1996) Nature Genetics 14:441-447; Lockhart *et al.* (1996) Nature Biotechnol. 14:1675-1680; and De Risi *et al.* (1996) Nature Genetics 14:457-460.

Antibodies specific for ASTH1 polymorphisms may be used in screening immunoassays. A reduction or increase in neutral ASTH1 and/or presence of  
5 asthma associated polymorphisms is indicative that asthma is ASTH1-associated. A sample is taken from a patient suspected of having ASTH1-associated asthma. Samples, as used herein, include biological fluids such as tracheal lavage, blood, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid and the like; organ or tissue culture derived fluids; and fluids extracted from physiological tissues. Also included  
10 in the term are derivatives and fractions of such fluids. Biopsy samples are of particular interest, *e.g.* trachea scrapings, *etc.* The number of cells in a sample will generally be at least about  $10^3$ , usually at least  $10^4$  more usually at least about  $10^5$ . The cells may be dissociated, in the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared.

15       Diagnosis may be performed by a number of methods. The different methods all determine the absence or presence or altered amounts of normal or abnormal ASTH1 in patient cells suspected of having a predisposing polymorphism in ASTH1. For example, detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. The antibodies of  
20 interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the  
25 primary antibody may be conjugated to biotin, with horseradish peroxidase-conjugated avidin added as a second stage reagent. Final detection uses a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation  
30 counting, *etc.*

An alternative method for diagnosis depends on the *in vitro* detection of binding between antibodies and ASTH1 in a lysate. Measuring the concentration of

ASTH1 binding in a sample or fraction thereof may be accomplished by a variety of specific assays. A conventional sandwich type assay may be used. For example, a sandwich assay may first attach ASTH1-specific antibodies to an insoluble surface or support. The particular manner of binding is not crucial so long as it is

5 compatible with the reagents and overall methods of the invention. They may be bound to the plates covalently or non-covalently, preferably non-covalently.

The insoluble supports may be any compositions to which polypeptides can be bound, which is readily separated from soluble material, and which is otherwise compatible with the overall method. The surface of such supports may be solid or

10 porous and of any convenient shape. Examples of suitable insoluble supports to which the receptor is bound include beads, *e.g.* magnetic beads, membranes and microtiter plates. These are typically made of glass, plastic (*e.g.* polystyrene), polysaccharides, nylon or nitrocellulose. Microtiter plates are especially convenient because a large number of assays can be carried out simultaneously, using small

15 amounts of reagents and samples.

Patient sample lysates are then added to separately assayable supports (for example, separate wells of a microtiter plate) containing antibodies. Preferably, a series of standards, containing known concentrations of normal and/or abnormal ASTH1 is assayed in parallel with the samples or aliquots thereof to serve as

20 controls. Preferably, each sample and standard will be added to multiple wells so that mean values can be obtained for each. The incubation time should be sufficient for binding, generally, from about 0.1 to 3 hr is sufficient. After incubation, the insoluble support is generally washed of non-bound components. Generally, a dilute non-ionic detergent medium at an appropriate pH, generally 7-8, is used as a

25 wash medium. From one to six washes may be employed, with sufficient volume to thoroughly wash non-specifically bound proteins present in the sample.

After washing, a solution containing a second antibody is applied. The antibody will bind ASTH1 with sufficient specificity such that it can be distinguished from other components present. The second antibodies may be labeled to facilitate

30 direct, or indirect quantification of binding. Examples of labels that permit direct measurement of second receptor binding include radiolabels, such as  $^3\text{H}$  or  $^{125}\text{I}$ , fluorescers, dyes, beads, chemiluminescers, colloidal particles, and the like.

Examples of labels which permit indirect measurement of binding include enzymes where the substrate may provide for a colored or fluorescent product. In a preferred embodiment, the antibodies are labeled with a covalently bound enzyme capable of providing a detectable product signal after addition of suitable substrate. Examples  
5 of suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase and the like. Where not commercially available, such antibody-enzyme conjugates are readily produced by techniques known to those skilled in the art. The incubation time should be sufficient for the labeled ligand to bind available molecules. Generally, from about 0.1 to 3 hr is  
10 sufficient, usually 1 hr sufficing.

After the second binding step, the insoluble support is again washed free of non-specifically bound material. The signal produced by the bound conjugate is detected by conventional means. Where an enzyme conjugate is used, an appropriate enzyme substrate is provided so a detectable product is formed.

15 Other immunoassays are known in the art and may find use as diagnostics. Ouchterlony plates provide a simple determination of antibody binding. Western blots may be performed on protein gels or protein spots on filters, using a detection system specific for ASTH1 as desired, conveniently using a labeling method as described for the sandwich assay.

20 Other diagnostic assays of interest are based on the functional properties of ASTH1 proteins. Such assays are particularly useful where a large number of different sequence changes lead to a common phenotype, *i.e.* altered protein function leading to bronchial hyperreactivity. For example, a functional assay may be based on the transcriptional changes mediated by *ASTH1* gene products. Other  
25 assays may, for example, detect conformational changes, size changes resulting from insertions, deletions or truncations, or changes in the subcellular localization of ASTH1 proteins.

In a protein truncation test, PCR fragments amplified from the *ASTH1* gene or its transcript are used as templates for *in vivo* transcription/translation reactions  
30 to generate protein products. Separation by gel electrophoresis is performed to determine whether the polymorphic gene encodes a truncated protein, where truncations may be associated with a loss of function.

Diagnostic screening may also be performed for polymorphisms that are genetically linked to a predisposition for bronchial hyperreactivity, particularly through the use of microsatellite markers or single nucleotide polymorphisms. Frequently the microsatellite polymorphism itself is not phenotypically expressed, but is linked to sequences that result in a disease predisposition. However, in some cases the microsatellite sequence itself may affect gene expression. Microsatellite linkage analysis may be performed alone, or in combination with direct detection of polymorphisms, as described above. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994) Genomics 24:225-233; Ziegler *et al.* (1992) Genomics 14:1026-1031; Dib *et al.*, *supra*.

Microsatellite loci that are useful in the subject methods have the general formula:

$$U (R)_n U', \text{ where}$$

U and U' are non-repetitive flanking sequences that uniquely identify the particular locus, R is a repeat motif, and n is the number of repeats. The repeat motif is at least 2 nucleotides in length, up to 7, usually 2-4 nucleotides in length. Repeats can be simple or complex. The flanking sequences U and U' uniquely identify the microsatellite locus within the human genome. U and U' are at least about 18 nucleotides in length, and may extend several hundred bases up to about 1 kb on either side of the repeat. Within U and U', sequences are selected for amplification primers. The exact composition of the primer sequences are not critical to the invention, but they must hybridize to the flanking sequences U and U', respectively, under stringent conditions. Criteria for selection of amplification primers are as previously discussed. To maximize the resolution of size differences at the locus, it is preferable to choose a primer sequence that is close to the repeat sequence, such that the total amplification product is between 100-500 nucleotides in length.

The number of repeats at a specific locus, n, is polymorphic in a population, thereby generating individual differences in the length of DNA that lies between the amplification primers. The number will vary from at least 1 repeat to as many as about 100 repeats or more.

The primers are used to amplify the region of genomic DNA that contains the repeats. Conveniently, a detectable label will be included in the amplification reaction, as previously described. Multiplex amplification may be performed in which several sets of primers are combined in the same reaction tube. This is particularly advantageous when limited amounts of sample DNA are available for analysis. Conveniently, each of the sets of primers is labeled with a different fluorochrome.

After amplification, the products are size fractionated. Fractionation may be performed by gel electrophoresis, particularly denaturing acrylamide or agarose gels. A convenient system uses denaturing polyacrylamide gels in combination with an automated DNA sequencer, see Hunkapillar *et al.* (1991) Science 254:59-74. The automated sequencer is particularly useful with multiplex amplification or pooled products of separate PCR reactions. Capillary electrophoresis may also be used for fractionation. A review of capillary electrophoresis may be found in Landers, *et al.* (1993) BioTechniques 14:98-111. The size of the amplification product is proportional to the number of repeats (n) that are present at the locus specified by the primers. The size will be polymorphic in the population, and is therefore an allelic marker for that locus.

A number of markers in the region of the ASTH1 locus have been identified, and are listed in Table 1 in the Experimental section (SEQ ID NOs:160-273). Of particular interest for diagnostic purposes is the marker D11S2008, in which individuals having alleles C or F at this locus, particularly in combination with the CAAT box polymorphism and other polymorphisms, are predisposed to develop bronchial hyperreactivity or asthma. The association of D11S2008 alleles is as follows:

Allele	Association with asthma	Number of TATC repeats relative to allele C (SEQ ID NO:15)
A	no	-2
B	no	-1
C	yes	equivalent
D	no	+1
E	no	+2
F	yes	+3
G	no	+4
H	no	+5

A DNA sequence of interest for diagnosis comprises the D11S2008 primer sequences shown in Table 1 (SEQ ID NO:242 and 243), flanking one or three repeats of SEQ ID NO:15.

Other microsatellite markers of interest for diagnostic purposes are CA39\_2;  
 5 774F; 774J; 774O; L19PENTA1; 65P14TE1; AFM205YG5; D11S907; D11S4200;  
 774N; CA11-11; 774L; AFM283WH9; ASMI14 and D11S1900 (primer sequences  
 are provided in Table 1, the repeats are provided in Table 1B).

#### Regulation of ASTH1 Expression

The *ASTH1* genes are useful for analysis of ASTH1 expression, e.g. in  
 10 determining developmental and tissue specific patterns of expression, and for  
 modulating expression *in vitro* and *in vivo*. The regulatory region of SEQ ID NO:1  
 may also be used to investigate analysis of *ASTH1* expression. Vectors useful for  
 introduction of the gene include plasmids and viral vectors. Of particular interest  
 are retroviral-based vectors, e.g. Moloney murine leukemia virus and modified  
 15 human immunodeficiency virus; adenovirus vectors, etc. that are maintained  
 transiently or stably in mammalian cells. A wide variety of vectors can be employed  
 for transfection and/or integration of the gene into the genome of the cells.  
 Alternatively, micro-injection may be employed, fusion, or the like for introduction of  
 genes into a suitable host cell. See, for example, Dhawan *et al.* (1991) Science  
 20 254:1509-1512 and Smith *et al.* (1990) Molecular and Cellular Biology 3268-3271.

Administration of vectors to the lungs is of particular interest. Frequently  
 such methods utilize liposomal formulations, as described in Eastman *et al.* (1997)  
Hum Gene Ther 8:765-773; Oudrhiri *et al.* (1997) P.N.A.S. 94:1651-1656;  
 McDonald *et al.* (1997) Hum Gene Ther 8:411-422.

25 The expression vector will have a transcriptional initiation region oriented to  
 produce functional mRNA. The native transcriptional initiation region, e.g. SEQ ID  
 NO:14, or an exogenous transcriptional initiation region may be employed. The  
 promoter may be introduced by recombinant methods *in vitro*, or as the result of  
 homologous integration of the sequence into a chromosome. Many strong  
 30 promoters are known in the art, including the  $\beta$ -actin promoter, SV40 early and late  
 promoters, human cytomegalovirus promoter, retroviral LTRs, methallothionein  
 responsive element (MRE), tetracycline-inducible promoter constructs, etc.



Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences.

Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, *e.g.* plasmid; retrovirus, *e.g.* lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

Antisense molecules are used to down-regulate expression of *ASTH1* in cells. The anti-sense reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, *e.g.* by reducing the amount of mRNA available for translation, through activation of RNase H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996) Nature Biotechnology 14:840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of

a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense

5 complementation.

Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1993) *supra.* and Milligan *et al.*, *supra.*)

Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A  
10 number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral  
15 phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH<sub>2</sub>-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The  $\alpha$ -anomer of deoxyribose may be used, where the base is inverted with respect  
20 to the natural  $\beta$ -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-  
25 propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, e.g. ribozymes, anti-sense conjugates, *etc.* may be used to inhibit gene expression.  
30 Ribozymes may be synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the

targeted cell (for example, see International patent application WO 9523225, and Beigelman et al. (1995) Nucl. Acids Res 23:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, e.g. terpyridylCu(II), capable of mediating mRNA hydrolysis  
5 are described in Bashkin *et al.* (1995) Appl Biochem Biotechnol 54:43-56.

#### Therapeutic Use of ASTH1 Protein

A host may be treated with intact ASTH1 protein, or an active fragment thereof to modulate or reduce bronchial hypereactivity. Desirably, the peptides will not induce an immune response, particularly an antibody response. Xenogeneic  
10 analogs may be screened for their ability to provide a therapeutic effect without raising an immune response. The protein or peptides may also be administered to *in vitro* cell cultures.

Various methods for administration may be employed. The polypeptide formulation may be given orally, or may be injected intravascularly, subcutaneously, peritoneally, *etc.* Methods of administration by inhalation are well-known in the art.  
15 The dosage of the therapeutic formulation will vary widely, depending upon the nature of the disease, the frequency of administration, the manner of administration, the clearance of the agent from the host, and the like. The initial dose may be larger, followed by smaller maintenance doses. The dose may be administered as  
20 infrequently as weekly or biweekly, or fractionated into smaller doses and administered daily, semi-weekly, *etc.* to maintain an effective dosage level. In many cases, oral administration will require a higher dose than if administered intravenously. The amide bonds, as well as the amino and carboxy termini, may be modified for greater stability on oral administration.

25 The subject peptides may be prepared as formulations at a pharmacologically effective dose in pharmaceutically acceptable media, for example normal saline, PBS, *etc.* The additives may include bactericidal agents, stabilizers, buffers, or the like. In order to enhance the half-life of the subject peptide or subject peptide conjugates, the peptides may be encapsulated,  
30 introduced into the lumen of liposomes, prepared as a colloid, or another conventional technique may be employed that provides for an extended lifetime of the peptides.

The peptides may be administered as a combination therapy with other pharmacologically active agents. The additional drugs may be administered separately or in conjunction with the peptide compositions, and may be included in the same formulation.

5

#### Models for Asthma

The subject nucleic acids can be used to generate genetically modified non-human animals or site specific gene modifications in cell lines. The term "transgenic" is intended to encompass genetically modified animals having a deletion or other knock-out of *ASTH1* gene activity, having an exogenous *ASTH1* gene that is stably transmitted in the host cells, or having an exogenous *ASTH1* promoter operably linked to a reporter gene. Transgenic animals may be made through homologous recombination, where the *ASTH1* locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic mammals, e.g. cows, pigs, goats, horses, etc., and particularly rodents, e.g. rats, mice, etc.

A "knock-out" animal is genetically manipulated to substantially reduce, or eliminate endogenous *ASTH1* function. Different approaches may be used to achieve the "knock-out". A chromosomal deletion of all or part of the native *ASTH1* homolog may be induced. Deletions of the non-coding regions, particularly the promoter region, 3' regulatory sequences, enhancers, or deletions of gene that activate expression of *ASTH1* genes. A functional knock-out may also be achieved by the introduction of an anti-sense construct that blocks expression of the native *ASTH1* genes (for example, see Li and Cohen (1996) Cell 85:319-329).

Transgenic animals may be made having exogenous *ASTH1* genes. The exogenous gene is usually either from a different species than the animal host, or is otherwise altered in its coding or non-coding sequence. The introduced gene may be a wild-type gene, naturally occurring polymorphism, or a genetically manipulated sequence, for example those previously described with deletions, substitutions or insertions in the coding or non-coding regions. The introduced sequence may encode an *ASTH1* polypeptide, or may utilize the *ASTH1* promoter operably linked to a reporter gene. Where the introduced gene is a coding sequence, it usually

operably linked to a promoter, which may be constitutive or inducible, and other regulatory sequences required for expression in the host animal.

Specific constructs of interest, but are not limited to, include anti-sense *ASTH1*, which will block *ASTH1* expression, expression of dominant negative *ASTH1* mutations, and over-expression of a *ASTH1* gene. A detectable marker, such as *lac Z* may be introduced into the *ASTH1* locus, where upregulation of *ASTH1* expression will result in an easily detected change in phenotype. Constructs utilizing the *ASTH1* promoter region, e.g. SEQ ID NO:1; SEQ ID NO:14, in combination with a reporter gene or with the coding region of *ASTH1J* or *ASTH1I* are also of interest.

The modified cells or animals are useful in the study of *ASTH1* function and regulation. Animals may be used in functional studies, drug screening, etc., e.g. to determine the effect of a candidate drug on asthma. A series of small deletions and/or substitutions may be made in the *ASTH1* gene to determine the role of different exons in DNA binding, transcriptional regulation, etc. By providing expression of *ASTH1* protein in cells in which it is otherwise not normally produced, one can induce changes in cell behavior. These animals are also useful for exploring models of inheritance of asthma, e.g. dominant v. recessive; relative effects of different alleles and synergistic effects between *ASTH1I* and *ASTH1J* and other asthma genes elsewhere in the genome.

DNA constructs for homologous recombination will comprise at least a portion of the *ASTH1* gene with the desired genetic modification, and will include regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown *et al.* (1990) Methods in Enzymology 185:527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig, etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of appropriate growth factors, such as leukemia inhibiting factor (LIF).

When ES cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and  
5 analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are  
10 returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting litters screened for mutant cells having the construct. By providing for a different phenotype of the blastocyst and the ES cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene  
15 and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture.

Investigation of genetic function may utilize non-mammalian models,  
20 particularly using those organisms that are biologically and genetically well-characterized, such as *C. elegans*, *D. melanogaster* and *S. cerevisiae*. For example, transposon (Tc1) insertions in the nematode homolog of an *ASTH1* gene or promoter region may be made. The subject gene sequences may be used to knock-out or to complement defined genetic lesions in order to determine the  
25 physiological and biochemical pathways involved in *ASTH1* function. A number of human genes have been shown to complement mutations in lower eukaryotes.

Drug screening may be performed in combination with the subject animal models. Many mammalian genes have homologs in yeast and lower animals. The study of such homologs' physiological role and interactions with other proteins can  
30 facilitate understanding of biological function. In addition to model systems based on genetic complementation, yeast has been shown to be a powerful tool for studying protein-protein interactions through the two hybrid system described in

Chien *et al.* (1991) P.N.A.S. **88**:9578-9582. Two-hybrid system analysis is of particular interest for exploring transcriptional activation by *ASTH1* proteins.

#### Drug Screening Assays

By providing for the production of large amounts of *ASTH1* protein, one can  
5 identify ligands or substrates that bind to, modulate or mimic the action of *ASTH1*. Areas of investigation are the development of asthma treatments. Drug screening identifies agents that provide a replacement or enhancement for *ASTH1* function in affected cells. Conversely, agents that reverse or inhibit *ASTH1* function may stimulate bronchial reactivity. Of particular interest are screening assays for agents  
10 that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, protein-DNA binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. The purified protein may also be used for determination of three-dimensional crystal structure, which can be used for modeling intermolecular  
15 interactions, transcriptional regulation, *etc.*

The term "agent" as used herein describes any molecule, *e.g.* protein or pharmaceutical, with the capability of altering or mimicking the physiological function of *ASTH1*. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various  
20 concentrations. Typically, one of these concentrations serves as a negative control, *i.e.* at zero concentration or below the level of detection.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate  
25 agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more  
30 of the above functional groups. Candidate agents are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids,

steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are  
5 available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified  
10 through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, *etc.* to produce structural analogs.

Where the screening assay is a binding assay, one or more of the molecules  
15 may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, *e.g.* magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin *etc.* For the specific binding members, the  
20 complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents like salts, neutral proteins, *e.g.* albumin, detergents, *etc.* that are used to facilitate optimal protein-protein binding and/or reduce non-specific or  
25 background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, *etc.* may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be  
30 optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.



Other assays of interest detect agents that mimic ASTH1 function. For example, candidate agents are added to a cell that lacks functional ASTH1, and screened for the ability to reproduce ASTH1 in a functional assay.

The compounds having the desired pharmacological activity may be  
5 administered in a physiologically acceptable carrier to a host for treatment of asthma attributable to a defect in ASTH1 function. The compounds may also be used to enhance ASTH1 function. The therapeutic agents may be administered in a variety of ways, orally, topically, parenterally *e.g.* subcutaneously, intraperitoneally, by viral infection, intravascularly, *etc.* Inhaled treatments are of  
10 particular interest. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%.

The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the  
15 like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an  
20 adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

#### Pharmacogenetics

Pharmacogenetics is the linkage between an individual's genotype and that individual's ability to metabolize or react to a therapeutic agent. Differences in  
25 metabolism or target sensitivity can lead to severe toxicity or therapeutic failure by altering the relation between bioactive dose and blood concentration of the drug. In the past few years, numerous studies have established good relationships between polymorphisms in metabolic enzymes or drug targets, and both response and toxicity. These relationships can be used to individualize therapeutic dose  
30 administration.

Genotyping of polymorphic alleles is used to evaluate whether an individual will respond well to a particular therapeutic regimen. The polymorphic sequences

are also used in drug screening assays, to determine the dose and specificity of a candidate therapeutic agent. A candidate ASTH1 polymorphism is screened with a target therapy to determine whether there is an influence on the effectiveness in treating asthma. Drug screening assays are performed as described above.

- 5 Typically two or more different sequence polymorphisms are tested for response to a therapy.

Drugs currently used to treat asthma include beta 2-agonists, glucocorticoids, theophylline, cromones, and anticholinergic agents. For acute, severe asthma, the inhaled beta 2-agonists are the most effective bronchodilators.

- 10 Short-acting forms give rapid relief; long-acting agents provide sustained relief and help nocturnal asthma. First-line therapy for chronic asthma is inhaled glucocorticoids, the only currently available agents that reduce airway inflammation. Theophylline is a bronchodilator that is useful for severe and nocturnal asthma, but recent studies suggest that it may also have an immunomodulatory effect.

- 15 Cromones work best for patients who have mild asthma: they have few adverse effects, but their activity is brief, so they must be given frequently. Cysteinil leukotrienes are important mediators of asthma, and inhibition of their effects may represent a potential breakthrough in the therapy of allergic rhinitis and asthma.

- Where a particular sequence polymorphism correlates with differential drug effectiveness, diagnostic screening may be performed. Diagnostic methods have been described in detail in a preceding section. The presence of a particular polymorphism is detected, and used to develop an effective therapeutic strategy for the affected individual.

25

## EXPERIMENTAL

- The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g. amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are
- 30

parts by weight, molecular weight is average molecular weight; temperature is in degrees centigrade; and pressure is at or near atmospheric.

## MATERIALS AND METHODS

### 5 *Asthma families for genetic mapping studies*

Asthma phenotype measurements and blood samples were obtained from the inhabitants of Tristan da Cunha, an isolated island in the South Atlantic, and from asthma families in Toronto, Canada (see Zamel *et al.*, (1996) *supra.*) The 282 inhabitants of Tristan da Cunha form a single large extended family descended from  
10 28 original founders. Settlement of Tristan da Cunha occurred beginning in 1817 with soldiers who remained behind when a British garrison was withdrawn from the island, followed by the survivors of several shipwrecks. In 1827 five women from St. Helena, one with children, emigrated to Tristan da Cunha and married island men. One of these women is said to have been asthmatic, and could be the origin  
15 of a genetic founder effect for asthma in this population. Inbreeding has resulted in kinship resemblances of at least first cousin levels for all individuals.

The Tristan da Cunha family pedigrees were ascertained through review of baptismal, marriage and medical records, as well as reliably accurate historical records of the early inhabitants (Zamel (1995) Can. Respir. J. 2:18). The  
20 prevalence of asthma on Tristan da Cunha is high; 23% had a definitive diagnosis of asthma.

The Toronto cohort included 59 small families having at least one affected individual. These were ascertained based on the following criteria: (i) an affected proband; (ii) availability of at least one sibling of the proband, either affected or  
25 unaffected; (iii) at least one living parent from whom DNA could be obtained. A set of 156 "triad" families consisting of an affected proband and his or her parents were also collected. Signed consent forms were obtained from each individual prior to commencement of phenotyping and blood sample collection. The Toronto patients were mainly of mixed European ancestry.

30

*Clinical characterization*

A standardized questionnaire based on that of the American Thoracic Society (American Lung Association recommended respiratory diseases questionnaire for use with adults and children in epidemiology research. 1978.

- 5 American Review of Respiratory Disease 118(2):7-53) was used to record the presence of respiratory symptoms such as cough, sputum and wheezing; the presence of other chest disorders including recent upper respiratory tract infection, allergic history; asthmatic attacks including onset, offset, confirmation by a physician, prevalence, severity and precipitating factors; other illnesses and  
10 smoking history; and all medications used within the previous 3 months. A physician-confirmed asthmatic attack was the principal criterion for a diagnosis of asthma.

Skin atopy was determined by skin prick tests to common allergens:

- A. fumigatus*, *Cladosporium*, *Alternaria*, egg, milk, wheat, tree, dog, grass, horse,  
15 house dust, cat, feathers, house dust mite *D. farinae*, and house dust mite *D. pteronyssinus*. Atopy testing of Toronto subjects omitted *D. pteronyssinus* and added cockroach and ragweed allergens. Saline and histamine controls were also performed (Bencard Laboratories, Mississauga, Ontario). Antihistamines were withdrawn for at least 48 hours prior to testing. Wheal diameters were corrected by  
20 subtraction of the saline control wheal diameter, and a corrected wheal size of >3 mm recorded 10 min after application was considered a positive response.

Airway responsiveness was assessed by a methacholine challenge test in those subjects with a baseline FEV1 (forced exhalation volume in one second) > 70% of predicted (Crapo *et al.* (1981) Am. Rev. Respir. Dis. 123:659).

- 25 Methacholine challenge response was determined using the tidal breathing method (Cockcroft *et al.* (1977) Clin. Allergy 7:235). Doubling doses of methacholine from 0.03 to 16 mg/ml were administered using a Wright nebulizer at 4-min intervals to measure the provocative concentration of methacholine producing a 20% fall in FEV1 (PC20). If FEV1 was <70% of predicted, a bronchodilator response to 400  
30 mg salbutamol aerosol was used to determine airway responsiveness. Both methacholine challenges and bronchodilator responses were measured using a computerized bronchial challenge system (S&M Instrument Co. Inc., Doyleston, PA)

consisting of a software package and interface board installed in a Toshiba T1850C laptop computer and connected to a flow sensor (RS232FS). The power source for instruments used on Tristan da Cunha has been described (Zamel *et al.* (1996)

- 5 *supra.*) Increased airway responsiveness was defined as a PC20 < 4.0 mg/ml or a > 15% improvement in FEV1 15 min postbronchodilator. Participants were asked to withhold bronchodilators at least 8 h before testing; inhaled or systemic steroids were maintained at the usual dosage. Subjects with a history of an upper respiratory tract infection within a month of testing were rechallenged at a later date.

10 *Genotyping*

PCR primer pairs were synthesized using Applied Biosystems 394 automated oligo synthesizer. The forward primer of each pair was labeled with either FAM, HEX, or TET phosphoramidites (Applied Biosystems). No oligo purification step was performed.

- 15 Genomic DNA was extracted from whole blood. PCR was performed using PTC100 thermocyclers (MJ Research). Reactions contained 10 mM Tris-HCl, pH 8.3; 1.5-3.0 mM MgCl<sub>2</sub>; 50 mM KCl; 0.01% gelatin; 250 μM each dGTP, dATP, dTTP, dCTP; 20 μM each PCR primer; 20 ng genomic DNA; and 0.75 U Taq Polymerase (Perkin Elmer Cetus) in a final volume of 20 μl. Reactions were performed in 96 well polypropylene microtiter plates (Robbins Scientific) with an initial 94°C, 3 min. denaturation followed by 35 cycles of 30 sec. at 94°C, 30 sec. at the annealing temp., and 30 sec. at 72°C, with a final 2 min. extension at 72°C following the last cycle. Dye label, annealing temperature, and final magnesium concentration were specific to the individual marker.

- 25 Dye label intensity and quantity of PCR product (as assessed on agarose gels) were used to determine the amount to be pooled for each marker locus. The pooled products were precipitated and the product pellets mixed with 0.4 μl Genescan 500 Tamra size standard, 2 μl formamide, and 1 μl ABI loading dye. Plates of PCR product pools were heated to 80°C for 5 minutes and immediately placed on ice prior to gel loading.
- 30

PCR products were electrophoresed on denaturing 6% polyacrylamide gels at a constant 1000 volts using ABI 373a instruments. Peak detection, sizing, and stutter band filtering were achieved using Genescan 1.2 and Genotyper 1.1 software (Applied Biosystems). Genotype data were subsequently submitted to quality control and consistency checks (Hall *et al.* (1996) Genome Res. 6:781).

Genotyping of 'saturation' markers in the ASTH1 region was done by the method described above with several exceptions. In most cases, the unlabeled primer of each pair was modified with the sequence GTTCTT at the 5' end (Smith *et al.* 1995 Genome Res. 5:312). Amplitaq Gold (Perkin Elmer Cetus) and buffer D (2.5 mM MgCl<sub>2</sub>, 33.5 mM Tris-HCl pH 8.0, 8.3 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 25 mM KCl, 85 µg/ml BSA) were used in the PCR. A 'touchdown' amplification profile was employed in which the annealing temperature began at 66°C and decreased one degree per cycle to a final 20 cycles at 56°C. Products were run on 4.25% polyacrylamide gels using ABI 377 instruments. The data was processed with Genescan 2.1 and Genotyper 1.1 software.

#### *The Genome Scan*

A genome scan was performed in the population of Tristan da Cunha using 274 polymorphic microsatellite markers chosen from among those developed at Oxford (Reed *et al.* (1994) Nature Genetics 7:390), Genethon (Dib *et al.* (1996) Nature 380:152) and the Cooperative Human Linkage Center (CHLC, Murray *et al.* (1994) Science 265:2049). Markers with heterozygosity values of 0.75 or greater were selected to cover all the human chromosomes, as well as for ease of genotyping and size of PCR product for multiplexing of markers on gels. Fifteen multiplexed sets were used to provide a ladder of PCR products in each of three dyes when separated by size. Published distances were used initially to estimate map resolution. More accurate genetic distances were calculated using the study population as the data was generated. The 274 markers gave an average 14 cM interval for the genome scan.

30

*Linkage analysis*

Parametric linkage analyses of marker data were conducted using the methods of Haseman and Elston (1972) Behav. Genet. 2:3, and FASTLINK (Schaffer *et al.* (1996) Hum. Hered. 46:226), assuming a dominant mode of transmission with incomplete penetrance. Linkage to three primary phenotypes including asthma diagnosis (history), airway responsiveness (PC20 < 4 mg/ml for methacholine challenge) and atopy (one or more skin-prick test which yielded a wheal diameter > 3 mm) and combinations of these, were tested.

10 *Small scale yeast artificial chromosome (YAC) DNA preparation*

Small scale isolation of YAC DNA for STS mapping was done by a procedure which uses glass beads and physical shearing to damage the yeast cell wall (Scherer and Tsui (1991) Cloning and analysis of large DNA molecules, In Advanced Techniques in Chromosome Research. (K.W. Adolph, ed.) pp. 33-72.

15 Marcel Dekker, Inc. New York, Basel, Hong Kong.)

*YAC block prep and pulsed field gel electrophoresis (PFGE)*

A 50 ml culture of each YAC was grown in 2 x AHC at 30°C. The cells were pelleted by centrifugation and washed twice in sterile water. After resuspension of the cells in 4 ml of SCEM (1 M sorbitol, 0.1 M sodium citrate (pH 5.8), 10 mM EDTA, 30 mM  $\beta$ -mercaptoethanol), 5 ml of 1.2% low melting temperature agarose in SCEM was added, mixed, pipetted into 100 ml plug molds and allowed to solidify. Plugs were incubated overnight in 50 ml of SCEM containing 30 U/ml lyticase (Sigma). Plugs were rinsed 3 times in TE (10 mM Tris pH 8.0, 1 mM EDTA) and incubated twice for 12 hours each at 50°C in lysis solution (0.5 M EDTA, pH 8.0; 1% w/v sodium lauryl sarcosine; 0.5 mg/ml proteinase K). They were washed 5 times with TE and stored in 0.5 M EDTA (pH 8.0) at 4°C.

YACs and yeast chromosomes were separated on pulsed field gels using a CHEF Mapper (BIO-RAD) and according to methods supplied by the manufacturer, then transferred to nitrocellulose. YACs which comigrated with yeast chromosomes were visualized by hybridization of the blot with radiolabelled YAC vector sequences (Scherer and Tsui (1991) *supra*.)

*Hybridization of YAC DNA to bacterial artificial chromosome (BAC) and cosmid grids*

Size-purified YAC DNA was prepared by pulsed field gel electrophoresis on a low melting temperature Seaplaque GTG agarose (FMC) gel, purified by

5 GeneClean (BIO101) and radiolabeled for 30 mins with  $^{32}\text{P}$ -dCTP using the Prime-It II kit (Stratagene). 50  $\mu\text{l}$  of water was added and unincorporated nucleotide was removed by Quick Spin Column (Boehringer Mannheim). 23  $\mu\text{l}$  of 11.2 mg/ml human placental DNA (Sigma) and 36  $\mu\text{l}$  of 0.5 M  $\text{Na}_2\text{HPO}_4$ , pH 6.0 were added to the approximately 150  $\mu\text{l}$  of eluant. The probe was boiled for 5 mins and incubated

10 at 65°C for exactly 3 hours, then added to the prehybridized gridded BAC (Shizuya *et al.* (1992) Proc. Natl. Acad. Sci. **89**:8794; purchased from Research Genetics) or chromosome 11 cosmid [Resource Center/ Primary Database of the German Human Genome Project, Berlin; Lehrach *et al.* (1990), In Davies, K.E. and Tilghman, S.M. (eds.), Genome Analysis Volume 1: Genetic and Physical Mapping.

15 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 39-81] filters in dextran sulfate hybridization mix (10% dextran sulfate, 1% SDS, 1 M NaCl). Hybridizations were at 65°C for 12 - 48 hours, followed by 2 washes at room temperature in 2x SSC for 10 mins each, and 3 washes at 65°C in 0.2X SSC, 0.2% SDS for 20 mins each.

20

*Metaphase fluorescence in situ hybridization (FISH) and direct visual in situ hybridisation (DIRVISH)*

Metaphase FISH was carried out by standard methods (Heng and Tsui (1994) FISH detection on DAPI banded chromosomes. In Methods of Molecular

25 Biology: In Situ Hybridisation Protocols (K.H.A. Choo, ed.) pp. 35-49. Human Press, Clifton, N.J.). High resolution FISH, or DIRVISH, was used to map the relative positions of two or more clones on genomic DNA. The protocol used was as described by Parra and Windle (1993) Nature Genet. **5**:17. Briefly, slides containing stretched DNA were prepared by adding 2  $\mu\text{l}$  of a suspension of normal

30 human lymphoblast cells at one end of a glass slide and allowing to dry. 8  $\mu\text{l}$  lysis buffer (0.5% SDS, 50 mM EDTA, 200 mM Tris-HCL, pH 7.4) was added and the



slide incubated at room temperature for 5 minutes. The slide was tilted so that the DNA ran down the slide, then dried. The DNA was fixed by adding 400  $\mu$ l 3:1 methanol/acetic acid. Probes were labeled either with biotin or with digoxigenin by standard nick translation (Rigby *et al.* (1977) J. Mol. Biol. **113**:237). Hybridization and detections were carried out using standard fluorescence *in situ* hybridization techniques (Heng and Tsui (1994) *supra.*). Results were visualised using a Mikrophot SA microscope (Nikon) equipped with a CCD camera (Photometrics). Images were recorded using Smartcapture software (Vysis).

10 *Gap filling*

Clones flanking gaps in the map were end cloned by digestion with enzymes that do not cut the respective vector sequences (NsiI for BAC clones and XbaI for PAC clones), followed by religation and transformation into competent DH5 $\alpha$ . Clones which produced two end fragments and plasmid vector upon digestion with NotI and NsiI or XbaI were sequenced. Gaps in the tiling path were filled by screening a gridded BAC library with the end clone probes or by screening DNA pools of a human genomic PAC library (Ioannou *et al.* (1994) Nature Genetics **6**:84; licensed from Health Research, Inc.) by PCR using primers designed from end clone sequences.

20

*Direct cDNA selection*

Direct cDNA selection (Lovett *et al.*, (1991) Proc. Natl. Acad. Sci. **88**:9628) was carried out using cDNA derived from both adult whole lung tissue and fetal whole lung tissue (Clontech). 5  $\mu$ g of Poly(A)<sup>+</sup> RNA was converted to double stranded cDNA using the Superscript Choice System for cDNA synthesis and the supplied protocol (Gibco BRL). First strand priming was achieved by both oligo(dT) and random hexamers. The resulting cDNA was split into 2 equal aliquots and digested with either MboI or TaqI prior to the addition of specific linker primers. Linker primers for MboI-digested DNA were as described by Morgan *et al.* (1992) Nucleic Acid Res. **20**:5173. Linker primers for TaqI-digested DNA were a modification of these:

(SEQ ID NO:336 ) Taq1a: 5'-CGAGAATTCACCTCGAGCATCAGG;

(SEQ ID NO:337 ) Taq1b: 5'-CCTGATGCTCGAGTGAATTCT. The modified cDNA was ethanol precipitated and resuspended in 200  $\mu$ l of H<sub>2</sub>O. 1  $\mu$ l of cDNA was amplified with the linker primer Mbo1b in a 100  $\mu$ l PCR reaction. The resulting  
5 cDNA products, approximately 1  $\mu$ g, were blocked with 1  $\mu$ g of COT1 DNA (Gibco BRL) for 4 hours at 60°C in 120 mM NaPO<sub>4</sub> buffer, pH 7.0.

Approximately 1  $\mu$ g of the appropriate genomic clones was biotinylated using the BioNick Labeling System (Gibco BRL). Unincorporated biotin was removed by spin column chromatography. Approximately 100 ng of biotinylated genomic DNA  
10 was denatured and allowed to hybridize to 1  $\mu$ g of blocked cDNA in a total volume of 20  $\mu$ l in 120 mM NaPO<sub>4</sub> for 60 hours at 60°C under mineral oil. After hybridization, the biotinylated DNA was captured on streptavidin-coated magnetic beads (Dyna) in 100  $\mu$ l of binding buffer (1 M NaCl, 10 mM Tris, pH 7.4, 1 mM EDTA) for 20 minutes at room temperature with constant rotation. Two 15 minute  
15 washes at room temperature with 500  $\mu$ l of 1X SSC/0.1% SDS were followed by four washes for 20 minutes at 65°C with 500  $\mu$ l of 0.1X SSC/0.1% SDS with constant rotation. After each wash, the beads were collected on the side of the tube using magnet separation and the supernatant was removed with a pipette. Following the last wash, the beads were briefly rinsed once with wash solution prior  
20 to eluting the bound cDNA with 50  $\mu$ l of 0.1 M NaOH for 10 minutes at room temperature. The supernatant was removed and neutralized with 50  $\mu$ l 1 M Tris pH 7.4. The primary selected cDNA was desalted using a Sephadex G-50 column (Boehringer Mannheim). PCR was performed on 1, 2, 5, and 10  $\mu$ l of eluate with Mbo1b primers. Amplified products were analyzed on a 1.4% agarose gel. The  
25 reaction with the cleanest bands and least background was scaled up to produce approximately 1  $\mu$ g of primary selected cDNA. This amplified primary selected cDNA was blocked with 1  $\mu$ g of COT1 at 60°C for 1 hour followed by a second round of hybridization to 100 ng of the appropriate genomic DNA under the same conditions as the first round of selection. Washing of the bound cDNA, elution, and  
30 PCR of the selected cDNA was identical to the first round. 1  $\mu$ l of PCR amplified secondary selected cDNA was cloned using the TA cloning system according to the

manufacturers protocol (Invitrogen). Colonies were picked into 96-well microtiter plates and grown overnight prior to sequencing.

### *Exon Trapping*

5           Exon trapping was performed by the method of Buckler *et al.* (1991, Proc. Natl. Acad. Sci. USA **88**:4005) with modifications described in Church *et al.*, (1994) Nature Genetics **6**:98. Each BAC clone of the minimal set of clones required to the cover the ASTH1 region (*i.e.* the tiling path) was subject to exon trapping separately. Briefly, restriction fragments (PstI or BamHI/BglII) of each cosmid were  
10           shotgun subcloned into PstI- or BamHI-digested and phosphatase-treated pSPL3B which had been modified as in Burns *et al.* (1995) Gene **161**:183 (GIBCO BRL). Ligations were electroporated into ElectroMax HB101 cells (Gibco BRL) and plated on 20 cm diameter LB ampicillin plates. DNA was prepared from plates with > 2000 colonies by collection of the bacteria in LB ampicillin liquid and plasmid DNA  
15           purification by a standard alkaline lysis protocol (Sambrook *et al.* (1989) *supra.*) 5 µg of DNA from each plasmid pool preparation were electroporated into Cos 7 cells (ATCC) and RNA harvested using TRIZOL (Gibco BRL) after 48 hours of growth. RT-PCR products were digested with BstXI prior to a second PCR amplification. Products were cloned into pAMP10 (Gibco BRL) and transformed into DH5 cells  
20           (Gibco BRL). 96 colonies per BAC were picked and analyzed for insert size by PCR.

### *Northern blot hybridisation*

          Northern hybridisation was performed using Multiple Tissue Northern (MTN)  
25           blots (Clontech). DNA probes were radioactively labeled by random priming [Feinberg and Vogelstein (1984) Anal. Biochem. **137**:266] using the Prime-It II kit (Stratagene). Hybridizations were performed in ExpressHyb hybridisation solution (Clontech) according to the manufacturer's recommendations. Filters were exposed to autoradiographic film overnight or for 3 days.

30

*cDNA library screening*

Phage cDNA libraries were plated and screened with radiolabeled probes (exon trapping or cDNA selection products amplified by PCR from plasmids containing these sequences) by standard methods (Sambrook *et al.* (1989) *supra.*)

5

*Rapid amplification of cDNA ends (RACE)*

RACE libraries were constructed using polyA<sup>+</sup> RNA and the Marathon cDNA amplification kit (Clontech). Nested RACE primer sets were designed for each cDNA or potential gene fragment (trapped exon, predicted exon, conserved  
10 fragment, etc). The RACE libraries were tested by PCR using one primer pair for each potential gene fragment; the two strongly positive libraries were chosen for RACE experiments.

*Genomic sequencing*

15 DNA from cosmid, PAC, and BAC clones was prepared using Qiagen DNA prep kits and further purified by CsCl gradient. DNA was sonicated and DNA fragments were repaired using nuclease BAL-31 and T4 DNA polymerase. DNA fragments of 0.8-2.2 kb were size-fractionated by agarose gel electrophoresis and ligated into pUC9 vector. Inserts of the plasmid clones were amplified by PCR and  
20 sequenced using standard ABI dye-primer chemistry.

ABI sample file data was reanalyzed using Phred (Phil Green, University of Washington) for base calling and quality analysis. Sequence assembly of reanalyzed sequence data was accomplished using Phrap (Phil Green, University of Washington). Physical gaps between assembled contigs and unjoined but  
25 overlapping contigs were identified by inspection of the assembled data using GFP (licensed from Baylor College of Medicine) and Consed (Phil Green, University of Washington). Material for sequence data generation across gaps was obtained by PCR amplification. Low coverage regions were resequenced using dye-primer and dye-terminator chemistries (ABI). Final base-perfect editing (to > 99% accuracy)  
30 was accomplished using Consed.

*Single stranded conformational polymorphism (SSCP) analysis -*

- PCR primers flanking each exon of the ASTH1I and ASTH1J genes, or more than one primer pair for large exons, were designed from genomic sequence generated using Primer (publicly available from the Whitehead Institute for Biomedical Research) or Oligo 4.0 (licensed from National Biosciences).
- Radioactive SSCP was performed by the method of Orita *et al.* (1989, Proc. Natl. Acad. Sci. **86**:2766). Briefly, radioactively labeled PCR products between 150 and 300 bp and spanning exons of the ASTH1I and ASTH1J genes were generated from a set of asthma patient and control genomic template DNAs, by incorporating  $\alpha$ -<sup>32</sup>P dCTP in the PCR. PCR reactions (20  $\mu$ l) included 1x reaction buffer, 100  $\mu$ M dNTPs, 1  $\mu$ M each forward and reverse primer, and 1 unit Taq DNA polymerase (Perkin-Elmer) and 1  $\mu$ Ci  $\alpha$ -<sup>32</sup>P dCTP. A brief denaturation at 94°C was followed by 30-32 cycles of: 94°C for 30 sec, 30 sec at the annealing temperature, and 72°C for 30 sec; followed by 5 mins at 72°. Radiolabeled PCR products were diluted 1:20 in water, mixed with an equal volume of denaturing loading dye (95% formamide, 0.25% bromophenol blue), and denatured for 10 minutes at 80°C immediately prior to electrophoresis. 0.5x MDE (FMC) gels with and without 8% glycerol in 1x TBE were run at 8-12 Watts for 16-20 hours at room temperature. Dried gels were exposed to autoradiographic film (Kodak XAR) for 1-2 days at -80°C. PCR products from individuals carrying SSCP variants were subcloned into the PCR2.1 or pZeroBlunt plasmid vector (Invitrogen). Inserts of the plasmid clones were amplified by PCR and sequenced using standard ABI dye-primer chemistry to determine the nature of the sequence variant responsible for the conformational changes detected by SSCP.
- Fluorescent SSCP was carried out according to the recommended ABI protocol (ABI User Bulletin entitled 'Multi Color Fluorescent SSCP'). Unlabeled PCR primers were used to amplify genomic DNA segments containing different exons of the ASTH1I or ASTH1J genes, in patient or control DNA. Nested fluorescently labeled (TET, FAM or HEX) primers were then used to amplify smaller products, 150 to 300 bp containing the exon or region of interest. Amplification was done using a 'touchdown' PCR protocol, in which the annealing temperature

decreased from 57°C to 42°C, and Amplitaq Gold polymerase (Perkin Elmer, Cetus). In most cases the fluorescently labeled primers were identical in sequence to those used for conventional radioactive SSCP. The fluorescent PCR products were diluted and mixed with denaturing agents, GeneScan size standard

- 5 (Genescan 500 labelled with Tamra) and Blue dextran dye. Samples were heated at 90°C and quick chilled on ice prior to loading on 6.5% standard or 0.5 X MDE (manufacturer) polyacrylamide gels containing 2.5% glycerol and run using externally temperature controlled modified ABI 377 instruments. Gels were run at 1240V and 20°C for 7-9 hrs and analyzed using GeneScan software (ABI).

10

#### *Comparative (heterozygote detection) sequencing*

Unlabeled PCR primers were used to amplify genomic DNA segments containing different exons of the ASTH1I or ASTH1J genes, from patient or control DNAs. A set of nested PCR primers was then used to reamplify the fragment.

- 15 Unincorporated primers were removed from the PCR product by Centricon-100 column (Amicon), or by Centricon-30 column for products less than 130 bp. The nested primers and dye terminator sequencing chemistry (ABI PRISM dye terminator cycle sequencing ready reaction kit) were then used to cycle sequence the exon and flanking region. Volumes were scaled down to 5 µl and 10% DMSO
- 20 added to increase peak height uniformity. Sequences were compared between samples and heterozygous positions detected by visual inspection of chromatograms and using Sequence Navigator (licensed from ABI).

For some exons, PCR products were also compared by subcloning and sequencing, and comparison of sequences for ten or more clones.

25

## RESULTS

### *Genome scanning and linkage analysis*

- A genome scan was performed using polymorphic microsatellite markers from throughout the human genome, and DNA isolated from blood samples drawn
- 30 from the inhabitants of Tristan da Cunha. Linkage analysis, an established statistical method used to map the locations of genes and markers relative to other markers, was applied to verify the marker orders and relative distances between

markers on all human chromosomes, in the Tristan da Cunha population. Linkage analysis can detect cosegregation of a marker with disease, and was used as a means to detect genes influencing the development of asthma in this population. The most highly significant linkage in the genome scan ( $p = 0.0001$  for history of asthma and  $p = 0.0009$  for methacholine challenge) was obtained at D11S907, a marker on the short arm of chromosome 11. This significant linkage result indicated that a gene influencing predisposition to asthma in the Tristan da Cunha population was located near D11S907.

Replication of this finding was obtained in a collection of asthma families from Toronto, in which D11S907 and several nearby markers were tested for linkage. The significant linkage seen ( $p = 0.001$  for history of asthma and  $p = 0.05$  for methacholine challenge) supported the mapping of an asthma gene near D11S907 and indicated that the gene was likely to be relevant in the more diverse outbred Toronto group as well as in the inbred population of Tristan da Cunha.

The approximate genetic location of the ASTH1 gene in the Tristan da Cunha population was confirmed by genotyping and analyzing data from several markers near D11S907, spaced at intervals no greater than 5 cM across a possible linked region of about 30 cM. Sib-pair and affected pedigree member linkage analyses of these markers yielded confirmatory evidence for linkage and refined the genetic interval.

#### *Physical mapping at ASTH1: YAC contig construction*

Yeast artificial chromosome (YAC) clones were derived from the CEPH megaYAC library (Cohen *et al.* 1993 Nature **366**:698). Individual YAC addresses were obtained from a public physical map of CEPH megaYAC STS (sequence tagged site; Olson *et al.* (1989) Science **245**:1434) mapping data maintained by the Whitehead Institute and accessible through the world wide web (Cohen *et al.* 1993. *supra.*; [http://www-genome.wi.mit.edu/cgi-bin/contig/phys\\_map](http://www-genome.wi.mit.edu/cgi-bin/contig/phys_map)). YAC clones spanning or overlapping other YACs containing D11S907 were chosen for map construction; STSs mapping to these YACs were used for map and clone verification. Some YACs annotated in the public database as being chimeric were excluded from the analyses. Multiple colonies of each YAC, obtained from a freshly

- streaked plate inoculated from the CEPH megaYAC library masterplate, were scored using STS markers from the ASTH1 region. These markers included polymorphic microsatellite repeats, expressed sequence tags (ESTs) and STSs. Comparison of STS mapping data for each clone with the public map allowed
- 5 choice of the individual clone which retained the greatest number of ASTH1 region STSs, and was therefore least likely to be deleted. YAC addresses for which clones differed in STS content were interpreted to be prone to deletion; those for which a subset of clones contained no ASTH1 region STSs were presumed to be contaminated with yeast cells containing a YAC from another region of the genome.
- 10 Chimerism of the chosen clones was assessed by metaphase fluorescent *in situ* hybridization (FISH). Their sizes were determined by pulsed field gel electrophoresis (PFGE), Southern blotting and hybridization with a YAC vector probe. The PFGE analyses also showed that no YAC clone chosen contained more than one yeast artificial chromosome.
- 15 An STS map based on assuming the least number of deletions in the YAC clones was generated. The STS marker order was in agreement with that of the Whitehead map. The STS retention pattern of individual YACs, however, was slightly different from that of the public data. In general, the chosen clones were positive for a greater number ASTH1 region markers, showing that the data set was
- 20 likely to have fewer false negatives than the public map. Non-chimeric YAC clones spanning the region of greatest interest were chosen for use as hybridization probes for the identification of smaller BAC, PAC, P1 or cosmid clones from the region.

25 *Conversion to a plasmid-based clone map*

- The YAC map at *ASTH1* provided continuous coverage of a 4 Mb region, the central 1 Mb of which was of greatest interest. YAC clones comprising a minimal tiling path of this region were chosen, and the size purified artificial chromosomes were used as hybridization probes to identify BAC and cosmid clones. Gridded
- 30 filters of a 3x human genomic BAC library and of a human chromosome 11-specific cosmid library were hybridized with radiolabeled purified YAC. Clones corresponding to the grid coordinates of the positives were streaked to colony



purity, and filters gridded with four clones of each BAC or cosmid. These secondary filters were hybridized with size-purified YAC DNAs. A proportion of both the BACs and cosmids were found to be non-clonal by these analyses. A positively hybridizing clone of each was chosen for further analysis.

5           The BAC and cosmid clones were STS mapped to establish overlaps between the clones. The BACs were further localized by DIRVISH. BACs which did not contain an STS marker were mapped in pairwise fashion by simultaneous two-color DIRVISH with another BAC. The map produced had three gaps which were subsequently filled by end cloning and hybridization of the end clones to a  
10       human genomic PAC library. Genetic refinement of the *ASTH1* region had occurred concurrently with mapping, rendering it unnecessary to extend the BAC-contigged region. Mapping data was recorded in ACeDB (Eeckman and Durbin (1995) Methods Cell Biol. 48:583).

15       *Genomic sequencing and gene prediction*

A minimal tiling path of BAC and cosmid clones was chosen for genomic sequencing. Over 1 Mb of genomic sequence was generated at *ASTH1*. On average, sequencing was done to 12x coverage (12 times redundancy in sequences). Marker order was verified relative to the STS map.

20           BLAST searches (Altschul *et al.* (1990) *supra.*) were performed to identify sequences in public databases that were related to those in the *ASTH1* region. Sequence-based gene prediction was done with the GAIL [Roberts (1991) Science 254:805] and Geneparser [Snyder and Stormo (1993) Nucleic Acids Res. 21: 607] programs. Genomic sequence and feature data was stored in ACeBD.

25

*Development of new microsatellite markers for genetic refinement of the ASTH1 region*

Additional informative polymorphic markers were important for the genetic refinement of the *ASTH1* region. 'Saturation' cloning of every microsatellite in the  
30       1 Mb region surrounding D11S907 was performed. Plasmid libraries were constructed from PFGE purified DNA from each YAC, prescreened with a primer from each known microsatellite marker, then screened with radiolabeled (CA)<sub>15</sub> or

a pool of trinucleotide and tetranucleotide repeat oligonucleotides. The plasmid inserts were sequenced, the set of sequences compared with those of the known microsatellite markers in the region, using Power assembler (ABI) or Sequencher (Alsbyte). Primer pairs flanking each novel microsatellite repeat were designed, and the heterozygosity of each new marker was tested by Batched Analysis of Genotypes (BAGs; LeDuc *et al.*, 1995, PCR Methods and Applications 4:331). Additional microsatellites were found by analysis of the genomic sequence in AceDB. Table 1 lists all the microsatellite markers used for genotyping in the ASTH1 region and their repeat type, source and primers. Table 1B lists some repeat sequences.

TABLE 1  
Polymorphic microsatellite markers in the ASTH1 region

SEQ ID	MARKER	PRIMER 1
160.	110O5GT1	CTGCTGTGGACGAATAGG
161.		TCAATATAATCTTGCTTAACTTGG
162.	139C7GT1	GACCTGTTTGGGTTGATTTCAG
163.		GTTTCTTACAGTGTCTTGCTATCACATCACC
164.	171L24AT1	GAGGACTGGCAGTACCAAGTAAAC
165.		GTTTCTTTGGTTCATTCTAAGATGGCTGG
166.	253E6GT1	GCTGAGGCAGGAGAAAAGACAAG
167.		GTTTCTTCATGCAAAGGTCAGGAGGTAGG
168.	253E6TE1	GTTGCTTCCAGACGAGGTACATG
169.		GTTTCTTCAATGGCTCCACAAACATCTCTG
170.	253E6TR1	AGGTTTAGGGGACAGGGTTTGG
171.		GTTTCTTTCCTGGCTAACACGGTGAAATC
172.	65P14	GTTTCTTATTGCCTCCTCCCAAATTC
173.		AGAGGCCACTGGAAGACGAA
174.	65P14GT1	AACTGGAGTCAGGCAAACGTG
175.		GTTTCTTTGGCTGGTAAGGAAAGAAACCAC
176.	65P14TE1	GGCTAGGTTCATAACTCTGTGCTG
177.		GTTTCTTGATTGTTTGAGATCCTTGACCCAG
178.	65P14TE2	GCCGAAATCACAACACTGCATC
179.		GTTTCTTGATTCTGCTCTTACTCTTGCCCC

	180.	65P14TR1	GTAATAGAACCAAAGGGCTGAGAC
	181.		GTTTCTTCGGAGTCAGACCTTACATTGTTGAG
	182.	774F	ATCTCCCTGCTACCCACCTT
	183.		GTTTCTTGTTTTTCAGTGAGTTTCTGTTGGG
5	184.	774J	GTGTGCCAAACAACATTTGC
	185.		GTTTCTTCAAGCCATCAAGCTAGAGTGG
	186.	774L	GGGCTTTTAAACCCCTTATTTAACC
	187.		GTTTCTTAGGTGATCTCAGAGCCACTCA
	188.	774N	AGGGCAGGTGGGAACCTTACT
10	189.		GTTTCTTTGGAGTCAGTTGAGCTTCTACC
	190.	774O	TGAACTTGCCCTACCTCCCAG
	191.		GTTTCTTAGCATATATCCTTACACAAGCACA
	192.	774T	CATGGTTCCAAAGGCAAGTT
	193.		GTTTCTTTTGAGGCTGAATGAGCTGTG
15	194.	86J5AT2	ACAGGTGGGAAGACTGAATGTC
	195.		GTTTCTTGAGTACACATCACATGACCTTG
	196.	86J5CA1	GAAATAGGCGGAAACTGGTTC
	197.		GTTTCTTCGTTGTGGTTGTTCAGAAAGG
	198.	86J5GT1	GGTCAAGTGTTCAGAACGCATC
20	199.		GTTTCTTGAGGGATTATGCTAGGTCTGTAG
	200.	86J5GT2	AGCACTTCTGAGGAAGGGACAC
	201.		GTTTCTTAGGGCAGGCAGACATACAAAC
	202.	86J5TE1	GCCAATGTGTTCTAGAGCGAC
	203.		GTTTCTTTTAAAGGGGGTAGGGTGTCAAC
25	204.	8E.PENTA1	GGAAGGGAAAAGGACAAGGTTTTG
	205.		GTTTCTTAGCAAGAGCACTGGTGTAGGAGTC
	206.	8EP04D05	GCTTTTCAAGCACTTGTCTC
	207.		TGGGATTGTGACTTACCATG
	208.	8016GT1	ACTTGGTGTCTTATAGAAAGGTG
30	209.		GTTTCTTAGCTGTGTTTGCTGCATC
	210.	8016GT2	AGATGTGTGATGAGATGCAG
	211.		GTTTCTTCAAATAGTGCAACAAACCC
	212.	AFM198YB10 (G)	TGTCATTCTGAAAGTGCTTCC

	213.		GTTTCTTCTGTAACTAACGATCTGTAGTGGTG
	214.	AFM205YG5 (G)	TATCAAGGTAATATAGTAGCCACGG
	215.		AGGTCTTTCATGCAGAGTGG
	216.	AFM206XB2 (G)	ATTGCCAAAACCTTGAAGC
5	217.		AGGTGACATATCAAGACCCTG
	218.	AFM283WH9 (G)	TTGTCAACGAAGCCCAC
	219.		GTTTCTTGCAAGATTGTGTGTATGGATG
	220.	AFM324YH5 (G)	GCTCTCTATGTGTTGGGTG
	221.		AAGAGTACGCTAGTGGATGG
10	222.	AFMA154ZD1 (G)	TCCATTAGACCCAGAAAGG
	223.		GTTTCTTCACCAGGCTGAGATGTTACT
	224.	ASMI14	AATCGTTCCTTATCAGGTAATTTGG
	225.		GTTTCTTCAAAGAAAGCAATTCATCATAACA
	226.	ASMI14T	GCATTTGTTGAAGCAAGCGG
15	227.		CTTTGTTCCCTTGGCTGATGG
	228.	CA11_11	AATAGTACCAGACACACGTG
	229.		CAATGGTTCACAGCCCTTTT
	230.	CA39_2	AGCCTGGGAGACAGAGTGAG
	231.		GTTTCTTGCACTTTTTGGGGAAGGTG
20	232.	CD59 (L)	GTTCTCCCTTCCCTCTCC
	233.		GTTTCTTTCAGGGACTGGATTGTAG
	234.	D11S1301 (U)	GTGTTCTTTATGTGTAGTTC
	235.		GTTTCTTGGCAACAGAGTGAGACTCA
	236.	D11S1751 (G)	GTGACATCCAGTGTTGGGAG
25	237.		GTTTCTTCCTAAGCAAGCAAGCAATCA
	238.	D11S1776 (G)	AAAGGCAATTGGTGGACA
	239.		GTTTCTTTTCAATCCTTGATGCAAAGT
	240.	D11S1900 (U)	GGTGACAGAGCAAGATTTTCG
	241.		GTTTCTTGTAGAGTTGAGGGAGCAGC
30	242.	D11S2008/D11S1392 (C)	CATCCATCTCATCCCATCAT
	243.		GTTTCTTTTACCCTACTGCCAACTTC
	244.	D11S2014 (C)	CCGCCATTTTAGAGAGCATA

	245.		GTTTCTTTTCTGGGACAATTGGTAGGA
	246.	D11S4200 (G)	TTTGTGTTATTATTTTCAGGTGC
	247.		GTTTCTTGTTTTTTTGTTC A GTTTAGGAAC
	248.	D11S907 (G)	CATACCCAAATCGTTCTCTTCCTC
5	249.		GTTTCTTGGAAGCAAAG GCATCGTAGAG
	250.	D11S935 (G)	TACTAACCAGAGTTGGGG
	251.		CTATCATTCAGAAAATGTTGGC
	252.	GATA-P18492 (C)	GTATGGCAGTAGAGGGCATG
	253.		AAGGTTACATTTCAAGAAATAAAGT
10	254.	GATA-P6915 (C)	CTGTTCAAGCCTCAATATATACC
	255.		AAGAGGATAGGTGGGGTTTG
	256.	L19CA3	CCTCCCACCTAGACACAAT
	257.		ATATGATCTTGCATCCCTG
	258.	L19PENTA1	AAGAAAGACCTGGAAGGAAT
15	259.		AAACAGCAAAACCTCATCTC
	260.	L19TETRA5	CCACCACTTATTACCTGCAT
	261.		TGAATGAATGAATGAACGAA
	262.	LMP2	AACTGTGATTGTGCCACTGCACTC
	263.		GTTTCTTCACCGCCTTTATCCCTCAAATG
20	264.	LMP3	GATGGGTGGAGGGCAGTTAAAG
	265.		GTCAAGCAACTTGTCCAAGGCTAC
	266.	LMP4	CAGGCTATCAGTTTCCTTTGGAG
	267.		GGCAGGTAATACTGGAGAATTAGG
	268.	LMP7	GACGGATCTCAGAGCCACTC
25	269.		GTTTCTTAAAGATAAGGGCTTTTAAACC
	270.	T18_5	AGTTTCACAGCTTGTTATGG
	271.		GGTTGATGAAGTGAGACTTT
	272.	T29_9	ATGGTGGATGCATCCTGTG
	273.		GTTTCTTGTTATTGACTCCTCCTCTGC
30	274.	774L	CAGTAAACAT
	275.		TGTTGAGTGG
	276.	774N	TCTCCTCAATGTGCATGT

277. ATTCTACATA

278. ASMI14 GTGTTTGCAT

279. ACAAGTTGGC

280. CA11\_11 TAGTACCAGA

5 281. TACATCCAAGAAAA

The source of marker was Sequana Therapeutics, Inc. unless a letter in parenthesis is indicated after the name, where G = Genethon; L = Nothen and Dewald (1995) Clin. Genet. 47:165; U = the Utah genome center, see: The Utah Marker Development Group (1995) Am. J. Hum. Genet. 57:619; c= the cooperative Human Lineage Center.

Table 1B

SEQ	Marker	Repeat and flanking sequence
282.	CA39_2	GAGACTCTGA (CA) nAATATATATA
15 283.	774F	TGTTGATCGC (CA) nAACCAAATC
284.	774J	AATGCATGTA (TG) 2TATA (TG) nGTGTGGTATG (TG) 3TACATATG CG
285.	774O	CCTCCCAGAA (CA) n ATCATGATAA
286.	L19PENT A1	AGACAGTCTCAAAAAAT (ATTTT) nAAAGAAAAAGCTGGATAAAT
287.	65P14TE 1	AAC TAGCTTTAAGAAAAATAAGAAGAAAAAGAAAGAAG (AAAG) 2TAA G (AAAG) nAGAAAGAAAAG (AAAG) nAAAAG (AAAG) nAGGAATGAT TGAC
20 288.	65P14	CGCGCACATA (CA) nCCCTTTCTCT
289.	774L	CAGTAAACAT (CA) n TGTTGAGTGG
290.	774N	TCTCCTCAATGTGCATGT (GTGC) 2 ATGA (GTGC) 2 (AC) n ATTCTACATA
291.	ASMI14	GTGTTTGCAT (GT) n T (GT) 3 ACAAGTTGGC
292.	CA11_11	TAGTACCAGA (CA) 2 CG (TG) 2 (CA) 2 GGCAAGCG (CA) n C (CA) 3 TACATCCAAGAAAA

25

#### Genetic refinement of the *ASTH1* region

The microsatellite markers isolated from YACs from the *ASTH1* region were genotyped in both the Tristan da Cunha and Toronto cohorts. Genetic refinement of the *ASTH1* region was accomplished by applying the transmission/disequilibrium test (TDT; Spielman *et al.* (1993) Am. J. Hum. Genet. 52:506) to genetic data from the Tristan and Toronto populations, at markers throughout the *ASTH1* region. The TDT statistic reflects the level of association between a marker allele and disease

status. A multipoint version of the TDT test controls for variability in heterozygosities between loci, and results in a smoother regional TDT curve than would a plot of single locus TDT data. Significance of a TDT value is determined by means of the  $\chi^2$  test; A  $\chi^2$  value of 3.84 or greater is considered statistically

- 5 significant at a probability level of 0.05. Figure 1 shows graphs of  $\chi^2$  values for key ASTH1 region markers for both history of asthma with positive methacholine challenge, for the Toronto triad families.  $\chi^2$  is plotted vs. genomic location of the marker on the physical map.

The Toronto TDT peak is located at marker D11S2008 ( $\chi^2= 11.6$ ,  $p < .0001$ ).

- 10 The marker allele in disequilibrium is fairly rare (freq = 6%), representing the fourth most common allele at this marker. The relative risk of affection vs. normal for this allele is 5.25. This is also the peak marker for linkage and linkage disequilibrium in Tristan da Cunha, indicating that the ASTH1 gene is very close to this marker. The markers defining the limits of linkage disequilibrium were D11S907 and 65P14TE1.
- 15 The physical size of the refined region is approximately 100 kb.

A significant TDT test reflects the tendency of alleles of markers located near a disease locus (also said to be in "linkage disequilibrium" with the disease) to segregate with the disease locus, while alleles of markers located further from the disease locus segregate independently of affection status. An expectation that

- 20 derives from this is that a population for which a disease gene (*ie* a disease predisposing polymorphism) was recently introduced would show statistically significant TDT over a larger region surrounding the gene than would a population in which the mutant gene had been segregating for a greater length of time. In the latter case, time would have allowed more opportunity for markers in the vicinity of
- 25 the disease gene to recombine with it. This expectation is fulfilled in our populations. The Tristan da Cunha population, founded only 10 generations ago, shows a broader TDT curve than does the set of Toronto families, which are mixed European in derivation and thus represent an older and more diverse, less recently established population.

30

*Gene isolation and characterization*

The tiling path of BACs, cosmids and PAC clones was subjected to exon trapping and cDNA selection to isolate sequences derived from ASTH1 region genes. Exon trap clones were isolated on the basis of size and ability to cross-hybridize. Approximately 300 putatively non-identical clones were sequenced. cDNA selection was performed with adult and fetal lung RNA using pools of tiling path clones. The cDNA selection clones were sequenced and the sequences assembled with those of the exon trap clones. Representative exon trapping clones spanning each assembly were chosen, and arranged as "masterplates" (96-well microtitre dishes) of clones. Exon trap masterplate clones and cDNA selection clones were subjected to expression studies.

Human multi-tissue Northern blots were probed with PCR products of masterplate clones. In some cases, exon trapping clones did not detect RNA species, either because they did not represent expressed sequences, or represented genes with very restricted patterns of expression, or due to small size of the exon probe.

Masterplate clones detecting discrete RNA species on Northern blots were used to screen lambda phage based cDNA libraries chosen on the basis of the expression pattern of the clone. The sequences of the cDNAs were determined by end sequencing and sequence walking. cDNAs were also isolated, or extended, by 5' and 3' rapid amplification of cDNA ends (RACE). In most cases, 5' RACE was necessary to obtain the 5' end of the cDNA.

ASTH1I and ASTH1J were detected by exon trapping. ASTH1I exons detected a 2.8 kb mRNA expressed at high levels in trachea and prostate, and at lower levels in lung and kidney. ASTH1I exons were used as probes to screen prostate, lung and testis cDNA libraries; positive clones were obtained from each of these libraries. Isolation of a ASTH1I cDNA clone from testis demonstrates that this gene is expressed in this tissue, and possibly others, at a level not detectable by Northern blot analysis.

ASTH1J exons detected a 6.0 kb mRNA expressed at high levels in the trachea, prostate and pancreas and at lower levels in colon, small intestine, lung and stomach. Pancreas and prostate libraries were screened with exon clones



from ASTH1J. cDNA clone end sequences were assembled using Sequencher (Alsbyte) with the sequences of the exon trapped clones, producing sequence contigs used to design sequence walking and RACE primers. The additional sequences produced by these methods were assembled with the original  
5 sequences to produce longer contigs of cDNA sequences. It was evident from the sequence assemblies that both ASTH1I and ASTH1J are alternatively spliced and/or have alternative transcription start sites at their 5' ends, since not all clones of either gene contained the same 5' sequence.

ASTH1J has three splice forms consisting of the alt1 form, found in prostate  
10 and lung cDNA clones, and in which the exons (illustrated in Figure 1) are found in the order: 5' a, b, c, d, e, f, g, h, i 3'. A second form, alt2, in which the exon order is: 5' a2, b, c, d, e, f, g, h, i 3' was seen in a pancreas cDNA clone. A third form, alt3, contains an alternate exon, a3, between exons a2 and b. The start codon is within exon b, so that the open reading frame is identical for the three forms, which differ  
15 only in the 5' UTR. The ASTH1J cDNAs shown as SEQ ID NO:2 (form alt1); SEQ ID NO:3 (form alt2); SEQ ID NO:4 (form alt3) are 5427, 5510 and 5667 bp in length, respectively. The sequence of the entire protein coding region and alternate 5' UTRs are provided. The 3' terminus, where the polyA tail is added, varies by 7 bp between clones. The provided sequences are the longest of these variants. The  
20 encoded protein product is provided as SEQ ID NO:5.

ASTH1I was seen in three isoforms denoted as alt1, alt2, and alt3. The exons of ASTH1I and ASTH1J were given letter designations before the directionality of the cDNA was known, the order is different for the two genes. In the alt1 form of ASTH1I, exons are in the following order: 5' i, f, e, d, c, b, a 3'. In  
25 the alt2 form of ASTH1I, an alternative 5' exon, j, substitutes for exon i, with the following exon arrangement: 5' j, f, e, d, c, b, a 3'. The alt3 form of the gene has the exon order: 5' f, k, h, g, e, d, c, b, a 3'. The alternative splicing and start codons in each of exons i, f and e give the three forms of ASTH1I protein different amino termini. The common stop codon is located in exon a, which also contains a  
30 long 3' UTR. Two polyadenylation signals are present in the 3' UTR; some cDNA clones end with a polyA tract just after the first polyA signal and for others the polyA tract is at the end of the sequence shown. Since the sequences shown for the alt1,

alt2, and alt3 forms of ASTH1I (2428 bp; 2280 bp and 2498 bp; respectively) are close to the estimated Northern blot transcript size of 2.8 kb, these sequences are essentially full length.

## 5 EST matches

The nucleotide sequences of the alt1, alt2 and alt3 forms of ASTH1J and the alt1, alt2 and alt3 forms of ASTH1I were used in BLAST searches against dbEST in order to identify EST sequences representing these genes. Perfect or near perfect matches were taken to represent sequence identity rather than relatedness.

- 10 Accession numbers T65960, T64537, AA055924 and AA055327 represent the forward and reverse sequences of two clones which together span the last 546 bp (excluding the polyA tail) of the 3' UTR of ASTH1I. No ESTs spanned any part of the coding region of this gene. One colon cDNA clone (accession number AA149006) spanned 402 bp including the last 21 bp of the ASTH1J coding region
- 15 and part of the 3' UTR.

## Intron/exon structure determination

The genomic organization of genes in the ASTH1 region was determined by comparison by BLAST of cDNA sequences to the genomic sequence of the region.

- 20 The genomic sequence of the ASHT1 region 5' to and overlapping ASTH1J, is provided in SEQ ID NO:1. Genomic structure of the ASTH1I and ASTH1J genes is shown in Figure 1; the intron/exon junction sequences are in Table 2.

TABLE 2: Genomic organization of the ASTH1I and ASTH1J genes.

- 25 \*Exonic sequences are upper case, flanking sequences lower case.

SEQ NO	Exon	Size of exon (bp)	Sequences at the ends of and flanking the exons of ASTH1I and ASTH1J*
ASTH1I			
293.	i	>214	ggaggctgagCAGGGGTGCC...
294.			...ACTCCACAGgtacctgcag
30 295.	j	>66	...CTGCCCTCACgtaagcgcct

	296.	f	125	gctgttgcagGGTAATGTTG...
	297.			...CATCAGACAGgtgcgtaca
	298.	k	226	ggctggtgagGAGGGGCTGA...
	299.			...CGCTCTGTGGgtgagcttca
5	300.	h	93	tgtggaatagCCCAATTACA...
	301.			...AGGGTGCTGAgtagtagta
	302.	g	79	ttcttttccagGCCCTCGTGT...
	303.			...TGCTGACCCGgtatggtggt
	304.	e	232	tttgggtgcagCCTGTGACTC...
10	305.			...CGCACACAAGgtcagtgttc
	306.	d	51	tctttcccagGTTACTCCTT...
	307.			...ATCAAAGACTgtaagtaacc
	308.	c	69	tctatttcagATGCTGATTC...
	309.			...AGTAGAACAAgtaagtgcag
15	310.	b	196	ttttcaaaagGCCTCCAAAG...
	311.			...GAGCCCTGAGgtaagttaat
	312.	a	1522	gctttttcagATACTACTAT...
	313.			...TAACATGTTCaactgtctgt
	314.	a	146	tgttatatgcATTTATCTTC...
20	315.			...GGTAAATGAGgtaagtccctg
	316.	a2	229	tcttggttaagATCGCTCTCT...
	317.			...CCTTGCCCAGgttctcttaa
	318.	a3	157	gcaatcgcacCTGCACACCC...
	319.			...ACTGCCCATTtctggtaaag
25	320.	b	100	cccctaacagATCATGATTC...
	321.			...ACGTGCAATGgtaagagggc
	322.	c	246	tgtttttgcagTTTCCAGTGG...
	323.			...AAGTGAACGgtgactctct
	324.	d	63	tccttcacagGCCAGTGCAG...

```

325.          ...GAACAAACTGgtg agtagta
326.      e      69      ttttttgtagAGCCTTCCAT...
327.          ...AGCACAGTAGgtaactaact
328.      f      69      atggccacagATTTGTTGGA...
5  329.          ...CTTCCTGTTGgtaagctgtc
330.      g      63      ttctccttagCAGAGTCACC...
331.          ...AAAAAGCACAgtaagttggc
332.      h      196     ttttcatcagACCCGAGAGG...
333.          ...GAGCTATGAGgtgaggagtt
10 334.      i      4457  tttgttacagATATTACTAC...
335.          ...AGCCTGGAAAtgcgtgtttc

```

#### *The deduced ASTH1I and ASTH1J proteins*

The protein encoded by ASTH1J (SEQ ID NO:5) is 300 amino acids in  
length. A BLASTP search of the protein sequence against the public nonredundant  
sequence database (NCBI) revealed similarity to one protein domain of transcription  
factors of the *ets* family. The *ets* family, named for the E26 oncoprotein which  
originally defined this type of transcription factor, is a group of transcription factors  
which activate genes involved in a variety of immunological and other processes, or  
implicated in cancer. The family members most similar to ASTH1I and ASTH1J are:  
ETS1, ESX, ETS2, ELF, ELK1, TEL, NET, SAP-1, NERF and FLI. Secondary  
structure analysis and comparison of the protein sequence to the crystal structure of  
the human ETS1-DNA complex (Werner *et al.* (1995) Cell 83:761) confirmed that it  
has a winged helix turn helix motif characteristic of some DNA binding proteins  
which are transcription factors.

Multiple sequence alignment of ASTH1I, ASTH1J, and other ETS-domain  
proteins detected a second, N-terminal domain shared by ASTH1I, ASTH1J and  
some, but not all, ETS-domain proteins. Conservation of this motif have been  
observed (Tei *et al.* (1992) Proc. Natl. Acad. Sci. USA 89: 6856-6860), and its  
involvement in protein self-association have been documented for TEL, an ETS-  
domain protein, upon its fusion with platelet-derived growth factor  $\beta$  receptor (Carrol

*et al.* (1996) Proc. Natl. Acad. Sci. USA 93:14845-14850). Alignment of the N-terminal conserved domain in the ETS proteins was converted into a generalized sequence profile to scan the protein databases using the Smith-Waterman algorithm. This search revealed that the N-terminal domain in ASTH1I, ASTH1J and  
5 other ETS-domain proteins belongs to the SAM-domain family (Schultz *et al.* (1997) Protein Science 6:249-253). SAM domains are found in diverse developmental proteins where they are thought to mediate protein-protein interactions. Thus, both ASTH1I and ASTH1J are predicted to contain two conserved modules, the N-terminal protein interaction domain (SAM-domain) and the C-terminal DNA-binding  
10 domain (ETS-domain). The sequence segments between these two domains is predicted to have elongated, non-globular structure and may be hinges between the two functional domains in ASTH1I and ASTH1J.

The ASTH1I alt1 (SEQ ID NO:7), alt2 (SEQ ID NO:9) and alt3 (SEQ ID NO:11) forms are 265, 255 and 164 amino acids in length, respectively, and differ at  
15 their 5' ends. The ASTH1I and ASTH1J proteins show similarity to each other in the *ets* domain and between ASTH1J exon c and ASTH1I exon e. They are more related to each other than to other proteins. Over the *ets* domain they are 66% similar (*ie.* have amino acids with similar properties in the same positions) and 46% identical to each other. All three forms of ASTH1I have the helix turn helix motif  
20 located near the carboxy terminal end of the protein.

The alternate forms of the ASTH1I protein may differ in function in critical ways. The activity of *ets* transcription factors can be affected by the presence of independently folding protein structural motifs which interact with the *ets* protein binding domain (helix loop helix). The differing 5' ends of the ASTH1I proteins may  
25 help modulate activity of the proteins in a tissue-specific manner.

#### *Polymorphism analysis of ASTH1I and ASTH1J*

Affected and unaffected individuals from the Toronto cohort were used to determine sequence variants, as were approximately 25 controls derived from  
30 populations not selected for asthma. Affected and unaffected individuals from the Tristan da Cunha population were also chosen; the set to be assayed was also selected to represent all the major haplotypes for the ASTH1 region in that

population. This ensured that all chromosome types for Tristan were included in the analysis.

Polymorphism analysis was accomplished by three techniques: comparative (heterozygote detection) sequencing, radioactive SSCP and fluorescent SSCP.

- 5 Polymorphisms found by SSCP were sequenced to determine the exact sequence change involved.

PCR and sequencing primers were designed from genomic sequence flanking each exon of the coding region and 5' UTRs of ASTH1I and ASTH1J. For fluorescent SSCP, the forward and reverse PCR primers were labeled with different  
10 dyes to allow visualization of both strands of the PCR product. In general, a variant seen in one strand of the product was also apparent in the other strand. For comparative sequencing, heterozygotes were also detected in sequences from both DNA strands.

- Polymorphisms associated with the ASTH1I locus are listed in Table 3. The  
15 sequence flanking each variant is shown. Polymorphisms were also deduced from comparison of sequences from multiple independent cDNA clones spanning the same region of the transcripts, and comparison with genomic DNA sequence. The polymorphisms in the long 3' UTR regions of these genes were found by this method. One polymorphism in each gene is associated with an amino acid change  
20 in the protein sequence. An alanine/valine difference in exon c of ASTH1J is a conservative amino acid change. A serine/cysteine variant in exon g of ASTH1I is not a conservative change, but would be found only in the alt3 form of the protein.

The polymorphisms in the ASTH1I and J transcribed regions were genotyped in the whole Tristan da Cunha and Toronto populations, as well as in a larger  
25 sample of non-asthma selected controls, by high throughput methods such as OLA (oligonucleotide ligation assay; Tobe *et al.* (1996) Nucl. Acids Res. 24:3728) or Taqman (Holland *et al.* (1992) Clin. Chem. 38: 462), or by PCR and restriction enzyme digestion. The population-wide data were used in a statistical analysis for significant differences in the frequencies of ASTH1I or ASTH1J alleles between  
30 asthmatics and non-asthmatics.

TABLE 3: POLYMORPHISMS IN THE ASTH1I AND ASTH1J GENES.

	Polymorphism Location	Sequence
<b>SEQ</b>	<b>ASTH1I Transcribed region</b>	
	16. EXON B (+)170	ACAGAATGACRTATGAAAAGT
<b>5</b>	17. INTRON D (+)15	GTAACCAAGCKCAAGCCACCC
	18. INTRON F (+)24	AAGGAGCCCA <del>Y</del> CTGAGTGCAG
	19. EXON G (+)62 ser→cys	CGTTCATCT <del>S</del> TGCTCTGTGC
	20. EXON H (+)77	AGCGCCTCGGY <del>T</del> TGGCTGAGGG
	21. EXON A 3' UTR (+)1176	TGTATTCAAGY <del>G</del> CTATAACAC
<b>10</b>	22. EXON I (+)76	CACTGAGAAGCCC <del>/</del> -ACAGGCCTGT
	23. EXON I (+)86	CCCACAGGCC <del>W</del> GTCCCTCCAA
	24. INTRON J (+)93	CGTCCATCTCYAGCTCCAGGG
	<b>ASTH1J Transcribed region</b>	
	25. EXON A 5' UTR (+)38	GACTTGATAAYGCCCGTGGTG
<b>15</b>	26. EXON A 5' UTR (+)39	ACTTGATAAC <del>R</del> CCCGTGGTGC
	27. EXON A 5' UTR (+)99	CTCCCCTCCA <del>W</del> GAGCCACAGC
	28. INTRON A (+) 224/225	ATTTCCCTGCATT <del>/</del> -GTCTGGACTT
	29. INTRON A (+)48	ATCCAAACACY <del>T</del> GTAGTGGAAA
	30. EXON A3 (+)28	AGTTTCCTCARTGCGGGAGCT
<b>20</b>	31. EXON C (+)158	GCGAGCACCTY <del>T</del> GCAGCATGA
	32. EXON C (+)190 ala→val	TTCACCCGGGY <del>G</del> GCAGGGACG
	33. INTRON D (-)36/37	CTGGGGAAAA(GA) <del>/</del> TGATCGCTGAC
	34. INTRON F (-)22	GTCAATTAAAYGGCTCTCATT
	35. INTRON G (-)27	TAGATCATTC <del>R</del> TAACCTGCCT
<b>25</b>	36. EXON I (3' UTR) (+)22	AAAGAGAAAT <del>W</del> CTGGAGCGTG
	37. EXON I (3' UTR) (+)220	ATGAGGGGA <del>A</del> MAAGAACTAC
	38. EXON I (3' UTR) (+)475	TTTTGTATGT <del>K</del> ACATGATTTA
	39. EXON I (3' UTR) (+)871	AGCTTG <del>G</del> TTCTTTTGTCTCC
	40. EXON I (3' UTR) (+)1084	TTGACACCAG <del>R</del> AACCCCCCAG
<b>30</b>	<b>5' to ASTH1J</b>	
	41. CAAT box -165	AAATGAGCCARTGTTTGTAAAT

	42.	5PW1J_P01+399	ATCCATTTTGYATTTCCTCATT
	43.	5PW1J_P01+1604	CTGGAGCTCARACCAGACAGC
	44.	5PW1J_P02+1382	GCCAGTGCAGSCATCATTACC
	45.	5PW1J_P03+128	AGTTCAAATCRTAATTTTAT
5	46.	5PW1J_P03+556	TCATCAGAATYTAAATCTCCC
	47.	5PW1J_P03+712	GGAGATTCAGA/-TGAAGCAAGA
	48.	5PW1J_P03+781	TTTTTCCACAYCCAGCCTGGC
	49.	5PW1J_P03+791	CCCAGCCTGGYGAACCCTGGC
	50.	5PW1J_P03+820	CTCTTCATCAYGGTCAAATAC
10	51.	5PW1J_P03+1530	CAACTTGCTGYCAAAGTGCTG
	52.	5PW1J_P03+1605	TACTATGTGCTYAGATACTAAG
	53.	5PW1J_P04+542/543	ATGCCACTTTRRACAACCTGAG
	54.	5PW1J_P04+973	CGCATGCCTGKAAAGAAGAGA
	55.	5PW1J_P04+1079	GGATAAGCACMAGTGAGCCTG
15	56.	5PW1J_P04+1153	AAAGCCAGACRGCAACTTGTG
	57.	5PW1J_P04+1430	TCTCAAAAAGRGTGATAGGAG
	58.	5PW1J_P05+334	TCTGAATCCTSTCTCCTCCTT
	59.	5PW1J_P05+749	TAGAACCAGGWTGTGGGACCA
	60.	5PW1J_P05+915	TTCTTGCTGTCRGGCGCAAAC
20	61.	5PW1J_P06+529	AACCAACATGRAGAAACCCCA
	62.	5PW1J_P06+1290	AATAAACTATRGTTTCACCTAG
	63.	5PW1J_P06+1573	ACATATTTGTRTCTCATATGA
	64.	5PW1J_P06+1661	CAAAGCAGTTYCTAATAATCC
	65.	5PW1J_P07+335	AGATCCTAACYGCGGCTCCT
25	66.	5PW1J_P07+731	CTCTTTCTCTYTGCTTCCTCC
	67.	5PW1J_P07+1024	TTAGGAATCCWCAAATATGTA
	68.	5PW1J_P07+1610	GTCTGACTCCRCTCCTCAT
	69.	5PW1J_P08+398	GAATCACATCRTGAGAAATGT
	70.	5PW1J_P08+439	AATCAATCCYTACAGACTT
30	71.	5PW1J_P08+580	GTGTAGCCAGRGTTGCTAATT
	72.	5PW1J_P08+762	CCTAGAAATASCCAAGGGCAC
	73.	5PW1J_P08+952	AAATTCTCATRCCTCACCTC
	74.	5PW1J_P08+1172	TCCCACCCCTRTCACCTTCAT
	75.	5PW1J_P08+1393	CCTCATTTCTCRGAAGCCAACA
35	76.	5PW1J_P08+1433	GAAGAGCCGTYCAGTCCCTTT
	77.	5PW1J_P08+1670	TCCATAGGCTYTTTATTTGGC
	78.	5PW1J_P08+1730	TCGTTTAGTAYACAGGCTTTG
	79.	5PW1J_P09+59	GCCTCAGTTGYCCCAGCTATA
	80.	5PW1J_P09+145	AGCAAAATGCWCTATGCACTG
40	81.	5PW1J_P09+892	GTGTCCTGAC (TTGCACTCCAC) /- ACACTGCCTG
	82.	5PW1J_P10+1070	ATCAGATAACRCCTACACTTA
	83.	5PW1J_P10+1511	TCTCTCTTCTSCCTGCCCTGT
	84.	5PW1J_P09+1132	TGGACACAGGKAGGGGAATAT



	85.	5PW1J_P09+1688	TGTCACCTTGCR <u>C</u> ATACAAGGC
	86.	5PW1J_P09+1900	ATCATCAGATYAGCCCAGAAT
	87.	5PW1J W1R1-1060	TCAACAGAGARAGTTAATGGT
	88.	5PW1J W1R1-1831	AGCAATAATGYTTCCTTTTC
5	89.	5PW1J W1R1-2355	TCTAGCTTTTYTGTGTTTTT
	90.	5PW1J W1R1-3160	GATTCCTTAAYGCTTGATACT
	91.	5PW1J W1R1-3787	CCTCCTCCAGYACCAAAGTGG
	92.	W1J_CD+24	ATGGCCACAGRTCAAATCCTG
	93.	W1J_CA+564	ACTGAGTGTTYATGCCAATTT
10		5' to ASTH1I	
	94.	WI_CL+94	GACAAGCCCTRTCTGACACAC
	95.	WI_CN+134	TGAAAAGCCTYCTTGCTGCCT
	96.	WI_CQ-28	TCCTGGAGTTYCTTGCTCCC
	97.	WI_CQ+39	GATTCCAAATWAACTAAAGAT
15	98.	P14-16+191662	GACCTCAAGTCRTCCACCCGCC
	99.	P14-16+192592	AACAAATACTMCCCCGCAACCC
	100.	P14-16+192762	ATTTTTTTTTT/-AAGGAAAATA
	101.	P14-16+195066	AAATTTCCCCMAAACAAGCAG
	102.	P14-16+196590	GAGAAAGGGTRTGTGTGTGTG
20	103.	P14-16+196617	GTGTGTGTGTGT-/GTGTATGTGCGCGTG
	104.	P14-16+196902	ATCGGGAACCYCATACCCCAA
	105.	P14-16+198040	TTTGTTCGCMATGAGGTACG
	106.	P14-16+198240	TGAGGGTGTTSTGGGCTGGAC
	107.	P14-16+198840	TCTTCATTGGYATCTGAATGT
25	108.	P14-16+200120	GCGAGCACCTYTGCAGCATGA
	109.	P14-16+200617	AACCCCCCCCMCACACACACA
	110.	J5-16+4454	TCAGTGCTCTSTAATCAGTCA
	111.	J5-16+4825	TCTTTGTGAAA-(GA)AATTAGTCTG*
	112.	J5-16+5426	GCTGCCCTGASAGCTGGGCCA
30	113.	J5-16+5623	CCTTCTGATCYTTGTTTGCTG
	114.	J5-16+7386	GGAACACTGAKTCTTGATTAG
	115.	J5-16+7904	TAGGCTTCTCYTGATAATTGA
	116.	J5-16+8055	TCTTAAAATAMTTGGCTTGTA
	117.	J5-16+10595	TAGATCATTAARTAACCTGCCT
35	118.	J5-16+11140	ATGAGGGGAAMAAGAACTAC
	119.	J5-16+12004	TTGACACCAGRAACCCCCCAG
	120.	J5-16+12219	TGTTTTAAATRRTTAGGGACAA
	121.	J5-16+12303	GTAAGCATAGYAATGTAGCAG
	122.	J5-16+13504	GGCTCTTTCTKCAACCTTTCC
40	123.	J5-16+14120	GACCCAGGTTRTGAGTTTTCC
	124.	ASTH1I, exon B +169	GACAGAATGAYATATGAAAAAG
	125.	ASTH1I, exon I +69	TGTGTGACACYGAGAAGCCCA

	126.	ASTH1J, exon C +56	AGTACTGGAC <u>MA</u> AGTACCAGG
	127.	5' ASTH1J, WI_Cg -9	CCTGGGAGC <u>AR</u> GTATTGCATT
		ASTH1J Intron A	
	128.	WIJ_Ia01 +39	AGATTTGAGG <u>Y</u> CTCAGGTCCC
5	129.	WIJ_Ia01 +140	TGTCAATGTC <u>R</u> CATGATAAGC
	130.	WIJ_Ia01 +678	TTGCCCCAGT <u>K</u> TTCTCCGGGC
	131.	WIJ_Ia01 +855	TATGAGCAGC <u>R</u> TAGGGAGTGG
	132.	WIJ_Ia01 +929	AGTTGACTGA ( <u>AAAA</u> ) /-TAAATAAGAC
	133.	WIJ_Ia 03 +362	ATTCAAATAG <u>S</u> CTCTAGAAAC
10	134.	WIJ_Ia 03 +918	CCCAGAATTT <u>M</u> ATATCCATTC
	135.	WIJ_Ia 03 +943	TGACCCAACARAAACTCACTG
	136.	WIJ_Ia 03 +1569	CCAGAATATA <u>W</u> CATCAGCCCT
	137.	WIJ_Ia 03 +1580	CATCAGCCCT <u>W</u> CTGAGGAGAT
	138.	WIJ_Ia 02 +435	CCAGAACAG <u>A</u> YTTTATTCTGT
15	139.	WIJ_Ia 02 +583	TTCAGCCATC <u>Y</u> TTCCAGTTGT
	140.	WIJ_Ia 02 +643	TCACTAACTC <u>W</u> AAAACGACAT
	141.	WIJ_Ia 02 +648	AACTCAAAA <u>Y</u> GACATCCTCC
	142.	WIJ_Ia 02 +1048	GAACTGCAC <u>A</u> RGTGCACACT
	143.	WIJ_Ia 02 +1061	TTGTTCCATG <u>S</u> ACTACCTCCT
20	144.	WIJ_Ia 02 +1142	ACAGCAGGC <u>A</u> YTCACAAATT
	145.	WIJ_Ia 04 +410	TTATTTTTGG <u>S</u> TTTGTTTTAA
	146.	WIJ_Ia 04 +1056	TAGGCTGTT <u>C</u> YCTGCCATCAC
	147.	WIJ_Ia 05 +1484	GTGCTCTGGG <u>M</u> CACACAGCTC
	148.	WIJ_Ia 05 +1103	AGACCCGATAR <u>G</u> AGCTCCTTC
25	149.	WIJ_Ia 05 +1823	CATCTTGCGC <u>R</u> GTCATGTAAG
	150.	WIJ_Ia 05 +1852	CAGCACAGCT <u>R</u> TTCCCTCAAA
	151.	WIJ_Ia 05 +1906	TTTGGAAC <u>A</u> YGGTGAAGTAT
	152.	WIJ_Ia 05 +1913	ACACGGTGAAR <u>T</u> ATTGTCTCC
	153.	WIJ_Ia 06 +794	AAAAGTGGAT <u>M</u> CTCTGCAAAC
30	154.	WIJ_Ia 06 +814	CTTCAAATGCR <u>G</u> CTATTAAAG
	155.	WIJ_Ia 06 +1197	CCTGGGAGC <u>A</u> YGGTAAATCAG
	156.	WIJ_Ia 06 +1231	TGAAAATGTC <u>R</u> CTTCTCACCT
	157.	WIJ_Ia 06 +1256	CCTGATATTT <u>R</u> CCAACAAGAA
	158.	WIJ_Ia 06 +1535	AAAGGGTTAG <u>Y</u> TTGTCCCCTT
35	159.	WI_Caa +163	TGAAAATAAA <u>S</u> ACAATTTTTT

The sequences are listed with the variant residues represented by the appropriate single letter designation, i.e. A or G is shown by "R". The variant residues are underlined. Where the polymorphism is a deletion, the underlined residues are underlined, and the alternative form shown as a "-".

40 <sup>a</sup>Where intron 'a' is the intron 3' to exon 'a', etc.

<sup>b</sup>Position numbers correspond to the position within the intron or exon, with nucleotide +1 being the 5'-most base of the exon or the intron. Alternatively, negative numbers denote the number of bases from the 3' end of an intron.

<sup>c</sup>Position in cDNA = position # for the exon a form of ASTH1J or the exon i form of ASTH1I.

<sup>a</sup>Exonic sequences are uppercase, intronic sequences lower case.  
UTR = untranslated region. N/A = not applicable.

### *Cross-species sequence conservation*

5           Cross-species sequence conservation can reveal the presence of  
functionally important areas of sequence within a larger region. Approximately 90  
kb of sequence lie between ASTH1I and ASTH1J, which are transcribed in opposite  
directions (Figure 1). The transcriptional orientation of these genes may allow  
coordinate regulation of their expression. The expression patterns of these genes  
10   are similar but not identical. Sequences found 5' to genes are critical for  
expression. To search for regulatory or other important regions, the genomic  
sequence between ASTH1I and ASTH1J, was examined and plasmid clones  
derived from genomic sequencing experiments chosen for cross-species  
hybridization experiments. The criterion for probe choice was a lack of repeat  
15   elements such as Alu or LINEs. Inserts from these clones were used as probes on  
Southern blots of EcoRI-digested human, mouse and pig or cow genomic DNA.  
Probes that produced discrete bands in more than one species were considered  
conserved.

Conserved probes clustered in four locations. One region was located 5' to  
20   ASTH1I and spanned exon j of this gene. A second conserved region was located  
5' to ASTH1J, spanning approximately 10 kb and beginning 6 kb 5' to ASTH1J  
exon a (and is within SEQ ID NO:1). Two other clusters of conserved probes were  
noted in the region between ASTH1I and J. They are approximately 10 and 6 kb in  
length.

25           Promoters, enhancers and other important control regions are generally  
found near the 5' ends of genes or within introns. Methods of identifying and  
characterizing such regions include: luciferase assays, chloramphenicol acetyl  
transferase (CAT) assays, gel shift assays, DNaseI protection assays (footprinting),  
methylation interference assays, DNaseI hypersensitivity assays to detect  
30   functionally relevant chromatin-ree regions, other types of chemical protection  
assays, transgenic mice with putative promoter regions linked to a reporter gene  
such as  $\beta$ -galactosidase, etc. Such studies define the promoters and other critical

control regions of ASTH1I and ASTH1J and establish the functional significance of the evolutionarily conserved sequences between these genes.

### Discussion

5           The ASTH1 locus is associated with asthma and bronchial hyperreactivity. ASTH1I and ASTH1J are transcription factors expressed in trachea, lung and several other tissues. The main site of their effect upon asthma may therefore be in trachea and lung tissues. Since *ets* family genes are transcription factors, a function for ASTH1I and ASTH1J is activation of transcription of particular sets of  
10       genes within cells of the trachea and lung. Cytokines are extracellular signalling proteins important in inflammation, a common feature of asthma. Several *ets* family transcription factors activate expression of cytokines or cytokine receptors in response to their own activation by upstream signals. ELF, for example, activates IL-2, IL-3, IL-2 receptor  $\alpha$  and GM-CSF, factors involved in signaling between cell  
15       types important in asthma. NET activates transcription of the IL-1 receptor antagonist gene. ETS1 activates the T cell receptor  $\alpha$  gene, which has been linked to atopic asthma in some families (Moffatt *et al.* (1994) *supra.*)

          Activation of genes involved in inflammation by other members of the *ets* family suggest that the effect of these ASTH1 genes on development of asthma is  
20       exerted through influencing cytokine or receptor expression in trachea and/or lung. Cytokines are produced by structural cells within the airway, including epithelial cells, endothelial cells and fibroblasts, bringing about recruitment of inflammatory cells into the airway.

          A model for the role of ASTH1I and ASTH1J in asthma that is consistent with  
25       the phenotype linked to ASTH1, the expression pattern of these genes, the nature of the ASTH1I/J genes, and the known function of similar genes is that aberrant function of ASTH1I and/or ASTH1J in trachea or lung leads to altered expression of factors involved in the inflammatory process, leading to chronic inflammation and asthma.

Functional analysis of a ASTH1J promoter sequence variant and location of the ASTH1J promoter

Primer extension analyses performed using total RNA isolated from both bronchial and prostate epithelial cells have revealed one major and five minor transcription start sites for ASTH1J. The major site accounts for more than 90% of ASTH1J gene transcriptional initiation. None of these sites are found when the primer extension analysis is performed using mRNA isolated from human lung fibroblasts that do not express ASTH1J.

Identification of the ASTH1J transcriptional start site has allowed the localization of a putative TATA box (TTTAAAA) between positions -24 and -30 (24 to 30 bp 5' to the transcription start site). Although the sequence is not that of a typical TATA box, it conforms to the consensus sequence (TATAAAA) for TATA box protein binding as compared with 389 TATA elements (Transfac database: <http://transfac.gbf-braunschweig.de/>, ID: V\$TATA\_01).

Analysis of the CAAT box "G" polymorphism by gel shift assay

Binding of nuclear proteins to a polymorphism in the GCCAAT motif (GCCAAT or GCCAGT) found at position -140 (140 bp 5' to the transcription start of ASTH1J as defined by primer extension experiments, previously referred to as "-165 bp"), has been assessed using electrophoretic mobility shift assays. These experiments clearly showed a remarkable difference when binding of nuclear proteins to radioactively-labelled double stranded oligonucleotides containing the normal "A" vs the mutant "G" nucleotide was examined. A specific set of nuclear proteins was able to bind to the normal oligonucleotide, but did not bind to the "G" oligonucleotide. The specificity of the DNA binding complexes was further addressed by competition with either normal or mutant unlabeled oligonucleotides. Addition of increasing amounts of normal unlabeled oligonucleotide effectively competed binding of nuclear proteins to the labeled normal oligonucleotide, while the addition of increasing amounts of unlabelled "G" oligonucleotide did not.

The GCCAAT cis-element is found in many promoters at various locations relative to genes, as well as in distal enhancer elements. There is no known correlation between location of these elements and activity. Both positive and

negative regulatory trans-acting factors are known to bind this class of cis element. These factors can be grouped into the NF-1 and C/EBP families.

The nuclear factor-1 (NF-1) family of transcription factors comprises a large group of eukaryotic DNA binding proteins. Diversity within this gene family is contributed by multiple genes (including: NF-1A, NF-1B, NF-1C and NF-1X), differential splicing and heterodimerization.

Transcription factor C/EBP (CCAAT-enhancer binding protein) is a heat stable, sequence-specific DNA binding protein first purified from rat liver nuclei. C/EBP binds DNA through a bipartite structural motif and appears to function exclusively in terminally differentiated, growth arrested cells. C/EBP $\alpha$  was originally described as NF-IL-6; it is induced by IL-6 in liver, where it is the major C/EBP binding component. Three more recently described members of this gene family, designated CRP 1, C/EBP  $\beta$  and C/EBP  $\delta$ , exhibit similar DNA binding specificities and affinities to C/EBP  $\alpha$ . Furthermore, C/EBP  $\beta$  and C/EBP  $\delta$  readily form heterodimers with each other as well as with C/EBP  $\alpha$ .

Members of the C/EBP family of transcription factors, but not members of the NF-1 family, bind to the ASTH1J promoter region, as determined by the use of commercially available antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA) that recognize all NF-1 and C/EBP family members known to date, in electrophoretic mobility shift assays.

#### Fabricating a DNA array of polymorphic sequences

*DNA array:* is made by spotting DNA fragments onto glass microscope slides which are pretreated with poly-L-lysine. Spotting onto the array is accomplished by a robotic arrayer. The DNA is cross-linked to the glass by ultraviolet irradiation, and the free poly-L-lysine groups are blocked by treatment with 0.05% succinic anhydride, 50% 1-methyl-2-pyrrolidinone and 50% borate buffer.

The spots on the array are oligonucleotides synthesized on an ABI automated synthesizer. Each spot is one of the alternative polymorphic sequences indicated in Tables 3 to 8. For each pair of polymorphisms, both forms are included. Subsets include (1) the *ASTH1J* polymorphisms of Table 3, (2) the

*ASTH11* polymorphisms of Table 3; and (3) the polymorphisms of Table 4. Some internal standards and negative control spots including non-polymorphic coding region sequences and bacterial controls are included.

Genomic DNA from patient samples is isolated, amplified and subsequently  
5 labeled with fluorescent nucleotides as follows: isolated DNA is added to a standard PCR reaction containing primers (100 pmoles each), 250uM nucleotides, and 5 Units of Taq polymerase (Perkin Elmer). In addition, fluorescent nucleotides (Cy3-dUTP (green fluorescence) or Cy5-dUTP (red fluorescence), sold by Amersham) are added to a final concentration of 60 uM. The reaction is carried out  
10 in a Perkin Elmer thermocycler (PE9600) for 30 cycles using the following cycle profile: 92°C for 30 seconds, 58°C for 30 seconds, and 72°C for 2 minutes. Unincorporated fluorescent nucleotides are removed by size exclusion chromatography (Microcon-30 concentration devices, sold by Amicon).

Buffer replacement, removal of small nucleotides and primers and sample  
15 concentration is accomplished by ultrafiltration over an Amicon microconcentrator-30 (mwco = 30,000 Da) with three changes of 0.45 ml TE. The sample is reduced to 5 µl and supplemented with 1.4 µl 20X SSC and 5 µg yeast tRNA. Particles are removed from this mixture by filtration through a pre-wetted 0.45µ microspin filter (Ultrafree-MC, Millipore, Bedford, Ma.). SDS is added to a 0.28% final  
20 concentration. The fluorescently-labeled cDNA mixture is then heated to 98°C for 2 min., quickly cooled and applied to the DNA array on a microscope slide. Hybridization proceeds under a coverslip, and the slide assembly is kept in a humidified chamber at 65°C for 15 hours.

The slide is washed briefly in 1X SSC and 0.03% SDS, followed by a wash in  
25 0.06% SSC. The slide is kept in a humidified chamber until fluorescence scanning was done.

*Fluorescence scanning and data acquisition.* Fluorescence scanning is set for 20 microns/pixel and two readings are taken per pixel. Data for channel 1 is set to collect fluorescence from Cy3 with excitation at 520 nm and emission at 550-  
30 600 nm. Channel 2 collects signals excited at 647 nm and emitted at 660-705 nm, appropriate for Cy5. No neutral density filters are applied to the signal from either channel, and the photomultiplier tube gain is set to 5. Fine adjustments are then

made to the photomultiplier gain so that signals collected from the two spots are equivalent.

*Construction of an asth1J Transgenic Mouse*

5 *Isolation of mouse asth1-J genomic fragment:*

Phage MW1-J was isolated by screening a mouse 129Sv genomic phage library (Stratagene) with the 443bp BamHI-SmaI fragment from the 5' region of the human asth1-J cDNA clone PA1001A as probe. The 23kb insert in MW1-J was sequenced.

10

*Assembly of asth1-Jexb targeting construct:*

A 2.65kb SacI fragment (bp7115-bp9765) from MW1-J was isolated, cloned into the SacI site of pUC19, isolated from the resultant plasmid as an EcoRI-XbaI fragment, inserted into the EcoRI-XbaI sites of pBluescriptII KS+ (Stratagene), and  
15 the 2.5kb XhoI-MluI fragment isolated. A 5.4kb HindIII fragment (bp11515-bp16909) was isolated from MW1-J, inserted into the HindIII site of pBluescriptII KS+, reisolated as a XhoI-NotI fragment, inserted into the XhoI-NotI sites of pPNT, and the 9.5kb XhoI-MluI fragment isolated. The two XhoI-MluI fragments were ligated together to produce the final targeting construct plasmid, asth1exb. Asth1exb was  
20 linearized by digestion with NotI and purified by CsCl banding.

*Identification of targeted ES clones:*

Approximately 10 million RW4 ES cells (Genome Systems) were electroporated with 20 µg of linearized asth1exb and grown on mitomycin C  
25 inactivated MEFs (Mouse Embryo Fibroblasts) in ES cell medium (DMEM + 15% fetal bovine serum+1000U/ml LIF (Life Technologies)) and 400 µg/ml G418. After 24-48hrs, the cells were refed with ES cell medium. After 7-10 days in selection culture approximately 200 colonies were picked, trypsinized, grown in 96 well microtiter plates, and expanded in duplicate 24 well microtiter plates. Cells from  
30 one set of plates were trypsinized, resuspended in freezing medium (Joyner, A., ed., Gene Targeting, A Practical Approach. 1993. Oxford University Press), and stored at -85C. Genomic DNA was isolated from the other set of plates by standard



methods (Joyner, *supra*.) Approximately 10 µg of genomic DNA per clone were digested with NdeI and screened by southern blotting using a 100 bp fragment (bp6164-bp6260) as probe. A banding pattern consistent with targeted replacement by homologous recombination at the *asth1-J* locus was detected in 10 of 113 clones screened.

*Production of asth1-J knockout mice:*

Two of the targeted clones, cl#117 and cl#58, were expanded and injected into C57BL/6 blastocysts according to standard methods (Joyner, *supra*). High percentage male chimeric founder mice (as ascertained by extent of agouti coat color contribution) were bred to A/J and C57BL/6 female mice. Germline transmission was ascertained by chinchilla or albino coat color offspring from A/J outcrosses and by agouti coat color offspring from C57BL/6 outcrosses. The NdeI southern blot assay employed for ES cell screening was used to identify germline offspring carrying the targeted allele of *Asth1-J*. Germline offspring from both A/J and C57BL/6 outcrosses were identified and bred with A/J or C57BL/6 mates respectively.

Mice heterozygous for the *Asth1-J* targeted allele are interbred to obtain mice homozygous for the *asth1-J* targeted allele. Homozygotes are identified by NdeI Southern blot screening described above. The germline offspring of the chimeric founders are 50% A/J or C57BL/6 and 50% 129SvJ in genetic background. Subsequent generations of backcrossing with wild type A/J or C57BL/6 mates will result in halving of the 129SvJ contribution to the background. The percentage A/J or C57BL/6 background is calculated for each homozygous mouse from its breeding history.

*Molecular and cellular analysis of homozygous mice:*

Various tissues of homozygotes, heterozygotes and wild type littermates at various stages of development from embryonic stages to mature adults are isolated and processed to obtain RNA and protein. Northern and western expression analyses as well as *in situ* hybridizations and immunohistochemical analyses are

performed using cDNA probes and polyclonal and/or monoclonal antibodies specific for asth1-J protein.

*Phenotypic analysis of homozygous mice:*

- 5           A/J, C57BL/6, wild type, heterozygous and homozygous mice in both A/J and C57BL/6 backgrounds at varying stages of development are assessed for gross pathology and overt behavioral phenotypic differences such as weight, breeding performance, alertness and activity level, etc.

- Metacholine challenge tests are performed according to published protocols  
10   (De Sanctis *et al.* (1995). Quantitative Locus Analysis of Airway Hyperresponsiveness in A/J and C57BL/6J mice. Nat. Genet. 11:150-154.).

*Targeting at asth1-J exon C:*

*Assembly of exon C targeting construct:*

- 15           A 3.2kb HindIII-XbaI fragment (bp11515-bp14752) from MW1-J was isolated, cloned into the HindIII-XbaI site of pUC19, isolated from the resultant plasmid as a KpnI-XbaI fragment, inserted into the KpnI-XbaI sites of pBluescriptII KS+ (Stratagene), and the 4.5kb RsrII-MluI fragment isolated. A 3.4kb HindIII fragment (bp17217-bp20622) was isolated from MW1-J, inserted into the HindIII site of  
20   pBluescriptII KS+, reisolated as a XhoI-NotI fragment, inserted into the XhoI-NotI sites of pPNT, and the 9.5kb RsrII-MluI fragment isolated. The two RsrII-MluI fragments were ligated together to produce the final targeting construct plasmid, Asth1exc. Asth1exc was linearized by digestion with NotI and purified by CsCl  
banding.

25

*Identification of targeted ES clones:*

- Approximately 10 million RW4 ES cells (Genome Systems) were electroporated with 20µg of linearized asth1exc and grown on mitomycin C inactivated MEFs (Mouse Embryo Fibroblasts) in ES cell medium (DMEM + 15%  
30   fetal bovine serum+1000U/ml LIF (Life Technologies)) and 400 µg/ml G418. After 24-48hrs, the cells were refed with ES cell medium. After 7-10 days in selection culture approximately 200 colonies were picked, trypsinized, grown in 96 well

microtiter plates, and expanded in duplicate 24 well microtiter plates. Cells from one set of plates were trypsinized, resuspended in freezing medium (Joyner, *supra*), and stored at -85C. Genomic DNA was isolated from the other set of plates by standard methods (Joyner, *supra*). Approximately 10 µg of genomic DNA per clone were digested with NcoI and screened by southern blotting using a 518bp fragment (bp8043-bp8560) as probe. A banding pattern consistent with targeted replacement by homologous recombination at the Asth1-J locus was detected in 3 of 46 clones screened.

Targeted clones are injected into blastocysts and high percentage chimeras bred to A/J and C57BL/6 mates analogously to that done for asth1-Jexb knockout mice. Heterozygote, homozygote and wild type littermates are obtained and analyzed analogously to that done for asth1-Jexb knockout mice.

The data presented above demonstrate that ASTH1I and ASTH1J are novel human genes linked to a history of clinical asthma and bronchial hyperreactivity in two asthma cohorts, the population of Tristan da Cunha and a set of Canadian asthma families. A TDT curve in the ASTH1 region indicates that ASTH1I and ASTH1J are located in the region most highly associated with disease. The genes have been characterized and their genetic structure determined. Full length cDNA sequence for three isoforms of ASTH1I and three isoforms of ASTH1J are reported. The genes are novel members of the *ets* family of transcription factors, which have been implicated in the activation of a variety of genes including the TCRα gene and cytokine genes known to be important in the aetiology of asthma. Polymorphisms in the ASTH1I and ASTH1J genes are described. These polymorphisms are useful in the presymptomatic diagnosis of asthma susceptibility, and in the confirmation of diagnosis of asthma and of asthma subtypes.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from

5 the spirit or scope of the appended claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: AxyS Pharmaceuticals, Inc.
- (ii) TITLE OF THE INVENTION: Asthma Related Genes
- (iii) NUMBER OF SEQUENCES: 339
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Bozicevic & Reed, LLP
  - (B) STREET: 285 Hamilton Ave, Suite 200
  - (C) CITY: Palo Alto
  - (D) STATE: CA
  - (E) COUNTRY: USA
  - (F) ZIP: 94301
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: 21-JAN-1998
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Sherwood, Pamela J
  - (B) REGISTRATION NUMBER: 36,677
  - (C) REFERENCE/DOCKET NUMBER: SEQ-4P
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 650-327-3231
  - (B) TELEFAX: 650-327-3231
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 72928 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: Genomic DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCACCTTTTGTG GGAAGGTGG AAGAATAAAA GTAAGGGAGG TGTGCTGAGA CTTCAATTTT

60

AATATCTTAT	TTCTTAGGTT	GAGTGTAC	CAGGCATTG	TAATCATATA	TACTTTTGT	120
CACCTGAAAT	ATATATATTT	GTGTGTGTGT	GTGTGTGTGT	GTCAGAGTCT	CACTCTGTCT	180
CCCAGGCTGG	AGTGCACTGG	TGTGATCTTG	GCTCATTTGCA	ACCTCCACCT	CCCAGGTTCA	240
AGAGCTTTTT	GTGCCCTCCAT	CTCCTGAGTA	GCTGAGACTA	CAGGCAAGCA	CCACCACACC	300
GGCTAATTTT	TGTATTTT	GTAGAGATGG	GGTTTCACCA	TGTTGCCCG	GCTGGTCTCA	360
AATTCCTGGC	CTCAAGTGAT	CCAGTCACCT	TGGCCTCCCA	AAGTGCTGGA	ATTACAGGCG	420
TGAGCCACCA	TGCCCCGTCT	GAAATATTTT	AAAATGTAAA	AAAGCTAAAC	CCAAATCCAG	480
ATGTCTACTT	TCAAGGTGCT	CACAGGTCAG	ATCTAGGATT	ATTGCTACTA	ACTGATATTT	540
ATTATCCCAG	CACCAGCATG	TTTGGCTGTG	TGTCATGGGT	AAGTTACTCA	CCTTCTCTGC	600
GACAGTGTC	TCATTGTAAA	ATAGGGATAA	AAGAGTTTAG	ACCTTGACAG	GTCCTTCAGA	660
TTAAAGGAGA	TAATCAGTAC	GTGGCACTGA	GTACCTGCAA	TATATTAAAGT	GGTGTGTGCT	720
CAGAGATATG	ATCACATACA	GTATCTTGA	TCTGCCACAG	AACTCTATGA	AGATGAGGAA	780
ACAGACTCAG	GCAGGTCAGA	GCCAGAACAT	AATGTTTCTG	GAATTTGAAC	GTAAACGTTT	840
CCCTTCTCT	TATCCAGGCT	GAGTGTCTAA	GGAATTGTAA	AAATGGAATT	TGCCTGTTGC	900
CTGCATCTCC	CTCTCTTTT	CTTCTCTGT	GTCTCTGAA	TATCTAGCAC	CAGTGGGACT	960
TTACAGTGTT	GGCCTCAATG	CTGTAGGGTG	CTGTGTGCAC	ACTTGTCTTC	AGCTCCCTGA	1020
GTTAGCAGAG	CATTGCCCA	ACTCTGCCCT	CTGGCCAGCT	CATGTGCCCT	ACAACTTTCT	1080
GTTGCCAGAA	GAGAGCCCTG	CTCATTCTCT	AGACTCAACC	AACAAAAGCT	GCCTACCATT	1140
TTCAGAATGC	CAGTGGGCAG	TGAGAAGTGC	AGAGCTTGTG	TCCTGAGCTT	GGCAGCCATC	1200
TTGCTTGGTG	TTAACAAAGA	GTAATTAAGT	GATCTCATAA	AACTCAGTGG	TGGAGGTTGT	1260
GGTTCAGAGC	AAGCTGGGTC	AATGCCAAGG	CTACTTTGGC	TTTCTCTGGT	CCATAGCCCC	1320
ACATTTCTCT	TCTGATGGTT	CAGTTCGGGG	AATGAGAACC	AGTCTGAGTG	TAAGAAGACT	1380
TGGGTTTGAA	TCTGTCTCCT	CCAATCACTA	GCTGACCTTA	GAAAAGTGAC	TTAACCTCCC	1440
GAGCTGCTAT	TTCTCATCT	TAAATGGTGA	TAGTAATCTT	TCCTTACCTT	AAGGTTGTTG	1500
AGCAGCTTAA	ATAATATAAT	GAGTTGAAAG	CTTTTGTAT	GATCTGTTAT	TAGGAGTCCA	1560
GATAGTGTTT	TATAAACAAG	AGGATAAAAA	AAAAAAAAAA	AAAAAAAAACA	GGATTCTGAA	1620
GGCTGGACTC	ATTGCATTCC	TTGCAAACTA	CCCCTGAGC	CCCACTCTT	CCGTGAGCTC	1680
AAAGTCACTT	CTCAGAGCAA	ACCAGATTGT	CCTGAACCCA	GCACCTGCCA	ACATCTCCTC	1740
CTCTTCCCTG	ATGAAAACTC	TGGGCTGGAG	TTGTGGTGGG	TGAGGGGAAG	GCAGGATAAA	1800
TCAAAAATTG	ATGTTTAAAG	AAACTATGG	TATCTTGGGA	TGCAAAAGGCA	TGAGAATGAT	1860
ACCTTAGACT	TTGGGGCTTG	GGGAAAAGGG	TGGGGGGTGG	CGAGGGATAA	AAGACTACAC	1920
ATTGGGTTTA	GTGGACACTG	CTCGGGTTAT	GGGTGCACCA	AAATCTCAGA	AATCACCAC	1980
AAAGAACTGA	TTCAGGTAAC	CAAACACCAC	CTGTTCCCA	AAAACCTATT	GAAATAAAAA	2040
CAGAAAATTA	AAAAAAGAA	AACCTATGGT	ATTCTTGGAA	GAAGCACAGT	GGTGAAGTGG	2100
AGTAGACACA	GATGTGGAAG	TGATGTGAAC	TTTGGTAAAGT	TGCTGAGCCT	CTGAGGATGA	2160
TTTCCCTCAT	CTGTCAATCA	GGGAACAAA	TCCCTTACTT	GTACAATGAG	TATTATAAAG	2220
ATCAATTTCAG	ATGACGCATG	TAAAGATGCA	ATGTGGGACT	GGTAGGTAGT	AAGCATCCCA	2280
TAAATGGCAG	CTATTAATAA	GTAATAATCA	CCGAGTGGTG	GGCTGCCCTT	CATGAAAACA	2340
TTCCAGACAA	GCTGCTCTTC	TGTCGGCTCA	AAGTCACTTC	TCAGAGTAAA	TGAGATTGGC	2400
CAGTTCTTTC	TTTCCAAGGC	TTTTCTGGAT	ATTCATTTGT	CCCAGATTTC	TCCTGTATAC	2460
AAAGCTCAGG	AGTGAGGACC	CCCACAGTGG	GGCTTGCACA	AGGATAGCCT	TGGGGGGCTT	2520
TTTCTAAGAG	CTATGACTTT	GAATGCTCTC	TTCATCGATG	CTGACAGATG	AGGGCTGATG	2580
GAAGTGGTCA	TGTTTAAAA	TGTCGTATGT	CCAGAAACAC	AGAGATGTGT	ACGCAAAACA	2640
TTCATTTCATT	CAAGATGGAA	TTAGTGCCCC	AGACACAGAG	GCAGGGGATA	AATAGCAAAC	2700
AAGGCTTGAT	TCCTGCCTTC	ATAGAGCTTA	CTGTCTTGTA	GGGGAAACAT	GAGTAAATTC	2760
AGCAGAGTAA	GGGCTCTAAT	TGGGTAAATG	GGGGCTAGGC	TGCCTGTGTC	CTTGGGGTGG	2820
TGGGAAGGCT	GCTGATCTGG	GGTGCCAGAA	GACCTGAGTT	TTGATGCAGG	CTCTGTGACT	2880
TTGAGCAGGT	CGTTTCCAAC	TTCTGAGCTT	CCATTTCCTT	AGCTGAAAAT	GGGGGGCTTG	2940
CATACTCGAT	GCTGTACTCT	ATGAGTCTTT	GCAGCTCTGT	CATCTTTTTT	TCTTTTGGTC	3000
ACTCAGAGAC	TCCAGGATTG	GGAGAACAAC	CTGCATTCTG	ATTTAAAGTG	TGAATCTAAT	3060
AATTTCAAAA	AGAAAGGGAC	TAAAAGGGAC	AACTTGTTTT	CTGTTTATTT	TCCATCCTTC	3120
TTTGGGGAAG	TGTAACATTT	GAAATCAAAT	TCTCATTTGG	TTAGCCAATG	TGTAGACTTC	3180
GAGGGGAAAT	TCTCACTGCC	CAGAGAAGTG	ACTAAAAATG	ACCATTACAG	CCAAAAAGAG	3240
AAGTTTTTTT	TTTTTTAAAA	TCTGTGCTCT	ACAGATGGAT	GAAGTGCTGC	TGCACATGGA	3300
CAGAGTGGAT	CTGGACATTC	TGCATGAGCC	CAGGGATCCT	GAGAATGGAT	TGGCTGAGCA	3360
TAGACAGGGT	GACCTATCGA	TGTTCACTGT	GGTCTGTATC	TATGTGGCCT	CTTCTTAAGG	3420

GAAGATTTT	CTTAAGGTTG	TTTCCTTTCT	CAGCAGATAT	TTGTGAAGAA	ACTGTATCTG	3480
TAGTCTCATT	TTGTCCTTAT	AATGACCCGT	ATGGATGGGA	GGTAGAGGGA	TGATGATCAG	3540
TAAGAGCTGG	GAAAGCACCA	GGAAGTAGCA	AGAGCAGGAC	ACCTTTTCCA	CCACTAGGTA	3600
AATGGACCTA	GTGACTGCTG	GCACCGTGGG	TGAGGGGACT	GCCTGGCAGG	AGCTGTGGCC	3660
GTAGCTAGGG	GATTACAGCT	ACGGCCACAA	CTCTGGCCCT	GTACGGAGGG	AGTGGGGGAA	3720
ATAAAGAGTT	CATATCACTC	CCCTCTTTCC	CTGGAGTCTC	CTGCTGGTAC	CTTGCAATTGG	3780
CTGAGTCTAA	CTGGAAGCCA	GAGGGCAAAG	GAGGTACCCT	TTCCAGCTCT	GCAATTCTCT	3840
TCAGACAGGG	CTGGGATTTT	TGGAGAGAAT	TTGCAGAATC	AGAAAGCAGA	GCTTTCCAAT	3900
CAATGCCAAG	CAAGAGACTC	TGCAGACTCT	CATAGCCTTG	GGACCTGAGA	AACCAGGTAT	3960
CCAGTGAGCA	GTCACTTAAG	CCTGTTTACC	TGGCCCTCTC	TTACTTTCTC	TCCTATAGCA	4020
GCAGCAAAGG	AGCGATGGGC	CGAAGGGACT	TGCTGGGTAG	AAGTGGACCC	ACATTCTAAA	4080
AAGGAATGGA	AGAGAAACCT	GATTTCTTTG	ACTCGCCCTG	TCCCTGAAGA	TGAGGGGCAG	4140
GCACAGACCA	GCCCTCTCCA	GAAAGACAAA	TATATTCTTC	CATTCATGGG	AGGGGTAGTA	4200
GAGACTAACA	TTTGTTAAGT	ATCTATTACA	TGGGGGGTAT	GGAGGTAGGC	CCTTTGTGTG	4260
TGTTGCCTCT	TTTAATCCTT	TGGTGATCAA	CTCATGAAAA	TAAACAGCTC	CAGAGCCAGC	4320
TGCTTTTGGA	GGGTGTAGGC	AGGCCCGGCT	CTGGGAAACC	TGGTGACACT	GACCTAGTTT	4380
GACTTCCAAA	TCTTCTCTCT	TCTTCGATTG	TGGTGAGCCC	CACTCTAGCC	CCATAGTATG	4440
TATGGCCAAG	CACCCAGATA	CTGCTTCCAT	CAGGAGGAAA	TAACATACCT	GATGAATTTT	4500
TTCACTCAAG	GTGTTAGGAG	CTTAATGTGT	TTCCCCCGCC	CCCCGCACCA	AGAGAATTTG	4560
TGTTTTTCAA	GACAGTCAGA	GAGTGGGTGG	TGCTGAACTC	AAAGGAGTGA	ATCACTAATA	4620
GTGGAATCCC	AGGCATTGAG	GGAGGTCCTA	TTTCTGGGGT	GGGTTCTTTC	CTGACACTTC	4680
ATTTTCTACA	AAGGTGGCAG	CCACCTATTG	TCTCCAGAAA	GGAGGCTGTC	CCTGTGGGTG	4740
TGGTGACGGT	GGGAAAGGAG	AGGCACCTGC	AGGCTGAAGC	CAAGATCACC	TGATTTTCAA	4800
AACCAAATCT	GTCCCTACAA	AGGAGAAGTG	GCTTAAAAAT	CCACACAGCC	TCCCGAGTGG	4860
AGGGAAGAA	TCCCTCTCCT	CTCTGGAACA	GGGTTCCCTT	CACCCAGAAC	ACGGTGCTGT	4920
TGTTATGCAA	TGTCCTGTGT	GGCAAAGATA	TTTGAGCCCC	TTGTTTTTCA	GTCTGTGTCT	4980
TTTCCAAGAA	AGAGCTGTGG	CCTTTGAGTA	GGACTGGGCT	CCTGAATAGG	GTCCCTGGTG	5040
CCAAATGAGG	GAGCCAAGAA	AAGGCAGAGA	AGAGGAAAGT	CCTGACTTTT	ACATGAAGAT	5100
GAGACAGCCA	GCCCTGTGGC	AGCCAGATGG	CAGTCCTGTT	GCTCTGTAGT	GGCCTTGGGG	5160
TCAGACTAGG	GGCAGAGCTG	GGCTGAAGGC	AGGAAGGCCA	GGACAAGACA	GGTGAGAAGG	5220
GCAAAGTCTC	CTGTAACCTG	GTGAGAAAAT	GTGGGCTAAG	CCATTCTCAT	CTGGAGCTGA	5280
AGGCTTGGTG	GAGAAATGGC	CTCAACATTC	AAGTTCACAC	CCATGGATTT	ATAAAAGGCA	5340
GGGCTGGGGG	GAAAGGTTTT	TCCCATTTATA	CTTAATAACA	TTATCAACAA	CAATAATCAC	5400
TACTATCATT	TATTGAGCAT	TGACTCAAAA	GACAGTCCTT	TTATGAAAAT	TATTTACTTA	5460
AATCCTTACA	AAGCTTCTAT	TCATTACCCC	AACACATATT	TATTGAGTTC	CTACTATGAG	5520
CCAGGCATTA	TTCTAGGTGC	TTAATTTAGA	TCAAGGGACA	AGACAGACAA	AATCCCTGTT	5580
CTGGTGGCAG	GGCTACTACA	TGCAATTAAC	AGCAACCAAC	TCTAGGGGGA	GCCACATACA	5640
TGGGCCACCT	TATGAATGGT	GTGCCCTGAG	GTTAAGCATC	CTGGCAGCCC	CCTTCTGTGA	5700
CATTTCGATT	CTAGTGAAGG	GAGTCTAATA	CCAATGAAGT	AGATGTCATT	ATCCCCTGAC	5760
TACAGTTTAG	GAAACAGAGA	CACATAGGAA	TTAAGTAACT	TGCTGAGTTT	TTCAGCCAAA	5820
AATGACTGAC	CCATGATTTA	TACTGAAGTC	AGTCCTTGCA	ATTACCTGT	GCCACGTACT	5880
TGCCCTTCTC	TCCCTGGTGG	GCACAGGGAA	GAGGGAGTAG	CCAGGCTGGC	CAGATGAGTG	5940
CTGGGCTGGC	TGGCCAGTA	GAGGCACCAT	GTCTGACTG	GGTGGACAAA	GACTGGGTAG	6000
GAGGTAACAG	AGAATCCCTT	GGTGAGTCTA	ACTTAGCTAT	AAGAAGGCTT	GCTGAGAGCA	6060
GCTGCCTCCA	TGCAGAGGGT	GGGGTGACCG	GCCTTTAATC	CTTCCCAGCT	GAGGATTTAG	6120
TCAAAGAAGC	TTGTCTCTGG	GGATAGCCTA	TGGTCTTGAA	GGGCCTGAGT	TAGCTATTAG	6180
TTCACCCATT	TATTTAACAT	TCATTTCATTA	TTTTTAAAAA	ATTTCCTAGC	TATGTTTTGGG	6240
GGCAGAGAA	TGGGTCCAGA	GACCTAGAGG	TTTGCAAGGG	TAGCTTCTAA	ACTCCTTTGG	6300
TTCAGAACAG	AATAGAAAAGT	GTCTCGGGT	GACCTTGGGT	CTGCTTCCCA	AGCAAATTGA	6360
GCATACGCAG	CCAGAACAAA	GACTGCACTC	TACTCTAGTG	AGCTCAGCCT	GCTAGGCTTG	6420
GATCTAGATT	TTATAGCAAT	AAGCTTGGAG	TCTCACCTTT	GGGTCAGACA	GAGTACTACC	6480
CCAGACATGA	GGTAGGGAGA	GCCTAGTCTA	TATTCCTCTG	CCTTTGTCCA	AGCCTGCTTT	6540
GTCCTTCTCT	TTGACGAGGA	ATAAAGATGG	CTTCTGGGTG	TGCATCCCCT	TCCTTCTTCC	6600
ACCTGCAGAT	GTACCTGTTT	GTGTGCAGTG	GGCTTCTGAG	TCCTGGGCAG	GGATGCCAGA	6660
GACCGCAAGC	CAGATGCTTG	GGATGCCAAT	CCTTGGGACT	TTGAGGAGAA	AGAGAGGTTT	6720
TGAGGGGCAT	CTGTCTATGG	CACAGAGTCA	AATGGAACAC	ATGGAAGTCC	CTTAGAAGGC	6780

TGGTATCTAA	GTGTTGGCCA	CACAATGTCC	GTTCTTCCTC	CATTATTTGA	ATTTCTCCTT	6840
CTCTATCCTT	CTATCTTTCT	TGGCACCTTG	AGCCAGGTCT	GGGGTGAGAG	AAGGGATGGT	6900
GTAGGTGAAT	TAGTGGTAGT	TATTGGAGGA	AGGCAATAAA	CCCAGAAAAA	GTGTCACGTG	6960
ACTTCTTTCT	TGGGCCCAGT	GTGACGCTTC	TAGTTAGGCT	AACGTGGGTC	TTGGGACTGT	7020
TCCTGAGATT	TTGTGAAAAA	CTCTTTGTAT	TTGTGCTGGT	AACAGAAGGA	AACCAGAGTT	7080
AGGGCTGGTG	GGATGAAGCA	GTGGGAACAC	TGATTTCTCC	TTTTTTTTCAG	ATTCAGGGAT	7140
TTCTGTCAGA	GACATCCGTG	GGGGAGGGAT	GGGATTGGGA	GTGAGGAGAA	TCCCTTTCCCT	7200
CTCCTCTCAC	CATCTGGTGG	TCCCCGTGCC	CACGCACCAG	CTCGTTGGAT	GGACATTTTG	7260
ATTCCTCTAA	GATGTACATT	CTTCAAATCA	TTGTTTGTCA	TTAGCTCCCT	GGAGAAAATG	7320
GAGGGGCTGA	GATATTAGTG	AGAAAACATA	AAGTTAATTG	GGTGATGGAG	ACTGGGAGAA	7380
GGGGAATGTT	AGAAGAAAGT	GAGCGAGGTC	TGCTAAAAGT	GAACCTTTATC	TTCTTCTCAA	7440
TTTTGCCTAA	GACTCGTGTT	GCCTGGGCAG	TCTCTTTTGT	GAAGAGAAAT	TTTCATGACA	7500
GTTTGGGCCA	GAGATGGCAA	ATAAATGCCT	GACATGGTTG	CTGCCAGCCC	CTGTCTCCCCG	7560
ACACGTTTAC	AAGGGTGCAC	ACCCTTCTC	CTCTCTGTGA	CCATAGACTC	AGACCCATTG	7620
CAATCCAGCA	TCCTGCATGG	CCCCATTGGT	CAGAGTTGAC	ATTTGCAATG	AAGCTGCTTC	7680
CCTATGCCTG	GTTAGGCCTT	TTGCTATGAA	TTCTCTGGAG	TTAACTATTT	CCAAGGGGCT	7740
CCAACTTATT	CTTGTGATTT	CCACGGGATT	TGGAGCCCCA	GAAGACAATC	CCATGTGGAT	7800
TCACAAAATG	CCCTCTAAAT	TTGATGGCTG	TCAGTGACATA	CTAAGTATGA	CTGACTCACT	7860
GGTATCTGTT	TCCTCCGCTG	ACACAGCTGG	TTCTTAGGCT	CGGCAGGAGT	TTGGGCTGAG	7920
ACCTCTCATT	GCTCTATATT	CCCTCTGTGA	CTAATGAGGT	GTTGTTTCCTT	AATTACTAGG	7980
TGCTGGATAC	TAGAATTGCT	TTTCTTTGTT	TCAGGGGATT	TAGCAAAGGG	CTTATAAATA	8040
TTTCTTGTGT	CTGGCATGAA	CTACCTGATT	TTTTTATTCT	TCAGGTCCT	GAGCTGGCAA	8100
TAAAGGCAAC	TCAAAGTTAG	CTGGGAATCA	GAATGAAGGG	GGACTAGGAA	AAGTGATGCC	8160
TAGAACACCA	ACAGGTGTGG	GATCATCTTC	ATTGTACCTT	TCAGAGCCTA	AGATATAAGT	8220
CCTCTGGATA	CTCTCTGCTT	GTTTATTTAA	AGGAAAAAAT	AATCAGAATG	TGGGAGAAAT	8280
GGGTGCTTTG	GGTAATTTCA	TATTCTAATT	GATGAACGTG	TATGAAATTA	TAATATTTAA	8340
CCACTACTAG	CCCTTGCCGT	AAAAAATAT	TCCAAAATAG	CTGAGTCTAA	GTTCCTTGCC	8400
TCAGTGTGTC	CCACCTCTTG	CGCTTGAGTC	CTTAATGATC	CAGAGTTTCA	AGTCCCCAGT	8460
GCCCTAATCT	TGAAAAGCAG	AAACTTTAGA	AGTTTGCTGA	AGTTTATTAG	TTGGCTATAC	8520
GATCCATCAA	GAAATTGACT	TTTTTTGGATT	AAATTCAAGA	TAGTTTTTAA	AAAATCAGAA	8580
GTTTCTTTAT	CATGAAAGCT	AAAAAATAA	TTGAAGGTAG	AGGCTAGTTG	GAATCCCAGT	8640
TAATAGATGG	ATTTCTTCCT	TCTTGAAGAA	ACTTGTGTCC	AAGGGCAAAC	TGAATCCTGG	8700
TGGTCTATGC	TGGCCACATT	CAGCAAAAAA	TGGCCCCAGG	TTTTGATGGT	TATCATTCTC	8760
AAAACTGTTT	CTGCCAACAC	ACTCTGATCC	CAGGAGGTTA	CCTGACCTTT	ATAAGGCTCA	8820
GTTTCTCTCC	CTGTAAAATG	GGCAGGGTAA	TCAAGCTAGG	CAAAATATTT	AACCTAAGTG	8880
AGGAAATTGT	GCTATTAGTG	CCCTGAAAAA	CATGTAGAAA	GACATTAGAC	ATTATTTTAT	8940
TTAATATCAT	GTGAACTTA	TTTTTTAAAA	AGAAGACCTA	TTGGATTTTC	CAAGAACAAC	9000
TAAACTGATT	CCTTGTAGAC	AGTTTAGAGA	ATACAGAAAA	TTAGAAAATAG	GAAAAAAGCA	9060
AAACAAAACA	AAAACCATCA	AACAAAGTCT	ACGCAAAATAC	AGTTTCTCTT	AACTTTTGGT	9120
TTATTTCTCT	CTAGTCATTT	TTTAGGTGCA	TTTTTAAATT	GTGGTAAAAT	ATATGTAATG	9180
TAGAATTTAC	CATTGTAGCC	ATTTTTAAGT	GTAGAGTTCA	GTGGCATTA	GTACATTTAT	9240
ATTGCCGTGC	AACCATCACC	ACCATCTATC	TCCAGATTTT	ATAACCCAG	ACTGAAACTC	9300
CATATCCATT	AAATGATAAC	TCCCCATTCC	CCTCTCCCTA	CCCTGGTGAC	CACCATTTTA	9360
CTTTCTGTTT	TTATGAATTT	GACTTTCTTG	GCGCCTCTTA	TAAGTGGGAT	CATTTTTAGT	9420
TGTTTTTATA	ATCGGTTTCC	TTCTTTTAAA	AATATGAATG	GAGCCTAATG	AATATTGAAT	9480
TTAGTGACT	GGTTTCTTTG	AACATTTTCA	CATCATAAAC	ATGTTTTTGT	ATTCTACATT	9540
CTTCTTGAT	TGCTATATTC	TCTATAGGAA	TTTTTTTTTT	TTTTTTTGACA	GAGTCTCACT	9600
CTGTTGCCCA	GGCTGGAGTG	CAGTGGCACA	ATTTCAGCTC	ACTGCAACCT	CCGCCTACTG	9660
GGTTCAAATG	ATTCTCCTGC	CTCAGCCTCC	CAAGTAGCTG	GGACCAGAGG	TGCATGCCAC	9720
CATGCCTGGC	TAATTTTTGC	ATTTTTAGTA	GAGATGGGGT	TTCATCATGT	TGGCCAGGCT	9780
GGTCTTGAAC	TCCTGACCTC	AGGTGATCCG	CCCACCTTGG	CCTCCCAAAG	TGCTGGAATT	9840
ACAGGTGTGA	GCCATTGGCC	CCAGCCTTGA	ACATCATTTT	TAATGGCTGA	AGATTATAGA	9900
ATCCAGTGGG	TGTGCCATCC	ATTATTAGTA	TTCTGTTGTT	TCCAAATATT	TGCTGTTTTA	9960
AACAGTGTG	TGAAAACATA	TTTTTGTGTT	GAACCTTTAT	CATATTGAGA	GGCACTTCCT	10020
CTGTGCAGAA	TCAAGAAATT	AATTACCGGT	TTATAAGGAA	TGTGAACCTT	TCAGGCTCAT	10080
AATCTGTATT	ACCAAATGGT	TAGGAAAAAA	ATGTTTCAGAA	GGTGCCATTC	ACAGATGGAG	10140



TGGGCTTCCA	CCAGGGGCTG	TGAAGCTCTA	ATCTCAAAGG	ATGTTGACTA	CTGGTAGGGC	10200
TGATTCAAGT	ATTAGATATC	TAGGAAGGGT	GGGAAGGGCA	GAGAAGCTTC	CAAAATTCCT	10260
ATGTAGGAGA	GGCATAGGGG	TGCTGATCTC	TTCATAAGGG	GTGACGGGAA	TTTTCTTGA	10320
AACAGCATGT	GCAGATCAAG	CACTGTTCTT	TCCTTTAGAG	TGTGTGTTTA	TTTGGGGCGA	10380
CTTGGAGGGT	TGCTAATTGA	GATTATGGGG	AATCTAAAGC	CACACCCCAA	ACCGCCCTT	10440
GGTTCCCTTA	CCTGGGGGAG	AGTTGACACT	AGTCAAACCT	CTCCCATCTC	TGAGATTTTG	10500
TGAATCTAGG	ACTCTTGCCA	CTGCACAGAC	TCCAGCTGGA	CCCAGGGACT	CCAGCTTCTC	10560
ACATCACCCCT	GGCTCATCCA	TAAGTCTCTT	TTGTTTCATC	TCAAACATCA	CTGAGAGATG	10620
GCTGCCTCTT	CTCCCTTCCT	AGGAAAGCCC	ATGTCACAAT	AAGCGCGCCT	GTGCTTCTCA	10680
TCAGTGCTTT	CCTGGTAGCA	CCACCTGACA	AACACTGCTC	GCGGCTGCCT	TCAGCTGCTC	10740
TCCAAGAAGA	CGTCATAACC	ACAAGAGATC	TGAATCAGCC	CATTTTTTCC	CCTGTGGCAC	10800
TGTGTGCTTT	GGCTGCCTGG	CCAGAAAGCT	GGGACTGTAT	TTACCTATCA	TTTTGATACT	10860
ATCTTGGGGT	GTAATTGGAA	TTGAGCTCTT	AGTGTGGAAA	TTCTTACTCA	GAACACAAAG	10920
GATTGAAGAG	TGCTTGGAGG	CTGAAGTCTG	GAAGGACTCT	TCCCTGAGGC	CTCTTGGCAT	10980
CTGGCTCTTG	TTTCTTGGAG	CGGTGGTATG	GCCCACAGGT	GGGTGTTTCC	TTTGGGAGCA	11040
ATTTCTTGCT	TTTTCAGTAG	CTCTGGGCTG	TCATCGAGCC	CACTGTTCCCT	TGTCTTCTCT	11100
GCACCTTTTA	GTGATGATGT	AGGTGAATTG	CTCCACAGTT	TAATTCCAGT	GGTAGAGCAG	11160
TCACCATTTG	TTGGTTTCTT	TTTCTTATGG	GAAGTCTGGT	CTGCATCTCA	CTGTGTTTCC	11220
CTTGAACGTG	TCTGGGGTCC	TCCAAACAGC	TTCGTGTCCC	TCTGAGTGCG	GACACTCAGA	11280
TTCTAACTCA	GATTCTAAGT	CAATGGTCTC	AGCCTTTAGA	ACCGCAGGAG	GCCAGGCGCG	11340
GTGACTCACG	CCTGTAATCC	CAGGACTTTG	GGAGGCCTAC	GCGGGTGGAT	CACCTAAGGT	11400
CAGGAGTTCG	AGACCAGCCT	GGCCAACACA	GTGAAACCCC	ATCTCTACTA	AAAATACAAA	11460
AATTAGCCAG	ATGTGGTGGC	ATGTGCCTGT	AATCCCGGCT	ACTCAGGAGG	CTGAGGCAGA	11520
GGCAGGAGAA	TCGCTTGAAC	ACGGGAGGTG	GAGGTTGCAG	TGAGCCGAGA	TTGTGAGATT	11580
GTGCCATTGC	ACTCTAGCCT	GGGCAACAGA	GTGAGACTCC	ATCTCAAAAA	AAAAAAAAAA	11640
AAAAAAAAAA	AGAACCACAG	GAGGGAGAGA	TCATATATGA	CCCCGTATGT	GTGAAAAGTC	11700
CTACTATTGC	TACCCACACC	AACAATATTA	GTGAAAAAAT	GTCTTCAAAG	GACATTTCAT	11760
TCAATGATAC	ATGAGATTGT	CTTCCTTCCT	TAATTTTTCC	CTGTACAGCT	ATATAATGAT	11820
TTTTTCAATC	AGATCCTCTT	TTCCCCCTAT	TAATTGTATT	TATAGGATGA	GATTGATTCT	11880
AACACAATAG	CAAATGATGT	ATGCACATTT	AACACATTTT	GTGAAGGCAG	GAAAGGGCAC	11940
ACTATAAATT	CTGTGAAATC	CACATTAGAT	CATGCCTCTC	CTTTCTCAGT	TGGGAGGTGG	12000
GCTCTGACAG	TGCTCAAGAG	AAAAAAAAAAT	CAAGTTGTGA	CAGTTTAAAA	AATATTTTAA	12060
ATATTAAACT	ATTTATTATG	GAAGTTAAAA	CATACACAGA	AGTTGGCAGA	ATAACATCAT	12120
GTACCCTAAA	TATCTATCTC	CAAACCTCAA	CAGTGATCAA	CCTGTGGTCA	GTTCTGCCTC	12180
TTCTGGTTCC	CATCTGCTCT	CTGACTTCAG	TTTATTTTGA	AGCATGTCTC	AGACATCTTG	12240
TGACTTCAGT	ATTGCACGAT	GTATGTCCTA	AACGTAAGCA	TTCCCTTTAA	AACATGTATC	12300
TACTTTTTTA	ATGAAGAAC	ATTAGGTGCA	TTTTCTAAG	GGTTTTAGAA	AGGGAAGAAA	12360
CTGTATTCTT	TTAATTTAAA	AATGTATCAG	ACAACATAATC	CATGTTTACT	GTTTCTAACA	12420
CGGATACCAT	AATAATAGGA	TCATTCTATT	ATACATAGAC	TAGTGAGATC	AATTTGTCAG	12480
ATAAACTTAG	AAGGGCCATT	AAGAAAGTTA	TGTCATAATT	TTTGTCACTT	GCTGAAACCA	12540
AGACTTTAAT	TCTGCAGAAC	ATCATACCAG	GATTACAAT	TGTATACACT	GATTGTGTTT	12600
GTCCAGAGGT	AATCTCAGAT	CCACTGTATA	TAATTTTCCA	TTTGCCTAGC	TATGGGGTTG	12660
GACACGTCAG	TTTTTTCCAG	ACCAAGGGTC	TCCTAGCTTT	TTTTTTATTT	TTATTTTAT	12720
TTTTTGAGAC	AGAGTCTCTG	TTGCCTGTGC	TGGAGTACAC	TGGTGCATC	TCGGCTCACT	12780
GCACCTCCA	CCTCTCAGAT	TCAAGTGATT	CTTGTGTCTC	AGCCTCCTGA	GTTGTAGGTG	12840
GGACTACAGG	CACCTGCCAC	CATGCCCTGA	TTTTTTTTTT	GTTTTTTTGT	ATCTTTAGTA	12900
GAGATGGAGT	TTTGCCATGT	TGGCCAGGCT	GGTCTTGACC	TCTTGATCTT	AGAAGATCTG	12960
CCCACCTTGG	CCTCCCAAAG	CTGGGATTAC	AGGCATGAGC	CACTGTGCCC	AGCCTCCTAG	13020
CTGTTTTGGC	TGCACACTTC	TATCCGTAGA	TAATTAAGCA	TGTACCCTTA	CTATTTTCCG	13080
CAATATAAAT	TATTTACTTA	TAAATTACAT	TATGTACTCT	ATCACACTGG	TAAATTAAGT	13140
ATATTATAAA	ACAGAACTA	AAAGTATGAA	GTGAGAATTA	AAAATGAATA	GCAATTCTAA	13200
TATCTTCATC	TTCCCTCAG	TGGATCCTCC	TGTACATACT	CCAATTGCA	GACCACTGGA	13260
GGAGGCTGTA	GGAGGCAATA	TTATATCCCA	GTGAGGTGTG	TGGGTTGTAA	AGCCGAACAG	13320
CCTGAGTCCA	CATCCAGCT	CCACCACTCC	TTAGTTCTGT	GACTTGGA	CATCACTTAA	13380
CCTCTCTGAA	TCTATCTTCT	CACCTGTAAT	ATGAGGGCAT	TAACCCCTTA	CAGGTTATTG	13440
TAAGGTTTCT	TACACTGTGC	CTGTGGTAAG	CATCAATACA	TTTTAGCCAA	TAATAACAGT	13500

AATGATAATA	ACACATTCCT	AGAGGGCTGG	GATGGATCTA	GATTTTTCTT	CCCCTTTTAG	13560
TGGAAGACCA	CAGCATGATG	CATGAATTTA	CATTTCTCTA	GACATTCTGG	TGCTGATGAA	13620
GGTAAAGATG	GTGAGGCTGC	GATGATGGTT	TCAGGGATGG	GTGTGTTGGG	CGTGATGAAT	13680
AGCATGATGC	ATATTGTAC	TCATTTAGTT	TATCTGCACT	GATGATGATG	CTGATTATAT	13740
GATGACTGTT	ACAGGGATGG	TCACATTGTG	GGTGATGAAT	ATGACCAGAA	AGGGAAGACT	13800
TTACAGTTT	CTACCCGAAC	TACAACATCG	ATATTTTCAT	TTGTCTTTCC	TAGGAACCTCT	13860
TACCTTAATC	ACCTGACCAA	TATGCTGACG	ACTAACATGT	TGCGCCCTGC	CTTTCTTCCG	13920
GGCCTCTCTG	CCTTGCTGAT	CTGTTTGTCT	GGTGTGCCCT	CCACTGTGCT	CTTGGGTCTT	13980
TGTCTCTCGG	TAAAGCCTAG	TACTGTGGTT	GCTGTACACA	AAACCTGTAG	ATGATTAAGA	14040
TCTCTGTTCA	CTGCAGGGCC	ATTCATCTCC	CAGCAACTAT	TTTATCCTTA	AGTCAAGAGA	14100
CTTGCTCTC	AGCCCTGGG	GACCATGGAA	AGAGTGCTAG	AAACCTACAG	AGTATGACCC	14160
TTGTAGCCT	TATGCAAGAA	GTGACCTGTG	TCTTCTCTGT	CATGAGAGAG	GACAGACATT	14220
GCAGGAATCA	AACGCATAAC	ACTAGTGCAA	AACTGGGGAT	AATGCCCAA	CCTGGTTAGG	14280
CAGGGGCGCC	TGGAACATGC	TTGTCCAGGA	AATCTTCCAC	TCAGTTCTGC	TGCCTCCATG	14340
TCCCAGATGA	TCACAGAAGC	CTCCTGAGAA	GGGTGGAATC	CCCCGTCGCC	TGGGGATCCC	14400
AAGAAAGCTG	CAGAGGAAAG	ACTTCTCTT	CCAAGATCAG	AACAAAGGAC	GGTTAGCATT	14460
GTGCCCAGT	GTGCCAAAAG	GTAAGGTTGG	GTTAAAATA	GAATTTGCCT	TAAGCTCTTT	14520
TCCCGGGGGC	TTGTTTTTTT	CATTAACCTT	GTTGGCTGGA	CTTTAGGGAA	GTATGCACCA	14580
TCTTCTCCAG	AAGTGCTTCA	GATTTTATAT	TTTTAAGAAA	TTCAAGAGTC	TGAGTTAGGC	14640
ACTTTAATGT	AACCTCCCCA	AAGCTTTTGT	TCCAGGAATT	GACTTGGGGA	TTAATCTGTT	14700
TAGCAAATTC	TGACACAGAG	GCATCTCATA	ACCTTTTATT	TTTTCTACAG	ACCACATTGT	14760
ATCTACCTGG	GATGTTTTGA	AAATGAACAG	TGACACCTAA	GAATGTATAC	TTATCTCTTC	14820
ATGCCAATTC	TCCAAACTGG	ATGTTGCCCA	TGTCTCAAAA	TTACTTGCCCT	CCAATTTTAG	14880
GGCATAAAGT	GTGAGATTCT	GTAGCATGAG	ATCATATGCT	CTTAAAATAC	TAAGTATATA	14940
TAAATTATCC	CTTAGCATCT	TTAACATGCA	TTTTTTTTTT	GTAGAGACAG	TATCTCTACA	15000
AAAAAATCTC	TCTGTATTGC	TCAGGCTGGT	CTTGAAATCC	TGGGCTCAAG	AGATCTTCCC	15060
ATCTCGGCTT	CCCAAAATGC	TAGAATTACA	GGCATGAGTC	TCCACACCTG	GCCTAACATG	15120
AAATATTCTT	TAACAGTATT	CTTTAGGATA	ATATATTATT	CTATAGATTT	GAATAAATTT	15180
ATCAGTTCTA	TACTTAATTA	TAAATACTCT	TGGGAATAAA	ACATACTTAT	CTAATAAGCA	15240
AACAGTCGTG	CTATTCAAA	CAATTTGGGA	TTGCCTTTCC	AAGCATTTTT	TGGGGGTTTC	15300
TTCAACTGAT	TGAGAGACCC	CCGGCCGGGG	AAGAGAAAGA	GAATTTGATT	TGTGACACTG	15360
ATGGAATGGA	CTACAACCTT	TTGGTGGTGA	CTCTACTGGG	GACTTGTCAC	AGAGCTTATT	15420
TTCTAAACAG	ATGTGAAAAA	TGAAAGTCAG	GCTGCTGTCT	GGTTGGTAAG	ATAAAGCTTT	15480
CATTAATACT	TGGCAGCATT	ATTTTAGCTA	AAGTGTCAGA	TCAAACGCCC	ACATTATCAC	15540
CTCCCCTTCC	TGATTCCAAC	CGCCCATGAT	AGAAAAGAAA	TAAAAGACTA	GGAATAGGTC	15600
CATCAACTGG	TGAATGGCTA	AACAAAATGA	GGTATATACA	TACAATAGAT	GGTTATTGAA	15660
TCACATAGG	GAATGAAGTA	CTGATACATG	CTACAATATA	GATGATCGTC	ATAAACATCA	15720
TGCTACGTGA	AAGAGGCCAG	ATGCAAAAAT	CTACATATT	ATATGATTCT	ACTTAATTTGA	15780
AAAACCTCAA	GTAGGCAAAT	CCATAGAGAC	AGAAAGCAGA	CTGGTAGTTT	CCCAGTGCTG	15840
GGGAGAAGGC	AGACAGGGAA	GTGACTGCTT	AATGAGTATG	AAGTTTCCTT	TTGGGATGAT	15900
GAAAATGTCT	TGGGACTTAG	ATAGAAGTGA	TGGTTGCACA	ACACTGTGAA	TGTAGTAATT	15960
GCCATGGAGA	TGTACACCTC	AAAATGGCTA	AAATGAATTC	TATGTTATGT	GAATTTTACC	16020
TGAATTTAAA	GAAGAGTAGA	AACAAACACC	AAGAAAAAGG	GAGGAAAGGA	GGCATTATTG	16080
AACAAGACAT	TTCAACAAGT	TTTGGGAATAT	GGAAAAATATA	CGGAGAAGTG	GCAACTGACT	16140
TACCAGAGTG	GCAGAAGAAA	TAGTCTATGT	GAGTGTGGGG	AATGGGGTGG	ATGTGGAACC	16200
AGTGAGAAAT	AAGCCGCTTT	ACTGGGAAGA	ACTACAGAAA	GACTGAGGCT	TGGACGCAGC	16260
TTGTGCTACT	ACAGGTAGCA	GTAAACAGGG	GGATTTGTTG	AACTTCAGAA	TATAGAGAAT	16320
TTTGATGTAA	GAGGTTTTTT	TTTCTCTGTC	TCAAACAGG	AGACTTTTTT	TGTTCTCTAG	16380
GTGAGGGAGA	TCTAGAGACA	CCCAAGTACA	GGGTGCAGTA	TCATCTAGAA	AATAAAGAAG	16440
AGGTTTGAGT	CTGCAGGTGA	GACTCCTGCT	CTCTTCTGCT	AATGCTGGCA	GCCAGGCTTA	16500
GATCAGCCTC	TCTGCCCTGC	TCCAGGCAGA	AGATGGAAAG	ATCCCTTTCT	GGAGAAACTG	16560
ACTCATCCAA	GAGATAACAG	CTCATATTCT	TACTTTTTAG	AGCTCTCCAG	TAAAATGCAG	16620
CTCAACACTT	GATCAGTTTC	CAGCGATGAC	CCCTGATCAG	GCCCTCACTA	CGAACCTCTG	16680
GGTTTTAATT	GGTTATTTAG	TATCTCAATT	TAAAGATCA	AAGACAGGAT	CGCTTTTGAG	16740
GAAACTTCCA	ACTTTAATGA	AAGAATTTAA	AAAAAAAAG	GAAAAAAAAC	CTGATAGTGT	16800
AAAGAGCAGA	GAAATGGCAG	GGAAATGAAA	ATTAAGTTAA	AAAACAGAAA	CTTTTATATA	16860

ATTCTAATCC	TTTGCAGAGA	TAAAAAATA	CATTGCATAC	CTAAAACAAG	TACAAGTTGC	16920
CATGGAAACA	GATTCATTAG	TGAAGAGGAA	AGAGATCTTG	GAAATTAAAG	ACATAAAAGA	16980
CAAAATAAAA	ATTAAAAAAA	TTAAACAGAA	TTTAGAACAT	AATGTTGAAA	TGAGAGAACT	17040
TTAGATCTCA	AAAACAACAG	AGAATCAACC	CAGGAGATTG	TGTGTGACTA	AAGAAGTCTC	17100
AGAAAGAGAA	TAGAGGAAAG	GAAGGAATAT	TATAAGAAAA	GTTTCAAGAA	TAAAAGGTCA	17160
TGGGCCCTCA	GACTGATAAA	AATCCATCTT	GTACCCAGAA	AAAATTGACT	TTTCAAGAAC	17220
TGAATCAGAA	CCTATCCTGT	GAAATGTTAG	GACAAGTAGA	TCCTAAAAATC	TTCCAGAGGG	17280
AATCCATTCA	AAGGCCTTGA	ATGGCATTAG	ACTTCTCCAT	ATCAATACTG	GATGGTGAAA	17340
GAAAAAGAGC	AATACCTTAA	ACTTGCTAAA	AGAAAAATGAT	TTTTAACTAG	AATTCAATTT	17400
CCATCTCAAT	TAAAAAACCC	ACTGTAAAGA	AAAAATTCAA	ATCTTCTCAG	GCATATAATA	17460
ACTCTAAAAT	TCTACCTCCT	GTGCACCTAA	TTTTGGCAAG	TATCTCAGGA	AGATACACTT	17520
TGCTAGAACA	AGGACATAGT	TTAAGAAAGT	GGAGAAATC	AGATCTGGGA	ATCAGGGGAT	17580
CACATGATAC	AGAGGCACAG	CCAGAGGGAT	CCCAGGGAGA	GCATGTCCAG	TGTGACAAGG	17640
AGTGGACAGC	TTCAGAAGGG	ACAGCACCAG	GGGAAAAAAC	AAAATGAATA	TCTGATTGGC	17700
ATAAACATTT	GGAAAGTAGT	ATTAAAAATG	TGTGTAACAG	GTGTGTTGTT	ACATTTGCCA	17760
AAAAAGAGCA	AAAGGGAAAA	AAAACCCCAA	GCAGATGAAA	AGTAAAGAAG	GCAATGGTTA	17820
ACTACTGGAA	AAACAAAAAA	CAATATTCAA	GAAAGGAAAC	GAAATCATGG	TATACTTCTT	17880
GACTAATGGG	TGAAAAATGA	AGATGTACAT	AGTTATTAAA	ATGCAAACAT	TGATTATTGA	17940
GTTAACCCTA	AGTTGTGACA	TTTGAAGCA	CGGGTAGGCA	CAGTGGGGTG	TAAGAGACCT	18000
AAATCCTCAC	TTACCGTAAT	GTTTAAAAAA	TTGCCATGTC	AAAGAATAGC	AGCATATCAT	18060
ATTATTTAGA	AATATGGATG	CAAATGCCAG	AAGAAAAATT	AAAGGAAGTG	AAAAATGTTT	18120
TCCTCTAGGA	ATAGGACAGG	GGACGTAATA	GGGAACAGAT	ATTCTGCATT	ATCTCAATTA	18180
ATTCTCACAA	CTGTGACTGA	AGCTCTTTTG	CTCTCCTTGT	TTTGCAGATG	AGCAAACCTCA	18240
CAGAGGGATG	CAACTTGCCT	AGGATCGTAT	AGCCAGCAGC	TCATGAGTGT	GGAATGGGGA	18300
TTCAAATAAG	GTCTAGGAGA	CTCCAAAATC	CATGTGCTTA	ACCATGAAGT	TTTACTACCC	18360
CTTCTCTGCT	TCTTCATTAA	GTATTTTTAG	TGCCTAATTG	CCCATGCTCT	CTGCCAGGTG	18420
CAGTAAGGAA	GGATTACACA	GGTGCAATAT	GAGCCATGAC	TCTTGTGAA	ATCAGCACGT	18480
CAAAAATAAG	GCTAATGAGC	ACGTGAAAAG	ATGCTCAACA	TCACTAATCA	TTAGGGAAAT	18540
GCAAAAACGTC	ATTAAAATAT	CACCTCATAT	ACATTAGGAT	GGCTACTATG	AAAAAAACCA	18600
GAAAAATAACA	AATATTGGCA	AGGATGTGGA	ATAACTGGAA	CACTCATGCA	CTGTTGGTGG	18660
GAATGTAAAA	TGGTGCAGCT	GCTGTGGAAA	ACAGTATGAT	GGCTCTTAAA	AAAATTTTAA	18720
AAAAATAGAT	TTCTCATATA	ATTCTGCAAT	TCCATTCTCTG	GATATATACC	CCAAAGAATG	18780
GAGAAAACAG	GATCCTGGAG	AGATGTTTGT	ATACCCATGT	TCATAGCAGC	ATTATTACACA	18840
ATAGCTAACA	TCTGGCAGAA	CCCAATGAAT	GAGTGGATAA	ACAAAATGTA	GTATATACAC	18900
ACAATGGGAT	ATTAGTCTTA	AAAAGGAAGG	AAATTCTGAC	ACATGCCACA	ACATGGAGGT	18960
GCCTTGAGGA	CATTATGCTA	AGTGAAATAA	AGCCAGTCAC	AAAAGGACAA	ATATTATATG	19020
ATTCCATTGA	TATAAGCTAC	TTAGAGTGGT	CAAAATTCATA	GAGACAGAAA	GTAGAATGGT	19080
GGTTGCCGGG	GATGTAAAGG	TGGGCATTTT	TCAAAAAAAT	GAGAAATACA	GAAAAATAAA	19140
AATCACTCAC	TGTTTGCCAC	ACTTCTACCC	TGTTTCTTTT	TAAATCTATT	TTTCTTACTC	19200
AAAGAAATAC	ATGTTTATAG	TTTAAACATT	CAATAGTAC	TACAGGTTCTG	TAATAAACAA	19260
GAGCGGTCCA	ACTCCCCTCC	TCCTAGCCCT	GTGCTCCAGT	CCTTTCAGAT	GTGTTTCTG	19320
GTCTTTGTAT	TTCTCAATAA	CATGCCTAAA	TGTATTTTCT	GGCTCCTTGT	ATTGTTTATT	19380
TATTATTTGT	TGAGTTTATT	GCTATGAAAA	ATAGAGATTA	GATCACTTAC	AGGGTCTTCC	19440
TGACACCGTG	CTCACCTTCC	CCACCTATAT	GTACAATTCA	CCTTCCCTGT	CCTCATGGAA	19500
ATAATATTAC	TCTTTTAGTT	AAGTCACAGG	TCAGTATTTA	TGTTATGATT	ATGTAAATAT	19560
TGTTTATGTA	ATGTGCTAGG	GCTACTTTTT	TTTTCTTTAA	TTCTTATCC	TCCTTCACCC	19620
TCACCACCCA	ACCCCAATCT	CATCCTGGAG	TTACAGTTA	TCTCATTTT	CCTTTGCTTG	19680
GTTTTCTAAA	ATCTATCTCC	TGGCTCTTTC	TCCAACCTTT	CTCTCAGTAA	GATAGTTTCT	19740
CAGCTCTACC	TTTTCCCCTT	GTTGACATTG	CTCCAGAGCC	CTTCAACCTG	CTCAGGTGGC	19800
TATTCTGCTT	GGTCACTCAC	TTGTCTCCT	AGGTTTTCTT	ATCTCCATCA	TCTTGGGGAT	19860
TCTGGTCTCC	AATTTCTCTG	GTTAGACCAA	CTGTGCTCTG	GATCCCATAT	CTTTCTGTCT	19920
CTTAGTTTAT	TTCTTTGCTT	TGATTGAACA	TACTACCTAT	GACATTTCTG	AGAAACAATG	19980
AAAGAGAAAT	GATTTTTTGA	GTTGTGGGAT	GAATATTAAA	GTCACTACCC	GGGAAGGATC	20040
ATTGTGCCCTC	TATCTGTATG	AGGGATTCCC	CTTGCACCTC	TCAACCATAG	ACAGCTCTGT	20100
TCTGTCTCTT	GAGCTCTTGG	TGAACCCATC	CCCAGGACA	ACATTTCTAT	GTGTCTTGGT	20160
CTGGCACAAG	GTGACTACCT	ATTCCCAGCA	AATGCCAATC	AACACCTGTC	TTAATAATAC	20220

CTTAGCTTCA	ACACCCAAGG	TTTAAGTTGC	ATTAATCACT	TAATAAAGAA	ACCTTCACAA	20280
ATGCTAATTA	CTAACCTAGT	CCTTAAACCA	TACTCATTTA	AAGAGGTGGC	ATCTTAGAAG	20340
TTACAGTGTT	TATAGTCATT	CAACAAACAT	TTATTGTGAG	CCATATAGAA	GACACCATGC	20400
AAGGGCTTTA	CATGGGTAT	CCAATGTAGT	CCTCATGAAG	GTCTGTGAA	GTGGGAATTA	20460
TTGCCATTTG	TGAATGAGTT	TCAGAGAGAT	AAAACCTCTC	CAGCCATTCA	TTCAACACAT	20520
TTACTGAGTA	TCTACTATGT	GCTAGAAAAT	GAGGATACCG	CAGGGGGCAG	AGGCACATGT	20580
CCCTGACCTC	TTGGAGTTTC	TAGTCTAGCC	TAGTCTGTTT	CCAAGGGTAA	CAGATATTAA	20640
ATAAATAATT	TCACAAATAG	TCTATTAAAT	ACATTTGAGA	CAAGTGTCTAT	GAAAAAGAAG	20700
TACAAGATGC	TATGGGAATG	TATAAAGGCC	ATAAGCTGTC	CTAGTCTGGG	GCTCAGAGGT	20760
GGTTTTTCTG	AAGCAGTGCA	TTAAGTCTGC	AGGATAAGGA	AGAGTCAGCC	AGATGAAATG	20820
AAGTCTAAGG	TTGGAGAGAG	GGAGGGAACA	GCATGAGCAA	AGGCTCAGGG	GCAGGAAGGG	20880
GCTTTGCATA	TACGAAGAAC	TGAAAGGCCA	ATGCGGCTGG	AACAAAGAAT	GGAATGGTGT	20940
GGCATAAAGT	GCAGCAGGGA	CCGGGTCAGG	GAGAAGACCA	TAAAGCATT	GTGCACGCTG	21000
TTAAAGAATC	TGTATGCAAC	CTTGGTGGAC	GTGGGAGACA	TGACTGCTGA	ACTTGAAGCG	21060
CATCCCTGGA	GATGGGGATA	AATGGAGGGA	TGCGGGATGT	GTGAAGCAAG	AGGCTTGTTC	21120
ATGGTCAGAA	CCGGCATCTG	AACCCAGCTC	TCATGACAAG	TCTGCTGCTC	TTTTTGGTAT	21180
ACAAAACCCG	TTTCTTTCTC	TGTGTGAGAA	TGAACAAGGT	GCCTGCACAT	TTTTCTGCTC	21240
CAGTGCAGTG	TTTGAGGATG	CTAAGTTACA	CCCCAACAGC	TGTGCAAAAT	CTGTTTCTCT	21300
CTTGTGTAGT	GATGGAGGCT	ATACATTGTG	TTGTGAAAGG	TGTCACCTCAT	TTGGGAAATT	21360
AGAACAAAAC	ATAGTCATTG	CCTTTAACAG	CACACAGCCT	AATAGAGGCA	ATAGGAATGT	21420
AAACAGGGTC	CCAAGCCAAA	ACTTAACATG	AGCAAGTTAT	AGAATCATAT	ACAATTCTTA	21480
GGGTCATAAT	TCTAGGGCTA	CATGTTTTGA	CTGTTTGACC	ACACTATATG	CAGCAGTATC	21540
GTTAATGGTC	CTGGATCTAG	GCAGCATTTT	CCGAAGTAGA	CTTAAATAA	CATCACTCTT	21600
AGACTGGTCT	GATTCTCTGT	TTTGGCTAGA	AATTGTGTTC	CTCAAGAATA	ATAACACATT	21660
TAAAATCATC	CTTATTTTTT	AAGTTCAGAT	ATTCTGCTAA	ATCATTGATC	TCCATGAATT	21720
CATTGGTCAA	TGTTTTAAAA	CTTCTCACA	AACGGGCTTA	TTGGAAATGG	AGGCAGAAAA	21780
TAAGGTGTTT	AATAATATGA	CCACATGGTC	TAAATTTCTT	ACAATACGCT	TAGTTTACAT	21840
GTGCAACACC	TTTGTGAGAC	ATATACCCAA	TTTTGGTTTG	AAAATAGCAT	TTACTTCCCA	21900
GGAGTGGTGT	GTAGGAACTT	AAGGGTCTTA	GTATGTATGT	CTCTAGTGGA	AACTTTGGGG	21960
TTCAGTTTGA	AAAGGCAGTG	TATCTCATGT	GGATCCCTGT	GATTCTCAGG	GATTCTATAC	22020
TAGGCAGTCC	CTTGTGGATG	CCTGGGGAAG	TCGGGCTGTG	ATCCTTACAG	ACCTTCTCTG	22080
AGCTGCCATA	CAGATGGGGC	AGAGGGTGAA	TGATGGAAAA	AGAACAAATG	TTGCTGATGG	22140
TCCATGATTC	GTCCGCAAAT	ATTGTAAAAC	CCTGTACTAC	CTGGCTGATG	CTTTAACAAA	22200
ATAGCTTCAG	GGACATTAAA	AAAGTAGTGT	TTCTTGGTGT	GCTGGTAAAT	ATTTATTGAT	22260
ACAAAGATTG	TGTAATCACA	ATTTAAAAATA	TACAGTACTC	TTGATTGTAA	ATTCCTTATA	22320
ACCAATTGAT	CCCCACAGAA	TGCTCTTGTT	GACTTTTGT	TGAGGCTCTT	GTATCTATAG	22380
TGTATCCAAT	CTATTATTGC	AATTGATGGA	CAAGTGCCAT	TCTGATAAGA	ATGTGGGCTG	22440
AGATTTCCCT	TTATGTTAAT	GAGTAAGAAG	AAAGGGAAAC	AGCAGAGCTA	GACACTGGGC	22500
CTTCAATCGT	TTGTAAACAA	CACGAGCAAC	CTTTTTGTTG	AACTGGATAA	TAGTTTTTGA	22560
ATACTGGAAG	AATATTTCTT	CAGTCTTTTT	CTGTTATTCA	CCATGCATTG	GCTACAGTCA	22620
CATTTTAGAA	TTTAACCTGC	ATTATTAGCA	TTTCTCCATC	ACTTTTTATA	AGTCTAGACT	22680
GGGGATTATT	AACTGTGGT	CTAGGGGCCA	TATCTGGTCC	CCTGACCTGT	TTTCGTACAT	22740
AAAGTTTTCT	GGAACACAAC	CATGTCCACT	AGTTTTATAT	ATTGTATATG	GCTGCTTTTG	22800
TATTACAATA	GCAGAAGCAG	AGTCGAGTAG	GTTGGACAGA	GATTTAATGG	ACGCAAAGTC	22860
AAAATTATTT	AATATCTGGC	CTTTTGCAAA	ATAAGATTTA	CCAAGCCTTG	GTCTGGGTGG	22920
TCAACAAAAC	AATAAATCAA	GCCTTGATCT	GTAGTGCTG	CCAATTTCCA	TGGTGTAAAT	22980
ACTCCCATGA	TGGCCAATTT	CTATCTACCA	ACATGACACA	GCAAAACATA	GAGTTGGGAA	23040
GAGATGTGTA	AAGTACACCG	TTATAGAGTA	TTCTCACTCT	ATAGCTACAG	TGGCTATAAA	23100
TAAGTTCCAG	AGCATAGACA	ATAGTAAAAT	GTAGTCATAA	TTAAGAACTG	GTAAGTTTTG	23160
AGTGTTTATT	ACCTTTGTTT	CTAAATACAA	TTTATTTAAT	TTTAAGTTTA	TATTTTAAAT	23220
TCGAATAATG	GCTGGGTTTA	ACAAGTGGTT	TGCAAAATCT	CTGAGAACTT	AACAATCAGT	23280
TATCATGAGT	TGGCACTATT	GCTTTCCCTT	GGTGCCGAGC	TGTCTTCTTT	TTTCAGCCAT	23340
TTCCCTGTCT	CCAGGAGATA	ATCCTTTTTT	TTCTTCTCAG	CCTGTCTGCT	TCCCAAAGTA	23400
TCCTTTGTTT	TTTTCATGGC	CCTCTGGCTA	CGCAGGGACC	CCACTTTTTG	CCAAACTAAT	23460
CTTTTAAAAC	ATATGTCCCA	CAGAGTACCA	TTCCCTTCA	TCTGCTTCCC	ATCAATACTC	23520
TTATTTCTAC	AATAGGGTTG	ATACCAAATG	GCCAGCAACA	ATTTGTAATA	AGCTGTAAAT	23580

GATTAATGGC	CTGGAAACAC	TTGCATTTTA	AAAAAAGGAG	TCTTGTGAC	CCAAAGGTTA	23640
TAGGGTTTGA	ATGTCTGGCA	ACATTGCAGG	TGTGAGGAAC	GTCTTTGGAA	TTCTTAGTTC	23700
CCCCCAAAG	GTTACTGTCT	TCTTCAGTGA	CAACAACCA	ACCCAAGCGT	GTACCCTGAT	23760
GCTCCTCATT	ACCCCTCAAA	ACTTTTTCCT	TTTCAATCTT	TTTAGTTTTA	GCTCTTTATT	23820
TCCCCTCCAC	TTTCATTCCCT	TATTTAAACC	TCTCAATTGT	AACTGAAGCA	GATGTTATAT	23880
GGACTTGGGG	AAAGGGATCA	AGAAATCATT	CAGTTGTTTG	TGCTTATCTA	GAACGTGCAG	23940
CCCCTGAATT	GTGTGGTCTT	GGCTGGCATC	TGAGCACACC	TGGTGCATCA	GCAGAATCAG	24000
TGTTCTCTCA	GTTCTTGGTT	GGCTCTACTG	TCTGGCACCA	TTCGGCTGTT	TGTACTTATC	24060
TGGAAGTGCC	AATGGGAAGA	TCACATGGTC	ATTGAGAAAC	CGCACCCCTGA	AGAGATGGCT	24120
AAAAGCCTGG	AGGGCATGCC	CATCACAGCC	TTGCCGGGAG	TGTGAAAGGT	GGTGTGAAGA	24180
CCCTGGGGCT	CACAGGACTC	CCTCACCATG	GGGCACAGTG	TAAGAAGGTC	CACGGTGAAG	24240
ATGCAGTAGG	AGGCAGTTAC	ATCAGGCTCT	GGATCGATGA	TATCAAGGAA	CAACCCAGGC	24300
TGAAGGAAAA	GGCGTTTGTG	TTTCAGGAAA	GATGTATTGA	GCCTCATCCA	TGCTCCAGAC	24360
TTTGTTTAGG	CCCTGGGTTA	CAGCATGGAA	TGGAATGAAA	CCCCGTCTCT	TTAGTTTCTT	24420
ACATGTTGAG	TGGGTGAGAC	AGAAAGCAGC	AATATGGTAA	AGAGGGGGGA	ACAGGGGAAG	24480
AATGGTAGGA	GATCAAGTTA	GAGAGGGGAA	TGGGCTAGAT	CATGGAGCAA	CCGGGGCAAG	24540
ATGTCAGACC	CTTGGAAGGT	TTTGAGCAAG	TGGCTGTTAT	GTTCTGACTT	ACGCTTTGAA	24600
ACACTCTAGT	TGCTGTACAA	GGAGACCAGG	TCAGAGGCTA	TTGCAGTTGT	CCAGGTGAAG	24660
GTGGCCAGGT	AGCGATGGAG	GATGAGAAGT	AGAAAATTCT	GTGAAGGCAG	AGCTGACAGG	24720
ATTTACAGAT	GGATTGGCTC	ATGAGAGGAA	AAGAGGGACT	CACGGATGAT	GCCAAAGTTT	24780
TTGACCTGAG	AAACTGGAAG	AATGGAATTT	CCACTTACTA	TGATGGGAGA	GGTTGTGAAA	24840
GGATGACTTA	GGGGTTGGAG	AAAACCAGGA	GTTTGGATAT	GGGCCTTAGA	TATTGCCATG	24900
CAGATGTTGA	GTAGACAGCT	GCACATATGA	GTTGGGAGTG	CAGAGGGAGA	GGCTGGGGTT	24960
CTGGGTATCA	GTATATGAAT	CATCTGTGTC	CACATGGCAT	TTAAAGGCAT	GAGACCAGGT	25020
GACCCCCCTT	ATAGAAAGAT	TAGATCCAAA	AGAGTAGTGG	TCTGAGGACT	GGGCTTTAGG	25080
CCCTGATGCT	CAGAGGTGAG	GACCCAGGAA	AGGAGACACA	GAGAATCCTC	TTTGTACAG	25140
CATTACAAA	GGGCTATTTG	GAAATAGTTC	AGGTGGTGAC	TGGGTGAAAA	GCCCTTCGAA	25200
CAGCCTCAAG	GACCCAGGCT	GGTGGACTGC	TGGCTGAGTC	CTGTTGTGCC	TCAGAGGATA	25260
TTGTAATATT	TGGAAAAATT	TCTCCAAGTC	AAATTTAAAT	TAACATGAAT	GTCATATGGC	25320
TTTTTGGTAC	GTCCTACAGT	CAAGCAAATA	ACAATTGGAT	AGGGTAGCTG	CAGGAAGACT	25380
GGGTGTCTCT	ACAGTGGTCA	AGTTGGAAGA	ACAAAGAATG	AGTGATTGAT	CTTTTGCTAC	25440
TCCCCAAGGG	GAGAAGCCAC	TGATAGCTTC	CTTGAAGCA	CTTTGTACCT	CACCTGCCCC	25500
AGAGTAGATT	AAATATTAAG	TTTCCTCCCT	TCCTTCAAGT	CCTAGTGCTG	CCATTGATAG	25560
TGCTGTGACT	TCAGGAAAGT	TGCTTAACTT	TTCCAAACCT	CTATTTCCTC	ATTACTAATG	25620
AGTAATAATT	CCCACCATAG	GGTGTTTATA	AAGATTAAAT	AATTTTAAAT	ATGTTGAAGC	25680
ATGTAGTGAA	CTGCAAAGCA	ATATGCAAAT	ATAAGAGGTG	GAAATGACTA	TGCCTATAAT	25740
TACGTGGCTC	AATTTACACA	ATAATAGATT	TTACACCTTT	GCATAAATAA	TGAGGGTTTT	25800
TATACTCAAG	TCACTGAAC	TACTATCTTC	AGGATCCAAA	ATCCCCAAAC	AGAAGGCATC	25860
CCCTACTGTT	AGCTCAAATA	GCTCTTGCTG	GTTTAGAGAG	TTAATGCAAG	CCCCACTGCC	25920
TCCTGAGCTG	GAAACATGAA	ACAGAAGTTT	CAGTTCCCTA	ATCAATCCAT	TCTTTCTTCC	25980
TCTGGCTTCT	GATAGGCCTC	CTCCTTATCT	TTGTAAACCC	TGTAGCTGGT	TGCTAGTTGA	26040
AAGTGCCTCT	GATCTCCCTC	TTCTGCCTCC	CATGATGTTG	ATAAAAAGCA	CGAGGGCACA	26100
TGCAGGATGA	AAACGATCGT	GGTCCTGCCA	GCCTGAATTA	TTAAAGCATT	TCAGTCCATA	26160
GTATGAGGTG	TGTATATGTT	GGGGTGTGGA	GTGAGTTGTG	GAGATGAGAG	ACAGCTGAAT	26220
TACATAAAGT	TGAGAAGATC	TGAGTTCTAG	TCTTGAAATT	CACAAGCCAT	CTCTATACAA	26280
TAGTTCGGTT	ACTCAGTAAA	GTAAAAGCAT	TGGATCTAAG	CTTTAAGGAC	CCTTCTAGTT	26340
CTTTCTGATT	GGAAATCTGT	GACTTCATCT	TTTGTGGGTT	AGAAACTCAT	CACCTGTGTC	26400
AGTTATTTCT	ATATTATGCC	ACCAGATGGC	AATGTTTCTT	TAACCCCAAA	GAAAGTTTTC	26460
ATTCTGGTAA	AAAGTCAAGT	TTTGTGCGCA	ACTTTTCCCC	CTCTGAACGT	GCAAAAGAAT	26520
GATTTTCCGA	AGCTGTGGAG	GAAAGAAAGA	ACTCTCCTTC	TGAACATCTC	AGGTGGTTTA	26580
TGCTGGAAC	AGACAGGACC	CTGTTTAGAG	AAGATCTCTC	TTTTCTTCGT	GGACTGGGAA	26640
CTCCAGTTGG	AATGATGTCT	CCTGTGATTG	CGTATGGTGG	GAGGTGGGAG	ATGTTGGAAT	26700
TGGCGTGTCC	TCAGGAGGCT	TGGGGGTGGG	GGAGATGTGC	CCTAGCTGGT	GGGCCTGCAT	26760
GAGCCCTGCA	AAACTCTGAC	TTATAGAGGG	GCATCAGATG	CCAAGTTTTA	CCAGACCATG	26820
CAGAACTAGG	AATTGCCAGA	TGCACTCATA	GGGCAGCTAA	AATGGTCTCT	GCAGAATCAG	26880
ACTCTTTTCG	TCATAAAGGT	CAGAGACGCA	AGAAAGTGAC	ATAAAGTCCA	GCCCTTTTCT	26940

TGTGCAGATG	GGGAAATTGA	GGCCTAGAGC	AGGTCAGCTG	TCCTGATTCT	ATCTCCTTGC	27000
CAAGTTACTT	TGTATTTAAA	CATTTCAAGT	AGACTTTTCA	ATCATCTCAT	CTTGCTGTGT	27060
TCAGCTAGCG	CACCTTGTTA	AGCCTGTTGG	CCTCCGGGCC	TGCCAAGCCC	CTGCATCTAT	27120
ACACACCAGG	GCATGCTGCA	TGCGCTCAGT	GAGACTTCAA	CAGCTGACTG	ATTCGTTCAA	27180
ACCTATCAAA	CAGCAGACTT	AGCTAGTTGG	GGAGAAAAGT	CATTTAAAGT	AATTGCTTAT	27240
TAATCTGCAA	AACAAGTCTC	ATAGCAGGTT	TTTATTTTAT	TTTATTTTAT	TTTTTGTCTT	27300
TTAACAACGA	TATAATAACA	ACAAACATTT	GTTTAGTGTT	TCCTGTGGAC	CAGGCTCTGT	27360
GTAAAGCACT	TAACATCACT	ATATCATGCA	CTTTTGCTAA	TAAAGCTGTG	AAATAGTTAT	27420
TACTATTTCT	GCTTTACAGC	TGCAACAGAG	ACTCAGAGAG	GTTAGGTAAC	TTGCCCCAGG	27480
TCACAGAGCT	GGAAGGAGCA	GAGCCAATAT	TCACACCCTG	ATTTGCGTAA	TTCCAGATTT	27540
GATCTTCTAG	CTTCTATGCT	GTGCTGCCTC	TTCATGACAG	TTTTTCTCAT	GTACAGGATC	27600
TGATGCAGAA	ACTTATCGGA	GTTTCTTACC	GGAGCACCAG	TCACCTCTCA	TCATTTTCCT	27660
GTTTTGACGT	GAAGGCTCAG	TGATAGTGAG	CAGGCTCAGG	GTCTACAGAG	TTGGTGATAT	27720
CAGCATCACA	CAGGACATTC	AGAATGTTGA	CTCCAGGGAT	GTTGAGAGAT	ACTCCTGCAC	27780
AAAGCTGCCA	GCACCCGTGT	CCAAGAAACA	CTCAGAATCT	AGGTCTCCTT	GTATATTTTC	27840
CCCACTACCT	GCAAAGGTAA	AGAGGAACAG	GCAGTGCTGG	GACCGAGGGA	GCGCAGTCC	27900
TAATGGAAGC	TAGTGTGTTG	AGAGTCTCCT	CTGTGTCTATG	CTCTGAGCGA	CATGTTTTAT	27960
ATGCACGATC	TCATTTAGAC	CTTGTGACAG	CATGTTGTAG	CAAGGACCCC	ATCATCACAG	28020
GGGGCAAATG	TCTGCAGTGC	AGAAAGTCGT	CCTGAAGAAA	TGGATGTCAG	ATAAAAACAG	28080
TCTTCATAAA	TCAATGATCC	TGTTTTACCT	CAAAAGTGCA	TGAAATGGAA	ATGGAAATAT	28140
CTTGTGAAGA	TGTAGACAAA	TGACGGTCAT	TGCCCAGAGC	AGTAGTTACT	GTGAGAAAAA	28200
GAGATAAGGA	TTTCCAGTCT	GACAGACTGG	ATTCTCTGGT	CAACACCACC	CCCTTCTAAC	28260
CATGTGACCT	TGGGCAAATT	ACCTAACCTT	TTCTGAGTCT	CAATTTCTCT	ATCTTCCAAA	28320
AGGGGATAAT	ATCATATATG	TTCCAAGATT	GCTGTGAGTA	TTAAATGAGA	TGATGTATGT	28380
AAAGTACCTG	GCCAGCAGTT	TCTGGCACAT	AGTAAGTATT	CAATAAAGAC	TAATGGTGGA	28440
GATGAGTATA	GGGGCTACTA	ATGCCCATCC	TTACTCCAGA	GACTTCTTTC	TGACCATCAT	28500
GAGGCACCTT	TGAATATCTA	AACCCATTTA	AAGCCCACCT	TTCTCTATGG	CTGGCCATTT	28560
CTGCCTATTG	ACAGCTAATT	TGCCTCATCC	TACAGGACAC	CTTCCATGTT	TCCCCAGACT	28620
CCAGAAATCA	GGTATTAAAT	TATCAGGGCT	TCAGGAGCCA	TGGTCTATGA	TGAGTTTACT	28680
ACCTGTGCCC	AATAAATGTT	TAAGAAATAA	ATAAGAGCCA	ATATAACTAT	AAAGACCAAG	28740
AGCCAAAATA	AGTCTCTTTG	CTTGCGCTTT	AGATCTTAAAG	AGTCCTTTAT	ATTCAAGCTG	28800
CTCAGAGTCA	AACGTGTGCC	TAATAAACAT	TCTACAAAGG	TCCTGGCGTG	GTGTGACCAA	28860
AGGAAGAGAG	AGGGCTCCAG	TGTCTGTCAC	TGGGAGACCA	GATGGACAGC	CACGTGGGGC	28920
AGGGCCACTG	GTGCCACATG	TCCAGGTCTG	TTAAGCCCTA	TGAAAGACAC	TTGAGTCAAA	28980
ATGTATTTCT	ATCTAAGAAA	GAAGACTATA	AATGGAAAAG	GGAGAGGGGA	GAAGACCTCT	29040
CAAGGGCATC	TCCCTCTAGA	AGTAGAGATT	GTGAATCTGC	AGCAGAAAAG	TTTTAAACAA	29100
GGGATAGCAG	AATGCCTGGA	TGGTGTCTTA	TGCGCTGAAT	GGAAAAAGGC	CACATTGACC	29160
AACAAATCCC	ACCTACATCC	GCCTTCCTCG	CTGCCTGAAA	TCCCACCATT	AGGATTTTTT	29220
TCCTTTTGGG	TTAGCAACCA	AGAAAGAGTA	AAGTCTGGAA	GACTCTTATT	CCACATCTTC	29280
ACTTTGCAGC	GCCTCTTTTT	TTTTTTTTTT	TTGAGATAGA	GTCTTGCTCT	GTCAACCAGG	29340
CTGGAGTGCA	GTGATGCGAT	CTCAGCTCAC	TGCAAGCTCT	GCTTCTTGGG	TTACATCAT	29400
TCTCGTGCTT	CAGCCTCCCG	AGTAGCTGGG	ACTACAGGCA	CCTGCCACCA	CTCCCAGCTA	29460
TTTTTTTTTG	TATTTTATAGT	GGAGACAGGG	TTTCACCGTG	TTAGCCAGGA	TGGTCTTGAC	29520
CTCATGATCC	GTCCGCCTTG	GCCTCCCAAA	GTGCTGGGAT	TACCACCTCT	TCTTAATTAC	29580
AAACATAAAC	AAAAACTAAC	AACCTTCTAG	TTTTTCTTTT	TTCTTTTTTT	TTAAATTACA	29640
AAAGAGATCC	ATATTCGTCA	GAGAATAATT	GGAAAAAGA	GATAAGCAAA	ATCAGAAAAA	29700
TAAATTCAGC	CTGTAATCAC	CCAGAGATAA	CAATTATTAA	AATTTAGGTA	TTCACTTTGT	29760
TATTTCCCTT	TATAACAAAA	CTTTTTTTTT	TTGTGAAATT	TAATAGAATA	CAATTGAACT	29820
ATTTTTCTCT	TTATGGTTAA	TGATTCCTGT	TTCTTATTTA	GGAAATCATT	TCCTGAGTCA	29880
TAAAGAATTC	TCTCATATTT	TCTTCTAAAG	CTTTATACAG	TTTTGCCCTT	CAAATAAGGT	29940
TAATAACCCA	CCTAGAATTG	ATTTCTGTGT	ATGGCATGCA	GTAGAGACAA	GTTCTACTTT	30000
TTTCTCTCAA	ATGAATATTC	AGTTGGACCA	AGGCTGTCCT	TTCTCCACTA	CTTTGCAGTT	30060
TCACTTTTTG	TTGAAAAATC	AATTGTTTCAT	ACATGGGTAG	ATCTCTTTCT	GGGCACTCTT	30120
GGAGTCTATT	GGTCTGTCTA	TAAGTTGAAC	AGGATCAGAC	AGGCTGTGCT	TTGTTTCAGG	30180
TAACAAAGAA	CCCCAACATC	TCAGTGATGA	ATACACTAAA	GTCATTTTTG	TTTTCCATTG	30240
GCAGTTCACT	TCTGATGCAG	GAGATGCATC	AGGGCAATCG	CCCTTTGCAA	GGTGAAGTGT	30300

CTGCACCATT	GGAAGTACTC	TCCATCCAGG	GGAGAGAGAC	TGGAAATGGT	CCATGAGGTT	30360
TTCATCGACC	CAGAATGAAA	GCATCACCCA	TCATTCCCTT	CTTGTTACAG	CCTATTGTGC	30420
AGAACCAGTC	AGAGTTCCAC	CCACCTGCAA	AAGGTTGTGA	CGTGCTGTTT	GCGATTTGCC	30480
TGGAAGGAGG	GAATACCCAG	ATACAGGAAA	ATGCTAGTGA	CGTGCACTTC	CATCTAACTA	30540
TCTTTGAATG	AAAATGACAG	TCTTAATTAC	TGCAGTAAGA	TAAGCAGACT	CTATACCTGG	30600
TAGAGCAAGT	CCTCTTACCC	CATTTCTTCT	TCAAGAAGGT	CTTGCTAGT	TTGGAACCTT	30660
GGCAATCCCA	TATAAACTTT	AGAAAATGCT	AGTTAAGTTC	TTTAAAAATC	CTGCTGAGAC	30720
TTTTATTGAA	TCCATAGCTT	CATTTAGAGA	GAGCTGACAT	TTAAATTAGG	GAGTGTCTCA	30780
AGCCACTAAC	ATAGAATTTT	TCTCTTTTAC	TCCAGGTCTT	CTTTAATTTT	TCTCGAGTGT	30840
TTTGTAATGT	TTTGCACAAA	GTTCTTGCAC	ATCTTTTGAT	AGATTTCCTC	CTAGGTTTGT	30900
GATATTTTTA	AGATGCTAGT	GTAATGTGTA	TTGCTATATA	TTTTTCATTT	TACAAATATA	30960
TGTGTTTAGT	ATATAGAAAT	TTAATTCATG	TTTCTGTATT	GACTTTATTG	AGTAACCTTA	31020
TGAAACTTTC	TTAAATTCTA	AAAATTATCC	ACAGCTTCCC	ATAGATTTTC	TATGTAGGTA	31080
ATAACATAAT	CCACAAAAAT	GACACTTCAA	TTTTTTCCTT	TCTGTTTCTT	ATGTCTTTAT	31140
TTCTCTTTCT	TGCATTTCCC	ATGTGGGGTC	CCTAGACACT	GTTGAATAGA	TGTCGTGATA	31200
GTGAGCATCC	CTGTTCTGTA	CACAGCCTCG	AAAGGAAAAAT	TTTCAGAGTT	TTGTTTTAAA	31260
CAATCTGGTT	GTTATAGGTT	TTATTGTAGC	AGCTCTTCAC	CAGATTACCT	GCATGTTTTT	31320
TTTTTTCTAG	TTTCTAAGAC	TTTAAATCCA	TTAATGAGTG	GATGTTGAAT	TTTAACAAAT	31380
GCTTGTCTCT	GCATGTATTG	AAATGACTAT	ATGACTTTTC	CCCAATTGAT	CTGTTAAGTT	31440
GGTAAATTAC	ACTGATATTC	CAAAGTTAAA	GCAATTTTTA	CACTGGCACC	CTCAAGTAAG	31500
CCAAATTTGG	ACATGATGTA	TTTTTAAATA	TATATTGCTG	GTGTTGGCCT	GTTAATATTT	31560
TATTTAGAAT	TGTTGAGCCT	ATGTTCAAGA	ATAAAATTGG	CTTGTGATTT	TCCTTCACAT	31620
ACTGTTTATA	TTGGGTTTTG	GTATCAAGAT	TACTCAAGCC	TCACAAAATA	ACATAGGGAG	31680
TCTCATTTTT	TCTATTTTCT	GGAAGAGTTT	GCATAAGTGT	GGCATTATAT	CTTCTTTATC	31740
TCATAAAATT	TGCTTGAGCC	ATCAAATCTT	AACATTTTAT	GACAGGTTGA	TTTTTTATTA	31800
AATCAATGAT	TTTAATAGTT	ATAGGATTAT	TAGGATTTTT	TATTTCTTCT	TTTGTTAATT	31860
TTAGTAAGTA	GTGTTTTTCT	AGGAATTTGT	CTATTTTATC	AAAAATTATA	AATTAATTCA	31920
CAGAGTTGTT	TATAATATCT	TCTAATTATC	TTTCTAATGT	CTGCAACACA	TGTAATAATG	31980
TTATTTTTGC	TTATAAATTG	ACAAATTATA	ATTGCGTATA	CTTATGGGGC	ACAAAACAAT	32040
GTTATGATTT	ATGAAAGCAA	TGTGGAATAA	TTAAATCTAG	CAAATTAATA	TATCCATCAC	32100
CTTAAATACT	CATCATTTTT	TGTGGTGAAA	ACATTTGAAA	TTCACTTTTT	TTCACAATTT	32160
AAAAATGCAC	AGTACACTAT	TATTATCTAC	AGGTGGTTCC	TGACTTCTTA	TGATGATTTG	32220
AATTATCACT	TTTCAACTTT	ACAATAATGT	GAAAGGAATA	TGCATTCAGT	ATGCTCTATG	32280
ACTTATGTTG	GGATTATGTC	TGGATAAACC	CATAGTAAGT	TGAAAATATC	AATGGGGCTCA	32340
TCCAGATATA	ACTCCATCAT	AATTTGAGAA	GCAGCTGTAT	ATTTATCATG	GTGTGCAATA	32400
AATCTCAAAA	AAAGACTTAT	TCCCTCCGTC	TGAGATTTTG	TACCCTTTGG	CCATGACTCC	32460
TTCAATCCCC	TCACCCACAG	CCCCTGTAAC	TACCATTCTA	CTCTCTGCTT	CTATGATTTT	32520
GATTGCTTGA	GATTCCACAT	GTAAGTGAGA	ACATGTGGTG	TTTGTCTTTC	TGTGTCTGGC	32580
TTATTTTTACT	TAGCATGATG	TTCTCCAGTT	TCAGTGATGT	TGTTGCAAAT	GATAGAATTT	32640
CCTTCTGTTT	AAAGGCTGAA	TTATCCCAT	GCATGTATAT	ACTACATTTT	ATTTATCCAT	32700
TCATCCATTG	ATAGACACTT	AGGTGATTC	CATAACTTGG	CTAGTGTAAT	TAGTGTGCA	32760
GTGAACATGG	GAGTAAGGAC	ATGTCTTAGA	CAATCTGATT	TCAATATTTG	GATAAACACC	32820
CAGAAGTGGA	GTTACTTGGT	CATATGATAA	TCTAGTTTTA	GTTTTTAAAG	TAACTTTCAA	32880
ATAGTTTTTC	ATGATGGCAG	TACTAACATA	CACTCCCAAC	AGTGTAACAAG	GGTCTCTCTT	32940
TCTCCACAGA	TGTTCTCTTT	TTCAATCTAG	ACATGAGTTA	TCTGTGCCTT	TCCCATTTTT	33000
TGTCTTCATC	TGTCTCAGCA	GAGGTTTATC	AATTTTATCA	TTTTAAAGGT	AAAAATGTGT	33060
ACCTTTTAAA	TCTTGTCTAT	TGTATTTTTT	TGTTTCATTA	ATTTTGTCTC	TGATTTTGT	33120
ACTTCTTTT	TTCCATATTT	TTAGGAGATG	ACTTTGCTGT	TCTTCTAACT	TCTCTTTCTA	33180
GGACTCCTAG	AAATATGTTA	AGTCTGCTCA	TTGTATTTTT	CTCACCTTTA	TATTTTCCAT	33240
TGTTTTATCT	CTTTCTTATT	CATTCTGGGT	AGTTTCTTCT	AATCTACCTT	CCAGTTCATT	33300
AATTATCTCT	TTACCTGTGT	TGAATTTGCT	ATTAAACCTA	TCTGAATGAC	TTTTTCATTT	33360
TTTATTGGGT	TTTTAAATGT	TAAAATTCTC	ATTCCTATTT	GGTTCTTCCT	CAAATTTGCA	33420
ATGATTTTGT	TTTCTGCTAT	TGCCAAAACG	TTTTTAGTTT	AAGTTCATCT	CTTTGAGCAT	33480
AGTGAGCACT	GTTGTTTTTAC	AGTCTTTATG	TAAATACCTT	CTCTTTTATT	AATCTTTCCA	33540
CGTTTCTGGT	GGAGGGACTG	GCTATGAGAG	ACAAAACTT	TCTTTCAGGT	GCTTTTAGGA	33600
CTTACCCATA	TTTCTTTCAT	GGTGCTTATT	ATTTTATTAT	CTCATTATTT	AGATACTTTT	33660

CTCCTCTACT	AAACTAATGG	TTCAAGGCTT	ATCAAAGATA	AATCCTCTGT	CTTGTTTCATC	33720
TCTGTGTCTC	TCATGGTATC	TAGCAGACTT	CCACCCAAGA	TATAAAGACA	CTATGACTAA	33780
GTGAATGATT	TTAGTCTTAC	CTACCTGCCT	GTTAACTTAC	CTACTTGCAT	CTCACTTATA	33840
CTTCAACTTT	TGGCTTCTTC	CTCAACCTCA	ACTACCCCAT	TCTTCCCATG	GCTCACTGTG	33900
CTCACTGGCC	TCCATACTGT	CCCTTAAATA	AGGAAAGCTG	CCCTAGCCTC	AGGGCCTTTG	33960
CACCTGCTCT	GCCTGCTGTT	TGGAATGCTC	TTCTTCCCAT	ATACCCATCT	GTTTTAATCC	34020
CTCATCTTTT	ATTCCCTCAT	CCCATCTCTT	CAAATGTGAT	TTCTACAGAG	GGTTCTCTGA	34080
CCACCTTATC	CAATAACCAG	CATTCCGTCT	CCCCTCTGCC	ATTCTCCATC	ATCTCACCAT	34140
GCTTTATATC	ACATATCACT	AAGTGACAGT	ATACTATAAA	CGTACCCATT	TGTTTACTGT	34200
CTGCCTCCCT	AACTAATGTA	TAAGCTCTCT	GAGGGCAGGG	ACTCTGTTTT	ATTGTACAC	34260
CACAATTATC	TCCAGTGCCT	TGAATAGTGT	CTGGCATGTA	GAAGGAATTC	AAGAAATACT	34320
TGTCAAGCTA	GGTGCTGTGA	TAACTACTTT	ATATGAAATT	AAGTATTTCT	CCTCCAGCAG	34380
CTCTAAAAGT	TTAGTATGTT	ATTATTGTCT	CTGTTTTACT	GATGAGTGAA	CTGAGGTTCA	34440
GAGAGGTTAT	TTAGCATACG	TATGAAGACA	GAATTAGTGA	GTGATTGACC	TGAGATTTGA	34500
ACTCAACCTG	TGCTGTCTAA	AGCTAGCCAG	GCAGCCTCAC	ATACATGGCA	AATGCCTACT	34560
GAGACATGAA	CATGCAGGTT	GGGATCCCAA	ACTGTTGGGA	AGCATAAAAG	AAAAACACTA	34620
AAGATGTGGG	GAGTGTAGGA	CTTTTTTTTT	TAATAGGCCA	GTGGCCCTCT	CTGCAACCCCT	34680
TTGAATGATC	AGCTTGATCA	GAGAATCCCC	TACCCCTACC	CCTGCCTCAG	CCAGTTTCTA	34740
TCTGGCTGTG	TCATCAGCTG	GCTGATCCAA	ACAGCAATGT	CAACAAAAGA	ATGGTGATCA	34800
GGCAGCTAAA	GCAATGTGTC	AGAAAGAAAG	AAAAGGCAGC	TCAGATGATG	CAAGATCATC	34860
CAGATGTCAA	GCACTGTGTG	GTGGCACACT	TGCCCCGTTCA	TGTTGTTGAT	TTTTTAAACA	34920
TTTGTGATAA	GAACAAAAC	TTAGTTGCTT	CCCTCAGGTC	CTCCCTGTAT	GGATTAGTGC	34980
AGACATCTGC	CGCTTCAGGC	TTTCTGATTG	GTTCCCACTG	GTTTGGGGCA	AAACCCGAAA	35040
CTTCTGAGCC	AAGTGCAGGG	GCAGAAGAGC	TCCCAAGAGC	TCCTGGGAAA	ACTAGGAAGG	35100
ACAATCAAGA	AACCACCGGC	AGCTCCATTT	GCAGGATCTC	ATCCCATCAG	GGGCTGTCTC	35160
AGGAGGGGGA	ATTGGAATAC	CATTCACCTG	TCCCCTTTGC	AGATACACCA	ATGTCTCGTT	35220
CAAGAACAAG	CAGAAAGGAA	ACACCAGATT	GCCCAGAGCA	CAGGATTAGG	ACACACCACA	35280
CAGAGCCAAC	TCAGCGTATC	ATTGTTTGCA	TTGATCATCT	GGGGATGAAG	CAGGCTCCGT	35340
TCTGGAAGGG	GCAACCTGAA	TAGAGAAGAG	TCTGACATTG	GAGTCAAGCA	GAACCTGGTT	35400
GGAAATTTGGC	TCATTGCTGG	GTGATCCAGA	GACAGTTATT	TAATCTGAGA	ATCAGATATC	35460
TTGTCTGTTA	AATGGAATTT	ATAGTAGCCA	CTTCACAGGA	TTGCTGTAAA	GAGTACATAA	35520
AACCAGGTAC	CTGCAATGTA	TAGTGCTAAG	CCTGACACGT	AGCAGGGTGT	TAGTAAGTGG	35580
TACCTCTGAC	TGGGGATGGA	AGCCAGAGGA	GCTGGACCTT	TATTTGACTG	GCCAGAAGCC	35640
AGCTCTCTAG	TCACCTTCCT	GATCCTTCCT	TCTTCTGTGT	GTACACGGAC	AATGTTTTTC	35700
TACATAATGG	AACAGTGGCC	CTCAAACTT	GTTTTCATAA	GAATTATCCA	GGTTGCTAGT	35760
TATTAATACT	AGTTATCCAG	GTTGCTAGTT	ATTAATACTA	GTTATCTGTG	TTGCTAGCTA	35820
AAAATACACT	CAGTTCCTAT	CCCCAGATTT	TTCTATTTC	GTAGGTGGTA	GTGGGTTTCAG	35880
GAAATCTGTG	TTTTTACCAA	AGTATCCCTT	ACTATAGAAT	TAATTTTTGT	GTTCCCCCTT	35940
CATTATATG	TTGACATTTA	AACCTCCACT	GTGATGATAC	CAGGTGGCTT	TGGGAGGTGA	36000
TTAGGTGATA	ACGATGAAGC	CCTCATAAAT	GTGATTACTG	ACCTAATAAA	AGAGACCCCA	36060
GAATGCCCCC	TTGTCCCTTC	TGCCATGTGA	GGTCACGGTG	AGAAGATGGC	ATCTATGAAC	36120
TAGGAAGTGG	GCCCTCACCA	GACGCTGAAT	CTGCTGGTGC	CTTGCTCTTG	GACTTCCAG	36180
CCTCTAGAAT	TCTGAATAAT	AAATTTCCGT	TGCTTGTAGC	CTAGTCTATG	ACATTCTTTT	36240
GTGCGACCGT	AAATGGACTA	AGATGTGCAC	CCTCATGCCC	TTTAGGGAAT	TGTGACTTTG	36300
AGAAATGCTG	CCCTAGGATT	TACAGAAATG	TGACAAAGCT	TTGTTGACTC	AAATGCAAAA	36360
TATTCTTATA	AAGACCAAAA	TAGAAATGAA	TACTCCCTTG	AACTCCTTTG	GATGTGCACT	36420
TTGCGTAGTT	ATAGCACCTT	TTTATCATGT	GCAAAATGAA	CGCAAATGAA	TCCTTAGTTT	36480
GACCCAGATA	GAATGTCTTT	GCTGGTAGGG	ACTACGGGAG	AGAGAGAAGA	GCCAGAATAC	36540
TGTAGGAAAA	TTAACACCGG	CCACGAGACA	ACTGGTTGCT	AGCTCGGTAG	CTGTGCAACA	36600
TTGCGCATGT	ACTTGAACTT	CTAGAAATCT	GTTCTTTCTT	CTGTAAAATG	AATATGGTCT	36660
GGAAAGTAAA	GACCAGTCAC	CTCCTCTATC	AGTTGGAGTC	TAATCAGGAA	GAAACCTAAG	36720
TGTCTTCAAC	AGAGGGAATT	TAATGCAGGG	AATGGGTCAC	ACCAGTGTTA	GAAAAGCTGC	36780
AATGCCAAAAG	AGGGGATAAA	GAGATAGCTC	AAAGGTTAAT	AAGAGCAGAA	AGTCACTAGT	36840
ATTATAGGCT	TGAAAAGAGA	AAGGGAGGAG	ATAGTGTTC	CGGAATCCCT	GATGGGCTTG	36900
TCTGGAGGGC	GCTGGGGCCA	TGGAGGAAAT	GTAGTAGCTG	CTGGAGGCAT	GCTCAGGGCA	36960
GAGAGGGAGC	AGAGAAAATAC	CCTGGCTTCT	CATTTTCTTT	CTCCAGTCCT	TGCAGGCACC	37020



TCACTGGCTG	AACTCAGGGG	AGCATTTCTC	CTCTACAGAA	CAGAGTCTCC	TTGCATACAA	37080
CAAGAGGGTC	AAACAGAGGA	TGGCTTAATT	TTTCCTTCCA	TTTCTCACTT	CTATGATTCT	37140
CTCCCTTCAG	GTTAAGTAAG	TGAGGGTAAG	TAAGCTGCCC	AGTAAGTGAA	CAGTTTTCCA	37200
AAACAAGCCCA	CAGCACCACC	TCTATATACA	GCAACTCTCT	GTTTATCAGC	ACTGCATTAA	37260
CCAGGACTCT	CTATTAAC TG	GGACTTCCAG	TTCTTAAAT	TTCTTCATGG	TTCTGTGTGA	37320
CTCCCAAAGC	ATCTTCATCA	AACAAACATT	AAGTTACGCT	TAGAGACCAT	TTCTCAATTG	37380
AATATAGATA	AAAGATTCTA	AGGCCTTGAA	AAAAATTAAT	ACATGCATAT	TAGATATAGC	37440
TATAAAAGCC	AGACTATCTG	ATTAATTATG	TGACTGGTGT	TAAACTGTTT	GGACAAAGGT	37500
TGGCTAAATT	CCCTATGAAT	ACTTACTTCC	CTACTTCTGT	GGACAAGGAA	AAATAGACCA	37560
AAGGTTTCAGA	TAAAAGCTTG	ATTCAATGTC	ATCTCTTTTC	TCACGAATCT	TGGTCATGTG	37620
TGGGAAGTGA	CCCAGATCTA	GAACCTTAGC	CTTTGGGACT	TAAAAAATAA	ACAAAAAACT	37680
GTTGAGTTGA	ATCATTAAAGT	GTTACTGAGG	GACAGGAGAG	AGGAGGGTAG	CTTTCTTAGT	37740
TCCAAGACAA	ATTTTGTTAA	CAAAGATCTG	TGGGTAGACT	TGTGTCTGGG	CAAAAGATCA	37800
GAAGATGTGC	TGTTCTAGGC	CTCTTTGCCC	TCAGACCCAT	TCCCTATCCT	TTCCCTTCA	37860
CTGTACCTCC	TTATCTCCTC	TTCTGTCTGC	TTCTCTGGG	CCTGATGCTT	GAGGATCCAG	37920
AAGTTTTCTCA	GGCTCCCATG	TCCAGCAAT	CCAGGCCTCC	TTCCAGTAA	GGGATGAGTA	37980
CAGGGGCCAC	ACATAGCCCT	GCAAGTTTTG	TAATCCAAC	TGAAATCCAA	TGGCAGAATG	38040
AATGGTTATA	TATGGTGTGA	CCCAGGACCA	CATGCAGTTG	TATCACATGC	ACTTACAAAA	38100
GAGCCCCATT	TCTTGGACTC	ATTCCCAGAC	TCAATCTCTC	TGAGGGTAGG	ACCAGGAATT	38160
CGGCCCTTTT	CACAATCTTC	CCAGGTGATT	CTCTACATAG	TATAATAACA	CAAACTCATG	38220
GAAATATATT	TAATGAAAAA	TGAATAAAAG	AATAAATGAA	ATAACAAATG	GTGATGGCTG	38280
GCACAATGTG	TGTATCCATT	CTCCTACTGA	GGTGCACTTA	CTTTGCTTCC	AAATGTTTCA	38340
TTGACAAGTA	GTGATGCATT	GAATATCCTT	GTACATGTGA	GCATGCAGTA	AAGTTTCCAT	38400
GGGCTTATAT	TTGCTGGATT	ATGGGCACGT	GCATCTTCCT	CTTTTCTAGA	TATTAACAAA	38460
TCACCTCTCCA	AAGTATTTAT	AACAATCAAC	ACTCCTGAAC	AAGCAGTGGG	TTGGAATTCC	38520
TTCTCTCATCA	CATCCTGGCC	AACAATTATT	ATCATCAGAT	TTTTTAATTT	TGCCAATTTG	38580
AAGGAAATGC	AGTGGCTTCT	CATGTGTTAG	TGTTTCTGAT	GATCAGTGAG	GTTGAGTGTC	38640
ATTTTTTTTT	TTTTTTTTTT	TTTTTTTTGA	GATGGAGTTT	TGCTCTTGTT	GCCCAGGCTG	38700
GAGTGCAATG	GTGCTATCTT	GGCTCACTGC	AACCTCCGCC	TCCCGGGTTC	AAGTGATTCT	38760
CCTGCTTCAG	CCTCCCAAGT	AGATGGGATT	ACAGGCATGC	ACCACCATGC	CTGGCTAAGT	38820
TTTATATTTT	TAGTAGAGAC	AGGGTTTCAC	CATGTTGGTC	AGGCTGGTCT	CAAACCTCTG	38880
ACCTCAAGTG	ATCTGCCTGC	CTCGGCCTCC	CAAAGTGCTG	GGATTACAGG	CACGAGCCAC	38940
TGCACCTGGC	CGATTGAGCA	TCTTTTTATG	TGTTTAATGA	TGCTCATTTT	TTATTGACTT	39000
CCTTCTGTGC	TTTCTTTTTT	TAGCAGTGA	ATTTGAGTTG	TAAGAATATG	TATTTCTTTC	39060
ACTCTGGGAT	TCACCTACAT	AAAGTAATTT	TCATTTGAAT	GAAAAAGAAA	TCAGTTGTAT	39120
AAACATCTGT	TTTTTCTGAA	TTTTACTGGT	TGAAAAATGG	CCACTCAGCC	CTGGAAGAAA	39180
CAAAGGCAC	TTGCCAAGTG	AAGTTGCAGA	TGGGAAATTT	TTAGAAAGGT	CCTGTTCAAC	39240
CTCTGGAAGG	GGAAGATCAT	ATCTGAAAGT	CAGGGTAATC	CACCCAACCC	AAATGTTTCT	39300
TCTACTATGG	GTTCTGAGGA	TTCGTCCATG	TGCTTCTTCT	GCATTGCTGC	CATCTGATTT	39360
CCTTTGCTAG	GCTCCTCTTG	CAACTTGGGC	TACAAAGAGG	TGCTTCATAG	TCCACAGTCT	39420
TTGCCTCACC	TTCAGTCTTG	AGGTGGTCCC	CTAGGAGTTA	TTGGTAGTTG	CCGCTGGAAG	39480
CCATTCTAAC	AAACCTGGCG	AAGGCACAAA	AGGATAGAAA	GCCTTTAGCC	AATATGGTGC	39540
CATCAAAAAC	AAACAGAGCA	CGCTGCCCAG	TCCTCTTCTG	GTTGCCTTTA	CTAATGCATC	39600
AGTCATACTT	CTTCTGCACT	CGATCTTAGC	CAAGAGGTCG	AGAAGCCATA	GTCATAATTC	39660
TTCTGAAATT	AATCTCTTCC	TGCCCCACCT	CCCCATCATC	TGTCTTTGAA	TTCCAGGGGC	39720
TAGTACTCAT	AAGATTATCT	CTTTCTTCTC	CTTTTAGAGG	AGACCCATTG	TTTTTCACAA	39780
ACCAGCCACA	AAAGCAAGTG	TCATTACCCC	CTACCGGAAA	TACCAGACAG	AGAGTTCAATC	39840
TGGGGTTAGT	TTCTAATCAA	GCCTCCTGCC	CGGGTTTTTC	CTGCTCCTGT	CTTGAAGCGA	39900
CCACAGGGGG	AGAGCAGTTT	CCAAATATGA	TCCCTCCTTT	CCACTGTCAC	TTGTCCAACC	39960
CCGACCACTA	TCATTCTTTT	ATTTGCTTCT	CCCCTGAGCC	AGCCAAGAGC	CTAGGTCAGT	40020
GACAGGGCAG	GCAGAAGAGA	GAGGGGCTTC	CAGGAAGGAG	AGGGAGCAAC	CCACAGAAGA	40080
GGCAGCAAGA	CAGGAAGGCG	GGCAGGGGCT	GAAAATCCAA	TACATATCTA	AGTACATTTT	40140
TCTAGGATGG	GCTTCTACAC	TCAGCCAAAA	CATATATTGC	ATATTGTTTG	TATTTTTTTAG	40200
AGGTTTACAG	GTCTCCCTGA	AAGTCCCTCT	GTGGAATTAT	AAACCTCTAA	TAAAAAATCC	40260
CAGGGTTAAA	GAAAGGAAAA	GATGAAGGAG	AGGCCACAC	TCTGAAAGGA	AAGGGTTTCAG	40320
CGACTCCTGG	AAGGTTCTGG	ATGGTGCTTC	CTTGACCAAG	TCAGCTGCTT	CTTCTACCTG	40380

GTCTCCTTTG	TGGTTCAGCT	GGGGTGGGGC	TTACTAGAAA	AAGCTGTGGG	AGGTGGTTGC	40440
TCCAACGTAT	GGGGGCTGTC	TGTAAGTGTA	GGTGTATCT	GATGAAAGCT	GGCCCCGGTG	40500
AGGGTTTGTA	CAGAAAGCTC	CTGGTGGTGG	GGAGATAATG	TCAAGCTTCT	CTCTCTCTCC	40560
CAGATCCTGG	TTGTATCCCT	TGTCCCTCTC	CACCCCCACC	CACTCACCCA	CAGAGTTCCA	40620
AGGAACCGGC	GCCTGCAGAC	ATGCCTCTCT	GATGCCCTCC	CAGTAACCCC	TGGCAGGCAG	40680
CACAGCGCCA	AACCTCTTGG	CCTTACCCCA	CTGGGCCCAT	GACCCAGTGG	CTGTGCCTCT	40740
GGGTCTCTCC	TGTCCTGCAA	AGAGAACTGG	GCCCTCAGTC	AGGTTCTTCT	GCTCCAACCC	40800
AGTGGCCACC	TGTGCTCTTG	GGGAGCTCGG	GGGAGGCTGG	GAAACTTTCA	AAGAGCAGTT	40860
AATCACTAAC	TAGCTGGAGA	TAAGAGAGAG	AGAATGAAAC	AATTGAGAAA	ATGCCCCAACC	40920
CAGAGGTTAG	TGCTTCCCTG	CCTGCACACG	CCAGAACCTG	GCCCCGCCAG	AGAAACTGGC	40980
GATCAAACCTG	AGTTTGTTCA	CTGGAGAGAG	CTGACATACA	GTCTCTAAGG	GGCTGCAGTA	41040
TCCCAGGCTG	AGGTCCAGTG	GCAGCCGCTG	CCCTTTTCCT	CCTAGGCCCC	TTTCCTTCAG	41100
CCATGCCTCA	GCCCTGAAGA	CAAAACAGGAG	CAGTTTTCAA	GGAGCCCTTC	CCTTATCTCT	41160
AAGGTCTGGG	CCTGGAATTG	AGCTTGGCCC	ATTTACTATG	CCAGCTCTGT	GCAGGGTGCA	41220
GAGATCCAAG	ATAAATCAGA	CAGGGTCTCT	GTCTCAGTG	TGCTCAAGGA	AAGAGCTTTT	41280
TAGGGGAAAC	AAATCTAAAC	GACTGCCAGC	TGGAACCTCA	ACTCTGTAAA	GCAGCACCTT	41340
GCCACATCTG	CCTGCTGGAA	CATTTTCATC	TGCTGGGCTC	ACGTAGCTGT	GCAACAGCTG	41400
GGGCTGGGGT	CACATTCTGG	GCTAATCTGA	TGATTATTTT	GGCTAGAGTG	AGCTCATCCT	41460
TTTTGTTTTT	AGGAGCTGTT	CAAGGGTGGT	CTGATGGTTT	GGATCAAGAC	TAGCTGTATC	41520
CCGGAGAAGA	ATACGTTGAC	TTTCTGGGGG	TGGGGTCTGG	GGCAGAAAGC	AAGAAGGCTG	41580
CCTTACTTCA	AGGAAGGCTC	TCCTCCACC	TTCTGCCCTC	TGAGTGCCCT	GTATGCGCAA	41640
GTGACACTAG	ACAAAGTGCT	TAACACTTAT	TACCTGACTT	GAATCTCCCA	ATGGCCCTGT	41700
AAAGCAGGTA	CTCCATTATC	ATCACCACCC	TTCTTTTAC	AGGCAAGAAA	ACCAAGGCAC	41760
AGTCAGTTTA	AATAACTGGC	TCAAGGCTGC	ACGGCCGATA	AGTAGCAAAT	TTGGACTTCG	41820
AATCTGGGCG	CTCTGGCTTC	AAAGTGTGCT	TGCCATTGTT	CAGGTTCTGG	TCTGGTACTG	41880
GCAATGTCTAG	CCACACCTGG	AAGCTTGCTA	GGACTATAGA	ATCCCCAGCT	GACCCCAAAC	41940
TCCCCAAATT	AGCACCATGA	TTTTAACAAG	ATCTCAGGTG	ATTGGTGTAC	ACATTACAGT	42000
TAGAGAAACA	CTGCCCTTTT	CACATTATAT	GGCTCTGTGC	TCAGTACAGA	TTTAATTTTC	42060
TTTTTTTTTT	TTTTATTATA	CTTTGAGTTC	TGGGGTACAT	GCGCAGAAAC	TGCAGGTTTG	42120
TTACATAGGT	ATATATGTGC	CATGGTGGCT	TGCTGCACCC	ATCAACAGGC	CCCGGTGTGT	42180
GATATTCCCC	TCCCTGTGTC	CATGTGTTCT	CATTGTTCAA	CTCCCACTTA	TGAGTGAGAA	42240
TGCGGTGTTT	GGTTTTCTGT	TCTTGTGTTA	GTTTCACAAT	CATTCTCAGA	TTTAGCTTTC	42300
AAACTATTCA	TTCCACCTGC	CAACAATTAG	CGAGCTCCAG	ACATTGTGCC	AGGTGAATGA	42360
TGGAGGTGAA	GAGACAAATT	TCCTTATAGA	ACTTGGCCAT	GCCCTTCATG	CAGGCAGTGT	42420
GTGGATGACA	AGTCAGGACA	CTTGGATCTA	AATCCAGTGC	TACCACCTGC	CGGCTGCGAG	42480
ACTGTGGCTG	AGTCATTTCA	CCTTCTTGGG	TCCCAGGTTT	CTAATCGGTA	AAACCGGGAG	42540
GCAAGCCAGA	GATGTCCGGC	CCCAGCAGCA	TATTCTATGT	GAACAGGATG	AGGTGCCCAG	42600
CAGGCAATCA	GTGGGGATCT	GCTGAATGAG	GGAACCAGTA	AATGAGTGAG	TGAACCGATC	42660
ATCCACCACA	AGGAAAGAGC	CCTCCATTTC	CAAATGAAGA	AAAGAAAGTAT	GCTAGTGGAG	42720
GGGAGACGGG	ATTATCTGCT	GTGTGTCAGG	GAAGAGTAGG	GCCTTCCCAA	GCTCCCTTAA	42780
TACTAACATT	ACACAGGGGT	CCTCGCTTGC	CCTTCTCAAT	GGTCCACTCA	GATGATTTCT	42840
CTTGGCGAAT	GTCTGCCCCA	CATCTGTGTG	TCACTCAGCA	ACTTTGGCCA	CCTATCCAGT	42900
GTGAGATCTC	TAGATCACAA	GGTGGGGAAA	GGGGTGAGGA	ATGACCTAGA	ATCCTGGCCT	42960
CTGGCCTTAG	AGCCTCACTT	GTTAAAGGGA	AAGGGGCAAA	TAAGATCTGA	ACATCAAAAA	43020
TTATTTTCA	TTGCCTTCCC	TCTCACTTTT	CTCTGTCCCC	TTCTCCTCTT	GTCTTCCCTG	43080
CAAAACCACT	TGAGTCTCCT	TTGGTTACCA	AGATAAAACC	AATCCACATT	AACATAGGCT	43140
GGTATTTTTT	TCGCTTTTAC	TCCAAGCCAG	TGCATAGTGC	ATTTTGCTCA	CATTAGAGTA	43200
TGGAATCCTT	CAAACAACCT	GATGATGAGT	GGGTGCCATT	GATACCCCCA	TTTTATAGCT	43260
GGGACAACCTG	AGGCACAGGG	TTGTTAAGCA	GCTAACCTGA	GGCCACTCGG	TCACTTCCTT	43320
GTGGTGGACC	CAGGATTTGA	ATCCAGGTTT	GCTCAACTCC	AAAGCCTGTG	TACTAAACGA	43380
CACTTCCTGC	CTTGATAAGA	TAATTGTGGT	TGTTACTTGG	CCAAATAAAA	AGCCTATGGA	43440
GAAGTTGTTT	CCAATGAAGC	ATATCAGCTT	CTAAATCTGG	CTGAACATTG	GACTCTCCAA	43500
AGGGGACACAA	AATACAGCTT	TCCGGGCACC	ATCTTGAAAT	GACTGATTCA	GCAAATTGGT	43560
CGTAGGCAGC	GAGGCACCTG	TAGTTTGGTA	AAGCTCCCAG	GTGATTCTGA	TAATGAGCTT	43620
GTGCAGAACC	CATTTACCTA	AGGAGAACGC	GGGTTCAAAG	GGACTGGACG	GCTCTTCCTT	43680
ATTTAGAGTA	GGAGGCTGTT	GGCTTCTGAG	AATGAGGGCT	AATTAACCTT	GGGGAGCTTC	43740

CTGCAGTGAC	CTTTGCCTTC	GGGGAAAGTG	TGGGGATTGA	GATAAGAGAG	AGAAATCCTT	43800
GGCGGCTAGG	AGGAAGGGTA	GGGTGTTTGC	TGTCAGGCTC	CAGGCTTAGC	CCTCGTGGTG	43860
TCCCTCCTGG	AGATGGTGTG	CACTGAGTGC	AGTGCGTGCT	GGAGAGTGGG	TGGAGAGATG	43920
AAGGTGATAG	GGGTGGGATT	AATTAAAAATA	TCAGGCAGTG	TGGCTGGGCG	CAGTGGTTCA	43980
CACCTGTAAT	CCCAGCGCTT	TAGGAGGCCA	AGGCAGGTGG	ATCACCTGAG	ATTGGGAATT	44040
CGAGTTTAGC	GTGGCCAACA	TGACGAAACC	CTGTCTCTAC	TAAAAAAATG	TAAAAATTAG	44100
CTGGGTGTGG	TGGTGCAC TG	CAATCCCAGC	TACTCGGGAG	GGTGAGGTAT	GAGAATTTCT	44160
CAAACCCAGG	AGGCAGAGGC	TGCAAGTGAG	CGGAGATCAC	ACCACTGCAC	TCCGGCTGGG	44220
ACAACAGAGA	GAGACTCTGT	CTCAAAGAAA	AGAAGCAGTG	AACCTTTAGA	TTATCCCACT	44280
CTAAAAGTGA	GGCAACCTTA	GTTTTTCTGG	GTCTTTAGAA	GCAGAAAGTG	CCTTGGGTAT	44340
TTCTAGGCTG	AGGGCCCCAC	CTAGTTCAAG	CCTTCTAAAC	ATCCAGTGTT	TTGCTATATT	44400
CATTTACCAC	TTGTCTTATT	AGACTCTTAG	GTCTTTTTTT	TTAATGACTC	ACTTATTAAA	44460
GAATGTGCAT	TTATTTACAA	GGCAATAATA	TCACTACCTT	TAATGGAAAA	TTAGCAACCC	44520
TGGCTACACC	TAGAAGGTAA	CTGTTAATAA	ATAGGATGAA	ACCCAAGGCT	GGAATTAAC T	44580
TCTCATGACC	TCCTGCAGCC	TATGCTCCTT	TCACTGAAGG	GTGATATCAG	CCAAC TGAGA	44640
CCTCCTCTAA	AGTCTGTGAA	GGATTGAATT	AAGAGAATTG	GAAAGGGCAC	ACATTTCTCA	44700
TGATGTGATT	CAATATTGAT	TAATTCCAGG	TTCACTTATT	ATCTAAAAACC	ATGTTACTGA	44760
AAGTGGCTTA	TAAATACCGC	AGCACCAGAA	TGTAAACTCC	ACAAGGGCAG	AGTTTTTGGT	44820
TTTGT TTTGT	CTTTTAAAAA	TCTGTTCATT	GCTTTATTCC	TAGACTCTGG	AACAGTACTT	44880
GGAATATAGT	AGGTGTTTAC	ATATTTATTG	ACTACGTGGA	CTCTTTT TAG	ACTGAGAAGC	44940
GGAATATAAA	GTCAGAGGGT	CCGACTGGTG	ATCGAATGCC	TTCTGTTCTGT	ACTCAAGCCC	45000
ACTCACCCAC	TTAGTTTTGA	GAACCTGCGT	GACCCAACCT	ACAGCCTGTC	CCACCTTCAA	45060
CTTATTCCCA	TTCTTGGGT	GCACGTGTTG	CTGTGAGGAT	CAGATGAGGT	CATGGATGGG	45120
CAGGACTCTG	AACTGCGTGC	CCTCTGCACA	GGGAAACAGC	TGGGCCGATT	ATAAATTGCA	45180
AAGGGATGAG	CTGATGGTGG	CCCCATGACT	TTTCATATGC	TTTGGGCTGT	TGTGAGAGAG	45240
AGTGCCCAAA	GCCTGATTCT	GGAACATTTT	CTTTGCTGTC	TTCTAAATGA	GAACCTGCTT	45300
GCTTCAATTC	TCCCAC TGAG	CAATCATGCT	GACATGAGGG	AGGCGGAGTC	AGACCTTACA	45360
TTGTTGAGAC	CAGATTCTGT	GTTCTACGAG	TATTGGGAAG	GGTGATGCAG	GCAGGCACCC	45420
ACCATGTTCC	CTGTGAGTGC	TTATTTT TAA	TAAAAACCTT	GGTATACTGC	TATTAATGAA	45480
AATAATAATA	ATAATAATAA	TTACTCCTGC	TAATAATATA	AGGAAACACC	CACTGGTCTG	45540
TGACTGAGCC	AGCCTTGCC T	GAAGGCAGGG	GAATGAATTC	AATGACCTCT	TGACACTGGT	45600
CTCAGCCCTT	TGGTTCTATT	ACCACCTTGT	AAACCTGAGG	TTGTTCTGTT	TTTATCCCTA	45660
GGGAGTTGTG	GTTAGAACCT	GCCAGAAATT	TCTCACTATG	AATCAATCTT	CCATTGGTCA	45720
CTGCCCTTTT	CAACATGCCT	GTCATTCAAG	ACTTACGATT	TCCTAGGCAT	TGACAGAGAG	45780
AAAGGGATCA	TGTGGACCAA	GGCAGTGGGA	TTTACGTGAC	ACCCGCCAAG	CCGGTGGGGC	45840
TAAGTTCCAT	TGCTGAAGTC	TGATACCTGT	CATCTGCTGT	GGGGTGACAT	CCACACCATG	45900
TCATTCTCCA	TTGTTTCAAT	ACATATTTGT	GGATTCTTAA	AATGCCCCCTG	CTGCTGTGAT	45960
AGTCCAGCTC	AAGAGAGAGG	AAGTACATGA	GATGTTACCA	CACAGTGTGG	TATGTGCTGG	46020
AGAGGTGAAG	ACTCTGGAGC	AGAGAGGCAA	CAACTCAGGT	GGGGACTGAA	TGGTGGCGGG	46080
GTGAGCTCAT	CAGGAAAGGC	CCCCCAGGG	AAGCTGTGTT	TGGGCTGGGG	TCTAAGGATG	46140
AGCAGCAGTT	AGCCAGGGAA	GACAAGGAGT	AAATGTACCT	AGGCATGTGG	GGCAGTCTAT	46200
GCAATAATGT	GGGGAGGAAG	CAAAGAGAAA	GAGAATGGGA	GAATGGCCTG	CCTGTTTGGG	46260
GAAATGAAAG	GAGCCAGTAT	GTA AAAATCA	GGTGAGAGAC	AGCTGGAGAT	GAGGCTGCAG	46320
AAATAGGTAG	GTGCCAGGTC	ACAGAGGGCC	TTGTGAATAG	TATCATGGAC	GCTGGACTTT	46380
ACTCCAAAGG	GCATGGGAGC	CATCAAAGGG	TGTTGAACAA	GGAGATGCAC	ATTATAGAAA	46440
GGCCAGGAAG	GCCTCTGGGA	TCTCCTCTTC	TCCAAACTGT	GGCTCTGGGG	ACAGCTCCCT	46500
ATAGTGGTCT	TGGGCAGCAC	CAAACTGGTG	TTTAGGCTCA	GCTCACATGC	AGCTCACAGC	46560
AAGATGGTGA	CAAATGACTC	ATCCTCAAAC	AACAGAGCAG	GCATAGGAAG	GAGGCCCCAG	46620
TTAGGATCTT	GCTTACCTGG	TTTGCTGGTG	GCCTATGCAT	TTAATTGTAG	AACAGAATGC	46680
CAAGCCACTT	TTTAACCTTT	CTTCTACACC	ATGCCCTGCA	CCTCCCCTTC	TCTCTCTGCT	46740
CTTCTCCCTT	CCACCCTCAA	ATTTCTAAGC	CATGTCCAGG	TCTCGTTTTT	ACCTGTGCCA	46800
GAGAAGATCT	ATCTGACTTT	GGCCATGGAA	GAGGTATAGC	AGGTATCAGT	TGGAGAGGGC	46860
TGGAAAAGCT	CCCTGGTGCT	AGATATGGAC	GACCTGAGCT	TCCAGTCCTG	GCTCTTG CAG	46920
CCACCAGGCA	TTTGACATGG	GCAGAAGCAC	TTTTCCTCAC	TGAGCCTCTG	TTTCCCTCATC	46980
TGTAAAATGG	GAATCATGGT	GATGGTGTGA	TATTTGAACA	AGTTTTTTTT	TTTTTTTCAA	47040
AATTGCTTTG	TAAACTGCAA	AGCTCTGAAT	AAGTGTTTAT	TTGGGATTAT	TAGGAACTGC	47100

TTTGCTGGAA	CAGTCTACCA	GAGGGATGGA	AGGAGAGGAA	CTGAGAAATC	GATTCTTTGA	47160
AATATTTTTA	TCATATGAGA	TACAAATATG	TATCTATATA	AATATAGATA	TAAATATGAA	47220
CAAATATATC	TGTCATAAAA	TTTAAAAAAG	GATGAACCTT	GCCCCAATC	TCACCCCTAG	47280
CAGCAACTAT	TAATTTTTTG	TTGTATATCT	GCCCAGACAC	ATATAAAATA	TATATTCAAA	47340
CAAAAAATAT	AATCATATTA	TAAACTTTGT	TTTTTAGCTT	GTTTATTCAC	ATTACATGGA	47400
AATCTTTCAG	CATCATGGCA	TATAGATCTG	TCTTTTTAAT	ATTACTTCAT	GGTCTAGGTG	47460
AACCATAGTT	TATTTAGCAT	TTTCCTTTTG	GTAAACATTA	AAGTTAGTTG	CAATTTTTCA	47520
TCATATATTT	TTTCTGGTCT	TTTGTACATA	TATCTATGAG	AGAAATTCCT	AGAAATAGGG	47580
TTGCTGACTC	AAAGGATACC	AGCATTTTAA	ATTTTGGTAG	GTACTACCAA	ATTGCTCTTC	47640
ATAAAGAGTG	TACAAATACA	CCCTCCCACA	AACAGAGTGC	CTGCCTTCCA	TGCCTGGACC	47700
AACCACAGGC	ATTACCACCT	CTGCTGAAGC	TTTTTCATGA	GACAAGGTCT	TGCTCTGTTG	47760
CCCAGGCTGG	AGTGCAGTGG	CGTGATCTCT	GCTCACTTCA	ACCTCTGCCT	CCCAGGTTCA	47820
AGTGACTGTC	ATGTCTCAGC	CTCTGGAGTA	GCTGGGACTA	CAGGTGCGTG	CCACCAAACC	47880
TGGCTAATTT	TTGTATTTTT	GGTAGAGATG	GGGTTTTGCC	ATGTTGGCCA	GGCTGGTCTC	47940
GAATCCCTGG	CCTCAAGTGA	TTTGACTGCC	TTGGCCTCCC	AAAGTGCTGG	AATTACAGGC	48000
GTGAGCCACC	ATGTCTGGAC	TGCTGAGGTT	TTTTTTTTTT	TTTTGAGACC	AAGTTTCACT	48060
CTTGTAGCCC	AGGCTGCAGT	GCAATGGCAT	GATCTTGGCT	CACTGCAACC	TCCGCCTCCC	48120
AGGTTCAAGG	GATTCTCCTG	CCTCAGCCTT	CCAAGTAGCT	GGGATTATAG	GCATGTGCCA	48180
CCATGCCAG	CTAATTTTGT	ATTTTATAGT	GAGATGGGGT	TTCTTCATGT	TGGTTAGGCT	48240
GGTCTCGAAC	TCCCAACCTC	AGGTGATCTG	CCCGCCTTGG	CCTCTCAAAG	TGCTGGGATT	48300
ACAGGCATGA	ACCACTGCGC	CCAGCCTTGC	TGAGGCTTTT	AAAACCATGA	AACGCTCCTC	48360
CTCCCTCAAA	TGGTCATGTG	GCCACTGCCT	GCTTCATCAC	ACTGCTCCTC	TGTCTGACAA	48420
GCCTGTTCTT	ATATAACACC	AGTAGGTAGG	GCCATCCGAG	ACATGGTTAT	CCAATAAAAT	48480
GGTAAGAACC	AGCCCTAGGG	TATTTGGGAA	ACTGGCTGTG	AGGGTTCAAT	GGAATATTCA	48540
CATTTCCAAA	CATAAAATCT	AGCAGCAATG	GAGAAACGTA	CTTTAAGCAG	AGAGTTTTCG	48600
GCCTGACACA	AGAAATTATT	ATTATTGTTG	TTATTGAAAG	TTCTGACACA	CAGATCTCGG	48660
TTGTGTTTGG	AAGGAGGATA	GTCAGAGAGA	GGAGGAAGGT	ATGAAGAGGT	CGAGGTGTTA	48720
GTTTTAAAAA	GTGTGTCTTT	GTCATTGTCT	AGCTGTGGCT	GGTCCCACAA	CCTGGTTCTA	48780
TCAGGCCTTT	GGTGTTACAA	AATGCAAAAC	ACCAGGCAAC	CAAATAGCGT	TTCCATGGAA	48840
GTATCCCATG	ACCTCTGGTG	CTGTGTACAG	GTGAGACAGT	GAGCACTCAG	AAAGGGATGG	48900
CCTGGGTGGG	GAGGGCGAAA	GGGGCCTCTC	CAGCCTCTGC	AACATAAAAC	AAGGGGCCAA	48960
TGGAAAGTTC	TGGAAGTGGG	TCACTAAGAA	GACAGGCCCC	ACTGCTGGCA	TGAGTGGGAT	49020
GACCAAAGAA	TTAGGAAACT	GAGATTGGAG	TTGGTCACCA	ATTCAACTGG	CCCATTAAAA	49080
AATTTTCATA	AGCAGGGACA	GAGGATCAAG	CCAAGAGCAC	TAGGGAGATG	GTGATGAATG	49140
GAAATTGTGT	AAGGTAGATG	GCTATGTGCC	GGGGAAGGAG	GAGAGAGGAT	TGAGATTAT	49200
AGGAATTAATA	CATGAAATGA	GTCACAAAAG	TAGCCTTTTA	TGTGTGTTAT	GTAATTTAAT	49260
CCTCTTAACC	TTATAGAGTT	AGCACTGTCA	GGATCCACAT	TAAAAAATAA	AAAGACGAAG	49320
CAGAAGCTCG	GAGAAGTCAA	ATTACTTGGC	CAAGGTCAAG	GTACACACAG	CACATGTGGC	49380
AAATCTGGAA	TACAACTTA	GGTCTATCTG	ACTTTAAACC	AAAATGCTGC	ATATAGCTTC	49440
GATTTTCAGCA	CAGCAGGGTT	CAACTTGGAG	ATAGAGGGTG	GTGTTATAGA	TTACCAGATA	49500
CGATAGTGGT	AGGTTTTCTT	CTGTCTTGAT	GAAAGATGAG	CTATTTTTAT	CCTGTTGCAG	49560
GACAACGCGA	AGGATCATGA	CTTCCATTTT	TGAAGTACCA	TTGTAGATTT	GTGTATATTT	49620
GACAGCTCTA	CCACATTCCC	AACCCTATGC	CCTCCTATCA	CTCTTTTTGA	GAATACTGGG	49680
CTAGTTGGGG	GCAGTGTGGG	GGGACTTGGG	CCTGGGCGTA	TGCTGGGAGG	AAAGGCAAGG	49740
AGATTATGCA	GTGTGGTAGT	AGGGACTGGG	GGAAGTTTTT	TTGTTTTTTG	TTTTTGTGTT	49800
TAAAATCCTA	GTTGGTCCCC	AGTGGAGCCT	CCAGACCTCC	TCAAAGTCTT	TGAGGTGTGT	49860
ATTAATTACC	ATATAAACTA	GACAGTCCTT	GGCCTTGGTG	TTGCCATTCC	AGCCTGTAAT	49920
TATCTTCATC	ACAAGTTGCT	GTCTGGCTTT	GTTCTGTAGG	TAGAGGCTCT	TTCGTAGGTC	49980
CCTGCATGTC	CCTGAGTCAC	TAGCAGGCTC	ACTTGTGCTT	ATCCAAACTG	GTGAATCATT	50040
AGCTGTCACC	CTGGAGAGCA	GTGCAGTTTG	GGAAGGCGTG	GGTGCGCCCA	TGGAGAGGGT	50100
GATCCCTCT	CTCTTCTTTC	CAGGCATGCG	TAAGGAGCAG	TGGCAGAGAA	TTACGGAACA	50160
GAGGATGCTA	TCATAGGTGA	CCTATGAGCC	AGGCACGTAC	ATACGTGTCA	TCTCAATGAA	50220
AGCTTTACAG	CACAGGTTAT	ACAAGTAGTA	CACAGGGATA	AACAGCAAGG	TTCTTAGGTG	50280
GGTTTCAGAC	CTGGCTCTGT	CATTTATCTA	GAGGTATGAC	CTTGGCCCAA	CCTTCCTAAC	50340
TTGTCTATGC	CTTGATTTC	TCAACTATAA	AATAGAGATA	AAAATGGTAA	CTGCATCCAA	50400
GAGCTTTTGA	GAGGAATTGA	TGCAAAGATG	CAAGTACAGT	GCCTAGCAAA	CTGAAGCACT	50460

CCATGAGGAG	TGGTGATGCG	GATGCTAATG	CTGATGCTGG	GACAAACTTA	CACCCACTTT	50520
ACAGATGGGA	GAAGTGAAGC	TCAAGTTGTT	TAAAGTGGCA	TAGCTAGTAA	GTGGTAGACT	50580
TGGGATGAAA	ACCCAGTCT	GTTTCCAAGT	CAGGAACCTT	TTCCTCCATA	ATGCCGTCTG	50640
CATAAATAG	ACTGTTGGAC	TGAAAAACAA	TCCGTTCAAA	CCACAAGGGT	ACATTGGCCC	50700
AGGTTGCTTC	TATGTTTTAT	CCTCAATCTG	AAGCAATATA	ATGAGCAATG	TAATGAGATT	50760
ATGTTAATAT	TTACTCAGGG	TTCTGGGAAA	CCCAGAAGGG	TTTCAGGGTA	AACCATCTCC	50820
CAGCAAGCAA	GGGCTCGCCC	GCTAATTCCC	CTTTCTTCCA	AGACTGATCA	GATTGCCAG	50880
TGCCTAGTAA	AATGCCAGTT	TCCTTCTATG	TGGAAGGGAG	CAAAGCTGTC	AGCTCCTGCT	50940
GGGGCACAGG	GAGAGGATGT	TTCTTGTGGA	TAGGTAGGTG	GTGCTTAGGG	GTAGAGGCTC	51000
TGAGATCAGG	CAGACATGGT	TTCTATCTGT	CCTCCCAGCA	GTGTGTCTTT	GGGTAAGTTA	51060
CTTAATGTTT	CTCAGCTTCA	ATGTCTCAT	CTTAAGATGA	GGGATTATCA	TGCTACTTTG	51120
TGGGGCCTTT	GTGAGGATTA	AATGAGATCT	TAGTATCTGG	CACATAGTAA	GTGCTTAATA	51180
AAAATAATAA	GGCAGAGCTG	GGTAGATTGA	GGGTTTGGTT	TACAGCACTT	TGACAGCAAG	51240
TTGCTTGTTT	CCTGCCATTG	AGAGACCTG	GCCAACTAT	GTCCATTGTG	GCCACAAGAC	51300
CATTGGCATG	TCAGCCTCCA	AAAGAGAGAT	GACTGCTCAG	CAGGCATTAA	CCAGATCAGA	51360
GGTTCCTTGA	TTCAGCACAG	TGCTCTCTTT	TTGCACTGCT	CTCAGTCTAC	CAACAGTATC	51420
AATCACAGCA	ACCATTCTATG	GTGCAAGGTG	ATCTCCCTAA	ACTTACATTA	TATCTTTAAT	51480
CCTCACAGCA	GCCTTGGGGG	ATGGTATTAT	TTCCATCTGT	AGATGAGACA	ATAGGGGCTC	51540
AGAGATGGTA	GGTAATTGCC	CAAGGACACA	TAGCTGTTGG	AGAAAGTAGT	ATTGGAGCAA	51600
AATCTATGTG	TGTGCATCTA	GATTGACCAA	CCTTCTGGT	TTGCCTGGGA	ATATGGGGTT	51660
TTCTAGGATG	TGGGGCATTC	AGTGCTAAAA	TCAGGAAAGT	CTAAGATGAG	TTGGTTACTC	51720
TATATGCGGC	CTCTCCGTGG	AGGGTTGGTT	GGTGGGCCCTG	GAAAAGGGAT	AGGGATAAGA	51780
GAGAGAAGAG	GAGGACGCAG	AGAGAATGGC	AGAAGCAACT	CTGCACTGTT	TCTTCTGCA	51840
AAGATGTCTT	TTCAATTCAA	CCTGCTTGTT	CAGTTCAACA	AGCAGGTTTG	AATGCCCTCG	51900
TCCTTGAGAG	GAGTCACGTC	AGGACTTTCC	GGGTATTGTA	CCGTGATGAA	GAGCGCTGTC	51960
TGCCAGGGTT	CGCCAGGCTG	GGTGTGGAAA	AATGGTGCCC	CAAACCAGCC	CCACATGGCA	52020
GAATAGGAAA	CATGCTGTCA	TCTTGCTTCA	TCTGAATCTC	CATTCCATGA	GGGCAGGAAT	52080
TGTTTTCTTT	TTTACTTCTA	TAGCTGAAGC	CCCAGTGCCC	AGAATATGGC	AGAAACTCCA	52140
GAAACATTGG	TGGAATGTAG	ACTATTGAAT	AATTCCAAGT	ACAAACCAAT	GGTCCAGGGA	52200
GATTTAGATT	CTGATGAAGG	CAATCTGGGG	AAGACTGAAT	GGAGAAATAG	CATTGGAAAC	52260
GGTTTGATA	CCACGTGTTG	GGATCAGGAA	GCAGAGGAGC	ACAGAATGCT	TGTGCAGAAG	52320
TGACATGGGC	CCACTGCACC	TGGGGTGGAC	CCTGTGAGGT	AGAGTTGGAG	ACCAAGGGCC	52380
TGAGGACTGG	ACATGTCGGT	GGAGACCAGG	TGGTGGAGGA	TGGAGAATGC	CATGCCCTCA	52440
GGGAGTTTGG	ACTGCCGTGC	GTTAAGCCAT	TTTTTCTTCC	AAATTTCAAT	CCCCCTCAT	52500
CCATTGTAC	CATATTTGCC	ATGCTGTGT	ACCTACCTAT	ATTACTTATT	TAACACTTTT	52560
CCTTCAAGTG	ACTTACTTTT	GAACCTTACA	TTTGTTTTCA	TATCAAACAC	ACATGGCTGT	52620
TAAAAATAAA	ATTACGATTT	GAACCTTAGAA	TCATCTTGCC	TACCACATGA	GGTAGGTGTA	52680
CTTCCCTCTG	AGGACCACAG	CTCCAGCAAC	TGGGGAACCG	ACAAAGATTT	TTGAAAGAAG	52740
AAATGATTCA	GTTGCTTTTT	GGGAAGACTA	CACACGTGAG	GAAGTACTGA	GTGGAAGATA	52800
TGTGCATAAA	ACATTGGCGC	AATTGTGACT	AACATGGTAA	GAAATATTAT	CAACGCAAGT	52860
TTGGGGGGCA	TTTCAAAGTC	TCTCAATGGT	CATCCGGATG	AAATATGCAA	GAAGTGTCT	52920
CTCTCTCTCT	CTCTCTGTCT	TTTCTCTTCT	TGGTCTCACT	TTGCCCTCTT	TCCCAGCAGC	52980
TCTGCCCTTCT	CCCCCATGCT	TGCTGCCAAC	AGCTCTGAGG	AATGGGAGGG	ATTGCAGTTC	53040
AAAGAGTAAA	CAGGTCTACT	CTGAGTAAGG	CTGTGGGCTG	TGCAGTGACC	CCCAGTGGGT	53100
CTGGGTGCTT	GGTAATGATG	CCTGCACTGG	CTGATGCTG	TGGCTTTCCA	GGCTTGTTTT	53160
ACCTGGTTGT	GCAAAGAATG	TTACCCCCAG	CCAAGGCTCA	AGTTACACAG	CCATTGGCCC	53220
ATCCCTAAT	AAGCATATTA	TTCCCAGCTG	GGCATTGAAC	TTCCAAGTTA	AGGTGACCTG	53280
CCAAACTGGA	AAGAAAATGG	ATTTGCAAAA	ATCAGATGTT	TGCCAACAGC	ACCATCCCCC	53340
ACCACAACCA	TAGACAATTG	TGAGATCTAA	AGTTGGACTC	CCTGAGGTTT	TCTGCCCTGG	53400
TGGTTCTGGC	AACCTCTGGA	GAGCCACAGA	CTGATGAATT	TGAGGATCAT	AAACCTTAAG	53460
AAGACTTTAA	AGTATTTTGT	GCATTAATTG	ACAAAGTCCA	CAGCAAGCCA	GGCATGCTCT	53520
TCTCTCCAC	TCCCCTTGTC	AGAGATGTCT	CTTTCCCTTT	GCTCTTCTTA	CCCCATTCTT	53580
TCCAGCATAA	CCAAGCTTAA	TAGCTTCCAT	GTTTCCACTG	TAAGGAAGTG	AGCCGAGTGT	53640
GGTTGGTCTG	TTTCACAGCA	GGGCTATCCT	CACACGAAAA	GTTTTTCAGAT	GCATTGACTA	53700
TGCAGATTTT	TGGCTCAGTT	TGCAGAAGAC	TTCTTATTTT	CAGTTTTTACT	GTACACCCAC	53760
CTACATAATA	CTTTTTGGTT	CTTAGAATTT	CAGAGCTATT	AACCTCTAAA	CTTAAATCAA	53820

AATTCTCATC	AAACTTTCCT	AGGGCCTTGT	CATAAAAGAA	ACTAAGTCTC	AAAATAGGAC	53880
TTTTTGGCCT	AATTTCCCTG	TCCAGGAAGA	CAGATTGACT	AATTCCAAAC	CCTGGACTCA	53940
CATGTGATTG	CTAAGAATAG	GGGTGGGGGA	GAGAGAGGGG	ACAAAAGTCA	TAGACATGCC	54000
ATGACACATA	TTGGGAGATT	TCATCTGAAT	TCCCTTGAG	TATGAAATTA	TTCAGAAATA	54060
ATTCCAAGGG	CTTCTTTTCT	GACATTCCAC	CAGTGTGCAG	GTGCATATGT	TTTGAATGAA	54120
CTGAATGGAT	AATTTATTTA	TACAAATGAG	TCTTTTGGAA	TAGTTGCAAT	GGATGTGCTG	54180
TCAACTCTCC	AATATCACTT	CCAGGGGGTT	TGTAGATGCA	TTCTTTCCAT	GGGCATCAGC	54240
AGGTCTGGAT	CTCCTGCTTT	CTATCTGAAA	GGCACTGGTC	TGGATCTCCT	GCTTTCTATC	54300
TGAAAGGCAT	TATGGGCAGC	AGTCTGGTTG	ATTTTATACT	ACTTTGATAC	ACTCTCAATT	54360
GCATACTAAG	AATGAGGATG	GAGAAACTGA	TAGTGACCCT	CACCCCAATT	AGGTTTCACT	54420
ACTGCCCTTG	ACCTTCATAT	TTAATGCCTT	TGTTATCACA	GCAACTCTTT	GCTCTATTTT	54480
TGGATCCAAA	TGCCTAAGGA	TCTCCCTGGG	GTGTTAAGCT	TGCTCAGTGC	TATTAAACCT	54540
GGTGGGTGGC	AGAGTGACCT	TTGTATCACA	AGAGCCTCAT	GACTTCCCAG	GCAAGACCAA	54600
GTCAACAATT	TTCCAATGGA	TTTCCCCTCG	ATTCTTATTC	TGAGCATTTA	GCTTTTAA	54660
TATTTGGCTC	TGAAGGGCAG	GGGCTAAACA	TGTCTGTGTA	AGATCCAAAC	CTGCTGTGAT	54720
ATTTTATACT	TTTGTTTTTT	CATTTCAACT	TTCCGATCTC	GCTCTTCTGA	GAAACATTCA	54780
CATTTCCAAT	TGCATTCCAG	AACTGAGCTT	GACTTTCCAT	GTCCATGTAA	GATCTTGTA	54840
TTCAAATTTT	AGCCAGCTGC	TAAGCTTCTC	TTTTCTGGAG	GGGATTGTGG	TTAAGAGATC	54900
TTGTTTTGCA	ATGACGCTGT	CTGGTCTGAG	CTCCAGCTAC	TTGTCTTATT	TACTGTGCAA	54960
CCTTGGCCAT	GTAACTTAT	CAGGCTCATG	AGGCTCGGTT	TTCTCATCTA	TAAAGTGAGA	55020
AAATGAATAG	TACCTATCTG	ATGGAGTTTT	TCTAAGGCTT	AAATGAAGTA	ATGCAAATTA	55080
AATTCCTTAGT	CTAGTCACTG	GGAAAAGATG	AAAACCTAAC	GAATATGAAT	AGTCACTATT	55140
CTGTTTCTTT	TTTTCTATGC	CATTCCGGCT	TCACCTCCTT	CTCTTACTTT	TTCCCTTTCT	55200
TTTTTCATT	GTTTTCTTTT	TTTTTTTTTT	CTTTTTTGAG	ATGGAGTTTC	GCTCTTGTTG	55260
CCCAGACTGG	AGTACAATGG	CATGATCTTG	GCTCGCTGCA	ACCTCCACCT	CCCAGGTTCA	55320
AGCGATTCTC	CTGCCTCAGC	CTCTCGAGTA	CCTGGGATTA	CAGGTGCCCA	CCACCATGCC	55380
TGGCTAATTT	TTGTATTTT	AGTAGAGATG	GGGTTTCACC	ATGTTGGCCA	GGCTGGTCTT	55440
GAACCTCTGA	CCTCAGGTGA	TCCACCCACC	TCAGCCTCCC	AAAGTGCTGG	GATAACAGGA	55500
TGCCGCACCA	CTGTGCCTGG	CCTCTTCTAC	TTTTTCTTAG	AAACATGGAG	GGTAGTTCT	55560
CTGGCCACTC	ATATGAAACT	TCATTCCCTG	CTAAGGTGGA	AGTATTGGAG	TTCAAGCTCT	55620
ACACTTAGTG	GAGGGAGTAA	ATAAGCATTT	CCAGAGAGCC	CACCAAGTGC	CATGCAATCT	55680
CCTAATGCTT	TGTACTATTT	CTCATTTAAC	CCCCCAAACA	GCTCACTGAG	TATGTTAATA	55740
TCCCCAATAA	ACAGATAGGG	AAACTGAGAC	CTAAAGTTTG	AGCAAATATG	GCAAAGTTT	55800
CCTAGGCTGT	CTGGCTTTAA	AAACAATGTC	CTTTCAACGC	ATCAGGCTGC	TTCTGAGGAG	55860
CAGAGCCACC	TTGCTTTTGT	AAGTCTGTTG	GAATAGGCTC	TGAGATGCCA	CACGTTATCC	55920
CAAATAATTA	GGCATCTGGA	TGGAGATTTT	ATACATTTTC	TACTTGGACC	TGAGTTTGCT	55980
GTCTCTCATG	GTTCTCGGGT	GAAAGAGGCC	AGGCCCTGAG	ACCTTTACCC	AAGGTTGGCT	56040
CTACCAAAAT	ATCTTCTTGA	GTGAGTTCTC	TGGTTGATCA	TCTGTGGAAC	AATGTGGGAG	56100
CCTACTAAAT	ATGAATGGAA	AATGAGGAAT	GCAAAATGGA	TGGTTTTCTC	CACTATCACC	56160
TCACCTTGG	AGGTGTTTGC	TGATTTGGTA	GATGTGTGGA	GGAACCTCAGG	AGTCTGAATT	56220
TGTAAAGGTA	ATTTGGATGC	TTCATTAGCT	TAGAAAGGAC	ACAGCAGGGA	GAACTATATA	56280
GCAGAGAAGG	CTGGATGCCT	ATGAGGGTAG	GGAAGGGAAA	ACAAGGGGGT	GGGGCTGTAG	56340
CTGCCCTACC	TCCGGTCCAT	ATATGGCTGC	ATTTCTTTAA	TCTCTTTTAC	TTTTGGGATT	56400
CCATGGTAGT	AAACAAAGAG	TTCTTATGTT	AAAACAATTG	CTATCTAATT	GTACAGCATG	56460
GTGAATATAG	TCAATAACAA	TGTATCATGT	ATTTGCAAAAT	TGCTAAGAGA	GTAGATTGTG	56520
TTTTCAACCAC	ACACAAAAAT	GGCAAGTATG	TGAGGTAATG	CCCATGTTAA	TTAGCTCAAT	56580
TTAGCCACTC	CACAATGTGT	GTGTGTGTGT	GTGTGTGTGT	GTATATATAT	ATATATGTTT	56640
ATGTATATAT	ACACACACAC	ATATATATGA	CATGTCAGAA	TGTCATGTTT	TATTCCATAA	56700
ATATATACAA	ATTTTATTTG	TCAATATAAA	AAGAATAATA	CCTGGAAAAA	CAAAAAAAA	56760
ATCCTAAGTG	CTATACTTAT	AAAGAAATCT	TCCTCATACA	AAAAAGAAGA	AATTCTGGCC	56820
ACAGGAAGGT	TGCCTGAAAA	TGGCCACCTT	TTTCATGATT	TTCCCTCCCT	TTCTGAGACT	56880
GAGAAATGAG	CCTTCTTGAA	GACCCTGATG	GAAATACTGT	GAAGAACTA	AGACAGTTGG	56940
ATTCAAGAAC	CAAAATGCTT	ATCGTAGCAG	TGAGGTTGGC	TTGAAGTCAG	GGAACAGTGT	57000
AAAGCTATTT	GTGGGGAAAG	ATAAGGCCAG	AAAGAGATTG	ATAAAATACA	GGCGAGACCA	57060
AAGGAACAGG	GCAGGGGCAA	ATTAGTTTAG	GCAAGAAATG	AGGCGTCTTG	ATATTAATTA	57120
AAATATGGAG	GAGGAGTCCA	GAAAATTCAT	CCTTGGTGCT	TGGGTAAGTT	TAGCAACATG	57180

TTACAGATGCC	TGAGTTTTGT	GTGTGTATGT	GTGTGGGCAT	GCACGTGTGT	GTGTACACAG	57240
TGGGTCATTC	TTCTCAGGAA	GAGTGAGCCA	CTCTCCCCCTC	CTCCAGCACC	AAAGTGGCCC	57300
CCACCTTGGC	ACGCCAGTGG	CACATGCCAT	TGGGCCAGGA	TTTGCTCAGA	ATGCAGGCAC	57360
ACAGACATAA	TGTCAGGAGG	CATTGCTGGT	GTGTGTCACA	TCAACCTGTT	AGAACAACCTG	57420
TCAACGTGTG	ACCTCCCAA	CAGAACTCAG	GTGCCCCCTT	CAGAGACCGT	AAAGCTTGTC	57480
CTTAGAGGAT	AATGAAGATC	CCCAGGAACC	TCATCTAATC	CAAAACCAA	AGATTTGGGA	57540
AATGTGACCT	TTAGAGGGGA	GTAGCATTAA	GAAGCAAAAT	GATACTTATT	AATTCTGTTG	57600
CTTATTTGAC	TGTAACCACT	ATAATAAATG	ATCATATTCT	GCTCGATTTA	ATTCCCCCTC	57660
CCCATAGTT	TCACAAGACC	AGAAGGAGTT	TCTTCTTCCC	ATTGGTCTTA	CATTAATATT	57720
CTTGACGGC	TTTCACTAAA	TAGATGCCGT	GTTCTGCCCT	GGAGGTAACA	CCACGTCATT	57780
AGGAGGAGAT	GATAGACAGA	AATATATACA	AACACACACT	TGCTTTCAAA	AATAAATATA	57840
GGCCCTCTAG	TTAAAAGGTA	TTGTGTAAAG	TGTGTGAGCA	TCCTCTTCT	TGCAAAGCAA	57900
GCACACAGCT	TCCATTAATC	TTGTAGCCAC	AGCCTGTGTT	GGTGTTAAGA	CTCAGATTCC	57960
TTAACGCTTG	ATACTTGGCT	TAAAGAGATT	CTTTGTCTCTG	GCCTTGATT	GGGAATTAAAG	58020
ATCCCTAGGG	TTTTTGGTTT	TACAGTATGG	ATCTTCTAGG	AGACAACCCG	ACTGACCTCC	58080
GGGTCTCCAG	GCCACCACAC	ACAACCTGGT	TCTTTTGTCT	CTGTTCCCCT	TTTCCCTGTG	58140
GGGGACCAGC	ACAGGACTCA	ACTCAAGGGC	TCTGTGTCTG	TGCACAGGTT	GGAGAGGGTG	58200
ATAGGGCCTT	GACCTGTAGG	GACAACCAGG	AAGATTCTTA	TGCAGAGTAA	TTGGGTTTCT	58260
AGAGTTTGTT	TCAGTTGATT	TGAGGGCAAG	CTGCTTGGCC	TCTCTCTCTT	GATTCTTCCC	58320
ATCCACAGAA	TAAAGACAAT	CAGCTTTGTT	TATCACTCTG	TTCATTTTGC	TATGTCCTTA	58380
TCAGCCCCC	AGAGAATTCA	GGAGCACAGA	ACAAGTGCTG	GAGGTCTCTC	TTGCCAGAGT	58440
CCTCCTTGAG	AACTTACAAT	GTGTCCATAT	TAAGGATCTG	CTGTGTTTGA	TGATTTTGTG	58500
ATTACACTTT	AAACTTCTTA	TCCATAAAGG	ACATACTTGA	TATATCTGAG	ACTTGTAGTA	58560
GAAGGCCTTG	AGACATCCAT	CTCATCCCAT	CATTATCTAT	CTATCATCTA	TCTATCTATC	58620
TATCTATCTA	TCTATCTATC	TATCTATCTA	TCTATCATCT	ATCTATCTAT	CGCCAGTACT	58680
GTCTTGTTGA	AGTTGGCAGT	AGGGTGAAAG	ACCTCAAAC	CCAAAGGACT	TTCCGTATGG	58740
ATGCAATATA	CCTGCAATTC	TAGCTTTTTT	GTGTTTTTTT	TTTTAGGTTG	GGGGTGAGGG	58800
GTATTGTTTT	CATTTTTGTT	TTTCTTCTGG	AAGGTTCAAC	TAAGACCCAA	GTAAAAAGAA	58860
GAATCAATAC	TTAATAAGTA	CCCAGCAAGT	AGCAGGCACA	CTTTTAGGTA	CTTTATTTAC	58920
AAAAAAACCT	CCACAAATAA	AGTGGCTTGT	GAGTATGAGG	TGACATCTTT	CCCTCCCCCTC	58980
CCACCATCAC	TACCCCAATA	TGACTCGTCT	CAATAGCCCT	CCAATCTAAA	ATGGACTAAA	59040
TACAAGTGGA	TAAAGAAATG	GAGATTTAAC	CAGAATTCTT	CAGCTATAAA	TTACAGGGCC	59100
TATAATTTAA	GGTGATTGGG	ACTGGGTCAG	AGAGCCACAT	CACCTTTGTG	GTTGCATTTG	59160
AAGTTCACCTA	TCTCTTGACC	ACACAACCCT	AGCCCTTCTA	CTCCCACCCT	GCTGTCTCAG	59220
GTTAATCTCA	GGCAATGGTG	TAAAGAAGGC	CAAGTTTGTT	TCCCTGGAGT	CCCACGGGCT	59280
CTAGCAATAA	TGCTTCCCTT	TTCTCATGAG	TGCCCCGCCA	CCCACCCCCC	TTCCACCTCA	59340
CTACACACAA	ATGCCCTGCA	GTGGGTGGAA	TGTAGTTACT	TCAGGTGTG	CCTGATTGTG	59400
CTCTCAAGCA	AAACTCCAGC	AGGCCATTCC	CTCAGGGCCC	TGCTCTCAGA	TCTGGAACCTG	59460
ATAGACTAAT	TGGGGCTAAT	GTGATAATGG	GAAATAATGA	AATTGTGTTG	TTTTATCAGT	59520
GTGTATATGG	GGCGGGGTTT	ACATTTGCAT	TTTCACAGGG	CCCTGGGCAA	GTTACACAGGG	59580
TTGAACAGTT	GGGAAGGGTG	GGAATGTCTG	GGGCAGGTTA	GGGAGGCAGA	GGGATTATT	59640
AGAACTCCCC	TAAACTGCAC	TGACCAAGC	CTCAAGCCCT	TCTTCAAGAC	CTGCCAGCT	59700
TCCAAGACCT	TCCCAAGTCC	ACCCTTGTTT	TCCCCTGAG	TCTTTTACAC	TTTCAGAAAC	59760
CTCTGAATTT	GTGTAGAAAC	TAGAAAAAAT	AAGTAAGAAA	AGACTAATAC	TACTGCACAC	59820
TCACTGTTCC	CCCTTAATAT	AATAACCAGT	TTTTATTCTA	TTCAGTCAGC	CTTTGACCAT	59880
AAGCAGACCT	TTTTTTTTTC	TTTTTAACAC	AAGTAACTTC	TTGGTTTTGA	TCACAAAATC	59940
TTTATCTCTG	CCAAATCTCA	ACTTCCCTTC	CCTCTCCCAC	AAAAGGGAGG	CCCGTTGAGT	60000
CAAAGAAATC	TGCTTAGACA	CTTGCTCAT	GCCAGGCCAG	TGTCCTGGAA	GGTTCAACAG	60060
AGAGAGTTAA	TGGTTGGGGG	ATGGTATTTT	TCTTTGCTAG	GAGCAGTCAT	TCACCCGTAT	60120
GGGAGAAGGT	ACATTTGTGA	CCCAGTGAAG	CAGGTACAGG	TAACTCCCCA	TATGTCCTTT	60180
GGCCCAAGGG	AATAGAGGTT	GCCTGGGTAT	TTGAATCCGT	AGATCCTCCC	TAATATTCCA	60240
CCTTCTTCTT	GTCCAAACTG	TGCTTTTTTA	TTTCCAGTTT	CAGCATTTTG	GTCTTCTCAT	60300
CTCTAACTCT	TATAGGGAGT	GTCAATAAAC	CTTTTAAAAA	AGATCATGTA	AGTGTAAGA	60360
GGAAGTGAAG	AACCTAGATA	ATCCACCAAC	CGGATAATCA	GCTCTTGCAT	ATTTGAGAGT	60420
TGACTGCTTG	ACCTAAGCAT	CTCCTCATAA	GGTACCCTCC	CTCCCAGGAC	CTTCCCTTTC	60480
AAACCTCTCA	AGGCTCTTAC	CTGGGGCCAG	GGGAGATAGG	CTTTTCAAAG	TCCATTGAAT	60540

TGCCAAGAGT	CTCTGTCAAG	AAGGCAGTCA	TGGTGCCTGG	AGAGGGAAGT	TGCTGGGAGC	60600
CCCTTCAGAG	CCTGGTACTT	ATAGAGCTAG	GGAAAAGATC	TTGATGCCAA	AGCAGGGTGG	60660
ACTAAATACA	GACTAATAAA	TGAGACAGGT	GCTCAAGAGG	GCCCCCTCAT	ACCATCATCT	60720
CCTCCAGATT	TGGACTTCTA	CTCACTTTGC	TTTTACATTC	CCTCTTCCCG	ATGGTGTCTT	60780
TGGTGAGCAG	GGTGCTTTTC	ACCTGAAACA	GCCTCTGAGC	TGAAAAGAAC	AGTCACCACC	60840
AAATCAATTC	CTCATCCATT	AACAGGTTGT	CTCTCTGTTC	TTGAGACACA	GGCATTACCT	60900
GGTTAGACCT	GTTTTGTTTG	AACACTAACG	TGTGAGTTGG	CCAAATGCAA	ATGAGCCAAT	60960
GTTTGTAATC	CTTTATTTTA	TTTTTTTAAA	GGGCTGGGTA	GCCAATCAGA	AGAGGGGGAA	61020
GTGACTTAGG	GAATTCCTCG	TTGGTGGCTT	ATTGCTTAAC	ATCCTACAAA	ATGATTTAAA	61080
ATTATTGTTA	TATGCATTTA	TCTTCACTCT	GATGAGGGCT	CAGACTTGAT	AACGCCCGTG	61140
GTGCCCCATC	CCTATAGGAG	CTGGTGAGAT	TGCAGCCTGC	TGCCTCCCCT	CCATCAGCCA	61200
CAGCTATTGG	ATTTCCCAAC	CAGAATCTTT	AGGTAAATGA	GGTAAGTCCT	GATTTTTTAA	61260
ACTTCTTTTG	AATCTGGAAT	CCAAACACTT	GAGTGGAAAG	AGAAGCCTGC	TTTAAACTGG	61320
ACAGATGAAA	CTAGAACAGA	CTCTTGAGAG	CGGCTGGCAG	GAAGTGAAGC	TCACCTTACC	61380
TGGGCTTACC	TCACTGGGTC	AAATCAGAAT	TTTATTTTGG	AGGGCAGGTT	GGCTACTTTG	61440
GATATTATCT	GTGAATTTCC	TGCATTGTCT	GGACTTCTAA	TCTCTGTGAA	TTTAAAGGCC	61500
CCCTCGTTTC	CCTATGCCTG	GGTGGCAAAA	CCATTCCCTT	GGGTTGAATT	CTTCTGGAAC	61560
AAATAGGCAG	CTAGAGATAG	GTGGCTCTGA	TATAGCTCAG	AGAAGAAGTG	GTTGGCTAAG	61620
TAGCTGTTAG	GGCTCAGAGT	ACACGGTCTC	GCTTTCTAGA	GATGTCTTCT	GCTGGTAATT	61680
TTTCTGACTT	ATGAGCTACA	TGGAAAGGCC	AATTTGTTTT	TAATATGTTC	CAGGACTGGA	61740
AAATGGCTAG	AAATAGGCAA	GAACATACAC	AATCACACTG	GAAAAAGTGG	CCAGGCAGCC	61800
AAGGCAGGCA	GAGGTATTGG	GGAGAGCTGA	ATATCTACAA	AAACAAAAAT	TCAGAAAAAA	61860
CAAAAAATCAA	TTTTGGCAAA	GGGCTTCACT	GTATAACAAG	GGGACAAACT	AACCCTTTGT	61920
TTACAAACTA	ACCCTTTGTT	TACTCCATTT	TGTCCAGAAA	ATACAACAAT	CAGTTTTGGC	61980
AAAGGGCTTC	ACTGTGTAAC	AAGGGGACAA	ACTAACCCTT	TGTTTACTCC	ATTTTGGGAG	62040
ACTATGATCA	GACAGGCAGT	TGTGACTCAG	CAGCAACAAA	TGCCCTCTGA	GACAGGGATT	62100
CTTTTGATTT	TGCTTGGACA	TTGTGGAGAA	GTGTTAGCCC	CAATGTGGAC	TGATCTGGGA	62160
ACAGTGGGAA	ATTAACCTCT	TGTTGGCAAA	TATCAGGCTG	AGGTGAGAAA	GCGACATTTT	62220
CACCGTCCAT	CTTTGCTGAT	TTACCGTGCT	CCCAGGATGG	TGGGAGTGTG	TGTTTTTAAG	62280
ATGGAGAGTG	TATGCTTCTG	GGTTCAAGTT	CACAGGTGTC	TCTGCTGGTT	ATCTGCACTC	62340
ACCTTGGTAA	CAGGGAGAAA	GTGAGTGAAT	GGATTCCAAG	AACTTACTGA	TGGAAGTCTA	62400
ATTCAGGAGT	TGGTTCTGCA	GCCATGGAGG	TAAAGATGTG	TTGATAGTCT	TTCAATGTGT	62460
AAAAGGGCAA	TTAGAGATTG	TGTGTGACTG	TGTGTTAATT	CCACTGGGGT	CAGGGGAAAA	62520
ATTTATTTCT	AACAGAAAAG	AAGAAGATAC	GTTATTAGGA	AGAATTTTCAT	GGCTAGGAGA	62580
TACTATCAGA	AAAGGCTCTT	AAGAGATTTT	AAGGATGACT	TTAATAGCCG	CATTTGAAGT	62640
TTGCAGAGGA	TCCACTTTTC	CTCTTTTGTG	GACCTAAAAAT	TCTGGGATGA	TGAAATAACT	62700
CACCAATTTCC	ATCTTCTTAT	AATATGGAGT	CATGTAGACA	ACACCATTTT	CACACAAATG	62760
GCTAATGGTA	TTTAAAAACC	ATGATGGAAT	GTGAATTGGG	AGTCATTTGG	AGGTCTGTAG	62820
TTGAACTTGA	AAAAATAATA	AATGTAATGG	AGACAATACT	TCACCGTGTT	TCCAAAATAT	62880
TTTACAGAGG	CATTTTAAAT	GAAAGTCACT	TTGAGGGAAC	AGCTGTGCTG	TAAGTTCTCT	62940
TACATGACTG	CGCAAGATGG	TAGCCTTCAT	CAAGACCTCT	CAAGGTAGTG	TGGGTAGGGT	63000
GACGTGTTTG	ATTCAGGCCT	CGTTTGTTAT	GAAAAGGCTC	AAATTCAATT	GTATTTGTTA	63060
TTTTTTTGGT	TAAAAAGCAC	CTATTTGTTT	AATTCAAACA	ATCCTTTTTG	GTTTTTTTTT	63120
GAGATGAAGT	CTCCGTCGCC	CAGCCTGGAG	TGCAGTGGCA	TGATCTTGGC	TGACTGCAAC	63180
CTCCGCCTCC	CAGGTTCAAG	TGATTCTCCC	AACTCAGCCC	CCCGAGTAGC	TGGGATTACA	63240
TGTGCTCGCC	ACTATGCCCA	GTTAAGTTTT	GTATTTTATG	TAGAGACGGG	GTTTTGCCAT	63300
GTGAGCCAGG	CTGGTTTTGA	ACTCTGACC	TCAGGTGATC	CACCTGCCTC	AGCCTCCCAA	63360
AGTGCTGGGA	TTATAGGCTT	CAGCCACCGT	GCCCAGCCAT	ATTGTTTTCA	TTTTTAATCT	63420
ATTAGTCTAT	CGTGATCTCC	CAGTGGAAAGT	ATCTTTGGCC	TTTGTGGACG	TCAGGAAAGC	63480
CCTACATTCC	CACTCGCGAT	TCCATGTTTA	TGGGTACCCT	AAATGCTCCC	ATTAATTGAC	63540
CAACTTTACC	CTGATCTTCT	TTCAATATCT	TTCTGACTCC	TTGAAGGTAT	GAGACAAAAT	63600
GGAAACTGAG	AGGTTAAAAG	GTTTACTAGG	TTGCATTCAA	TTAGCGAATT	GGAACTGGA	63660
AGGAGCTCCT	ATCGGGTCTC	AGGTGAGAAC	GTGAGTGCTT	TTGGCCAAAG	TTCACTTCTG	63720
AGGAAGTAGA	ATTTGCTTTT	CTGGAATCTT	GCGATATTTT	ATTTCTCTTA	TATCTTTCCC	63780
ATGCCCCCGA	CCCACCCAAT	CTCCACAAAT	TTGGGGATTT	GAGCACTGGG	TTGTGATCGT	63840
TAGACCATCT	TGCTTTTCTG	AAAGCCCAGG	GCAAGACCCC	TGCTTCATGT	CACAGTATCA	63900



AACACAGACA	TAGAAGCTTG	TACAAATTAT	TGAGAAGTTA	TTGTCTTTTC	TCCCTTCCTC	63960
CATATGGAGT	CATCTCTATG	CCCTTTTCATA	CAGATGTGAT	TTACGAAGAC	CTCTGGGTTA	64020
GGGGTGGGGT	GGTGAGCAAG	AATCCCGTGG	CAGAATCTGC	TAACACACTT	GAGAAGCAAT	64080
GTTGTGGTTT	TAAGGAAGTC	AATCTAAAGC	TTGAACCTGA	TTTTTCAGGGA	TACCATTTTG	64140
CTGCCGTTTC	AGCCCATTTT	TCTTGTTAAG	ATCGCTCTCT	GGTAGAGTTG	ACGTGACACT	64200
CATTTCTGTT	GTGGGTGGGG	CCCTGGTTGG	GAGGCATTGG	CTCCACTGCA	GCCTGGGTGT	64260
CTAGAGACCA	CATTCTCACC	CTGCCCTTGT	TACTGGGAAA	CCGAACGCGG	CGCTGTGGCT	64320
TTCAGCTTGG	GTAAGCCGGG	TCTGCGGCGG	GGATTGCCAT	CTGAAGACAG	AGGCAGGAGG	64380
GCAGCCACAC	CTTGCCCAAG	TTCTCTTAAA	TCTCTTGCTC	TATAACTGAA	AGGAGGGCAT	64440
AGATAATTAA	CTTTATTTGA	CATTTTTTCAT	ATCTAATTTT	TAAGAATATG	ATTTTAAAAAT	64500
AATAGATTTG	TTCTAAAGAG	CAAACAATCT	TGCTGTTATT	AAAAACGTGT	TTACTTAAAT	64560
TGAACGGGGT	TTCAAAGGGC	CAAGCTACTA	AGCTGTGCAG	GAAACAAACA	GTGCAGTGAG	64620
GAGAATGGCT	CCTCACCACA	GCTATTCTTA	GGGTGGGACA	TAGTTTCAAG	CCAAATGACA	64680
TTGATGTCCG	GAAACCAGGA	TGTGCTGAAG	TAGAAATTTT	CAGGGATCCC	TCAGAGTTAT	64740
TTGCTAAAAT	GTTTATTATT	CTTCAGAGGG	GGGTGGAAAT	ATTTCTTTTAA	GAGTCTTCCT	64800
TGAAGAATTT	TGAAGCTCAG	CTTTGGAGTG	ATGGGAGCAC	AGTGCAGGGA	AGGCGGGATG	64860
TGAGGTGGTG	TGCTGGACGG	CAGTCTAGGG	ACCTGGTCTA	GCACTGGCAG	AGCTGTGTGT	64920
CCCAGAGCAC	ACATTCCCCT	TTGCCAGGCT	TTAGTTTCCT	CCTCTAGGCA	AAAGGGTTTG	64980
AACCTGACCA	TCTTTAAGAT	CCATTTTAAAC	CCTCAGATTC	TGTGGCTGTG	GTGATTGGGG	65040
GTGGTGGGAG	TACCTGGGGG	TCAGCAGGAT	AAGCACGAAT	CTGTGAGAGC	TGAGAACAGG	65100
TGGGAGAAGC	CTTCTAAGGA	TGAGGCAGGA	AAGATTAGCA	AGAGCCCTTA	AATGGATTCT	65160
TTAGGGCCTT	CAGAAATTTG	GCTAAAGGCT	ATACTAGTGG	AGGTACTAAG	ACCTGACACC	65220
TGGAGCCTTT	ATTAAGGATG	TTAGAATCCA	CTCCCATGAC	AACATCCCAG	CTTTGCCAAT	65280
TTGCCCTCATG	TGTCTCAAGC	TGGTGGGAAT	GTAGAAGTGG	ATGAAACAGA	CTGTTTTGTG	65340
ATGGCAGGGA	ACAGCCTATG	CACAGGGGCA	GGTGCTCTAC	TGGTGTCTTC	TATAAAACGC	65400
CAAAGCAGCC	CGCCAGAAAA	TGGACATTTA	GGCACTCGTG	GTGTCTACTG	AGTTTGTATG	65460
GTACTGATGA	GCTTGCTTGA	CTGATTATCC	ATGACTTACT	GAGTAGATCG	AACGTATGTG	65520
GACTCACTTC	TCCTAGAGGA	AGACCCTGTG	GCTGCCCCAG	CCACTGAGCA	GCCTAACCTG	65580
GAGACCCTGA	TGTGCCCAGA	AAGCGTCAAC	CTTGATCTCTG	GAGAAACCAG	AACCTGCAAC	65640
AGGGCCAAGC	AGGGTGGCCC	ATTTAAAGAG	GCTCCTAGGG	TTTTAATTGA	CCTTGTTTTTA	65700
AAAGAGACAC	CCTGTAAAAT	ACTCCTATGA	AACTTTATTT	CACAAGCACC	TAACCGCATT	65760
CTGTCTTTGG	TTTGTTTTAC	GGGGCCGGGC	CCCTTGTTC	GGTCAATTGG	TCTGCATTAT	65820
CTCTCCTCCT	CCAATCTCAC	CACACACCTT	GGCCTCTGGG	AGGCTTCCTC	CCTTCTTTTT	65880
TTTTGTGTTG	TTTGTTTTTT	TAGCATCTTA	GTTGTTACTA	GGGGTACTTG	CCTACTTATT	65940
TAAATATGG	CCAGTATAGG	TGCATACAAA	ATGTCCTTTC	TGATTAATAA	AAAGCCAAAA	66000
ATAAAAAGAA	ACCAAAATGC	CTATTATAGT	AGTTGGATTT	TTAGACTAAC	AGACCACCTC	66060
ATTAACCCCTG	TCATTTTACC	ATAACAACCT	ATTTTTATCT	TTGTATGACC	TTGTCTCAAT	66120
GTCCTTTTTT	TTTGATGTTG	TTGCAATTAT	GAACATCAAA	TTTCATAGCT	GCTTTTCCAC	66180
CCCCTTTTCT	ATCACAGAAG	CACAATAAAT	AATCTTGGGG	GCTGGGCTCT	TGTTGGCCCA	66240
ACTGTGGCTT	CAAAACATTT	CAGTTGCCTG	TCCAGCCCTT	TCTTAGCCTG	ATACAACATC	66300
CCCCAAAAGT	CTGTTGAGCT	TTTCCTGGAA	TAAGAAGAGG	GTCTTCTACT	TTTTGAATAG	66360
AGCAATGGAG	ATTGGAGAAT	ATGGTCATCT	TGTGGAGGTT	ATTCCAGGCT	TCTTCTTAGG	66420
AACCTTAAAA	AAAATCTCCT	CAGTAGGGCT	GATGATATAT	TCTGGACAAT	AAGGTGAGCA	66480
GAGTCTGAAA	GATGAGAGCA	ATTTTCAATC	TTGTCATGAT	TTCATCTAGT	CAGCCTCATT	66540
TCATCTAGTC	ATGAGGCTGA	CTAATGATAA	GACTTGCTTT	GTCTTTGCAG	TGTACTCTAG	66600
ATTTGACTCT	AAATTCAGCC	TCTGTCTTGA	TGATGCCCAC	TTAGAAAAAT	AGAGTGCAGC	66660
TAGCTACCTT	TTTAGTCATC	TTAATTCCAC	TAGGCAGAAG	GCTGTGGGTC	AAGGAATGTT	66720
GATGGAGTAA	AATTTGACTG	CATGTGTATC	TGAAGGGGTA	GGAGGCTAAG	AGATTTTATG	66780
GCTTGGAAGC	TGCTGAGATG	TGGTGTAAG	AACACTGGAC	TTAGAGTCCA	GACACCTGAG	66840
TTTAAGCTGG	ACTCTACCAC	TGGGTAGTTG	AATGACTTTG	AGTGAGTTAT	ATAAGCTCTA	66900
GCATCTAAGT	TTTCTCATCT	GGAAAATGGA	GTTAATAACA	TCTACTGCAT	TGGGCTGTTG	66960
TAAAGATTAA	ATTAACAAAG	AATGTGAAAG	CACCTGAACA	AAAGCTTGTTG	AGTAAATAAT	67020
TAGTAATTTG	TGGAATGAAC	ATCAAGGGAA	GTCTTCAATT	TGGGTGTTTT	CAGTGAGTTT	67080
CTGTTGGGTC	AGAGTGAATG	GATATTAAAT	TCTGGGATTT	TGGTTTGTGT	GTGTGTGTGT	67140
GTGTGTGTGT	GTGTGTGTGT	GGCGATCAAC	ATTGGTTCTT	CACGTGACCC	TTAGGAAAGA	67200
AATGCAATAG	GGTTTTTATT	GGGAAGGTGG	GTAGCAGGGA	GATGCATGAA	CCATATTAAAG	67260

GGGGGACCTC	CAAATTGAAC	CTTGTTTTGA	GTCAACTGCA	AACCACAACC	AAGGAGGTCC	67320
TGGGAGACCT	GGGGTGACTT	GGGGTGATTG	GGTATGCAGC	ACATTCCTGT	TCTTGTGTCC	67380
TGATGCCTGT	CAAGTAGGGA	CCTGCAGAAA	ATACTGATTG	TCCTCCAGGC	AGTTCCACATG	67440
ACTAGCTTTT	AGGAGTGAGT	ATACCGTTGC	CCACCCCTAA	AATTCCTGAT	CATGTCTCCA	67500
GATGTCTACT	GACCACTGAT	GCTGAGGTCA	TGAATCTTGG	GCATTCTAGA	GGCTTTGGGA	67560
AAAAAAATTC	TACTTACTTC	TTTTGCCCAG	ACACTCTGGG	GTCTACCTCT	TGGTAAATTA	67620
TTCAAATGAG	GTTTCTGGTC	ATGCAAATGT	GGTTTCTAGA	GCCTATTTGA	ATTGAACAAG	67680
TAGTTCTTAT	TATTAGTAAA	ACAGCAAGGA	TCCCTAACTT	GGGGTCCAAG	GGTAAATTCA	67740
GGGTTTCTGT	GAACCTGGAT	GTAAAAAAA	ATTGTGTTTA	TTTTCAATAA	TCTCTAACTA	67800
GAATTTAACA	TTTTCTTTCA	ATATGAATGT	AGGCAAAACT	CCATGGTAGT	ATTAGCTGCA	67860
ATTGTGACTA	TCACCAGGAT	AAATCACATT	TTCATGTCTT	ATTACACCTA	TTACATATAT	67920
CACAAAAAGT	GGGTATTTGA	TATCAAGTTA	GATCTGCACT	AGGTAGATAT	TCTTATTTAA	67980
TGTATTAACA	AGGAAGCACA	TATATTGTTA	TCAGGTTGGT	GCAAAAGTAA	TTGTGGTTCT	68040
TGCCATTAAA	AATAATTACA	AAAACAGCCA	GTCTGGCCAA	CATGGCGAAA	CCCCATCTCT	68100
ACTAAAAATA	CAGGTGTGGT	AGCACACACC	TGTAATCCCA	GCTACTTGGG	AGGCTGAGGC	68160
AGGAGAATCA	TTTGAACCTG	GGAAGCAGAG	GCTGCAGTGA	GCCAAGATCA	CACCATCTCA	68220
CTCTAGCCTG	AGCAACAGAG	TGAGACTCTG	TCTCAAAAAA	ATTAAAAAAT	AAAAAAAAC	68280
TCTGTAATTA	CTTTTGCAAC	AACATAATAT	GATATCACAC	ATTTATTTTA	AAAAGTATTT	68340
TGACATTGTC	TTTTAATATA	AATTTTTTTA	AATCTTATAA	TATTTTAATT	TGTCATGTAA	68400
AAATATTATT	TTGAGAAGAG	GCCTGTAGGC	CTCACTAGAT	TACAAAACAG	ATCCATCGTA	68460
CAGATGAAAG	GTTAAGAACA	CCTCATTTAC	AGCATTCTCT	CACACACGAC	TAACGAAATG	68520
ACTTCTGAAC	AGCGCCAGTT	GATAGATGTT	CTCTGCCAAA	AGGGGAATAT	GATCTTCCCA	68580
TATGTTCCTG	CCTATGGGTA	GCCTTGGAGT	TGTGAAGGGA	CTTTGGCATA	ATGAAGATGA	68640
TAATAAGAA	GATAATGGTA	ATTTGTTGAG	TGCCTGCTGT	AAGCCAGGTG	GTTACAGTCC	68700
TGTTCAATGT	CATGTTTAGT	TTAATCCTCC	CAATGACCTC	AGGAGGTAGT	GCATGGAACA	68760
AAGACAGAAG	AGATCCCCTG	CCCACCCACG	GTAAATGAAAC	ATGGGTACAG	GTGAAGGCAA	68820
AAGTGGGGAC	TGACCCTTTG	GAGATGGCTG	ATGTCACGAG	TGTGCAACCT	GTGCAGTTCC	68880
ACGGGGCCCC	ATGCTTAGAA	AGGTTCCATG	TTTGGTTTTA	GGCTCTGCTG	TTGCCATCTT	68940
AAAATCTTTC	GTAAGTTTTG	AACAAAGGGC	CCTGCATGTT	CCTTTTACAC	TGAGCTCTGC	69000
AAATGATGTA	GCTGGTCCCTG	CCTCTGGTTA	TGGTGAAATG	GAATGTATGA	CAACTCCTGA	69060
GACTGGGAGT	CTGGGAAGCT	GCTGCGGAGA	GCCCTCTCCT	CATTTTCATC	AGGCTCAGCT	69120
ACGCAACCTC	TGGTGGAAG	CTATGGCCTG	TTGAGGAGGG	AGGATGTCGT	TTTTGAGTTA	69180
GTGAGTTTTT	CAGTTTTGTT	TGAGCTCCAA	AGCTTTCCTC	CAAACAACCTG	GAAAGATGGC	69240
TGAATAATTG	GCTGAAAGGG	ATTTAATCCC	TTGAAAAACC	TTTCTGGTAG	GGAGTTGCTG	69300
GCAATCTGG	TGGGTTTTTC	ATGATTTTAT	TTACAGAGG	GCTTGCTACG	TAAACCAGTG	69360
AGCCAGGAGA	AACAGAATAA	AGTCTGTTCT	GTAAGGAAAA	ATGAGACCTG	GTGTGCCACG	69420
AGTCTAGTGT	TCTCATAGGA	AGGCTCTAAA	AACAAACTCA	GCTTTCCTGC	TATTGAATGA	69480
TTATCTCTAT	AAAAGGAAAC	TTTACTTCTT	CTAAAGGAGA	GGTCGTCTAA	TTTGTGAGAA	69540
AATTCAGATG	TTATTTGCTT	CTTAAGCTGC	AAGGATGCTA	ATGAAATAAT	TCTCATGAAG	69600
TTCTGTGGT	GTTTTAGGGC	TAAGTTTTTA	TAGACTGTTT	CAAAATTCAA	AACAGGGATG	69660
TGGACGTAGT	GATGGTGGAA	GAGGGGAAGA	CTTTTCCTCG	ATTTCTTTGC	CTGAGGGATG	69720
GAATTCAGGC	TCCCCCAATA	ACATATTTCAT	GGTCTTTCTC	TGGTCAGTCA	GTGATGTTCA	69780
TAACACAAGC	AAGCCTGTCA	TCAGGACCAA	TCTGTGATGG	CTGAGACATC	AGGTGCTCTT	69840
CCAAAAGAGC	CATAATTTCAC	CCTTCATTTT	CCAAGGTTTT	TTTTTCTTGG	CTGTTATTAC	69900
TGCTCTTTTA	TCATGGTTAA	TAAGTCTGAG	GTGGCTTCAG	ACAGCCAGTC	CTAACCCCTG	69960
AGTCAATCTG	GGGCCCTTAA	CAGGAAGCCA	GACTGAAGTT	CTGATAGATG	GGTTTGAGTG	70020
GCTGTGAAC	GTGTTTCTGT	AGCATCCAGA	CTGATTTGCA	CTGAAAGGGA	GCTTCCATAT	70080
TAGGGTACAA	GGATGATCAA	TATGTCTCCT	GTTTATATTT	GGTGAAAAA	GTTGTGGGAA	70140
TCGTGCTTAA	AGGATCTCAA	CTTTGAAATT	AAAAGTATAA	CGTCCTAACA	GACATCCTCC	70200
TTCTCTTTAG	AAACACAAGG	ATCCATTTTC	AAGTAATTTT	AAAAGAATAA	TGTTGCTTTT	70260
CCCACCCCTT	CCCAAGTACA	CTTATTATAA	TATATCCAGT	CCATTTGCTA	GCTTTGTGTC	70320
TTTAGAAAAG	TTGCTTAACC	TCTCTCTGTA	AAATGGTGCT	TATATTAGTA	CTAACATTCA	70380
GGGTTATTGT	GAGGATTAAA	TGAGGTAATT	CATGTAATGA	CTAGTTCTAT	TTCTAGCACA	70440
ATTTAAACCC	TCAACAAATA	TGAACATTTA	TCACTGTTCAT	AGTTTTTGTT	GTTGTTTTCT	70500
AATTATATAA	TCTTCAAGAT	TCTGAGATGG	GGGCTGTTGC	TCTTTCCTTG	ACTTGAACAT	70560
CTTGGTCTTT	TCCTAGGAGG	AAACTTGACT	CTTGAATGG	TCAAATCCAT	TGTCCTAGTT	70620

CATCCTGACC	CCTCCCTGGC	TCCAATCCCC	ACCCCTTACC	GTCTCCACC	CTTCCTACAT	70680
TCCTGCACAG	TTGGTCTTAT	TTATTTTCA	GTCAACTAAG	GGTGTGTGA	AATCTTTTAT	70740
TTTTCTGCTG	CCCGATTTGG	TTCTAAGCAC	TCCACTCCCT	ACGCTGCTCA	TAACAAGAAT	70800
GCCTGGGAAC	GCTCAGTCAG	CCATATCCCT	CCCCTGTGG	AACACCCAGT	TCTTAATGCT	70860
CCTGGAGAGG	CAACATTTCT	GAGGCCCCAC	TGCCATAAGC	CCCCCTCCCC	CATGAAGCCA	70920
GTGGTCTGGT	AGTAATGAAC	CCCCAACGGC	CCGGAGAAAA	CTGGGGCAAG	GTGTTTGTCT	70980
GGGGAAATGT	TGCATGTTGC	CTTGACTGTG	CTTTCTTCTA	CAAAGCTTAA	AAAGAGATAT	71040
TATATTATTT	TATTTTATT	TTTATTTTGG	AGATGGAGTC	TTACTTGGTT	GCCCAGGCTG	71100
GGTGTGCAGT	GGCACAGTCA	TGGCTCACTG	CAACCTCCAC	CTCCTGGGTT	CAAGTGATTC	71160
TCCTGCCTCA	GCCTCCCAAG	TAGCTGGGAC	TACAGGCACA	TGCCACCATG	CCTGGCTAAT	71220
TTGTATATTT	TTAGTAGAGA	CGGGGTTTCA	CCATATTAAC	TACATTGGTC	TTGAACTCCT	71280
GACCTCAAGT	GATATGCCCC	CCTCGGACTC	CCAAAGTGCT	GGGATTAAAA	GCATGAGCCA	71340
CTGCGCCCCG	CCAAAAAGAG	ATATTCAAAA	GCTCCCTCTG	ACTGTGTGTG	CTGAAGGCTG	71400
AGTGCTGATG	CCATTGCTTA	ATTAATGTTG	TTCATGATCT	CCATTTGGGC	GATTTGTTTA	71460
GCTCCTTGTT	GCCCTTTTGG	GACTTAGCTT	ATCATGTGAC	ATTGACAAAT	TAATGAGAAG	71520
TGACATGTG	ATGATGCTTG	GATTAGGACA	GAAATCACAT	CTAGGACATC	TCAGGCCCTT	71580
TCCACCTGGG	ACCTGAGACC	TCAAATCTCT	TGGCAGGAGA	TGAGTGGGTC	TACACAGCCC	71640
GATTTTGAGG	TAGGTGTGGC	TAGCCTCATT	TATGCGATGG	GAAAACGTG	GTCCGGGAAC	71700
CAGGGGTTTT	CAAATTATGC	TTTTTGCCCA	GGGCTGGATG	TAGGATGTCT	GGGGGAGAGG	71760
CTTGACTGAG	ATCTGGGTAC	ACTGAGCCTC	CACCTTAGGA	GGTAACCTAG	AGACTACACC	71820
TACTCCCTAA	ACTGTATTGA	CTTTTGGAAG	TCAACCATTT	AGAAGAGTGT	GGTTTTGGTT	71880
TCGATCGTAT	CCCAGCAGTC	TTTTCTCTGC	CCTTGTTAAT	CTGATTCATG	ATCTGAACCT	71940
GGGCTGGCTG	GAGGCTGGCC	ATGTCACTTT	GCAGACCATG	GACACCCCTG	AGTGCCCTCA	72000
CAGAACCAGC	CAATGGAAAA	GTACAACGTC	TTCTGGCTTC	TCAGCCTTGC	CATCTCCCTC	72060
TGGCCTATTT	GATACCCCTT	TTTATATTGA	GGGAGTGAAA	ATGTAGCATC	CAAAGTGAAA	72120
ACGCAGGTTT	TTCTTTGGTT	TTTATAGGAA	AAACAAATTG	GCATGAACAC	TCAGTCAAAC	72180
CAGCTCAGGC	TGTTTGGGCA	GATGCCTTTC	TTTGCTTTTT	TCTGTTTATT	TTCTTACAAA	72240
TCAATGCTTA	ACTGCGTTGT	TATCGGAGCA	GAGCAACAGG	TGCAAAAAAA	TAAGTCTGCT	72300
GCCAACTCAA	ATGAAAAGGT	AGGGCTTATA	CCCTCTGGGA	GGTATTCAGA	AGATAACAGA	72360
AGCCCTTGCC	AGCAACTGAA	TTAACAGCTC	TGTTTACGGT	GGGTTTTATG	TTAACAACCT	72420
GCTCCTGACC	CTCCTACACA	TAAACACACC	ATTGTCTCAG	AGAGAGACAT	TCAGCCATCC	72480
AGACAACCCA	CTGCTTTATT	CTGCCCTGAG	TGGAGATTGG	TTTTGGCTCA	GGCTGCTTTG	72540
TGAAACTCAG	AAGCATTATC	CTCTCTGCCA	ACTCCACGTC	CTAGTCAGAG	TTTTCTGTGA	72600
AGGCAAGGGC	ATGGGGTTGC	CGGAGAGAAG	AGGATTGGTC	CTGCTTTTAA	GCCTAGCTGA	72660
AATTCTTTTC	AAGGTTGGTC	ATTCTCAAAT	GCCAGAGAGG	GTTGCCCGGC	TCTCTCTGCT	72720
CTTGCCCCAT	TCCATTACAC	ACAGGAGGTG	GGGAATGAGC	TCAGATGACT	TTGGAAGGAG	72780
CCACTATTAT	TTTGAAGGCC	GTGTCTTGT	GAATAGTCCA	TCAGGGTAGG	GCAGCGTCTA	72840
TGTTTTGTGA	ACTATTGTAT	CGCCAGCACC	TAGCAAAGTG	CCCAGCATCT	AGTAGACACT	72900
TGGTAAATAT	GTATGAATTA	CAGAGGGT				72928

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5427 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATTTATCTTC	ACTCTGATGA	GGGCTCAGAC	TTGATAACGC	CCGTGGTGCC	CCATCCCTAT	60
AGGAGCTGGT	GAGATTGCAG	CCTGCTGCCT	CCCTCCATC	AGCCACAGCT	ATTGGATTTC	120
CCACCCAGAA	TCTTTAGGTA	AATGAGATCA	TGATTCTGGA	AGGAGGTGGT	GTAATGAATC	180
TCAACCCCGG	CAACAACCTC	CTTCACCAGC	CGCCAGCCTG	GACAGACAGC	TACTCCACGT	240

GCAATGTTTC	CAGTGGGTTT	TTTGGAGGCC	AGTGGCATGA	AATTCATCCT	CAGTACTGGA	300
CCAAGTACCA	GGTGTGGGAG	TGGCTCCAGC	ACCTCCTGGA	CACCAACCAG	CTGGATGCCA	360
ATTGTATCCC	TTTCCAAGAG	TTCGACATCA	ACGGCGAGCA	CCTCTGCAGC	ATGAGTTTGC	420
AGGAGTTCAC	CCGGGCGGCA	GGGACGGCGG	GGCAGCTCCT	CTACAGCAAC	TTGCAGCATC	480
TGAAGTGGAA	CGGCCAGTGC	AGTAGTGACC	TGTTCCAGTC	CACACACAAT	GTCAATTGTCA	540
AGACTGAACA	AACTGAGCCT	TCCATCATGA	ACACCTGGAA	AGACGAGAAC	TATTTATATG	600
ACACCAACTA	TGGTAGCACA	GTAGATTTGT	TGGACAGCAA	AACTTTCTGC	CGGGCTCAGA	660
TCTCCATGAC	AACCACCAGT	CACCTTCCTG	TTGCAGAGTC	ACCTGATATG	AAAAAGGAGC	720
AAGACCCCCC	TGCCAAGTGC	CACACCAAAA	AGCACAACCC	GAGAGGGACT	CAC TTATGGG	780
AATTCATCCG	CGACATCCTC	TTGAACCCAG	ACAAGAACCC	AGGATTAATA	AAATGGGAAG	840
ACCGATCTGA	GGGCGTCTTC	AGGTTCTTGA	AATCAGAGGC	AGTGGCTCAG	CTATGGGGTA	900
AAAAGAAGAA	CAACAGCAGC	ATGACCTATG	AAAAGCTCAG	CCGAGCTATG	AGATATTACT	960
ACAAAAGAGA	AATACTGGAG	CGTGTGGATG	GACGAAGACT	GGTATATAAA	TTTGGGAAGA	1020
ATGCCCGAGG	ATGGAGAGAA	AATGAAAAC	GAAGCTGCCA	ATACTTTGGA	CACAAACCAA	1080
AACACACACC	AAATAATCAG	AAACAAAGAA	CTCCTGGACG	TAAATATTTT	AAAGACTACT	1140
TTTCTCTGAT	ATTTATGTAC	CATGAGGGGA	AAAAGAAACT	ACTTCTAACG	GGAGAAGAA	1200
ACACTACAGT	CGATTAAAAA	AATTATTTTG	TTACTTCGAA	GTATGTCCTA	TATGGGGAAA	1260
AAACGTACAC	AGTTTTCTGT	GAAATATGAT	GCTGTATGTG	GTGTGATTTT	TTTTTCACCT	1320
CTATTGTGAA	TTCTTTTTC	CTGCAAGAGT	AACAGGATTT	GTAGCCTTGT	GCTTCTTGCT	1380
AAGAGAAAGA	AAAACAAAAT	CAGAGGGCAT	TAAATGTTTT	GTATGTGACA	TGATTTAGAA	1440
AAAGGTGATG	CATCCTCCTC	ACATAAGCAT	CCATATGGCT	TCGTCAAGGG	AGGTGAACAT	1500
TGTTGTCTGAG	TTAAATTCCA	GGGTCTCAGA	TGGTTAGGAC	AAAGTGGATG	GATGCCGGGA	1560
AGTTTAACTT	GAGCCTTAGG	ATCCAATGAG	TGGAGAATGG	GGACTTCCAA	AACCCAAGGT	1620
TGGCTATAAT	CTCTGCATAA	CCACATGACT	TGGAATGCTT	AAATCAGCAA	GAAGAATAAT	1680
GGTGGGGTCT	TTATACTCAT	TCAGGAATGG	TTTATCTGAT	GCCAGGGCTG	TCTTCCTTTC	1740
TCCCCTTTGG	ATGGTTGGTG	AAATACTTTA	ATTGCCCTGT	CTGCTCACTT	CTAGCTATTT	1800
AAGAGAGAAC	CCAGCTTGGT	TCTTTTTTGC	TCCAAGTGCT	TAAAAATAAG	TTGGAAAAAG	1860
GACACGGTGG	TGTGGAAATG	GCTGAAGAGT	TTGCTCTTGT	ATCCCTATAG	TCCAAGGTTT	1920
CTCAATCTGC	ACAATTGACA	TTTTTGGCCG	GAGTGTTCTT	TGTGGTGAGG	GCTTTCCTGT	1980
GCATTGTAAG	ATGTTTCAGCA	GTATCCACTC	ATGGTCTCTA	ACCACTTGAC	ACCAGAAACC	2040
CCCCAGCTGT	GATAACGCAA	AATGTCTCTA	GACATCACCA	AATGTTCCCT	GGGGGTGGCA	2100
AATTTGCCCT	TGATTGAGAA	CCACCAGTTT	AGCTAGTCAA	TATGAGGATG	GTGGTTTATT	2160
CTCAGAAGAA	AAAGATATGT	AAGGTCTTTT	AGCTCCTTAG	AGTGAAGCAA	AAGCAAGACT	2220
TCAACCTCAA	CCTATCTTTA	TGTTTTAAAT	ATTAGGGACA	ATAAGTTGAA	ATAGCTAGAG	2280
GAGCTTCTTT	TCAGAACCCC	AGATGAGAGC	CAATGTCAGA	TAAAGTAAGC	ATAGCAATGT	2340
AGCAGGAAC	ACAATAGAAG	ACATTTTCAC	TGGAATTACA	AAGCAGAATT	AAAATTATAT	2400
TGTAGAAGGA	AACACCAAGA	AAAGAATTTT	CAGGGAAAAA	CCTCTTTGCA	GGTATTAAAT	2460
CTTATAAATT	TTTGTCTTTT	GGATTATCTG	TTTACTGTCT	CATCTGAAC	GATCCCAGGT	2520
GAACGGTTTA	TTGCCTAGAT	TTGTACTCAG	AGGAATTTTT	TTTGTTTTGT	TTTGTCTTTT	2580
AAGAAAGGAA	AGAAAGGATG	AAAAAAATAA	ACAGAAAAC	CAGCTCAGGC	ACAATTGTCA	2640
CCAAGGAGTT	AAAAGCTTCT	TCTTCAATAG	AGGAATTGTT	CTGGGGGTCC	TGGAGACTTA	2700
CCATTGAGCC	ATGCAATCTG	GGAAGCACAG	GAATAAGTAG	ACACTTTGAA	AATGGATTGG	2760
AATGTTCTCA	TCCCTTTTGC	AGCTTTTCTT	TTTGGCTCTC	TCATGTCCTT	GGCTTGCTCC	2820
TCTATTCTAC	CTCTCTTTCT	CCAGCAATAA	TATGCAAATG	AAGACATGTA	TCCATAAGAA	2880
GGAGTGCTCT	TCATCAACTA	ATAGAGCACC	TACCACAGTG	TCATACCTGG	TAGAGGTGAG	2940
CAATTCATAT	TCAAAGGTTG	CAAAGTGTTT	GTAATATATT	CATGAGGCTG	GAAGTAAGAA	3000
GAATTAAGAA	TTTGTCTTAA	TTACAATGAG	AACCATTTCTA	GGTAGTGATC	TTGGAGCACA	3060
CATGAATAAC	TTTCTGAAGG	TGCAACCAAA	TCCATTTTTA	TTTCTGCCTG	GCTTGGTCAC	3120
CTCTGTAAAG	GTTTAACTTA	GTGTTGTCAA	GTAACAGTTA	CTGAAAGAGC	TGAGAAAAAG	3180
AACAATGAAC	AGCAACGATC	TTGACTGTGC	AACCTCAGACA	TTCCTGCAGA	AAAGACATAT	3240
GTTGCTTTAC	AAGAAGGCCA	AAGAAGTATG	GGGCCTTCCC	AGCATTTGAC	TGTTCAATTGC	3300
ATAGAATGAA	TTAAATATCC	AGTTACTTGA	ATGGGTATAA	CGCATGAATA	TTTGTGTGTC	3360
TGTGTGTGTG	TCTGAGTTGT	GTGATTTTAT	TAGGGGCATC	TGCCAATTCT	CTCACTGTGG	3420
TTCCCTTCTCT	GACTTTGCCT	GTTTCATCATC	TAAGGAGGCT	AGATCCTTCG	CTGACTTCAC	3480
CATTCCCTCAA	ACCTGTAAGT	TTCTCACTTC	TTCCAAATTG	GCTTTGGCTC	TTTCTTCAAC	3540
CTTTCCATTCT	AAGAGCAATC	TTTGCTAAGG	AGTAAGTGAA	TGTGAAGAGT	ACCAACTACA	3600

ACAATTCCTAC	AGATAATTAG	TGGATTGTGT	TGTTTGTTGA	GAGTGAAGGT	TTCTTGGCAT	3660
CTGGTGCCCTG	ATTAAGGCTT	GAGTATTAAG	TTCTCAGCAT	ATCTCTCTAT	TGCTTGACT	3720
TGAGTTTGCT	GCATTTTCTA	TGTGCTGTTC	GTGACTTGGA	GAACTTAAAG	TAATCGAGCT	3780
ATGCCAACTT	GGGGTGGTAA	CAGAGTACTT	CCCACCACAG	TGTTGAAAGG	GAGAGCAAAG	3840
TCTTATGGAT	AAACCCCTCCT	TTCTTTTGGG	GACACATGGC	TCTCACTTGA	GAAGCTCACC	3900
TGTGCTGAAT	GTCCACATGG	TCACTAAACA	TGTTATCCTT	AAACCCCCCG	TATGCCTGAG	3960
TTGAAAGGGC	TCTCTCTTAT	TAGGTTTTCA	TGGGAACATG	AGGCAGCAAA	TCTATTGCTA	4020
AGACTTTACC	AGGCTCAAAT	CATCTGAGGC	TGATAGATAT	TTGACTTGGT	AAGACTTAAG	4080
TAAGGCTCTG	GCTCCCAGGG	GCATAAGCAA	CAGTTTCTTG	AATGTGCCAT	CTGAGAAGGG	4140
AGACCCAGGT	TATGAGTTTT	CCTTTGAACA	CATTGGTCTT	TTCTCAAAGT	TCCTGCCTTG	4200
CTAGACTGTT	AGCTCTTTGA	GGACAGGGAC	TATGTCTTAT	CAATCACTAT	TATTTCTCTG	4260
TTACCTAGCA	TGGGACAAGT	ACACAACACA	TATTTGTTCA	ATGAATGAAT	GAATGTCTTC	4320
TAAAAGACTC	CTCTGATTGG	GAGACCATAT	CTATAATTGG	GATGTGAATC	ATTTCTTCAG	4380
TGGAATAAGA	GCACAACGGC	ACAACCTTCA	AGGACATATT	ATCTACTATG	AACATTTTAC	4440
TGTGAGACTC	TTTATTTTGC	CTTCTACTTG	CGTGAAATG	AAACCAAAAC	AGGCCGTTGG	4500
GTTCCACAAG	TCAATATATG	TTGGATGAGG	ATTCTGTTGC	CTTATTGGGA	ACTGTGAGAC	4560
TTATCTGGTA	TGAGAAGCCA	GTAATAAACC	TTTGACCTGT	TTTAACCAAT	GAAGATTATG	4620
AATATGTTAA	TATGATGTAA	ATTGCTATTT	AAGTGTAAG	CAGTTCTAAG	TTTGTAGTATT	4680
TGGGGGATTG	GTTTTTATTA	TTTTTTTCTT	TTTTGAAAAA	TACTGAGGGA	TCTTTTGATA	4740
AAGTTAGTAA	TGCATGTTAG	ATTTTAGTTT	TGCAAGCATG	TTGTTTTTCA	AATATATCAA	4800
GTATAGAAAA	AGGTAAACA	GTTAAGAAGG	AAGGCAATTA	TATTATTCTT	CTGTAGTTAA	4860
GCAAACACTT	GTTGAGTGCC	TGCTATGTGC	ACGGCATGGG	CCCATATGTG	TGAGGAGCTT	4920
GTCTAATTAT	GTAGGAAGCA	ATAGATCTCG	GTAGTTACGT	ATTGGGCAGA	TACTTACTGT	4980
ATGAATGAAA	GAACATCACA	GTAATCACAA	TATCAGAGCT	GAATTATCCT	CAGTGTAGCT	5040
TCTTGGAATT	CAGTTTCTGG	AACTAGAGAT	AGAGCATTTA	TTAAAAAAA	CTCCTGTTGA	5100
GACTGTGTCT	TATGAACCTC	TGAAACGTAC	AAGCCTTCAC	AAGTTTAACT	AAATTGGGAT	5160
TAATCTTTCT	GTAGTTATCT	GCATAATTCT	TGTTTTTCTT	TCCATCTGGC	TCCTGGGTTG	5220
ACAATTTGTG	GAAACAACCTC	TATTGCTACT	ATTTAAAAAA	AATCAGAAAT	CTTTCCCTTT	5280
AAGCTATGTT	AAATTCAAAC	TATTCCTGCT	ATTCCTGTTT	TGTCAAAGAA	TTATATTTTT	5340
CAAAATATGT	TTATTTGTTT	GATGGGTCCC	AGGAAACACT	AATAAAAACC	ACAGAGACCA	5400
GCCTGAAAAA	AAAAAAAAAA	AAAAAAA				5427

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5510 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATCGCTCTCT	GGTAGAGTTG	ACGTGACACT	CATTTCTGTT	GTGGGTGGGG	CCCTGGTTGG	60
GAGGCATTGG	CTCCACTGCA	GCCTGGGTGT	CTAGAGACCA	CATTCTCACC	CTGCCTTTGT	120
TACTGGGAAA	CCGAACGCGG	CGCTGTGGCT	TTCCAGTTGG	GTAAGCCGGG	TCTGCGGCGG	180
GGATTGCCAT	CTGAAGACAG	AGGCAGGAGG	GCAGCCACAC	CTTGCCAGAG	TCATGATTCT	240
GGAAGGAGGT	GGTGTAATGA	ATCTCAACCC	CGGCAACAAC	CTCCTTCACC	AGCCGCCAGC	300
CTGGACAGAC	AGCTACTCCA	CGTGCAATGT	TTCCAGTGGG	TTTTTTGGAG	GCCAGTGGCA	360
TGAAATTCAT	CCTCAGTACT	GGACCAAGTA	CCAGGTGTGG	GAGTGGCTCC	AGCACCTCCT	420
GGACACCAAC	CAGCTGGATG	CCAATTGTAT	CCCTTTCCAA	GAGTTCGACA	TCAACGGCGA	480
GCACCTCTGC	AGCATGAGTT	TGCAGGAGTT	CACCCGGGCG	GCAGGGACGG	CGGGGCAGCT	540
CCTCTACAGC	AACTTGCAGC	ATCTGAAGTG	GAACGGCCAG	TGCAGTAGTG	ACCTGTTCCA	600
GTCCACACAC	AATGTCATTG	TCAAGACTGA	ACAAACTGAG	CCTTCCATCA	TGAACACCTG	660
GAAAGACGAG	AACTATTTAT	ATGACACCAA	CTATGGTAGC	ACAGTAGATT	TGTTGGACAG	720

CAAAACTTTTC	TGCCGGGCTC	AGATCTCCAT	GACAACCACC	AGTCACCTTC	CTGTTGCAGA	780
GTCACCTGAT	ATGAAAAAGG	AGCAAGACCC	CCCTGCCAAG	TGCCACACCA	AAAAGCACAA	840
CCCGAGAGGG	ACTCACTTAT	GGGAATTCAT	CCGCGACATC	CTCTTGAACC	CAGACAAGAA	900
CCCAGGATTA	ATAAAATGGG	AAGACCGATC	TGAGGGCGTC	TTCAGGTTCT	TGAAATCAGA	960
GGCAGTGGCT	CAGCTATGGG	GTAAAAAGAA	GAACAACAGC	AGCATGACCT	ATGAAAAGCT	1020
CAGCCGAGCT	ATGAGATATT	ACTACAAAAG	AGAAATACTG	GAGCGTGTGG	ATGGACGAAG	1080
ACTGGTATAT	AAATTTGGGA	AGAATGCCCG	AGGATGGAGA	GAAAATGAAA	ACTGAAGCTG	1140
CCAATACTTT	GGACACAAAC	CAAAACACAC	ACCAAATAAT	CAGAAACAAA	GAACTCCTGG	1200
ACGTAAATAT	TTCAAAGACT	ACTTTTCTCT	GATATTTATG	TACCATGAGG	GGAAAAAGAA	1260
ACTACTTCTA	ACGGGAAGAA	GAAACACTAC	AGTCGATTAA	AAAAATTATT	TTGTTACTTC	1320
GAAGTATGTC	CTATATGGGG	AAAAAACGTA	CACAGTTTTT	TGTGAAATAT	GATGCTGTAT	1380
GTGGTTGTGA	TTTTTTTTCA	CCTCTATTGT	GAATTCTTTT	TCACTGCAAG	AGTAACAGGA	1440
TTTGTAGCCT	TGTGCTTCTT	GCTAAGAGAA	AGAAAAACAA	AATCAGAGGG	CATTAAATGT	1500
TTTGTATGTG	ACATGATTTA	GAAAAAGGTG	ATGCATCCTC	CTCACATAAG	CATCCATATG	1560
GCTTCGTCAA	GGGAGGTGAA	CATTGTTGCT	GAGTTAAATT	CCAGGGTCTC	AGATGGTTAG	1620
GACAAAGTGG	ATGGATGCCG	GGAAAGTTTAA	CCTGAGCCTT	AGGATCCAAT	GAGTGGAGAA	1680
TGGGGACTTC	CAAAACCCAA	GGTTGGCTAT	AATCTCTGCA	TAACCACATG	ACTTGGAATG	1740
CTTAAATCAG	CAAGAAGAAT	AATGGTGGGG	TCTTTATACT	CATTGAGGAA	TGGTTTATCT	1800
GATGCCAGGG	CTGTCTTCCT	TTCTCCCCTT	TGGATGGTTG	GTGAAATACT	TTAATTGCCC	1860
TGTCTGCTCA	CTTCTAGCTA	TTTAAGAGAG	AACCCAGCTT	GGTTCCTTTT	TGCTCCAAGT	1920
GCTTAAAAAT	AAGTTGGAAG	AAGGAGACGG	TGGTGTGGAA	ATGGCTGAAG	AGTTTGCTCT	1980
TGTATCCCTA	TAGTCCAAGG	TTTCTCAATC	TGCACAATTG	ACATTTTTTG	CCGGAGTGTT	2040
CTTTGTGGTG	AGGGCTTTCC	TGTGCAATTG	AAGATGTTCA	GCAGTATCCA	CTCATGGTCT	2100
CTAACCACTT	GACACCAGAA	ACCCCCAGC	TGTGATAACG	CAAAATGTCT	CTAGACATCA	2160
CCAAATGTTT	CCTGGGGGTG	GCAAATTTGC	CCTTGATTGA	GAACCACCAG	TTTAGCTAGT	2220
CAATATGAGG	ATGGTGGTTT	ATTCTCAGAA	GAAAAAGATA	TGTAAGGTCT	TTTAGCTCCT	2280
TAGAGTGAAG	CAAAAGCAAG	ACTTCAACCT	CAACCTATCT	TTATGTTTTA	AATATTAGGG	2340
ACAATAAGTT	GAAATAGCTA	GAGGAGCTTC	TTTTTCAGAAC	CCCAGATGAG	AGCCAATGTC	2400
AGATAAAGTA	AGCATAGCAA	TGTAGCAGGA	ACTACAATAG	AAGACATTTT	CACTGGAATT	2460
ACAAAGCAGA	ATTAAAATTA	TATTGTAGAA	GGAAACACCA	AGAAAAGAAT	TTCCAGGGAA	2520
AATCCTCTTT	GCAGGTATTA	ATTCTTATAA	TTTTTTGTCT	TTTGGATTAT	CTGTTTACTG	2580
TCTCATCTGA	ACTGATCCCA	GGTGAACGGT	TTATTGCCTA	GATTTGTACT	CAGAGGAATT	2640
TTTTTTGTTT	TGTTTTGTCT	TTTAAGAAAG	GAAAGAAAGG	ATGAAAAAAA	TAAACAGAAA	2700
ACTCAGCTCA	GGCACAATTG	TCACCAAGGA	GTTAAAAGCT	TCTTCTTCAA	TAGAGGAATT	2760
GTTCTGGGGG	TCCTGGAGAC	TTACCATTGA	GCCATGCAAT	CTGGGAAGCA	CAGGAATAAG	2820
TAGACACTTT	GAAAATGGAT	TTGAATGTTT	TCATCCCTTT	TGCAGCTTTT	CTTTTTGGCT	2880
CTCTCATGTC	CTTGGCTTGC	TCCTCTATTC	TACCTCTCTT	TCTCCAGCAA	TAATATGCAA	2940
ATGAAGACAT	GTATCCATAA	GAAGGAGTGC	TCTTCATCAA	CTAATAGAGC	ACCTACCACA	3000
GTGTCATACC	TGGTAGAGGT	GAGCAATTCA	TATTCAAAGG	TTGCAAAGTG	TTTGTAATAT	3060
ATTCATGAGG	CTGGAAGTAA	GAAGAATTAA	AAATTTGTCC	TAATTACAAT	GAGAACCATT	3120
CTAGGTAGTG	ATCTTGGAGC	ACACATGAAT	AACCTTCTGA	AGGTGCAACC	AAATCCATTT	3180
TTATTTCTAG	CTGGCTTGGT	CACCTCTGTA	AAGGTTTAA	TTAGTGTGTG	CAAGTAACAG	3240
TTACTGAAAG	AGCTGAGAAA	AAGAACAATG	AACAGCAACG	ATCTTGACTG	TGCAACTCAG	3300
ACATTCTCTG	AGAAAAGACA	TATGTTGCCT	TACAAGAAGG	CCAAAGAACT	ATGGGGCCTT	3360
CCCAGCATTT	GACTGTTTCA	TGCATAGAAT	GAATTAAATA	TCCAGTTACT	TGAATGGGTA	3420
TAACGCATGA	ATATTTGTGT	GTCTGTGTGT	GTGTCTGAGT	TGTGTGATTT	TATTAGGGGC	3480
ATCTGCCAAT	TCTCTCACTG	TGGTTCCTTC	TCTGACTTTG	CCTGTTCATC	ATCTAAGGAG	3540
GCTAGATCCT	TCGCTGACTT	CACCATTTCCT	CAAACCTGTA	AGTTTCTCAC	TTCTTCCAAA	3600
TTGGCTTTGG	CTCTTTCTTC	AACCTTTCCA	TTCAAGAGCA	ATCTTTGCTA	AGGAGTAAGT	3660
GAATGTGAAG	AGTACCAACT	ACAACAATTC	TACAGATAAT	TAGTGGATTG	TGTTGTTTGT	3720
TGAGAGTGAA	GGTTTCTTGG	CATCTGGTGC	CTGATTAAGG	CTTGAGTATT	AAGTTCCTCAG	3780
CATATCTCTC	TATTGTCTTG	ACTTGAGTTT	GCTGCATTTT	CTATGTGCTG	TTCTGACTT	3840
GGAGAACTTA	AAGTAATCGA	GCTATGCCAA	CTTGGGGTGG	TAACAGAGTA	CTTCCCACCA	3900
CAGTGTTGAA	AGGGAGAGCA	AAGTCTTATG	GATAAACCTT	CCTTTCTTTT	GGGGACACAT	3960
GGCTCTCACT	TGAGAAGCTC	ACCTGTGCTG	AATGTCCACA	TGGTCACTAA	ACATGTTTATC	4020
CTTAAACCCC	CCGTATGCCT	GAGTTGAAAG	GGCTCTCTCT	TATTAGGTTT	TCATGGGAAC	4080

ATGAGGCAGC	AAATCTATTG	CTAAGACTTT	ACCAGGCTCA	AATCATCTGA	GGCTGATAGA	4140
TATTTGACTT	GGTAAGACTT	AAGTAAGGCT	CTGGCTCCCA	GGGGCATAAG	CAACAGTTTC	4200
TTGAATGTGC	CATCTGAGAA	GGGAGACCCA	GGTTATGAGT	TTTCCTTTGA	ACACATTGGT	4260
CTTTTCTCAA	AGTTCCTGCC	TTGCTAGACT	GTTAGCTCTT	TGAGGACAGG	GACTATGTCT	4320
TATCAATCAC	TATTATTTTC	CTGTTACCTA	GCATGGGACA	AGTACACAAC	ACATATTTGT	4380
TCAATGAATG	AATGAATGTC	TTCTAAAAGA	CTCCTCTGAT	TGGGAGACCA	TATCTATAAT	4440
TGGGATGTGA	ATCATTTCTT	CAGTGGAATA	AGAGCACAAAC	GGCACAACT	TCAAGGACAT	4500
ATTATCTACT	ATGAACATTT	TACTGTGAGA	CTCTTTATTT	TGCCTTCTAC	TTGCGCTGAA	4560
ATGAAACCAA	AACAGGCCGT	TGGGTTCCAC	AAGTCAATAT	ATGTTGGATG	AGGATTCTGT	4620
TGCCTTATTG	GGAAGTGTGA	GACTTATCTG	GTATGAGAAG	CCAGTAATAA	ACCTTTGACC	4680
TGTTTTAACC	AATGAAGATT	ATGAATATGT	TAATATGATG	TAAATTGCTA	TTTAAGTGTA	4740
AAGCAGTTCT	AAGTTTTAGT	ATTTGGGGGA	TTGGTTTTTA	TTATTTTTTT	CCTTTTTGAA	4800
AAATACGTAG	GGATCTTTTG	ATAAAGTTAG	TAATGCATGT	TAGATTTTAG	TTTTGCAAGC	4860
ATGTTGTTTT	TCAAATATAT	CAAGTATAGA	AAAAGGTAAA	ACAGTTAAGA	AGGAAGGCAA	4920
TTATATTATT	CTTCTGTAGT	TAAGCAAACA	CTTGTTGAGT	GCCTGCTATG	TGCACGGCAT	4980
GGGCCCATAT	GTGTGAGGAG	CTTGCTAAT	TATGTAGGAA	GCAATAGATC	TCGGTAGTTA	5040
CGTATTGGGC	AGATACTTAC	TGTATGAATG	AAAGAACATC	ACAGTAATCA	CAATATCAGA	5100
GCTGAATTAT	CCTCAGTGTA	GCTTCTTGGA	ATTCAGTTTC	TGGAAGTAGA	GATAGAGCAT	5160
TTATTAAAAA	AAACTCCTGT	TGAGACTGTG	TCTTATGAAC	CTCTGAAACG	TACAAGCCTT	5220
CACAAGTTTA	ACTAAATTGG	GATTAACTTT	TCTGTAGTTA	TCTGCATAAT	TCTTGTTTTT	5280
CTTTCCATCT	GGCTCCTGGG	TTGACAATTT	GTGGAAACAA	CTCTATTGCT	ACTATTTAAA	5340
AAAAATCAGA	AATCTTTCCC	TTTAAGCTAT	GTTAAATTCA	AACTATTCCT	GCTATTCCTG	5400
TTTTGTCAAA	GAATTATATT	TTTCAAAATA	TGTTTATTTG	TTTGATGGGT	CCCAGGAAAC	5460
ACTAATAAAA	ACCACAGAGA	CCAGCCTGGA	AAAAAAAAAA	AAAAAAAAAA		5510

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5667 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATCGCTCTCT	GGTAGAGTTG	ACGTGACACT	CATTCTGTGT	GTGGGTGGGG	CCCTGGTTGG	60
GAGGCATTGG	CTCCACTGCA	GCCTGGGTGT	CTAGAGACCA	CATTCTCACC	CTGCCTTTGT	120
TACTGGGAAA	CCGAACGCGG	CGCTGTGGCT	TTCAGCTTGG	GTAAGCCGGG	TCTGCGCGGG	180
GGATTGCCAT	CTGAAGACAG	AGGCAGGAGG	GCAGCCACAC	CTTGCCAGC	TGCACACCCA	240
GTAACAAGTT	TCCTCAGTGC	GGGTATCTGC	CACAGGCTGG	GCTGGTCATC	AAAGGGCCTC	300
AGTCATATTT	TAATAGAGCT	CTTCAAGTAT	CTGGCTTTGT	GATAATATCA	GGAATCAGTT	360
GGTTTCTCTG	ACAGACACTG	CCCATTATCA	TGATTTCTGA	AGGAGGTGGT	GTAATGAATC	420
TCAACCCCGG	CAACAACCTC	CTTCACCAGC	CGCCAGCCTG	GACAGACAGC	TACTCCACGT	480
GCAATGTTTT	CAGTGGGTTT	TTTGGAGGCC	AGTGGCATGA	AATTCATCCT	CAGTACTGGA	540
CCAAGTACCA	GGTGTGGGAG	TGGCTCCAGC	ACCTCCTGGA	CACCAACCAG	CTGGATGCCA	600
ATTGTATCCC	TTTCCAAGAG	TTCGACATCA	ACGGCGAGCA	CCTCTGCAGC	ATGAGTTTGC	660
AGGAGTTCAC	CCGGGCGGCA	GGGACGGCGG	GGCAGCTCCT	CTACAGCAAC	TTGCAGCATC	720
TGAAGTGGAA	CGGCCAGTGC	AGTAGTGACC	TGTTCCAGTC	CACACACAAT	GTCATTGTCA	780
AGACTGAACA	AACTGAGCCT	TCCATCATGA	ACACCTGGAA	AGACGAGAAC	TATTTATATG	840
ACACCAACTA	TGGTAGCACA	GTAGATTTGT	TGGACAGCAA	AACTTTCTGC	CGGGCTCAGA	900
TCTCCATGAC	AACCACCAGT	CACCTTCCTG	TTGCAGAGTC	ACCTGATATG	AAAAAGGAGC	960
AAGACCCCCC	TGCCAAGTGC	CACACCAAAA	AGCACAACCC	GAGAGGGACT	CACTTATGGG	1020
AATTCATCCG	CGACATCCTC	TTGAACCCAG	ACAAGAACCC	AGGATTAATA	AAATGGGAAG	1080
ACCGATCTGA	GGGCGTCTTC	AGGTTCTTGA	AATCAGAGGC	AGTGGCTCAG	CTATGGGGTA	1140

AAAAAGAAGAA	CAACAGCAGC	ATGACCTATG	AAAAGCTCAG	CCGAGCTATG	AGATATTACT	1200
ACAAAAGAGA	AATACTGGAG	CGTGTGGATG	GACGAAGACT	GGTATATAAA	TTTGGGAAGA	1260
ATGCCCCGAGG	ATGGAGAGAA	AATGAAAAC	GAAGCTGCCA	ATACTTTGGA	CACAAACCAA	1320
AACACACACC	AAATAATCAG	AAACAAAGAA	CTCCTGGACG	TAAATATTTC	AAAGACTACT	1380
TTTCTCTGAT	ATTTATGTAC	CATGAGGGGA	AAAAGAAACT	ACTTCTAACG	GGAAGAAGAA	1440
ACACTACAGT	CGATTAAAAA	AATTATTTTG	TTACTTCGAA	GTATGTCTTA	TATGGGGAAA	1500
AAACGTACAC	AGTTTTCTGT	GAAATATGAT	GCTGTATGTG	GTTGTGATTT	TTTTTCACCT	1560
CTATTGTGAA	TTCTTTTTCA	CTGCAAGAGT	AACAGGATTT	GTAGCCTTGT	GCTTCTTGCT	1620
AAGAGAAAGA	AAAACAAAAT	CAGAGGGCAT	TAAATGTTTT	GTATGTGACA	TGATTTAGAA	1680
AAAGGTGATG	CATCCTCCTC	ACATAAGCAT	CCATATGGCT	TCGTCAAGGG	AGGTGAACAT	1740
TGTTGCTGAG	TTAAATTCCA	GGGTCTCAGA	TGGTTAGGAC	AAAGTGGATG	GATGCCGGGA	1800
AGTTTAACCT	GAGCCTTAGG	ATCCAATGAG	TGGAGAATGG	GGACTTCCAA	AACCCAAGGT	1860
TGGCTATAAT	CTCTGCATAA	CCACATGACT	TGGAATGCTT	AAATCAGCAA	GAAGCAATAAT	1920
GGTGGGGTCT	TTATACTCAT	TCAGGAATGG	TTTATCTGAT	GCCAGGGCTG	TCTTCTTTTC	1980
TCCCCTTTGG	ATGGTTGGTG	AAATACTTTA	ATTGCCCTGT	CTGCTCACTT	CTAGCTATTT	2040
AAGAGAGAAC	CCAGCTTGGT	TCTTTTTTGC	TCCAAGTGCT	TAAAAATAAG	TTGGAAAAAG	2100
GAGACGGTGG	TGTGGAAATG	GCTGAAGAGT	TTGCTCTTGT	ATCCCTATAG	TCCAAGGTTT	2160
CTCAATCTGC	ACAATTGACA	TTTTTGGCCG	GAGTGTCTTT	TGTGGTGAGG	GCTTTCCTGT	2220
GCATTGTAAG	ATGTTTCAGCA	GTATCCACTC	ATGGTCTCTA	ACCCTTGAC	ACCAGAAACC	2280
CCCCAGCTGT	GATAACGCAA	AATGTCTCTA	GACATCACCA	AATGTTCCCT	GGGGGTGGCA	2340
AATTTGCCCT	TGATTGAGAA	CCACCAGTTT	AGCTAGTCAA	TATGAGGATG	GTGGTTTATT	2400
CTCAGAAGAA	AAAGATATGT	AAGGTCTTTT	AGCTCCTTAG	AGTGAAGCAA	AAGCAAGACT	2460
TCAACCTCAA	CCTATCTTTA	TGTTTTAAAT	ATTAGGGACA	ATAAGTTGAA	ATAGCTAGAG	2520
GAGCTTCTTT	TCAGAACCCC	AGATGAGAGC	CAATGTCAGA	TAAAGTAAGC	ATAGCAATGT	2580
AGCAGGAAC	ACAATAGAAG	ACATTTTCAC	TGGAATTACA	AAGCAGAATT	AAAATTATAT	2640
TGTAGAAGGA	AACACCAAGA	AAAGAATTTT	CAGGGGAAAAT	CCTCTTTGCA	GGTATTAAAT	2700
CTTATAATTT	TTTGTCTTTT	GGATTATCTG	TTTACTGTCT	CATCTGAACT	GATCCCAGGT	2760
GAACGGTTTA	TTGCCTAGAT	TTGTACTCAG	AGGAATTTTT	TTTGTTTTGT	TTTGTCTTTT	2820
AAGAAAGGAA	AGAAAGGATG	AAAAAATAA	ACAGAAACT	CAGCTCAGGC	ACAATTGTCA	2880
CCAAGGAGTT	AAAAGCTTCT	TCTTCAATAG	AGGAATTGTT	CTGGGGGTCC	TGGAGACTTA	2940
CCATTGAGCC	ATGCAATCTG	GGAAGCACAG	GAATAAGTAG	ACACTTTGAA	AATGGATTTG	3000
AATGTTCTCA	TCCCTTTTGC	AGCTTTTCTT	TTTGGCTCTC	TCATGTCCTT	GGCTTGCTCC	3060
TCTATTCTCT	CTCTCTTTCT	CCAGCAATAA	TATGCAATG	AAGACATGTA	TCCATAAGAA	3120
GGAGTGTCT	TCATCAACTA	ATAGAGCACC	TACCACAGTG	TCATACCTGG	TAGAGGTGAG	3180
CAATTCTAT	TCAAAGGTTG	CAAAGTGTTT	GTAATATATT	CATGAGGCTG	GAAGTAAGAA	3240
GAATTAAAAA	TTTGTCTTAA	TTACAATGAG	AACCATTCTA	GGTAGTGATC	TTGGAGCACA	3300
CATGAATAAC	TTTCTGAAGG	TGCAACCAAA	TCCATTTTTA	TTTCTGCCTG	GCTTGGTCAC	3360
CTCTGTAAAG	GTTTAACTTA	GTGTGTGCAA	GTAACAGTTA	CTGAAAGAGC	TGAGAAAAAG	3420
AACAATGAAC	AGCAACGATC	TTGACTGTGC	AACTCAGACA	TTCTGCAGA	AAAGACATAT	3480
GTGCTTTTAC	AAGAAGGCCA	AAGAACTATG	GGGCCTTCCC	AGCATTTGAC	TGTTTATTGC	3540
ATAGAATGAA	TTAAATATCC	AGTTACTTGA	ATGGGTATAA	CGCATGAATA	TTTGTGTGTC	3600
TGTGTGTGTG	TCTGAGTTGT	GTGATTTTAT	TAGGGGCATC	TGCCAATTCT	CTCACTGTGG	3660
TTCTTCTCT	GACTTTGCCT	GTTCATCATC	TAAGGAGGCT	AGATCCTTCG	CTGACTTCAC	3720
CATTCTCAA	ACCTGTAAGT	TTCTCACTTC	TTCCAAATTG	GCTTTGGCTC	TTTCTTCAAC	3780
CTTTCCATT	AAGAGCAATC	TTTGCTAAGG	AGTAAGTGAA	TGTGAAGAGT	ACCAACTACA	3840
ACAATTCTAC	AGATAATTAG	TGGATTGTGT	TGTTTGTGTA	GAGTGAAGGT	TTCTTGGCAT	3900
CTGGTGCTG	ATTAAGGCTT	GAGTATTAAG	TTCTCAGCAT	ATCTCTCTAT	TGTCTTGACT	3960
TGAGTTTGCT	GCATTTTCTA	TGTGCTGTTC	GTGACTTGGA	GAACTTAAAG	TAATCGAGCT	4020
ATGCCAATT	GGGGTGGTAA	CAGAGTACTT	CCCACCACAG	TGTTGAAAGG	GAGAGCAAAG	4080
TCTTATGGAT	AAACCTCCT	TTCTTTTGGG	GACACATGGC	TCTCACTTGA	GAAGCTCACC	4140
TGTGCTGAAT	GTCCACATGG	TCACTAAACA	TGTTATCCTT	AAACCCCCCG	TATGCCTGAG	4200
TTGAAAGGGC	TCTCTTTAT	TAGGTTTTC	TGGGAACATG	AGGCAGCAAA	TCTATTGCTA	4260
AGACTTTACC	AGGCTCAAAT	CATCTGAGGC	TGATAGATAT	TTGACTTGGT	AAGACTTAAG	4320
TAAGGCTCTG	GCTCCCAGGG	GCATAAGCAA	CAGTTTCTTG	AATGTGCCAT	CTGAGAAGGG	4380
AGACCCAGGT	TATGAGTTTT	CCTTTGAACA	CATTGGTCTT	TTCTCAAAGT	TCCTGCCTTG	4440
CTAGACTGTT	AGCTCTTTGA	GGACAGGGAC	TATGCTTAT	CAATCACTAT	TATTTTCTCTG	4500



TTACCTAGCA	TGGGACAAGT	ACACAACACA	TATTTGTTCA	ATGAATGAAT	GAATGTCTTC	4560
TAAAAGACTC	CTCTGATTGG	GAGACCATAT	CTATAATTGG	GATGTGAATC	ATTTCTTCAG	4620
TGGAATAAGA	GCACAACGGC	ACAACCTTCA	AGGACATATT	ATCTACTATG	AACATTTTAC	4680
TGTGAGACTC	TTTATTTTGC	CTTCTACTTG	CGCTGAAATG	AAACCAAAAC	AGGCCGTTGG	4740
GTTCCACAAG	TCAATATATG	TTGGATGAGG	ATTCTGTTGC	CTTATTGGGA	ACTGTGAGAC	4800
TTATCTGGTA	TGAGAAGCCA	GTAATAAACC	TTTGACCTGT	TTTAACCAAT	GAAGATTATG	4860
AATATGTAA	TATGATGTAA	ATTGCTATTT	AAGTGTAAG	CAGTTCTAAG	TTTTAGTATT	4920
TGGGGGATTG	GTTTTTATTA	TTTTTTTCCT	TTTGAAAAA	TACTGAGGGA	TCTTTTGATA	4980
AAGTTAGTAA	TGCATGTTAG	ATTTTAGTTT	TGCAAGCATG	TTGTTTTTCA	AATATATCAA	5040
GTATAGAAAA	AGGTAAAACA	GTTAAGAAGG	AAGGCAATTA	TATTATTCTT	CTGTAGTTAA	5100
GCAAACACTT	GTTGAGTGCC	TGCTATGTGC	ACGGCATGGG	CCCATATGTG	TGAGGAGCTT	5160
GTCTAATTAT	GTAGGAAGCA	ATAGATCTCG	GTAGTTACGT	ATTGGGCAGA	TACTTACTGT	5220
ATGAATGAAA	GAACATCACA	GTAATCACAA	TATCAGAGCT	GAATTATCCT	CAGTGTAGCT	5280
TCTTGGAATT	CAGTTTCTGG	AACTAGAGAT	AGAGCATTTA	TTAAAAAAA	CTCCTGTGA	5340
GACTGTGTCT	TATGAACCTC	TGAAACGTAC	AAGCCTTCAC	AAGTTTAACT	AAATTGGGAT	5400
TAATCTTTCT	GTAGTTATCT	GCATAATTCT	TGTTTTTCTT	TCCATCTGGC	TCCTGGGTTG	5460
ACAATTTGTG	GAAACAACCTC	TATTGCTACT	ATTTAAAAAA	AATCAGAAAT	CTTTCCTTTT	5520
AAGCTATGTT	AAATTCAAAC	TATTCCTGCT	ATTCCTGTTT	TGTCAAAGAA	TTATATTTTT	5580
CAAAATATGT	TTATTTGTTT	GATGGGTCCC	AGGAAACACT	AATAAAAACC	ACAGAGACCA	5640
GCCTGGAAAA	AAAAAAA	AAAAAAA				5667

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 300 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met	Ile	Leu	Glu	Gly	Gly	Gly	Val	Met	Asn	Leu	Asn	Pro	Gly	Asn	Asn
1				5					10					15	
Leu	Leu	His	Gln	Pro	Pro	Ala	Trp	Thr	Asp	Ser	Tyr	Ser	Thr	Cys	Asn
			20					25					30		
Val	Ser	Ser	Gly	Phe	Phe	Gly	Gly	Gln	Trp	His	Glu	Ile	His	Pro	Gln
		35				40					45				
Tyr	Trp	Thr	Lys	Tyr	Gln	Val	Trp	Glu	Trp	Leu	Gln	His	Leu	Leu	Asp
	50				55					60					
Thr	Asn	Gln	Leu	Asp	Ala	Asn	Cys	Ile	Pro	Phe	Gln	Glu	Phe	Asp	Ile
65					70				75					80	
Asn	Gly	Glu	His	Leu	Cys	Ser	Met	Ser	Leu	Gln	Glu	Phe	Thr	Arg	Ala
			85					90						95	
Ala	Gly	Thr	Ala	Gly	Gln	Leu	Leu	Tyr	Ser	Asn	Leu	Gln	His	Leu	Lys
			100					105					110		
Trp	Asn	Gly	Gln	Cys	Ser	Ser	Asp	Leu	Phe	Gln	Ser	Thr	His	Asn	Val
	115						120					125			
Ile	Val	Lys	Thr	Glu	Gln	Thr	Glu	Pro	Ser	Ile	Met	Asn	Thr	Trp	Lys
	130					135					140				
Asp	Glu	Asn	Tyr	Leu	Tyr	Asp	Thr	Asn	Tyr	Gly	Ser	Thr	Val	Asp	Leu
145					150					155				160	
Leu	Asp	Ser	Lys	Thr	Phe	Cys	Arg	Ala	Gln	Ile	Ser	Met	Thr	Thr	Thr
			165					170						175	
Ser	His	Leu	Pro	Val	Ala	Glu	Ser	Pro	Asp	Met	Lys	Lys	Glu	Gln	Asp

-104-

```

TTAATTGGAT TTAACATAGG TTCACAGAAA GTTTCCTAAC CAGAGCATCT TTTTGACCAC 1740
TCAGCAAAAC TTCCACAGAC ATCCTTCTGG ACTTAAACAC TTAACATTAA CCACATTATT 1800
AATTGTTGCT GAGTTTATTC CCCCTTCTAA CTGATGGCTG GCATCTGATA TGCAGAGTTA 1860
GTCAACAGAC ACTGGCATCA ATTACAAAAT CACTGCTGTT TCTGTGATT CAGCTGTCAA 1920
CACAATAAAA TCGAAATTCA TTGATTCCAT CTCTGGTCCA GATGTAAAC GTTTATAAAA 1980
CCGGAATGT CCTAACAACT CTGTAATGGC AAATTAAATT GTGTGTCTTT TTTGTTTGT 2040
CTTTCTACCT GATGTGTATT CAAGCGCTAT AACACGTATT TCCTTGACAA AAATAGTGAC 2100
AGTGAATTCA CACTAATAAA TGTTCATAGG TTAAAGTCTG CACTGACATT TTCTCATCAA 2160
TCACTGGTAT GTAAGTTATC AGTGACTGAC AGCTAGGTGG ACTGCCCTA GGACTTCTGT 2220
TTCACCAGAG CAGGAATCAA GTGGTGAGGC ACTGAATCGC TGTACAGGCT GAAGACCTCC 2280
TTATTAGAGT TGAACCTCAA AGTAACTTGT TTTAAAAAAT GTGAATTACT GTAAAAAAT 2340
CTATTTTGA TTCATGTGTT TTCCAGGTGG ATATAGTTTG TAAACAATGT GAATAAAGTA 2400
TTTAACATGT TCAAAAAAAA AAAAAAAA 2428

```

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 265 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

Met Pro Ser Leu Pro His Ser His Arg Val Met Leu Asp Ser Val Thr
 1             5             10             15
His Ser Thr Phe Leu Pro Asn Ala Ser Phe Cys Asp Pro Leu Met Ser
      20             25             30
Trp Thr Asp Leu Phe Ser Asn Glu Glu Tyr Tyr Pro Ala Phe Glu His
      35             40             45
Gln Thr Ala Cys Asp Ser Tyr Trp Thr Ser Val His Pro Glu Tyr Trp
 50             55             60
Thr Lys Arg His Val Trp Glu Trp Leu Gln Phe Cys Cys Asp Gln Tyr
 65             70             75             80
Lys Leu Asp Thr Asn Cys Ile Ser Phe Cys Asn Phe Asn Ile Ser Gly
      85             90             95
Leu Gln Leu Cys Ser Met Thr Gln Glu Glu Phe Val Glu Ala Ala Gly
      100            105            110
Leu Cys Gly Glu Tyr Leu Tyr Phe Ile Leu Gln Asn Ile Arg Thr Gln
      115            120            125
Gly Tyr Ser Phe Phe Asn Asp Ala Glu Glu Ser Lys Ala Thr Ile Lys
      130            135            140
Asp Tyr Ala Asp Ser Asn Cys Leu Lys Thr Ser Gly Ile Lys Ser Gln
      145            150            155            160
Asp Cys His Ser His Ser Arg Thr Ser Leu Gln Ser Ser His Leu Trp
      165            170            175
Glu Phe Val Arg Asp Leu Leu Leu Ser Pro Glu Glu Asn Cys Gly Ile
      180            185            190
Leu Glu Trp Glu Asp Arg Glu Gln Gly Ile Phe Arg Val Val Lys Ser
      195            200            205
Glu Ala Leu Ala Lys Met Trp Gly Gln Arg Lys Lys Asn Asp Arg Met
      210            215            220
Thr Tyr Glu Lys Leu Ser Arg Ala Leu Arg Tyr Tyr Tyr Lys Thr Gly
      225            230            235            240

```

Ile Leu Glu Arg Val Asp Arg Arg Leu Val Tyr Lys Phe Gly-Lys Asn  
 245 250 255  
 Ala His Gly Trp Gln Glu Asp Lys Leu  
 260 265

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2280 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTGGGAGCGC	CTGCCTTCTC	TTGCCTTGAA	AGCCTCCTCT	TTGGACCTAG	CCACCGCTGC	60
CCTCACGGTA	ATGTTGGACT	CGGTGACACA	CAGCACCTTC	CTGCCTAATG	CATCCTTCTG	120
CGATCCCCTG	ATGTCGTGGA	CTGATCTGTT	CAGCAATGAA	GAGTACTACC	CTGCCTTTGA	180
GCATCAGACA	GCCTGTGACT	CATACTGGAC	ATCAGTCCAC	CCTGAATACT	GGACTAAGCG	240
CCATGTGTGG	GAGTGGCTCC	AGTTCTGCTG	CGACCAGTAC	AAGTTGGACA	CCAATTGCAT	300
CTCCTTCTGC	AAC TTCAACA	TCAGTGGCCT	GCAGCTGTGC	AGCATGACAC	AGGAGGAGTT	360
CGTCGAGGCA	GCTGGCCTCT	GCGGCGAGTA	CCTGTACTTC	ATCCTCCAGA	ACATCCGCAC	420
ACAAGGTTAC	TCCTTTTTTA	ATGACGCTGA	AGAAAGCAAG	GCCACCATCA	AAGACTATGC	480
TGATTCCAAC	TGCTTGAAAA	CAAGTGGCAT	CAAAAGTCAA	GACTGTCACA	GTCCATAGTAG	540
AACAAGCCTC	CAAAGTTCTC	ATCTATGGGA	ATTTGTACGA	GACCTGCTTC	TATCTCCTGA	600
AGAAAACTGT	GGCATTCTGG	AATGGGAAGA	TAGGGAACAA	GGAATTTTTC	GGGTGGTTAA	660
ATCGGAAGCC	CTGGCAAAGA	TGTGGGGACA	AAGGAAGAAA	AATGACAGAA	TGACGTATGA	720
AAAGTTGAGC	AGAGCCCTGA	GATACTACTA	TAAACAGGA	ATTTTGGAGC	GGGTGACCG	780
AAGGTTAGTG	TACAAATTTG	GAAAAAATGC	ACACGGGTGG	CAGGAAGACA	AGCTATGATC	840
TGCTCCAGGC	ATCAAGCTCA	TTTTATGGAT	TTCTGTCTTT	TAAACAATC	AGATTGCAAT	900
AGACATTGCA	AAGGCTTCAT	TTTCTTCTCT	TTTTTTTTTA	CCTGCAAAAC	TGCTGATAAA	960
ATTTCTCCAC	ATCTCAGCTT	ACATTTGGAT	TCAGAGTTGT	TGTCTACGGA	GGGTGAGAGC	1020
AGAAACTCTT	AAGAAATCCT	TTCTTCTCCC	TAAGGGGATG	AGGGGATGAT	CTTTTGTGGT	1080
GTCTTGACTA	AAC TTTATTT	TCCTAGAGTT	TGGAATGAC	AACAGCCCAT	GCCATTGATG	1140
CTGATCAGAG	AAAAACTATT	CAATTCTGCC	ATTAGAGACA	CATCCAATGC	TCCCATCCCA	1200
AAGGTTCAAA	AGTTTTCAAA	TAATGTGGC	AGCTCACCAA	AGGTGGGGGA	AAGCATGATT	1260
AGTTTGCAGG	TTATGGTAGG	AGAGGGTGAG	ATATAAGACA	TACATACTTT	AGATTTTAAA	1320
TTATTAAAGT	CAAAAATCCA	TAGAAAAGTA	TCCCTTTTTT	TTTTTTTTGA	GACGGGTTCT	1380
CACTATGTTG	CCCAGGGCTG	GTCTTGAATC	CCTATGCTCA	AGTGATCCTC	CCACCTCGGC	1440
CTCCCAAAGT	ACTGTGATTA	CAAGCGTGAG	CCACGGCACC	TGGGCAGAAA	AGTATCTTAA	1500
TTAATGAAAG	AGCTAAGCCA	TCAAGCTGGG	ACTTAATTGG	ATTTAACATA	GGTTCACAGA	1560
AAGTTTCCTA	ACCAGAGCAT	CTTTTGGACC	ACTCAGCAAA	ACTTCCACAG	ACATCCTTCT	1620
GGACTTAAAC	ACTTAACATT	AACCACATTA	TTAATTGTTG	CTGAGTTTAT	TCCCCCTTCT	1680
AAC TGTGGC	TGGCATCTGA	TATGCAGAGT	TAGTCAACAG	AACTGGCAT	CAATTACAAA	1740
ATCACTGCTG	TTTCTGTGAT	TCAAGCTGTC	AACACAATAA	AATCGAAATT	CATTGATTCC	1800
ATCTCTGGTC	CAGATGTTAA	ACGTTTATAA	AACCGGAAAT	GTCTTAACAA	CTCTGTAATG	1860
GCAAATTAAA	TTGTGTGTCT	TTTTTGTTTT	GTCTTCTAC	CTGATGTGTA	TTCAAGCGCT	1920
ATAACACGTA	TTTCCTTGAC	AAAAATAGTG	ACAGTGAATT	CACACTAATA	AATGTTTATA	1980
GGTTAAAGTC	TGCACTGACA	TTTTCTCATC	AATCACTGGT	ATGTAAGTTA	TCAGTGACTG	2040
ACAGCTAGGT	GGACTGCCCC	TAGGACTTCT	GTTTACCAG	AGCAGGAATC	AAGTGGTGAG	2100
GCACTGAATC	GCTGTACAGG	CTGAAGACCT	CCTTATTAGA	GTTGAACCTC	AAAGTAACTT	2160
GTTTTAAAAA	ATGTGAATTA	CTGTAAATAA	ATCTATTTTG	GATTCATGTG	TTTTCCAGGT	2220
GGATATAGTT	TGTAAACAAT	GTGAATAAAG	TATTTAACAT	GTTCAAAAAA	AAAAAAAAAA	2280

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 255 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Met Leu Asp Ser Val Thr His Ser Thr Phe Leu Pro Asn Ala Ser Phe
 1             5             10             15
Cys Asp Pro Leu Met Ser Trp Thr Asp Leu Phe Ser Asn Glu Glu Tyr
          20             25             30
Tyr Pro Ala Phe Glu His Gln Thr Ala Cys Asp Ser Tyr Trp Thr Ser
          35             40             45
Val His Pro Glu Tyr Trp Thr Lys Arg His Val Trp Glu Trp Leu Gln
          50             55             60
Phe Cys Cys Asp Gln Tyr Lys Leu Asp Thr Asn Cys Ile Ser Phe Cys
65             70             75             80
Asn Phe Asn Ile Ser Gly Leu Gln Leu Cys Ser Met Thr Gln Glu Glu
          85             90             95
Phe Val Glu Ala Ala Gly Leu Cys Gly Glu Tyr Leu Tyr Phe Ile Leu
          100            105            110
Gln Asn Ile Arg Thr Gln Gly Tyr Ser Phe Phe Asn Asp Ala Glu Glu
          115            120            125
Ser Lys Ala Thr Ile Lys Asp Tyr Ala Asp Ser Asn Cys Leu Lys Thr
          130            135            140
Ser Gly Ile Lys Ser Gln Asp Cys His Ser His Ser Arg Thr Ser Leu
145            150            155            160
Gln Ser Ser His Leu Trp Glu Phe Val Arg Asp Leu Leu Leu Ser Pro
          165            170            175
Glu Glu Asn Cys Gly Ile Leu Glu Trp Glu Asp Arg Glu Gln Gly Ile
          180            185            190
Phe Arg Val Val Lys Ser Glu Ala Leu Ala Lys Met Trp Gly Gln Arg
          195            200            205
Lys Lys Asn Asp Arg Met Thr Tyr Glu Lys Leu Ser Arg Ala Leu Arg
          210            215            220
Tyr Tyr Tyr Lys Thr Gly Ile Leu Glu Arg Val Asp Arg Arg Leu Val
225            230            235            240
Tyr Lys Phe Gly Lys Asn Ala His Gly Trp Gln Glu Asp Lys Leu
          245            250            255

```

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2498 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GAGGGGGCTGA	CAGCGGCGTC	CCTCGTCTGG	GCAGCCTCCG	CTCTGCCACT	CTCCTCCCCT	60
CCTGAGGATG	GGACCCCGG	AAAAGCGGCC	TCTGGAGGCC	TGCCATGGCA	CCCAGAGCAG	120
CCATTTTCCT	CCCAGTTCTG	GGGCTTTTGA	AGGAGCTTGC	GGATGAGGAG	AGGGAGCCTC	180
CGCAGGGCTC	TGGCTCCCCT	CCAGGGGCCG	AGGCCGCACA	CAAAGCCGCT	CTGTGGCCCA	240
ATTACACCTA	CTGGATAGGA	TTGTTGAGGG	GACCTGAGAA	ACTTGAGACG	ACAAGAACGC	300
GTAGCGCCTC	GGCTGGCTGA	GGGTGCTGAG	CCCTCGTGTT	GTGTTCTCTC	CAGCTTTCCC	360
CGTGCCTCAG	CCACTCTTCA	CGTTCCATCT	GTGCTCTGTG	CTGACCCGCC	TGTACTCAT	420
ACTGGACATC	AGTCCACCCT	GAATACTGGA	CTAAGCGCCA	TGTGTGGGAG	TGGCTCCAGT	480
TCTGCTGCGA	CCAGTACAAG	TTGGACACCA	ATTGCATCTC	CTTCTGCAAC	TTCAACATCA	540
GTGGCCTGCA	GCTGTGCAGC	ATGACACAGG	AGGAGTTCGT	CGAGGCAGCT	GGCCTCTGCG	600
GCGAGTACCT	GTAATTCATC	CTCCAGAACA	TCCGCACACA	AGGTTACTCC	TTTTTTAATG	660
ACGCTGAAGA	AAGCAAGGCC	ACCATCAAAG	ACTATGCTGA	TTCCAACCTG	TTGAAAACAA	720
GTGGCATCAA	AAGTCAAGAC	TGTCACAGTC	ATAGTAGAAC	AAGCCTCCAA	AGTTCTCATC	780
TATGGGAATT	TGTACGAGAC	CTGCTTCTAT	CTCCTGAAGA	AAACTGTGGC	ATTCTGGAAT	840
GGGAAGATAG	GGAACAAGGA	ATTTTTCGGG	TGGTTAAATC	GGAAGCCCTG	GCAAAGATGT	900
GGGGACAAAG	GAAGAAAAAT	GACAGAATGA	CGTATGAAAA	GTTGAGCAGA	GCCCTGAGAT	960
ACTACTATAA	AACAGGAATT	TTGGAGCGGG	TTGACCGAAG	GTTAGTGTAC	AAATTTGGAA	1020
AAAATGCACA	CGGGTGGCAG	GAAGACAAGC	TATGATCTGC	TCCAGGCATC	AAGCTCATTT	1080
TATGGATTTC	TGTCTTTTAA	AACAATCAGA	TTGCAATAGA	CATTCGAAAG	GTTCATTTTT	1140
CTTCTCTTTT	TTTTTAACCT	GCAAACATGC	TGATAAAATT	TCTCCACATC	TCAGCTTACA	1200
TTTGGATTCA	GAGTTGTTGT	CTACGGAGGG	TGAGAGCAGA	AACTCTTAAG	AAATCCTTTC	1260
TTCTCCCTAA	GGGGATGAGG	GGATGATCTT	TTGTGGTGTC	TTGATCAAAC	TTTATTTTCC	1320
TAGAGTTGTG	GAATGACAAC	AGCCCATGCC	ATTGATGCTG	ATCAGAGAAA	AACATATTCAA	1380
TTCTGCCATT	AGAGACACAT	CCAATGCTCC	CATCCCAAAG	GTTCAAAAGT	TTCAAATAAA	1440
CTGTGGCAGC	TCACCAAAGG	TGGGGGAAAG	CATGATTAGT	TTGCAGGTTA	TGGTAGGAGA	1500
GGGTGAGATA	TAAGACATAC	ATACTTTAGA	TTTTAAATTA	TTAAAGTCAA	AAATCCATAG	1560
AAAAGTATCC	CTTTTTTTTT	TTTTTGAGAC	GGGTTCTCAC	TATGTTGCCC	AGGGCTGGTC	1620
TTGAATCCTT	ATGCTCAAGT	GATCCTCCCA	CCTCGGCCCTC	CCAAAGTACT	GTGATTACAA	1680
GCGTGAGCCA	CGGCACCTGG	GCAGAAAAGT	ATCTTAATTA	ATGAAAGAGC	TAAGCCATCA	1740
AGCTGGGACT	TAATTGGATT	TAACATAGGT	TCACAGAAAG	TTTCCTAACC	AGAGCATCTT	1800
TTTGACCACT	CAGCAAAACT	TCCACAGACA	TCCTTCTGGA	CTTAAACACT	TAACATTAAC	1860
CACATTATTA	ATTGTTGCTG	AGTTTATTCC	CCCTTCTAAC	TGATGGCTGG	CATCTGATAT	1920
GCAGAGTTAG	TCAACAGACA	CTGGCATCAA	TTACAAAATC	ACTGCTGTTT	CTGTGATTCA	1980
AGCTGTCAAC	ACAATAAAAT	CGAAATTCAT	TGATTCCATC	TCTGGTCCCA	GATGTTAAAC	2040
GTTTATAAAA	CCGGAAATGT	CCTAACAAC	CTGTAATGGC	AAATTAAATT	GTGTGTCTTT	2100
TTTGTTTTGT	CTTTCTACCT	GATGTGTATT	CAAGCGCTAT	AACACGTATT	TCCTTGACAA	2160
AAATAGTGAC	AGTGAATTCA	CACTAATAAA	TGTTTCATAGG	TTAAAGTCTG	CACTGACATT	2220
TTCTCATCAA	TCACTGGTAT	GTAAGTTATC	AGTGACTGAC	AGCTAGGTGG	ACTGCCCCTA	2280
GGACTTCTGT	TTCACCAGAG	CAGGAATCAA	GTGGTGAGGC	ACTGAATCGC	TGTACAGGCT	2340
GAAGACCTCC	TTATTAGAGT	TGAACCTCAA	AGTAACCTGT	TTTAAAAAAT	GTGAATTACT	2400
GTAATAAAT	CTATTTTGGA	TTCATGTGTT	TTCCAGGTGG	ATATAGTTTG	TAAACAATGT	2460
GAATAAAGTA	TTTAACATGT	TCAAAAAAAA	AAAAAAA			2498

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 164 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Thr Gln Glu Glu Phe Val Glu Ala Ala Gly Leu Cys Gly Glu Tyr

1	5	10	15
Leu Tyr Phe Ile	Leu Gln Asn Ile	Arg Thr Gln Gly Tyr	Ser Phe Phe
20	25	30	
Asn Asp Ala Glu	Glu Ser Lys Ala	Thr Ile Lys Asp	Tyr Ala Asp Ser
35	40	45	
Asn Cys Leu Lys	Thr Ser Gly Ile	Lys Ser Gln Asp	Cys His Ser His
50	55	60	
Ser Arg Thr Ser	Leu Gln Ser Ser	His Leu Trp Glu	Phe Val Arg Asp
65	70	75	80
Leu Leu Leu Ser	Pro Glu Glu Asn	Cys Gly Ile Leu	Glu Trp Glu Asp
85	90	95	
Arg Glu Gln Gly	Ile Phe Arg Val	Val Lys Ser Glu	Ala Leu Ala Lys
100	105	110	
Met Trp Gly Gln	Arg Lys Lys Asn	Asp Arg Met Thr	Tyr Glu Lys Leu
115	120	125	
Ser Arg Ala Leu	Arg Tyr Tyr Tyr	Lys Thr Gly Ile	Leu Glu Arg Val
130	135	140	
Asp Arg Arg Leu	Val Tyr Lys Phe	Gly Lys Asn Ala	His Gly Trp Gln
145	150	155	160
Glu Asp Lys Leu			

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Genomic DNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AAATGAGCCA ATGTTTGTAA T

21

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAATGAGCCA GTGTTTGTAA T

21

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 736 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```

AGGAAGTGAA GAACCTAGAT AATCCACCAA CCGGATAATC AGCTCTTGCA TATTTGAGAG      60
TTGACTGCTT GACCTAAGCA TCTCCTCATA AGGTACCCTC CCTCCCAGGA CCTTCCCTTT      120
CAAACCTCTC AAGGCTCTTA CCTGGGGCCA GGGGAGATAG GCTTTTCAAA GTCCATTGAA      180
TTGCCAAGAG TCTCTGTCAA GAAGGCAGTC ATGGTGCCCTG GAGAGGGAAC TTGCTGGGAG      240
CCCCCTCAGA GCCTGGTACT TATAGAGCTA GGGAAAAGAT CTTGATGCCA AAGCAGGGTG      300
GACTAAATAC AGACTAATAA ATGAGACAGG TGCTCAAGAG GGCCCCTCCA TACCATCATC      360
TCCTCCAGAT TTGGACTTCT ACTCACTTG CTTTTACATT CCCTCTTCCC GATGGTGTCT      420
TTGGTGAGCA GGGTGCTTTT CACCTGAAAC AGCCTCTGAG CTGAAAAGAA CAGTCACCAC      480
CAAATCAATT CCTCATCCAT TAACAGGTTG TCTCTCTGTT CTTGAGACAC AGGCATTACC      540
TGGTTAGACC TGTTTTGTTT GAACACTAAC GTGTGAGTTG GCCAAATGCA AATGAGCCAA      600
TGTTTGTAAT CCTTTATTTT ATTTTTTTAA AGGGCTGGGT AGCCAATCAG AAGAGGGGGA      660
AGTGACTTAG GGAATCCCCG GTTGGTGGCT TATTGCTTAA CATCCTACAA AATGATTTAA      720
AATTATTGTT ATATGC                                     736

```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 333 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

GCCAGAGTCC TCCTTGAGAA CTTACAATGT GTCCATATTA AGGATCTGCT GTGTTTGATG      60
ATTTGTGAT TACACTTTAA ACTTCTTATC CATAAAGGAC ATACTTGATA TATCTGAGAC      120
TTGTAGTAGA AGGCCTTGAG ACATCCATCT CATCCCATCA TTATCTATCT ATCATCTATC      180
TATCTATCTA TCTATCTATC TATCTATCTA TCTATCATCT ATCTATCTAT CGCCAGTACT      240
GTCTTGTTGA AGTTGGCAGT AGGGTGAAAG ACCTCAAACCT CCAAAGGACT TTCCGTATGG      300
ATGCAATATA CCTGCAATTC TAGCTTTTCT GTG                                     333

```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

ACAGAATGAC RTATGAAAAG T                                     21

```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs



- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTAACCAAGC KCAAGCCACC C

21

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AAGGAGCCCA YCTGAGTGCA G

21

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGTTCCATCT STGCTCTGTG C

21

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AGCGCCTCGG YTGCTGAGG G

21

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:  
TGTATTCAAG YGCTATAACA C 21

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:  
CACTGAGAAG CCNACAGGCC TGT 23

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:  
CCCACAGGCC WGTCCCTCCA A 21

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:  
CGTCCATCTC YAGCTCCAGG G 21

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:  
GACTTGATAA YGCCCGTGGT G 21

## (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ACTTGATAAC RCCCGTGGTG C

21

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CTCCCCCTCCA WGAGCCACAG C

21

## (2) INFORMATION FOR SEQ ID NO:28:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATTCCTGCA TNGTCTGGAC TT

22

## (2) INFORMATION FOR SEQ ID NO:29:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

ATCCAAACAC YTGAGTGGAA A

21

## (2) INFORMATION FOR SEQ ID NO:30:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AGTTTCCTCA RTGCGGGAGC T

21

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GCGAGCACCT YTGACGATG A

21

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TTCACCCGGG YGGCAGGGAC G

21

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CTGGGGAAAA NNGATCGCTG AC

22

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GTCAATTAAA YGGCTCTCAT T

21

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TAGATCATTC RTAACCTGCC T

21

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

AAAGAGAAAT WCTGGAGCGT G

21

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATGAGGGGAA MAAGAACTA C

21

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TTTTGTATGT KACATGATTT A

21

## (2) INFORMATION FOR SEQ ID NO:39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

AGCTTGGTTC YTTTTTGCTC C

21

## (2) INFORMATION FOR SEQ ID NO:40:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

TTGACACCAG RAACCCCCCA G

21

## (2) INFORMATION FOR SEQ ID NO:41:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AAATGAGCCA RTGTTTGTA T

21

## (2) INFORMATION FOR SEQ ID NO:42:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

ATCCATTTTG YATTCCTCAT T

21

## (2) INFORMATION FOR SEQ ID NO:43:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

CTGGAGCTCA RACCAGACAG C

21

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCCAGTGCAG SCATCATTAC C

21

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

AGTTCAAATC RTAATTTTTA T

21

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TCATCAGAAT YTAAATCTCC C

21

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GGAGATTCAG NTGAAGCAAG A

21

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

TTTTTCCACA YCCAGCCTGG C

21

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

CCCAGCCTGG YGAACCCTGG C

21

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

CTCTTCATCA YGGTCAAATA C

21

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

CAACTTGCTG YCAAAGTGCT G

21



## (2) INFORMATION FOR SEQ ID NO:52:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

TACTATGTGC YAGATACTAA G

21

## (2) INFORMATION FOR SEQ ID NO:53:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

ATGCCACTTT RRGACAACTT GAG

23

## (2) INFORMATION FOR SEQ ID NO:54:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

CGCATGCCTG KAAAGAAGAG A

21

## (2) INFORMATION FOR SEQ ID NO:55:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GGATAAGCAC MAGTGAGCCT G

21

## (2) INFORMATION FOR SEQ ID NO:56:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

AAAGCCAGAC RGCAACTTGT G

21

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

TCTCAAAAAG RGTGATAGGA G

21

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

TCTGAATCCT STCTCCTCCT T

21

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

TAGAACCAGG WTGTGGGACC A

21

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

TTCTTGTGTC RGGCGCAAAA C

21

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

AACCAACATG RAGAAACCCC A

21

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

AATAAACTAT RGTTCACCTA G

21

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

ACATATTTGT RTTCATATG A

21

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

CAAAGCAGTT YCTAATAATC C

21

## (2) INFORMATION FOR SEQ ID NO:65:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

AGATCCTAAC YGGGGCCTCC T

21

## (2) INFORMATION FOR SEQ ID NO:66:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

CTCTTTCTCT YTGCTTCCTC C

21

## (2) INFORMATION FOR SEQ ID NO:67:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

TTAGGAATCC WCAAATATGT A

21

## (2) INFORMATION FOR SEQ ID NO:68:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GTCTGACTCC RCCTCCCTCA T

21

## (2) INFORMATION FOR SEQ ID NO:69:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

GAATCACATC RTGAGAAATG T

21

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

AATTCAATCC YTCACAGACT T

21

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

GTGTAGCCAG RGTGCTAAT T

21

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

CCTAGAAATA SCCAAGGGCA C

21

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

AAATTCTCAT RCCTCACCCT C

21

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

TCCCACCCCT RTCACCTTCA T

21

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CCTCATTCTC RGAAGCCAAC A

21

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GAAGAGCCGT YCAGTCCCTT T

21

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

TCCATAGGCT YTTTATTGG C

21

## (2) INFORMATION FOR SEQ ID NO:78:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

TCGTTTAGTA YACAGGCTTT G

21

## (2) INFORMATION FOR SEQ ID NO:79:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

GCCTCAGTTG YCCCAGCTAT A

21

## (2) INFORMATION FOR SEQ ID NO:80:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

AGCAAAATGC WCTATGCACT G

21

## (2) INFORMATION FOR SEQ ID NO:81:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

GTGTCCTGAC NNNNNNNNNN NAACTGCCT G

31

## (2) INFORMATION FOR SEQ ID NO:82:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

ATCAGATAAC RCCTACACTT A

21

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

TCTCTCTTCT SCCTGCCCTG T

21

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TGGACACAGG KAGGGGAATA T

21

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

TGTCACCTTGC RCATACAAGG C

21

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

ATCATCAGAT YAGCCCAGAA T

21

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

TCAACAGAGA RAGTTAATGG T

21

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

AGCAATAATG YTTCCCTTTT C

21

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

TCTAGCTTTT YTGTTTTTTT T

21

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

GATTCCTTAA YGCTTGATAC T

21

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

CCTCCTCCAG YACCAAAGTG G

21

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

ATGGCCACAG RTCAAATCCT G

21

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

ACTGAGTGT TATGCCAATT T

21

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

GACAAGCCCT RTCTGACACA C

21

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

TGAAAAGCCT YCTTGCTGCC T

21

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

TCCTGGAGTT YCTTTGCTCC C

21

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

GATTCCAAAT WAACTAAAGA T

21

(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

GACCTCAAGT CRTCCACCCG CC

22

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

AACAAATACT MCCCCGCAAC CC

22

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

ATTTTTTTTT NAAGGAAAAT A

21

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

AAATTTCCCC MAAACAAGCA G

21

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

GAGAAAGGGT RTGTGTGTGT G

21

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

GTGTGTGTGT NNNNGTATGT GCGCGTG

27

## (2) INFORMATION FOR SEQ ID NO:104:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

ATCGGGAACC YCATACCCCA A

21

## (2) INFORMATION FOR SEQ ID NO:105:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

TTTGTTTCGC MATGAGGTAC G

21

## (2) INFORMATION FOR SEQ ID NO:106:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

TGAGGGTGTT STGGGCTGGA C

21

## (2) INFORMATION FOR SEQ ID NO:107:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

TCTTCATTGG YATCTGAATG T

21

## (2) INFORMATION FOR SEQ ID NO:108:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

GCGAGCACCT YTGACGATG A

21

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

AACCCCCCCC MCACACACAC A

21

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

TCAGTGCTCT STAATCAGTC A

21

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

TCTTTGTGAA ANNAATTAGT CTG

23

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

GCTGCCCTGA SAGCTGGGCC A

21

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

CCTTCTGATC YTTGTTTGCT G

21

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

GGAACACTGA KTCTTGATTA G

21

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

TAGGCTTCTC YTGATAATTG A

21

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

TCTTAAATA MTTGGCTTGT A

21

## (2) INFORMATION FOR SEQ ID NO:117:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

TAGATCATTAACTAACCTGCC T

21

## (2) INFORMATION FOR SEQ ID NO:118:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

ATGAGGGGAA MAAGAACTA C

21

## (2) INFORMATION FOR SEQ ID NO:119:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

TTGACACCAG RAACCCCCCA G

21

## (2) INFORMATION FOR SEQ ID NO:120:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

TGTTTTAAAT RTTAGGGACA A

21

## (2) INFORMATION FOR SEQ ID NO:121:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs



- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

GTAAGCATAG YAATGTAGCA G

21

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

GGCTCTTTCT KCAACCTTTC C

21

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GACCCAGGTT RTGAGTTTTC C

21

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

GACAGAATGA YATATGAAAA G

21

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

TGTGTGACAC YGAGAAGCCC A

21

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

AGTACTGGAC MAAGTACCAG G

21

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

CCTGGGAGCA RGTATTGCAT T

21

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

AGATTTGAGG YCTCAGGTCC C

21

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

TGTCAATGTC RCATGATAAG C

21

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

TTGCCCCAGT KTTCTCCGGG C

21

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

TATGAGCAGC RTAGGGAGTG G

21

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

AGTTGACTGA AAAANTAAAT AAGAC

25

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

ATTCAAATAG SCTCTAGAAA C

21

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

CCCAGAATTT MATATCCATT C

21

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

TGACCCAACA RAACTCACT G

21

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

CCAGAAATATA WCATCAGCCC T

21

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

CATCAGCCCT WCTGAGGAGA T

21

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

CCAGAACAGA YTTTATTCTG T

21

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

TTCAGCCATC YTTCCAGTTG T

21

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

TCACTAACTC WAAAACGACA T

21

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

AACTCAAAAA YGACATCCTC C

21

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

GAACTGCACA RGTTCACAC T

21

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

TTGTTCCATG SACTACCTCC T

21

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

ACAGCAGGCA YTCAACAAAT T

21

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

TTATTTTGG STTGTTT A

21

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

TAGGCTGTC YTGCCATCA C

21

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

GTGCTCTGGG MCACACAGCT C

21

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

AGACCCGATA RGAGCTCCTT C

21

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

CATCTTGCGC RGTTCATGTAA G

21

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

CAGCACAGCT RTTCCCTCAA A

21

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

TTTGAAACA YGGTGAAGTA T

21

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

ACACGGTGAA RTATTGTCTC C

21

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear



(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

AAAAGTGGAT MCTCTGCAAA C

21

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

CTTCAAATGC RGCTATTAAA G

21

(2) INFORMATION FOR SEQ ID NO:155:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

CCTGGGAGCA YGGTAAATCA G

21

(2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

TGAAAATGTC RCTTTCTCAC CT

22

(2) INFORMATION FOR SEQ ID NO:157:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

CCTGATATTT RCCAACAAGA A

21

(2) INFORMATION FOR SEQ ID NO:158:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

AAAGGGTTAG YTTGTCCCCT T

21

(2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

TGAAAATAAA ASACAATTTT TT

22

(2) INFORMATION FOR SEQ ID NO:160:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

CTGCTGTGGA CGAATAGG

18

(2) INFORMATION FOR SEQ ID NO:161:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

TCAATATAAT CTTGCTTAAC TTGG

24

(2) INFORMATION FOR SEQ ID NO:162:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

GACCTGTTTG GGTGATTTC AG

22

(2) INFORMATION FOR SEQ ID NO:163:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

GTTTCTTACA GTGTCTTGCT ATCACATCAC C

31

(2) INFORMATION FOR SEQ ID NO:164:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

GAGGACTGGC AGTACCAAGT AAAC

24

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

GTTTCTTTGG TTCATTCTAA GATGGCTGG

29

## (2) INFORMATION FOR SEQ ID NO:166:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

GCTGAGGCAG GAGAAAAGAC AAG

23

## (2) INFORMATION FOR SEQ ID NO:167:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

GTTTCTTCAT GCAAAGGTCA GGAGGTAGG

29

## (2) INFORMATION FOR SEQ ID NO:168:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

GTTGCTTCCA GACGAGGTAC ATG

23

## (2) INFORMATION FOR SEQ ID NO:169:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

GTTTCTTCAA TGGCTCCACA AACATCTCTG

30

## (2) INFORMATION FOR SEQ ID NO:170:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

AGGTTTAGGG GACAGGGTTT GG

22

(2) INFORMATION FOR SEQ ID NO:171:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

GTTTCTTTCC TGGCTAACAC GGTGAAATC

29

(2) INFORMATION FOR SEQ ID NO:172:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

GTTTCTTATT GCCTCCTCCC AAAATTC

27

(2) INFORMATION FOR SEQ ID NO:173:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

AGAGGCCACT GGAAGACGAA

20

(2) INFORMATION FOR SEQ ID NO:174:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

AACTGGAGTC AGGCAAAACG TG

22

(2) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

GTTTCTTTGG CTGGTAAGGA AAGAAACCAC

30

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

GGCTAGGTTT ATAAACTCTG TGCTG

25

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

GTTTCTTGAT TGTTGAGAT CCTTGACCCA G

31

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

GCCGAAATCA CAACACTGCA TC

22

## (2) INFORMATION FOR SEQ ID NO:179:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

GTTTCTTGAT TCTGCTCTTA CTCTTGCCCC

30

## (2) INFORMATION FOR SEQ ID NO:180:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

GTAATAGAAC CAAAGGGCTG AGAC

24

## (2) INFORMATION FOR SEQ ID NO:181:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

GTTTCTTCGG AGTCAGACCT TACATTGTTG AG

32

## (2) INFORMATION FOR SEQ ID NO:182:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

ATCTCCCTGC TACCCACCTT

20

## (2) INFORMATION FOR SEQ ID NO:183:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

GTTTCTTGTT TTCAGTGAGT TTCTGTTGGG

30

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

GTGTGCCAAA CAACATTTGC

20

(2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

GTTTCTTCAA GCCATCAAGC TAGAGTGG

28

(2) INFORMATION FOR SEQ ID NO:186:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

GGGCTTTTAA ACCCTTATTT AACC

24

(2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

GTTTCTTAGG TGATCTCAGA GCCACTCA

28

(2) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

AGGGCAGGTG GGAAGTTACT

20

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

GTTTCTTTGG AGTCAGTTGA GCTTTCTACC

30

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

TGAACTTGCC TACCTCCCAG

20

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

GTTTCTTAGC ATATATCCTT ACACAAGCAC A

31

## (2) INFORMATION FOR SEQ ID NO:192:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

CATGGTTCCA AAGGCAAGTT

20

## (2) INFORMATION FOR SEQ ID NO:193:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

GTTTCTTTTG AGGCTGAATG AGCTGTG

27

## (2) INFORMATION FOR SEQ ID NO:194:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

ACAGGTGGGA AGACTGAATG TC

22

## (2) INFORMATION FOR SEQ ID NO:195:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

GTTTCTTGCA GTACACATCA CATGACCTTG

30

## (2) INFORMATION FOR SEQ ID NO:196:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

GAAATAGGCG GAAACTGGTT C

21

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

GTTTCTTCGT TGTGGTTGTT CAGAAAGG

28

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

GGTCAAGTGT TCAGAACGCA TC

22

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

GTTTCTTGCA GGGATTATGC TAGGTCTGTA G

31

(2) INFORMATION FOR SEQ ID NO:200:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

AGCACTTCTG AGGAAGGGAC AC

22

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

GTTTCTTAGG GCAGGCAGAC ATACAAAC

28

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

GCCAATGTGT TCCTAGAGCG AC

22

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

GTTTCTTTTA AAGGGGGTAG GGTGTCACC

29

(2) INFORMATION FOR SEQ ID NO:204:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

GGAAGGGAAA AGGACAAGGT TTTG

24

## (2) INFORMATION FOR SEQ ID NO:205:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

GTTTCTTAGC AAGAGCACTG GTGTAGGAGT C 31

## (2) INFORMATION FOR SEQ ID NO:206:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

GCTTTTCAAG CACTTGTCTC 20

## (2) INFORMATION FOR SEQ ID NO:207:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

TGGGATTGTG ACTTACCATG 20

## (2) INFORMATION FOR SEQ ID NO:208:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

ACTTGGTGTG TTATAGAAAG GTG 23

## (2) INFORMATION FOR SEQ ID NO:209:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

GTTTCTTAGC TGTGTTTGCT GCATC

25

(2) INFORMATION FOR SEQ ID NO:210:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

AGATGTGTGA TGAGATGCAG

20

(2) INFORMATION FOR SEQ ID NO:211:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

GTTTCTTCAA ATAGTGCAAC AAACCC

26

(2) INFORMATION FOR SEQ ID NO:212:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

TGTCATTCTG AAAGTGCTTC C

21

(2) INFORMATION FOR SEQ ID NO:213:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

GTTTCTTCTG TAACTAACGA TCTGTAGTGG TG

32

(2) INFORMATION FOR SEQ ID NO:214:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

TATCAAGGTA ATATAGTAGC CACGG

25

(2) INFORMATION FOR SEQ ID NO:215:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

AGGTCTTTCA TGCAGAGTGG

20

(2) INFORMATION FOR SEQ ID NO:216:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

ATTGCCAAAA CTTGGAAGC

19

(2) INFORMATION FOR SEQ ID NO:217:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

AGGTGACATA TCAAGACCCT G

21

(2) INFORMATION FOR SEQ ID NO:218:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

TTGTCAACGA AGCCAC

17

(2) INFORMATION FOR SEQ ID NO:219:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

GTTTCTTGCA AGATTGTGTG TATGGATG

28

(2) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

GCTCTCTATG TGTTTGGGTG

20

(2) INFORMATION FOR SEQ ID NO:221:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

AAGAGTACGC TAGTGGATGG

20

(2) INFORMATION FOR SEQ ID NO:222:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs



- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

TCCATTAGAC CCAGAAAGG

19

(2) INFORMATION FOR SEQ ID NO:223:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

GTTTCTTCAC CAGGCTGAGA TGTACT

27

(2) INFORMATION FOR SEQ ID NO:224:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

AATCGTTCCT TATCAGGTAA TTTGG

25

(2) INFORMATION FOR SEQ ID NO:225:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

GTTTCTTCAA AGAAAGCAAT TCCATCATAA CA

32

(2) INFORMATION FOR SEQ ID NO:226:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

GCATTGTGTTG AAGCAAGCGG

20

(2) INFORMATION FOR SEQ ID NO:227:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

CTTTGTTCCT TGGCTGATGG

20

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

AATAGTACCA GACACACGTG

20

(2) INFORMATION FOR SEQ ID NO:229:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

CAATGGTTCA CAGCCCTTTT

20

(2) INFORMATION FOR SEQ ID NO:230:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

AGCCTGGGAG ACAGAGTGAG

20

## (2) INFORMATION FOR SEQ ID NO:231:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

GTTTCTTGCA CTTTTTGGGG AAGGTG

26

## (2) INFORMATION FOR SEQ ID NO:232:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

GTTCTCCCT TCCCTCTCC

19

## (2) INFORMATION FOR SEQ ID NO:233:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

GTTTCTTTCA GGGACTGGAT TGTA

25

## (2) INFORMATION FOR SEQ ID NO:234:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

GTGTTCTTTA TGTGTAGTTC

20

## (2) INFORMATION FOR SEQ ID NO:235:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

GTTTCTTGGC AACAGAGTGA GACTCA

26

(2) INFORMATION FOR SEQ ID NO:236:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

GTGACATCCA GTGTTGGGAG

20

(2) INFORMATION FOR SEQ ID NO:237:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

GTTTCTTCCT AAGCAAGCAA GCAATCA

27

(2) INFORMATION FOR SEQ ID NO:238:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

AAAGGCAATT GGTGGACA

18

(2) INFORMATION FOR SEQ ID NO:239:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

GTTTCTTTTC AATCCTTGAT GCAAAGT

27

(2) INFORMATION FOR SEQ ID NO:240:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:

GGTGACAGAG CAAGATTTTCG

20

(2) INFORMATION FOR SEQ ID NO:241:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

GTTTCTTGTA GAGTTGAGGG AGCAGC

26

(2) INFORMATION FOR SEQ ID NO:242:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

CATCCATCTC ATCCCATCAT

20

(2) INFORMATION FOR SEQ ID NO:243:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:

GTTTCTTTTC ACCCTACTGC CAACTTC

27

## (2) INFORMATION FOR SEQ ID NO:244:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:

CCGCCATTTT AGAGAGCATA

20

## (2) INFORMATION FOR SEQ ID NO:245:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:

GTTTCTTTTC TGGGACAATT GGTAGGA

27

## (2) INFORMATION FOR SEQ ID NO:246:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:

TTTGTGTTAT TATTTACAGGT GC

22

## (2) INFORMATION FOR SEQ ID NO:247:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:

GTTTCTTGTT TTTTGTTC GTTTAGGAAC

30

## (2) INFORMATION FOR SEQ ID NO:248:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:

CATACCCAAA TCGTTCTCTT CCTC

24

(2) INFORMATION FOR SEQ ID NO:249:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:

GTTTCTTGA AAAGCAAAGG CATCGTAGAG

30

(2) INFORMATION FOR SEQ ID NO:250:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

TACTAACCAA AAGAGTTGGG G

21

(2) INFORMATION FOR SEQ ID NO:251:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

CTATCATTCA GAAAATGTTG GC

22

(2) INFORMATION FOR SEQ ID NO:252:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:
- GTATGGCAGT AGAGGGCATG 20
- (2) INFORMATION FOR SEQ ID NO:253:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:
- AAGGTTACAT TTCAAGAAAT AAAGT 25
- (2) INFORMATION FOR SEQ ID NO:254:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:
- CTGTTCAGGC CTCAATATAT ACC 23
- (2) INFORMATION FOR SEQ ID NO:255:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:
- AAGAGGATAG GTGGGGTTTG 20
- (2) INFORMATION FOR SEQ ID NO:256:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:
- CCTCCACCT AGACACAAT 19



## (2) INFORMATION FOR SEQ ID NO:257:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:

ATATGATCTT TGCATCCCTG

20

## (2) INFORMATION FOR SEQ ID NO:258:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:

AAGAAAGACC TGGAAGGAAT

20

## (2) INFORMATION FOR SEQ ID NO:259:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:

AAACAGCAA ACCTCATCTC

20

## (2) INFORMATION FOR SEQ ID NO:260:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:

CCACCACTTA TTACCTGCAT

20

## (2) INFORMATION FOR SEQ ID NO:261:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

TGAATGAATG AATGAACGAA

20

(2) INFORMATION FOR SEQ ID NO:262:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:

AACTGTGATT GTGCCACTGC ACTC

24

(2) INFORMATION FOR SEQ ID NO:263:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:

GTTTCTTCAC CGCCTTTATC CCTCAAATG

29

(2) INFORMATION FOR SEQ ID NO:264:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:

GATGGGTGGA GGCAGTTAA AG

22

(2) INFORMATION FOR SEQ ID NO:265:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:

GTCAAGCAAC TTGTCCAAGG CTAC

24

(2) INFORMATION FOR SEQ ID NO:266:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

CAGGCTATCA GTTTCCTTTG GAG

23

(2) INFORMATION FOR SEQ ID NO:267:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:

GGCAGGTAAT ACTGGAGAAT TAGG

24

(2) INFORMATION FOR SEQ ID NO:268:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:

GACGGATCTC AGAGCCACTC

20

(2) INFORMATION FOR SEQ ID NO:269:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:

GTTTCTTAAA AGATAAGGGC TTTTAAACC

29

## (2) INFORMATION FOR SEQ ID NO:270:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:

AGTTTCACAG CTTGTTATGG

20

## (2) INFORMATION FOR SEQ ID NO:271:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

GGTTGATGAA GTGAGACTTT

20

## (2) INFORMATION FOR SEQ ID NO:272:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:

ATGGTGGATG CATCCTGTG

19

## (2) INFORMATION FOR SEQ ID NO:273:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:

GTTTCTTGTA TTGACTCCTC CTCTGC

26

## (2) INFORMATION FOR SEQ ID NO:274:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:

CAGTAAACAT

10

(2) INFORMATION FOR SEQ ID NO:275:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:

TGTTGAGTGG

10

(2) INFORMATION FOR SEQ ID NO:276:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:

TCTCCTCAAT GTGCATGT

18

(2) INFORMATION FOR SEQ ID NO:277:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:

ATTCTACATA

10

(2) INFORMATION FOR SEQ ID NO:278:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:

GTGTTTGCAT

10

(2) INFORMATION FOR SEQ ID NO:279:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:

ACAAGTTGGC

10

(2) INFORMATION FOR SEQ ID NO:280:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:

TAGTACCAGA

10

(2) INFORMATION FOR SEQ ID NO:281:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:

TACATCCAAG AAAA

14

(2) INFORMATION FOR SEQ ID NO:282:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:

GAGACTCTGA CAAATATATA TA

22

(2) INFORMATION FOR SEQ ID NO:283:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:

TGTTGATCGC CAAACCAAAA TC

22

(2) INFORMATION FOR SEQ ID NO:284:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:

AATGCATGTA TGTATATGGT GTGGTATGTG TACATATG

38

(2) INFORMATION FOR SEQ ID NO:285:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:285:

CCTCCCAGAA CAATCATGAT AA

22

(2) INFORMATION FOR SEQ ID NO:286:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:

AGACAGTCTC AAAAAATATT TTAAAGAAAA AGCTGGATAA ATAACTAGCT TTAAGAAAAT 60  
AAGAAGAAAA AGAAAGAAGA AAGTAA 86

(2) INFORMATION FOR SEQ ID NO:287:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:

AACTAGCTTT AAGAAAATAA GAAGAAAAAG AAAGAAGAAA GTAAGAAAGA GAAAGAAAAG 60  
AAAGAAAAGA AAGAGGAATG ATTGAC 86

(2) INFORMATION FOR SEQ ID NO:288:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:

CGCGCACATA CACCCTTCT CT 22

(2) INFORMATION FOR SEQ ID NO:289:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:

CAGTAAACAT CATGTTGAGT GG 22

(2) INFORMATION FOR SEQ ID NO:290:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:290:

TCTCCTCAAT GTGCATGTGT GCATGAGTGC ACATTCTACA TA

42

(2) INFORMATION FOR SEQ ID NO:291:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:

GTGTTTGCAT GTTGTACAAG TTGGC

25

(2) INFORMATION FOR SEQ ID NO:292:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:

TAGTACCAGA CACGTGCAGG CAAGCGCACC ATACATCCAA GAAAA

45

(2) INFORMATION FOR SEQ ID NO:293:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:

GGAGGCTGAG CAGGGGTGCC

20

(2) INFORMATION FOR SEQ ID NO:294:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:

ACTCCCACAG GTACCTGCAG

20

## (2) INFORMATION FOR SEQ ID NO:295:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:

CTGCCCTCAC GTAAGCGCCT

20

## (2) INFORMATION FOR SEQ ID NO:296:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:

GCTGTTGCAG GGTAATGTTG

20

## (2) INFORMATION FOR SEQ ID NO:297:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:

CATCAGACAG GTGCGTACA

19

## (2) INFORMATION FOR SEQ ID NO:298:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:

GGCTGCTGAG GAGGGGCTGA

20

## (2) INFORMATION FOR SEQ ID NO:299:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:299:

CGCTCTGTGG GTGAGCTTCA

20

## (2) INFORMATION FOR SEQ ID NO:300:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:

TGTGGAATAG CCCAATTACA

20

## (2) INFORMATION FOR SEQ ID NO:301:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:

AGGGTGCTGA GTGAGTAGTA

20

## (2) INFORMATION FOR SEQ ID NO:302:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:

TTCTTTTCAG GCCCTCGTGT

20

## (2) INFORMATION FOR SEQ ID NO:303:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:303:

TGCTGACCCG GTATGGTGGT

20

(2) INFORMATION FOR SEQ ID NO:304:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:304:

TTTGGTGCAG CCTGTGACTC

20

(2) INFORMATION FOR SEQ ID NO:305:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:

CGCACACAAG GTCAGTGTTT

20

(2) INFORMATION FOR SEQ ID NO:306:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:

TCTTTCCCAG GTTACTCCTT

20

(2) INFORMATION FOR SEQ ID NO:307:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:

ATCAAAGACT GTAAGTAACC

20

(2) INFORMATION FOR SEQ ID NO:308:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:

TCTATTTTCAG ATGCTGATTC

20

(2) INFORMATION FOR SEQ ID NO:309:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:

AGTAGAACAA GTAAGTGACAG

20

(2) INFORMATION FOR SEQ ID NO:310:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:

TTTTCAAAAG GCCTCCAAAG

20

(2) INFORMATION FOR SEQ ID NO:311:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:

GAGCCCTGAG GTAAGTTAAT

20

(2) INFORMATION FOR SEQ ID NO:312:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:312:

GCTTTTTCAG ATACTACTAT

20

## (2) INFORMATION FOR SEQ ID NO:313:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:

TAACATGTTC AACTGTCTGT

20

## (2) INFORMATION FOR SEQ ID NO:314:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:314:

TGTTATATGC ATTTATCTTC

20

## (2) INFORMATION FOR SEQ ID NO:315:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:315:

GGTAAATGAG GTAAGTCCTG

20

## (2) INFORMATION FOR SEQ ID NO:316:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:316:

TCTTGTTAAG ATCGCTCTCT

20

(2) INFORMATION FOR SEQ ID NO:317:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:317:

CCTTGCCCAG GTTCTCTTAA

20

(2) INFORMATION FOR SEQ ID NO:318:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:318:

GCAATCGCAC CTGCACACCC

20

(2) INFORMATION FOR SEQ ID NO:319:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:319:

ACTGCCCATT TCTGGTAAAG

20

(2) INFORMATION FOR SEQ ID NO:320:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:320:

CCCCTAACAG ATCATGATTC

20

(2) INFORMATION FOR SEQ ID NO:321:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:321:

ACGTGCAATG GTAAGAGGGC

20

(2) INFORMATION FOR SEQ ID NO:322:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:322:

TGTTTTGCAG TTTCCAGTGG

20

(2) INFORMATION FOR SEQ ID NO:323:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:323:

AAGTGGAACG GTGACTCTCT

20

(2) INFORMATION FOR SEQ ID NO:324:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:324:

TCCTTCACAG GCCAGTGCAG

20

(2) INFORMATION FOR SEQ ID NO:325:



## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:325:

GAACAACTG GTGAGTAGTA

20

## (2) INFORMATION FOR SEQ ID NO:326:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:326:

TTTTTTGTAG AGCCTTCCAT

20

## (2) INFORMATION FOR SEQ ID NO:327:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:327:

AGCACAGTAG GTAACAACT

20

## (2) INFORMATION FOR SEQ ID NO:328:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:328:

ATGGCCACAG ATTTGTTGGA

20

## (2) INFORMATION FOR SEQ ID NO:329:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:329:

CTTCCTGTTG GTAAGCTGTC

20

(2) INFORMATION FOR SEQ ID NO:330:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:330:

TTCTCCTTAG CAGAGTCACC

20

(2) INFORMATION FOR SEQ ID NO:331:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:331:

AAAAAGCACA GTAAGTTGGC

20

(2) INFORMATION FOR SEQ ID NO:332:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:332:

TTTTCATCAG ACCCGAGAGG

20

(2) INFORMATION FOR SEQ ID NO:333:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:333:

GAGCTATGAG GTGAGGAGTT

20

## (2) INFORMATION FOR SEQ ID NO:334:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:334:

TTTGTTACAG ATATTACTAC

20

## (2) INFORMATION FOR SEQ ID NO:335:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:335:

AGCCTGGAAA TCGTGTTTC

20

## (2) INFORMATION FOR SEQ ID NO:336:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:336:

CGAGAATTCA CTCGAGCATC AGG

23

## (2) INFORMATION FOR SEQ ID NO:337:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:337:

CCTGATGCTC GAGTGAATTC T

21

## (2) INFORMATION FOR SEQ ID NO:338:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 848 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 1...848
- (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:338:

ATG ATT CTG GAA GGA AGT GGT GTA ATG AAT CTC AAC CCA GCC AAC AAC	48
Met Ile Leu Glu Gly Ser Gly Val Met Asn Leu Asn Pro Ala Asn Asn	
1 5 10 15	
CTC CTT CAC CAG CAA CCA GCC TGG CCG GAC AGC TAC CCC ACA TGC AAT	96
Leu Leu His Gln Gln Pro Ala Trp Pro Asp Ser Tyr Pro Thr Cys Asn	
20 25 30	
GTT TCC AGC GGT TTT TTT GGA AGC CAG TGG CAT GAA ATC CAC CCT CAG	144
Val Ser Ser Gly Phe Phe Gly Ser Gln Trp His Glu Ile His Pro Gln	
35 40 45	
TAC TGG ACC AAA TAC CAG GTG TGG GAA TGG CTG CAG CAC CTC CTG GAC	192
Tyr Trp Thr Lys Tyr Gln Val Trp Glu Trp Leu Gln His Leu Leu Asp	
50 55 60	
ACC AAC CAG CTA GAC GCT AGC TGC ATC CCT TTC CAG GAG TTC GAC ATT	240
Thr Asn Gln Leu Asp Ala Ser Cys Ile Pro Phe Gln Glu Phe Asp Ile	
65 70 75 80	
AGC GGA GAA CAC CTG TGC AGC ATG AGT CTG CAG GAG TTC ACG AGG GCA	288
Ser Gly Glu His Leu Cys Ser Met Ser Leu Gln Glu Phe Thr Arg Ala	
85 90 95	
GCA GGC TCA GCT GGG CAG CTG CTC TAC AGC AAC CTA CAG CAT CTC AAG	336
Ala Gly Ser Ala Gly Gln Leu Leu Tyr Ser Asn Leu Gln His Leu Lys	
100 105 110	
TGG AAC GGC CAA TGC AGC AGT GAC CTT TTC CAG TCC GCA CAC AAT GTC	384
Trp Asn Gly Gln Cys Ser Ser Asp Leu Phe Gln Ser Ala His Asn Val	
115 120 125	
ATT GTC AAG ACT GAA CAA ACC GAT CCT TCC ATC ATG AAC ACA TGG AAA	432
Ile Val Lys Thr Glu Gln Thr Asp Pro Ser Ile Met Asn Thr Trp Lys	
130 135 140	
GAA GAA AAC TAT CTC TAT GAT CCC AGC TAT GGT AGC ACA GTA GAT CTG	480
Glu Glu Asn Tyr Leu Tyr Asp Pro Ser Tyr Gly Ser Thr Val Asp Leu	
145 150 155 160	

TTG GAC AGT AAG ACT TTC TGC CGG GCT CAG ATC TCC ATG ACA ACC TCC	528
Leu Asp Ser Lys Thr Phe Cys Arg Ala Gln Ile Ser Met Thr Thr Ser	
165 170 175	
AGT CAC CTT CCA GTT GCA GAG TCA CCT GAT ATG AAA AAG GAG CAA GAC	576
Ser His Leu Pro Val Ala Glu Ser Pro Asp Met Lys Lys Glu Gln Asp	
180 185 190	
CAC CCT GTA AAG TCC CAC ACC AAA AAG CAC AAC CCA AGA GGC ACT CAC	624
His Pro Val Lys Ser His Thr Lys Lys His Asn Pro Arg Gly Thr His	
195 200 205	
TTA TGG GAG TTC ATC CGA GAC ATT CTC TTG AGC CCA GAC AAG AAC CCA	672
Leu Trp Glu Phe Ile Arg Asp Ile Leu Leu Ser Pro Asp Lys Asn Pro	
210 215 220	
GGG CTG ATC AAA TGG GAA GAC CGT TCG GAA GGC ATC TTC AGG TTC CTG	720
Gly Leu Ile Lys Trp Glu Asp Arg Ser Glu Gly Ile Phe Arg Phe Leu	
225 230 235 240	
AAG TCA GAA GCT GTG GCT CAG CTG TGG GGG AAA AAG AAA AAT AAC AGT	768
Lys Ser Glu Ala Val Ala Gln Leu Trp Gly Lys Lys Lys Asn Asn Ser	
245 250 255	
AGC ATG ACA TAC GAG AAG CTC AGC CGG GCT ATG AGA TAT TAC TAC AAA	816
Ser Met Thr Tyr Glu Lys Leu Ser Arg Ala Met Arg Tyr Tyr Tyr Lys	
260 265 270	
CGA GAA ATC CTG GAA CGT GTG GAT GGA CGA CG	848
Arg Glu Ile Leu Glu Arg Val Asp Gly Arg Arg	
275 280	

## (2) INFORMATION FOR SEQ ID NO:339:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 283 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:339:

Met Ile Leu Glu Gly Ser Gly Val Met Asn Leu Asn Pro Ala Asn Asn	
1 5 10 15	
Leu Leu His Gln Gln Pro Ala Trp Pro Asp Ser Tyr Pro Thr Cys Asn	
20 25 30	
Val Ser Ser Gly Phe Phe Gly Ser Gln Trp His Glu Ile His Pro Gln	
35 40 45	
Tyr Trp Thr Lys Tyr Gln Val Trp Glu Trp Leu Gln His Leu Leu Asp	
50 55 60	
Thr Asn Gln Leu Asp Ala Ser Cys Ile Pro Phe Gln Glu Phe Asp Ile	
65 70 75 80	
Ser Gly Glu His Leu Cys Ser Met Ser Leu Gln Glu Phe Thr Arg Ala	

-188-

## WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a sequence within a mammalian *ASTH1* locus, or a polymorphic variant thereof.
- 5 2. An isolated nucleic acid molecule according to Claim 1, wherein said nucleic acid molecule encodes an *ASTH1* polypeptide.
3. An isolated nucleic acid molecule according to Claim 1 wherein said nucleic acid comprises a promoter or regulatory region.
- 10 4. An isolated nucleic acid molecule according to Claim 1 comprising a probe for detection of an *ASTH1* locus polymorphism.
5. An array of oligonucleotides comprising:  
15 two or more probes according to Claim 4.
6. An isolated nucleic acid comprising a microsatellite repeat associated with a predisposition to asthma.
- 20 7. A nucleic acid according to any of claim 1 to 5, wherein said *ASTH1* locus is human.
8. A cell comprising a nucleic acid composition according to any of claims 1 to 4.
- 25 9. A purified polypeptide composition comprising at least 50 weight % of the protein present as the product of the nucleic acid of Claim 1.
10. A method for detecting a predisposition to asthma in an individual, the  
30 method comprising:  
analyzing the genomic DNA or mRNA of said individual for the presence of at least one predisposing *ASTH1* locus polymorphism or a sequence linked to a

predisposing polymorphism; wherein the presence of said predisposing polymorphism is indicative of an increased susceptibility to asthma.

11. A method according to Claim 10, wherein said analyzing step  
5 comprises detection of specific binding between the genomic DNA or mRNA of said individual with a probe or probes according to either of Claims 4 or 5.

12. A method according to Claim 10, wherein said analyzing step  
comprises detection of specific binding between the genomic DNA or mRNA of said  
10 individual with a microsatellite marker listed in Table 1.

13. A non-human transgenic animal model for *ASTH1* gene function  
comprising one of:  
(a) a knockout of an *ASTH1* gene;  
15 (b) an exogenous and stably transmitted mammalian *ASTH1* gene  
sequence; or  
(c) an *ASTH1* promoter sequence operably linked to a reporter gene.

14. A method of screening for biologically active agents that modulate  
20 *ASTH1* function, the method comprising:  
combining a candidate biologically active agent with any one of:  
(a) a mammalian *ASTH1* polypeptide;  
(b) a cell comprising a nucleic acid encoding a mammalian *ASTH1*  
polypeptide; or  
25 (c) a non-human transgenic animal model for *ASTH1* gene function  
comprising one of: (i) a knockout of an *ASTH1* gene; (ii) an exogenous and stably  
transmitted mammalian *ASTH1* gene sequence; or (iii) an *ASTH1* promoter  
sequence operably linked to a reporter gene; and  
determining the effect of said agent on *ASTH1* function.

30




15. An isolated nucleic acid that hybridizes under stringent conditions to any one of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:328.

- 5            16. An isolated nucleic acid that encodes a polypeptide or fragment thereof having an amino acid sequence substantially identical to the sequence as set forth within any one of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, or SEQ ID NO:339.

1/1

FIGURE 1: GENOMIC STRUCTURE OF THE ASTH1I AND ASTH1J GENES



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/01260

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68

US CL : 435/6

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NONE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SANDFORD et al. Localisation of atopy and $\beta$ subunit of high-affinity IgE receptor (Fc $\epsilon$ R1) on chromosome 11q. The Lancet. 06 February 1993, Vol. 341, pages 332-334, see entire article.	1-14
Y	GERHARD et al. Isolation of 1001 New Markers from Human Chromosome 11, Excluding the Region of 11p13-p15.5, and Their Sublocalization by a New Series of Radiation-Reduced Somatic Cell Hybrids. Genomics. 1992, Vol. 13, pages 1133-1142, see entire article.	1-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*g* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 APRIL 1998

Date of mailing of the international search report

18 MAY 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EGGERTON CAMPBELL

Telephone No. (703) 308-0196